

Tuesday, April 09, 2019

Volume 50 No. 4



NOTICE – Items in this issue will be listed online weekly and printed monthly.

1347 PROPERTY INSURANCE HOLDINGS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	¹ 2017 (revised)	² 2016 (revised)
Net premiums earned	54,357	35,202	30,448
Net investment income	1,617	965	544
Other income	2,246	1,981	1,264
Total revenue	58,220	38,148	32,256
Net losses & loss adjustment expenses	27,413	15,900	16,372
Amortization of deferred policy acquisition costs	15,313	11,080	8,492
Accretion of discount on Series B preferred shares	33	372	355
Loss on repurchase of Series B preferred shares & performance shares	1,612
Total expenses	57,934	36,656	32,137
Income (loss) before income tax expense (benefit)	286	1,492	119
Current income tax expense	550	795	20
Deferred income tax expense (benefit)	(1,068)	403	88
Income tax expense (benefit)	(518)	1,198	108
Net income (loss)	804	294	11
Dividends declared on series A preferred shares	1,108
Net income (loss) attributable to common shareholders	(304)	294	...
Weighted average shares outstanding - basic	5,990	5,965	6,048
Weighted average shares outstanding - diluted	5,990	5,970	6,048
Year end shares outstanding	6,013	5,985	5,957
Net earnings (loss) per share - basic	\$(0.05)	\$0.05	\$0.00
Net earnings (loss) per share - diluted	\$(0.05)	\$0.05	\$0.00
Total number of employees	³ 37	³ 30	³ 27
Number of common stockholders	³ 14	³ 4	³ 3
Number of beneficiary stockholders	³ 600

¹ Reclassified to conform with 2018 presentation; ² Reclassified to conform with 2017 presentation; ³ As is; ⁴ As of March 26, 2018; ⁵ As of March 8, 2017; ⁶ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	¹ 2017 (revised)	² 2016 (revised)
Fixed income securities, at fair value	³ 76,310	³ 51,122	

	³ 2018	⁴ 2017	⁵ 2016
Equity investments, at fair value	³ 3,263	⁴ 2,707	
Short-term investments, at cost	474	417	
Other investments	3,287	945	
Cash & cash equivalents	30,902	23,575	
Deferred policy acquisition costs, net	9,111	6,785	
Premiums receivable	⁶ 7,720	⁶ 10,831	
Ceded unearned premiums	6,525	3,655	
Reinsurance recoverable on paid losses	530	1,952	
Reinsurance recoverable on loss & loss adjustment expense reserves	5,661	8,971	
Funds deposited with reinsured companies	287	2,250	
Current income taxes recoverable	1,119	64	
Deferred tax asset, net	1,279	70	
Property & equipment, net	315	205	
Accrued interest on investments	406	285	
Security deposits for facility leases	25	38	
Prepaid expenses	683	556	
Other receivables	26	9	
Other assets	1,140	888	
Total assets	147,923	114,437	
Loss & loss adjustment expense reserves	15,151	13,488	
Unearned premium reserves	51,907	39,523	
Ceded reinsurance premiums payable	9,495	5,532	
Agent commissions payable	802	695	
Premiums collected in advance	1,840	1,078	
Funds held under reinsurance treaties	162	206	
Accrued premium taxes & assessments	3,059	2,689	
Accrued employee compensation	271	51	
Accrued professional fees	516	587	
Unearned policy fees	1,701	454	
Capital lease obligations	118	...	
Other accounts payable	154	492	
Accounts payable & other accrued expenses	2,760	1,584	
Series B preferred shares	...	2,840	
Total liabilities	85,176	67,635	
Series A preferred shares	17,500	...	
Common stock	6	6	
Additional paid-in capital	46,340	47,064	
Retained earnings (deficit)	639	910	
Accumulated other comprehensive (income) loss	(729)	(169)	
Shareholders' equity before treasury stock	63,756	47,811	
Less: treasury stock at cost	1,009	1,009	
Total shareholders' equity	62,747	46,802	

¹ Reclassified to conform with 2018 presentation; ² Amortized cost - fixed income securities: \$77,366,000; ³ Amortized cost - fixed income securities: \$51,503,000; ⁴ Cost - equity investments, at fair value: \$3,130,000; ⁵ Cost - equity investments, at fair value: \$2,582,000; ⁶ Net of allowance for credit losses - premiums receivable: \$50,000; ⁷ Net of allowance for credit losses - premiums receivable: \$33,000

Recent Dividends:

1. 1347 Property Insurance Holdings Inc common. No dividends paid.
2. 1347 Property Insurance Holdings Inc series B preferred. No dividends paid.

Annual Dividends:

1. 1347 Property Insurance Holdings Inc common. No dividends paid.
2. 1347 Property Insurance Holdings Inc series B preferred. No dividends paid.

ACLARIS THERAPEUTICS INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	¹ 2017 (revised)	² 2016 (revised)
Product sales, net	3,940
Contract research	4,651	1,683	...
Other revenue	1,500
Total revenue, net	10,091	1,683	...
Cost of revenue	6,850	1,207	...
Gross profit (loss)	3,241	476	...
Research & development expenses	63,009	39,790	33,476
Sales & marketing expenses	47,997	13,769	3,295
General & administrative expenses	27,649	19,340	11,796
Total operating expenses	138,655	72,899	48,567
Income (loss) from operations	(135,414)	(72,423)	(48,567)
Other income, net	2,676	2,070	488
Income (loss) before income taxes - U.S.	(132,473)	(63,665)	(40,597)
Income (loss) before income taxes - foreign	(265)	(6,688)	(7,482)
Income (loss) before income taxes	(132,738)	(70,353)	(48,079)
Provision for (benefit from) income taxes	...	(1,830)	...
Net income (loss)	(132,738)	(68,523)	(48,079)
Weighted average shares outstanding - basic	32,910	28,102	21,416
Weighted average shares outstanding - diluted	32,910	28,102	21,416
Year end shares outstanding	³ 41,211	30,857	³ 26,059
Net income (loss) per share - basic	\$(4.03)	\$(2.44)	\$(2.25)
Net income (loss) per share - diluted	\$(4.03)	\$(2.44)	\$(2.25)
Total number of employees	³ 169	³ 96	³ 31

Number of common stockholders	71	70	41
Foreign currency translation adjustments		144	(225)

¹ Reclassified to conform with 2018 presentation; ² Shares increased due to issuance of common stock in connection with public offering and Confluence development milestone, exercise of stock options and vesting of RSUs; ³ Shares increased due to issuance of common shares in connection with follow-on public offering; ⁴ As is; ⁵ As of March 15, 2019; ⁶ As of March 9, 2018; ⁷ As of March 14, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):			
	2018	2017	
		(revised)	
Cash & cash equivalents	57,019	20,202	
Marketable securities	110,953	173,655	
Accounts receivable, net	4,861	481	
Inventory	791	...	
Prepaid expenses & other current assets	5,875	5,883	
Total current assets	179,499	200,221	
Marketable securities	...	14,997	
Computer equipment	1,292	650	
Fleet vehicles	2,131	...	
Manufacturing equipment	604	511	
Lab equipment	1,068	721	
Furniture & fixtures	524	327	
Leasehold improvements	332	430	
Property & equipment, gross	5,951	2,639	
Less: accumulated depreciation	1,671	480	
Property & equipment, net	4,280	2,159	
Intangible assets	72,951	7,349	
Goodwill	18,504	18,504	
Other assets	332	279	
Total assets	275,566	243,509	
Accounts payable	14,755	7,822	
Employee compensation expenses	5,293	3,010	
Sales incentives & rebates	2,650	...	
Marketing expenses	453	39	
Research & development expenses	1,437	627	
Capital leases, current portion	601	142	
Professional fees	1,123	108	
Payable to NST Consulting, LLC	...	590	
Other accrued expenses	1,030	424	
Accrued expenses	12,587	4,940	
Total current liabilities	27,342	12,762	
Other liabilities	1,703	558	
Long-term debt	29,914	...	
Contingent consideration	934	4,378	
Deferred tax liability	549	549	
Total liabilities	60,442	18,247	
Additional paid-in capital	507,366	384,943	
Accumulated other comprehensive income (loss)	(69)	(246)	
Retained earnings (accumulated deficit)	(292,173)	(159,435)	
Total stockholders' equity (deficit)	215,124	225,262	

¹ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Aclaris Therapeutics Inc series B redeemable convertible preferred.			
No dividends paid.			
2. Aclaris Therapeutics Inc common.			
No dividends paid.			
3. Aclaris Therapeutics Inc series A redeemable convertible preferred.			
No dividends paid.			
Annual Dividends:			

1. Aclaris Therapeutics Inc series B redeemable convertible preferred.			
No dividends paid.			
2. Aclaris Therapeutics Inc common.			
No dividends paid.			
3. Aclaris Therapeutics Inc series A redeemable convertible preferred.			
No dividends paid.			

ADDUS HOMECARE CORP Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)
Net service revenues	518,119	425,994	400,929
Cost of service revenues	379,843	310,119	294,593
Gross profit	138,276	115,875	106,336
General & administrative expenses	105,025	76,902	76,840
Gain (loss) on sale of assets	(38)	2,467	...
Depreciation & amortization	8,642	6,663	6,647
Provision for doubtful accounts	272	8,409	7,373
Total operating expenses	113,977	89,507	90,860
Operating income (loss) from continuing operations	24,299	26,368	15,476
Interest income	2,592	66	2,812
Interest expense	5,016	4,472	2,332
Total interest income (expense), net	(2,424)	(4,406)	480
Other income	...	217	206
Income (loss) from continuing operations before income taxes	21,875	22,179	16,162
Current federal income taxes	2,969	5,828	4,486
Current state income taxes	1,588	1,079	927
Deferred federal income taxes	(47)	1,672	(1,147)
Deferred state income taxes	(12)	66	(167)
Income tax expense (benefit)	4,498	8,645	4,099
Net income (loss) from continuing operations	17,377	13,534	12,063
Earnings (loss) from discontinued operations	126	147	97
Net income (loss)	17,503	13,681	12,160
Weighted average shares outstanding - basic	12,049	11,470	11,292
Weighted average shares outstanding - diluted	12,383	11,623	11,349
Year end shares outstanding	13,126	11,632	11,527
Income (loss) per share from continuing operations - basic	\$1.44	\$1.18	\$1.06
Income (loss) per share - discontinued operations - basic	\$0.01	\$0.01	\$0.01
Net income (loss) per share - basic	\$1.45	\$1.19	\$1.07
Income (loss) per share from continuing operations - diluted	\$1.40	\$1.16	\$1.06

Income (loss) per share - discontinued operations - diluted	\$0.01	\$0.01	\$0.01
Net income (loss) per share - diluted	\$1.41	\$1.17	\$1.07
Number of full time employees	4,875
Number of part time employees	28,278
Total number of employees	33,153
Number of common stockholders	8,500

¹ Restated to reflect the corrections of understatement of revenues & provision for doubtful accounts, increase in cumulative incremental tax expense, overpayments by payors and adoption of ASU 2014-09; ² As is; ³ Approximately; ⁴ As of February 20, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
		(revised)
Cash	70,406	53,754
Accounts receivable, gross	108,700	104,033
Less: allowances	700	10,500
Accounts receivable, net of allowances	108,000	93,533
Prepaid workers' compensation & liability insurance	1,840	1,332
Workers' compensation insurance receivable	1,692	543
Prepaid rent	1,191	555
Health insurance receivable	564	2,349
Other prepaid expenses & other current assets	1,811	3,600
Total current assets	185,504	155,666
Computer equipment	3,768	2,770
Furniture & equipment	3,161	3,392
Transportation equipment	156	152
Leasehold improvements	2,962	2,749
Computer software	6,712	3,269
Property & equipment, gross	16,759	12,332
Less: accumulated depreciation & amortization	6,101	4,843
Property & equipment, net of accumulated depreciation & amortization	10,658	7,489
Goodwill	135,442	90,339
Intangibles, net of accumulated amortization	23,784	16,596
Deferred tax assets, net	...	1,601
Total assets	355,388	271,691
Accounts payable	12,238	7,381
Current portion of long-term debt, net of debt issuance costs	62	3,099
Accrued payroll	22,449	19,783
Accrued workers' compensation insurance	15,169	12,574
Accrued health insurance	3,926	6,471
Accrued professional fees	2,260	1,312
Accrued payroll taxes	769	1,065
Other accrued expenses	4,631	3,391
Accrued expenses	49,204	44,596
Total current liabilities	61,504	55,076
Term loan under the credit facility	...	44,438
Revolving loan under the credit facility	20,000	...
Capital lease	81	1,002
Less unamortized issuance costs	(2,797)	(2,481)
Less: current maturities	62	3,099
Long-term debt, less current portion, net of		

debt issuance costs	17,222	39,860	2018	2017	2016	expense (benefit) - state	4,308,000	894,000	458,000
Deferred tax liabilities, net	494	...	Consumables	8,733,000	4,246,000	Total current income tax expense (benefit)	5,190,000	1,413,000	458,000
Other long-term liabilities	635	446	License royalties, related party	15,140,000	9,672,000	Deferred income tax expense (benefit) - federal	4,766,000	23,003,000	(61,396,000)
Total long-term liabilities	18,351	40,306	Equipment sales	72,000	31,446,000	Deferred income tax expense (benefit) - state	467,000	(264,000)	...
Total liabilities	79,855	95,382	Chemicals	Total deferred income tax expense (benefit)	5,233,000	22,739,000	(61,396,000)
Common stock	13	12	Consulting services & other revenues	Income tax expense (benefit)	10,423,000	24,152,000	(60,938,000)
Additional paid-in capital	177,683	95,963	Total revenues	23,945,000	45,364,000	Net income (loss)	35,454,000	27,873,000	97,678,000
Retained earnings (accumulated deficit)	97,837	80,334	Consumables cost of revenue, net	6,606,000	3,434,000	Less: dividends & undistributed income (loss) allocated to participating securities	112,000	171,000	1,105,000
Total stockholders' equity	275,533	176,309	Equipment cost of revenue, exclusive of depreciation & amortization	(353,000)	28,451,000	Income (loss) attributable to common stockholders	35,342,000	27,702,000	96,573,000

Revised to reflect the corrections of understatement of revenues & provision for doubtful accounts, increase in cumulative incremental tax expense, overpayments by payors and adoption of ASU 2014-09

Recent Dividends:

1. Addus HomeCare Corp common.

No dividends paid.

Annual Dividends:

1. Addus HomeCare Corp common.

No dividends paid.

ADVANTAGE TECHNOLOGIES GROUP, INC.

Interest Sale Completed On Mar. 28, 2019, Co. sold its property, located at 2675 E. 28th Street, Sedalia, Missouri 65301, to David Chymiak LLC, a company controlled by David Chymiak, Co.'s Chief Technology Officer, Board member and a substantial shareholder for a cash purchase price of \$1,350,000 pursuant to the terms contained in the Purchase and Sale Agreement dated as of Mar. 22, 2019, as amended on Mar. 28, 2019. This property houses Co.'s Comtech Services business.

ADVANTAGE TECHNOLOGIES GROUP, INC.

Interest Sale Development On Mar. 22, 2019, Co. entered into an Agreement for the Purchase and Sale of Real Estate in which David Chymiak LLC, a company controlled by David Chymiak, Co.'s Chief Technology Officer, Board member and a substantial shareholder agreed to purchase Co.'s property located at 375 Ivyland Road, Warminster, PA 18974. This property houses Co.'s NCS Industries business. This agreement provides for a purchase price of \$725,000 for the Warminster, Pennsylvania property, which will be paid 80% in cash upon closing, with the remainder due at the earlier of either the closing of the Cable TV segment sale or six months. Subject to title review and other customary provisions, closing is scheduled before the end of Apr. 2019.

ADOBE INC

Earnings, 3 mos. to (Consol. - \$000):

	03/01/19	03/02/18
Total Revenues	2,600,946	2,078,947
Cost & expenses	1,859,550	1,359,068
Operating income	694,830	702,733
Interest expense	40,593	19,899
Gains or losses	174	(998)
Invest. income	43,532	3,873
Foreign currency	(11,857)	(5,889)
Net before taxes	702,334	702,502
Income taxes	28,093	119,426
Net income	674,241	583,076
Earnings common share		
Primary	\$1.38	\$1.18
Fully Diluted	\$1.36	\$1.17
Common Shares:		
Full Diluted	494,188	499,433
Year-end	488,504	492,880

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2019
Cash & equivalents	1,738,846
Current assets	5,133,715
Net property & equip.	1,104,065
Total assets	19,505,536
Liabilities:	
Current liabilities	5,313,736
Long-term debt	3,236,833
Stockholders' equity	9,871,485
Net current assets	(180,021)

ADVANCED EMISSIONS SOLUTIONS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2018	2017	2016	expense (benefit) - state	4,308,000	894,000	458,000
8,733,000	4,246,000	...	Total current income tax expense (benefit)	5,190,000	1,413,000	458,000
15,140,000	9,672,000	...	Deferred income tax expense (benefit) - federal	4,766,000	23,003,000	(61,396,000)
72,000	31,446,000	46,949,000	Deferred income tax expense (benefit) - state	467,000	(264,000)	...
...	...	3,025,000	Total deferred income tax expense (benefit)	5,233,000	22,739,000	(61,396,000)
...	...	648,000	Income tax expense (benefit)	10,423,000	24,152,000	(60,938,000)
23,945,000	45,364,000	50,622,000	Net income (loss)	35,454,000	27,873,000	97,678,000
6,606,000	3,434,000	...	Less: dividends & undistributed income (loss) allocated to participating securities	112,000	171,000	1,105,000
(353,000)	28,451,000	37,741,000	Income (loss) attributable to common stockholders	35,342,000	27,702,000	96,573,000
...	...	1,700,000	Weighted average shares outstanding - basic	19,901,000	21,367,000	21,931,000
10,639,000	7,669,000	12,390,000	Weighted average shares outstanding - diluted	20,033,000	21,413,000	22,234,000
1,141,000	795,000	2,168,000	Year end shares outstanding	18,576,489	20,752,055	22,024,675
8,230,000	4,354,000	8,293,000	Net earnings (loss) per share - basic	\$1.78	\$1.30	\$4.40
3,359,000	4,014,000	3,721,000	Net earnings (loss) per share - diluted	\$1.76	\$1.29	\$4.34
723,000	789,000	...	Cash dividends declared per common share	\$1.00	\$0.75	...
...	...	(648,000)	Total number of employees	128	29	25
30,345,000	49,506,000	66,720,000	Number of common stockholders	700	900	1,006
(6,400,000)	(4,142,000)	(16,098,000)	Number of beneficiary stockholders	4,600	4,372	2,260
54,208,000	53,843,000	45,584,000				
...	...	6,125,000				
239,000	54,000	268,000				
2,151,000	3,024,000	5,066,000				
...	...	(3,269,000)				
...	464,000	1,760,000				
...	3,500,000	...				
...	1,000,000	...				
...	...	2,078,000				
...	...	1,019,000				
...	...	891,000				
(19,000)	(11,000)	235,000				
(19,000)	2,025,000	2,463,000				
52,277,000	56,167,000	52,838,000				
45,877,000	52,025,000	36,740,000				
882,000	519,000	...				

Reclassified to conform with 2018 presentation; Reclassified to conform with 2017 presentation; Approximately; As of March 8, 2019; As of March 2, 2018; As of March 8, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2018	2017
18,577,000	30,693,000
10,121,000	1,240,000
567,000	127,000
9,554,000	1,113,000
4,284,000	3,247,000
21,791,000	74,000
1,233,000	1,678,000
2,940,000	...
1,397,000	83,000
5,570,000	1,761,000
59,776,000	36,888,000
5,195,000	...
1,277,000	1,429,000
249,000	205,000
2,302,000	...
32,999,000	...
6,668,000	...
701,000	262,000
44,196,000	1,896,000

amortization	1,499,000	1,486,000
Property & equipment, net	42,697,000	410,000
Intangible assets, net	4,830,000	805,000
Equity method investments	6,634,000	4,351,000
Deferred tax assets	32,539,000	38,661,000
Spare parts	3,278,000	...
Mine development costs, net	2,531,000	...
Long-term receivable, net	408,000	...
Deposits	269,000	223,000
Cost method investment	552,000	552,000
Other long-term assets	955,000	728,000
Total other long-term assets	7,993,000	1,503,000
Total assets	159,664,000	82,618,000
Accounts payable	6,235,000	1,000,000
Accrued payroll & related liabilities	8,279,000	1,384,000
Current portion of borrowings	24,067,000	...
Billings in excess of costs on uncompleted contracts	...	1,830,000
Estimated Company contribution to 401(k) plan	...	1,000,000
Accrued interest	407,000	...
Accrued losses on equipment contracts	...	69,000
Taxes payable	479,000	207,000
Warranty liabilities	12,000	316,000
Other current liabilities	1,240,000	1,072,000
Total other current liabilities	2,138,000	4,494,000
Total current liabilities	40,719,000	6,878,000
Long-term portion of borrowings	50,058,000	...
Deferred revenue, related party	...	2,000,000
Deferred rent	106,000	192,000
Mine reclamation liability	624,000	...
Other long-term liabilities	210,000	93,000
Total other long-term liabilities	940,000	2,285,000
Total liabilities	91,717,000	9,163,000
Common stock	23,000	22,000
Treasury stock, at cost	41,740,000	16,397,000
Additional paid-in capital	96,750,000	105,308,000
Retained earnings (accumulated deficit)	12,914,000	(15,478,000)
Total stockholders' equity (deficit)	67,947,000	73,455,000

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Advanced Emissions Solutions Inc common.

ExDate	Amt	Declared	Record	Payable
06/26/2017	0.25	06/14/2017	06/28/2017	07/17/2017
08/17/2017	0.25	08/07/2017	08/21/2017	09/07/2017
11/16/2017	0.25	11/06/2017	11/17/2017	12/06/2017
02/20/2018	0.25	02/08/2018	02/21/2018	03/08/2018
05/21/2018	0.25	05/09/2018	05/22/2018	06/08/2018
08/17/2018	0.25	08/06/2018	08/20/2018	09/06/2018
11/19/2018	0.25	11/06/2018	11/20/2018	12/06/2018
02/15/2019	0.25	02/05/2019	02/19/2019	03/07/2019

Annual Dividends:

1. Advanced Emissions Solutions Inc common.

2017	0.75	2018	1.00	2019	0.25
------	------	------	------	------	------

ADVANCED ENERGY INDUSTRIES INC

New Accountant On Mar. 25, 2019, Co. dismissed Grant Thornton LLP as its independent public accounting firm. On Mar. 27, 2019, Co. engaged Ernst & Young LLP as its new independent public accounting firm.

AKEBIA THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Product revenue, net	6,824,000
License, collaboration & other revenue	200,918,000	181,227,000	1,535,000
Total revenues	207,742,000	181,227,000	1,535,000
Cost of goods sold - product	6,251,000
Cost of goods sold - amortization of intangibles	1,517,000
Total cost of goods sold	7,768,000
Research & development expenses	291,007,000	230,893,000	115,785,000
Selling, general & administrative	87,061,000	27,008,000	22,210,000
License expense	67,000
Total operating expenses	378,135,000	257,901,000	137,995,000
Operating income (loss)	(178,161,000)	(76,674,000)	(136,460,000)
Interest income (expense), net	6,154,000	2,799,000	901,000
Other income (expense)	81,000	204,000	(188,000)
Net income (loss) before income taxes	(171,926,000)	(73,671,000)	(135,747,000)
Current provision (benefit) - federal	23,000
Current provision (benefit) - state	104,000
Total current income taxes	127,000
Deferred provision (benefit) - federal	(16,383,000)
Deferred provision (benefit) - state	(12,082,000)
Total deferred income taxes	(28,465,000)
Provision (benefit) for income taxes	(28,338,000)
Net income (loss)	(143,588,000)	(73,671,000)	(135,747,000)
Weighted average shares outstanding - basic	58,038,252	43,500,795	37,716,949
Weighted average shares outstanding - diluted	58,038,252	43,500,795	37,716,949
Year end shares outstanding	116,887,518	47,612,619	38,615,709
Net income (loss) per common share - basic	\$(2.47)	\$(1.69)	\$(3.60)
Net income (loss) per common share - diluted	\$(2.47)	\$(1.69)	\$(3.60)
Number of full time employees	324	113	89
Number of part time employees	1	1	1
Total number of employees	325	114	90
Number of common stockholders	24	22	27

Restated to reflect adoption of ASU 2014-09, (Topic 606); Shares increased due to Keryx Merger, issuance of Baupost Additional shares, sale of stock, exercise of options, & restricted stock unit vesting; Shares increased due to the effect of sale of stock under employee stock purchase plan, exercise of options and restricted stock unit vesting; Shares increase due to the effect of issuance of common stock, sales of stock, restricted common stock and exercise of options; As of March 01, 2019; Approximately; As of March 1, 2018; As of March 1, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	104,644,000	70,156,000

	2018	2017
Available for sale securities	216,996,000	247,636,000
Inventory	114,245,000	...
Accounts receivable	16,666,000	34,216,000
Prepaid expenses & other current assets	15,724,000	6,348,000
Total current assets	468,275,000	358,356,000
Computer equipment & software	1,593,000	630,000
Furniture & fixtures	1,170,000	800,000
Equipment	1,780,000	628,000
Leasehold improvements	5,324,000	2,582,000
Office equipment under capital lease	114,000	36,000
Property & equipment, gross	9,981,000	4,676,000
Less accumulated depreciation	1,958,000	1,059,000
Property & equipment, net	8,023,000	3,617,000
Goodwill	55,053,000	...
Other intangible assets, net	328,153,000	...
Other assets	137,036,000	2,274,000
Total assets	996,540,000	364,247,000
Accounts payable	42,796,000	6,998,000
Accrued clinical	71,881,000	43,297,000
Product revenue allowances	22,861,000	...
Merger costs	16,071,000	...
Accrued bonus	9,537,000	3,388,000
Accrued commercial manufacturing	6,383,000	...
Accrued severance	3,962,000	...
Royalties	2,430,000	...
Income tax payable	...	987,000
Professional fees	2,367,000	808,000
Accrued vacation	1,088,000	797,000
Accrued payroll	2,255,000	795,000
Other accrued expenses	12,082,000	2,369,000
Accrued expenses	150,917,000	52,441,000
Debt	15,000,000	...
Short-term deferred revenue	56,980,000	81,667,000
Total current liabilities	265,693,000	141,106,000
Deferred rent, net of current portion	3,006,000	2,588,000
Deferred revenue, net of current portion	55,709,000	97,957,000
Deferred tax liabilities	6,631,000	...
Other non-current liabilities	29,573,000	22,000
Total liabilities	360,612,000	241,673,000
Common stock	1,000	...
Additional paid-in capital	1,150,583,000	493,823,000
Accumulated other comprehensive income (loss)	(261,000)	(442,000)
Retained earnings (accumulated deficit)	(514,395,000)	(370,807,000)
Total stockholders' equity (deficit)	635,928,000	122,574,000

Recent Dividends:

1. Akebia Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Akebia Therapeutics Inc common.

No dividends paid.

ALECTOR INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Collaboration revenue	27,508	2,872	...
Grant revenue	169	863	416
Total revenues	27,677	3,735	416
Research & development	73,031	29,911	13,674
General &

administrative	11,934	6,503	1,874
Total operating expenses	84,965	36,414	15,548
Income (loss) from operations	(57,288)	(32,679)	(15,132)
Other income, net	5,040	199	22
Net income (loss)	(52,248)	(32,480)	(15,110)
Weighted average shares outstanding - basic	11,303	9,143	7,173
Weighted average shares outstanding - diluted	11,303	9,143	7,173
Year end shares outstanding	13,765	13,776	0
Net earnings (loss) per share - basic	\$(4.62)	\$(3.55)	\$(2.11)
Net earnings (loss) per share - diluted	\$(4.62)	\$(3.55)	\$(2.11)
Number of full time employees	78	...	78
Number of common stockholders	104	103	...

As Is; As of December 31, 2018; Approximately; As of March 15, 2019; As of September 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017	
Cash & cash equivalents	65,470	32,451	
Marketable securities - available for sale	224,938	...	
Receivable from collaboration partner	...	200,000	
Accounts receivable, net	...	238	
Prepaid expenses & other current assets	2,768	285	
Total current assets	293,176	232,974	
Lab equipment	4,599	3,527	
Computer equipment	449	157	
Leasehold improvements	210	113	
Office equipment	131	17	
Construction in progress	7,449	...	
Total property & equipment, gross	12,838	3,814	
Less: accumulated depreciation	1,901	980	
Property & equipment, net	10,937	2,834	
Restricted cash	1,472	...	
Other assets	2,774	252	
Total assets	308,359	236,060	
Accounts payable	126	1,140	
Accrued clinical supply costs	4,463	3,820	
Accrued research & development costs	3,821	1,471	
Accrued employee compensation	2,766	1,294	
Deferred offering costs	792	...	
Accrued professional services	588	387	
Accrued property & equipment	293	201	
Other accrued liabilities	179	102	
Accrued liabilities	8,439	3,455	
Deferred revenue, current portion	34,905	18,978	
Deferred rent, current portion	15	10	
Total current liabilities	47,948	27,403	
Deferred revenue, long-term portion	139,715	183,150	
Deferred rent, long-term portion	7,478	41	
Other long-term liabilities	96	14	
Total liabilities	195,237	210,608	
Convertible preferred stock	210,520	77,485	
Common stock	1	1	
Additional paid-in capital	17,078	10,153	

Net unrealized gain (loss) on marketable securities	(42)	...
Accumulated other comprehensive income (loss)	(42)	...
Retained earnings (accumulated deficit)	(114,435)	(62,187)
Total shareholders' equity (deficit)	(97,398)	(52,033)

Recent Dividends:
1. Alector Inc common.
 No dividends paid.
Annual Dividends:
1. Alector Inc common.
 No dividends paid.

ALPINE IMMUNE SCIENCES INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Collaboration revenue	705,000	1,731,000	...
Research & development expenses	28,970,000	10,626,000	23,316,000
General & administrative expenses	8,362,000	6,079,000	8,586,000
Gain (loss) on sale of intangible asset	(1,203,000)
Total operating expenses	38,535,000	16,705,000	...
Income (loss) from operations	(37,830,000)	(14,974,000)	(31,902,000)
Bargain purchase gain	...	6,601,000	...
Other income	439,000
Interest expense	319,000	152,000	...
Interest & other income	1,296,000	542,000	...
Income (loss) before taxes	(36,853,000)	(7,983,000)	...
Current U.S. federal income tax expense (benefit)	...	(1,000)	...
Current U.S. state income tax expense (benefit)	(61,000)	5,000	...
Total current income tax expense (benefit)	(61,000)	4,000	...
Deferred U.S. federal income tax expense (benefit)	(305,000)	(204,000)	...
Total deferred income tax expense (benefit)	(305,000)	(204,000)	...
Income tax expense (benefit)	(366,000)	(200,000)	...
Net income (loss) attributable to common stockholders	(36,487,000)	(7,783,000)	(31,463,000)
Weighted average shares outstanding - basic	13,849,470	6,481,665	3,873,000
Weighted average shares outstanding - diluted	13,849,470	6,481,665	3,873,000
Year end shares outstanding	13,854,205	13,831,178	3,891,493
Net earnings (loss) per share - basic	\$(2.63)	\$(1.20)	\$(8.12)
Net earnings (loss) per share - diluted	\$(2.63)	\$(1.20)	\$(8.12)
Number of full time employees	15
Total number of employees	48	38	...
Number of common stockholders

stockholders 29 27 24
 March 31, 2017 and prior financial are for the Company prior to merger with Nivalis Therapeutics, Inc.; Adjusted for 1-for-4 stock split, July 25, 2017; Shares increased due to conversion of preferred stock & common stock acquired in business combination; Approximately; As of March 6, 2019; As of March 20, 2018; As of January 31, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash & cash equivalents	10,711,000	8,000,000
Short-term investments	41,592,000	73,240,000
Deferred financing costs	477,000	...
Prepaid insurance	300,000	298,000
Prepaid research and development	83,000	791,000
Prepaid other expenses	145,000	91,000
Other receivables	237,000	128,000
Prepaid expenses & other current assets	1,242,000	1,308,000
Total current assets	53,545,000	82,548,000
Restricted cash	132,000	132,000
Laboratory equipment	1,506,000	1,161,000
General equipment & furniture	158,000	110,000
Computer equipment & software	103,000	82,000
Leasehold improvements	128,000	47,000
Property & equipment, at cost	1,895,000	1,400,000
Less accumulated depreciation & amortization	699,000	311,000
Property & equipment, net	1,196,000	1,089,000
Intangible assets	...	1,453,000
Total assets	54,873,000	85,222,000
Accounts payable	1,716,000	193,000
Accrued research & development services	2,457,000	197,000
Accrued employee compensation	1,009,000	4,000
Accrued legal & professional fees	646,000	112,000
Accrued other expenses	165,000	69,000
Accrued liabilities	4,277,000	382,000
Deferred revenue	...	277,000
Deferred rent, current portion	86,000	48,000
Current portion of long-term debt	2,048,000	995,000
Total current liabilities	8,127,000	1,895,000
Deferred rent, long-term portion	...	66,000
Deferred tax liability	...	305,000
Long-term debt	2,155,000	4,039,000
Total liabilities	10,282,000	6,305,000
Common stock	14,000	14,000
Additional paid-in capital	90,664,000	88,346,000
Accumulated other comprehensive income (loss)	(13,000)	(59,000)
Retained earnings (accumulated deficit)	(46,074,000)	(9,384,000)
Total stockholders' equity (loss)	44,591,000	78,917,000

Reclassified to conform with 2018 presentation

Recent Dividends:
1. Alpine Immune Sciences Inc common.
 No dividends paid.
Annual Dividends:
1. Alpine Immune Sciences Inc common.
 No dividends paid.

AMERISAFE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)

Gross premiums	359,670	355,025	379,011
Ceded premiums	(9,344)	(8,869)	(10,307)
Net premiums earned	350,326	346,156	368,704
Fixed maturity securities	28,762	28,961	27,837
Equity securities	448	201	...
Short-term investments & cash & cash equivalents ...	2,208	1,117	348
Other investments	104	1,568
Investment expenses	(966)	(1,102)	(1,647)
Net investment income	30,452	29,281	28,106
Net realized gains (losses) on investments	(1,536)	(647)	(494)
Net unrealized losses on equity securities	(2,088)
Fee & other income	599	418	346
Total revenues	377,753	375,208	396,662
Loss & loss adjustment expenses incurred	204,891	209,324	199,031
Underwriting & certain other operating costs	28,981	28,333	29,470
Commissions expense	26,160	24,812	26,243
Salaries & benefits expense	25,992	25,631	24,881
Policyholder dividends	4,148	4,868	4,216
Total expenses	290,172	292,968	283,841
Income before income taxes	87,581	82,240	112,821
Current federal income tax expense (benefit)	16,407	22,477	35,602
Current state income tax expense ..	1,004	732	1,603
Total current income tax expense (benefit)	17,411	23,209	37,205
Deferred federal income tax expense (benefit)	(1,389)	12,965	(2,120)
Deferred state income tax expense (benefit)	(73)	(165)	(129)
Total deferred income tax expense (benefit)	(1,462)	12,800	(2,249)
Income tax expense (benefit)	15,949	36,009	34,956
Net income (loss)	71,632	46,231	77,865
Weighted average shares outstanding - basic	19,209	19,165	19,106
Weighted average shares outstanding - diluted	19,293	19,246	19,204
Year end shares outstanding	19,270	19,246	19,230
Earnings (loss) per share - basic	\$3.73	\$2.41	\$4.08
Earnings (loss) per share - diluted	\$3.71	\$2.40	\$4.05
Cash dividends declared per common share	\$0.88	\$0.80	\$0.72
Number of full time employees	2426	2436	2437
Number of part time employees	23	22	22
Total number of employees	2449	2458	2459
Number of common stockholders	220	222	226

⁽¹⁾ Reclassified to conform with 2018 presentation; ⁽²⁾ As is; ⁽³⁾ As of February 15, 2019; ⁽⁴⁾ As of February 15, 2018; ⁽⁵⁾ As of February 15, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

2018	2017 (revised)	2016 (revised)
Fixed maturity securities - held-to-maturity, at amortized cost	613,878	629,668
Fixed maturity securities - available-for-sale, at fair value	478,730	465,594
Equity securities - available-for-sale, at fair value	18,651	9,282
Short-term investments	14,231	25,770
Cash & cash equivalents	40,344	55,559
Amounts recoverable from reinsurers	112,006	90,133
Premiums receivable, gross	167,868	179,460
Allowance for doubtful accounts	5,390	5,226
Premiums receivable, net of allowance	162,478	174,234
Deferred income taxes	21,852	19,262
Accrued interest receivable	10,197	10,635
Land & office building	7,798	7,713
Furniture & equipment	6,150	6,578
Software	7,339	6,856
Automobiles	74	74
Property & equipment, gross	21,361	21,221
Accumulated depreciation	15,103	15,093
Property & equipment, net	6,258	6,128
Deferred policy acquisition costs	19,734	20,251
Federal income tax recoverable	1,761
Other assets	17,572	9,959
Total assets	1,515,931	1,518,236
Reserves for loss & loss adjustment expenses	798,409	771,845
Unearned premiums	149,296	157,270
Amounts held for others	41,388	36,908
Policyholder deposits	46,795	48,364
Insurance-related assessments	28,258	28,246
Federal income tax payable	3,412	...
Accounts payable & other liabilities	38,611	37,076
Payable for investments purchased	13,104
Total liabilities	1,106,169	1,092,813
Voting common stock	205	204
Additional paid-in capital	211,431	210,081
Treasury stock at cost	22,370	22,370
Retained earnings (accumulated deficit)	221,328	233,896
Accumulated other comprehensive income (loss)	(832)	3,612
Total shareholders' equity (deficit)	409,762	425,423

⁽¹⁾ Fair value - Fixed maturity securities - held-to-maturity: \$616,772,000; ⁽²⁾ Fair value - Fixed maturity securities - held-to-maturity: \$69,309,000; ⁽³⁾ Cost - Fixed maturity securities - available-for-sale: \$479,772,000; ⁽⁴⁾ Cost - Fixed maturity securities - available-for-sale: \$461,236,000; ⁽⁵⁾ Cost - Equity securities - available-for-sale: \$19,962,000; ⁽⁶⁾ Cost - Equity securities - available-for-sale: \$8,503,000

Recent Dividends:

- Amerisafe Inc series C convertible redeemable preferred.**
No dividends paid.
 - Amerisafe Inc voting common.**
No dividends paid.
 - Amerisafe Inc series D convertible redeemable preferred.**
No dividends paid.
- Annual Dividends:**
1. Amerisafe Inc series C convertible redeemable preferred.
No dividends paid.

2. Amerisafe Inc voting common.
No dividends paid.
3. Amerisafe Inc series D convertible redeemable preferred.
No dividends paid.

**APPROACH RESOURCES INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2018	2017 (revised)	2016 (revised)
Oil, natural gas liquid & gas sales	114,035	105,349	90,302
Lease operating	21,129	17,902	19,250
Production & ad valorem taxes	8,923	8,644	8,217
Exploration	420	3,657	3,923
General & administrative	20,922	24,333	24,734
Depletion, depreciation & amortization	61,432	70,521	79,044
Total expenses	112,826	125,057	135,168
Operating income (loss)	1,209	(19,708)	(44,866)
Interest expense, net	25,117	21,053	27,259
Gain on debt extinguishment	5,053	...
Write-off of debt issuance costs	563
Commodity derivatives gain (loss)	(321)	(262)	(5,484)
Other income (expense)	(29)	32	1,511
Income (loss) before income tax provision (benefit) ...	(24,258)	(35,938)	(76,661)
Current federal income tax provision (benefit) ...	(66)	(66)	...
Current income tax provision (benefit) ...	(66)	(66)	...
Deferred federal income tax provision (benefit) ...	(4,747)	75,341	(24,957)
Deferred state income tax provision (benefit) ...	466	1,146	539
Deferred income tax provision (benefit) ...	(4,281)	76,487	(24,418)
Net income (loss)	(19,911)	(112,359)	(52,243)
Weighted average shares outstanding - basic	94,581	83,404	41,488
Weighted average shares outstanding - diluted	94,581	83,404	41,488
Year end shares outstanding	95,031	94,533	41,765
Net earnings (loss) per share - basic	\$(0.21)	\$(1.35)	\$(1.26)
Net earnings (loss) per share - diluted	\$(0.21)	\$(1.35)	\$(1.26)
Number of full time employees	2,099	2,097	2,100
Number of common stockholders	2179	2,162	2,161

⁽¹⁾ Reclassified to conform with 2017 presentation; ⁽²⁾ Including non-cash share-based compensation expense: general and administrative \$3,047,000; ⁽³⁾ Including non-cash share-based compensation expense: general and administrative \$4,656,000; ⁽⁴⁾ Including non-cash share-based compensation expense: general and administrative \$6,279,000; ⁽⁵⁾ As is; ⁽⁶⁾ As of February 19, 2019; ⁽⁷⁾ As of February 21, 2018; ⁽⁸⁾ As of February 22, 2017; ⁽⁹⁾ As of February 27, 2019; ⁽¹⁰⁾ As of February 20, 2018; ⁽¹¹⁾ As of February 21, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

Cash & cash equivalents	22	21
Accounts receivable -		

joint interest owners	89	117
Accounts receivable - oil, natural gas liquid (NGL) & gas sales	6,710	9,678
Derivative assets	5,946	1,398
Prepaid expenses & other current assets	3,458	5,486
Total current assets	16,225	16,700
Oil & gas properties, at cost, using the successful efforts method of accounting	1,976,699	1,930,577
Furniture, fixtures & equipment	5,689	5,658
Total properties & equipment	1,982,388	1,936,235
Less accumulated depletion, depreciation & amortization	913,966	853,359
Net properties & equipment	1,068,422	1,082,876
Total assets	1,084,647	1,099,576
Accounts payable	9,768	9,450
Oil, NGL & gas sales payable	4,968	5,363
Derivative liabilities	...	2,181
Total current liabilities	21,077	25,067
Senior secured credit facility, net	300,507	289,275
Senior notes, net	84,486	84,185
Deferred income taxes	77,821	82,102
Asset retirement obligations	11,424	11,065
Other non-current liabilities	87	466
Total liabilities	495,402	492,160
Common stock	950	945
Additional paid-in capital	744,126	742,391
Retained earnings (accumulated deficit)	(155,831)	(135,920)
Total stockholders' equity	589,245	607,416

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Approach Resources Inc common.
No dividends paid.

Annual Dividends:

1. Approach Resources Inc common.
No dividends paid.

APPROACH RESOURCES INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of Independent Auditors, Moss Adams LLP, as it appeared in Co.'s 2018 10-K report: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Approach Resources Inc. and subsidiaries (the "Company") as of December 31, 2018 and 2017, the related consolidated statement of operations, changes in stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2018 and 2017, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control U Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 18, 2019 expressed an unqualified opinion on the Company's internal control over financial reporting. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has determined that, based on its current operating forecast, it will not comply with its debt covenants contained in its revolving credit facility in 2019 which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are

also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

APTEVO THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):		
	2018	2017 (revised)
Product sales	23,067	10,949
Collaborations	...	3,709
Total revenues	23,067	14,658
Cost of product sales	11,214	5,010
Research & development	35,385	29,021
Selling, general & administrative	28,133	34,576
Impairment of goodwill & intangible assets	...	71,013
Income (loss) from operations	(51,665)	(53,949)
Other income (expense), net	(2,024)	(1,944)
Total other income (expense), net	...	(810)
Income (loss) before income taxes	(53,689)	(55,893)
Current federal income taxes	...	(12,051)
Current state income taxes	...	(710)
Current international income taxes	...	(2)
Total current income taxes	...	(12,763)
Deferred federal income taxes	...	(9,636)
Deferred state income taxes	...	(902)
Total deferred income taxes	...	(10,538)
Provision for (benefit from) income taxes	...	(23,301)
Net income (loss) from continuing operations	(53,689)	(32,592)
Income (loss) from discontinued operations, before income taxes	...	62,864
Income tax expense from discontinued operations	...	(23,299)
Income (loss) from discontinued operations	...	39,565
Net income (loss)	(53,689)	6,973
Weighted average shares outstanding - basic	22,500	21,335
Weighted average shares outstanding - diluted	22,500	21,335
Year end shares outstanding	22,808	21,606
Income (loss) per share from continuing operations - basic	\$(2.39)	\$(1.53)
Income (loss) per share from discontinued operations - basic	...	\$1.86
Net income (loss) per share - basic	\$(2.39)	\$0.33
Income (loss) per share from continuing operations - diluted	\$(2.39)	\$(1.53)

Income (loss) per share from discontinued operations - diluted	...	\$1.86	\$0.37
Net income (loss) per share - diluted	\$(2.39)	\$0.33	\$(5.55)
Number of full time employees	118	121	118
Number of common stockholders	254	19	17

□ Reclassified to conform with 2018 presentation; □ Restated to reflect the Hyperimmune Business as discontinued operations; □ As is; □ As of March 14, 2019; □ As of March 9, 2018; □ As of March 24, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	30,635	7,095
Short-term investments	...	73,688
Accounts receivable	5,220	2,141
Raw materials & supplies	194	56
Work-in-process	916	482
Finished goods	675	490
Inventories	1,785	1,028
Restricted cash	...	400
Prepaid expenses	6,907	4,022
Other current assets	4,142	6,710
Total current assets	48,689	95,084
Restricted cash, net of current portion	7,448	10,000
Leasehold improvements	2,278	2,228
Furniture & equipment	11,622	11,139
Property & equipment, gross	13,900	13,367
Less: accumulated depreciation	8,698	7,524
Property & equipment, net	5,202	5,843
Intangible assets, net	5,250	6,080
Other assets	905	...
Total assets	67,494	117,007
Accounts payable & other accrued liabilities	11,671	7,350
Accrued compensation	3,898	4,626
Current portion of long-term debt	...	3,333
Other current liabilities	796	2,578
Sales rebates & discounts payable	1,245	623
Total current liabilities	17,610	18,510
Long-term debt, net	19,278	15,728
Other liabilities	200	734
Total liabilities	37,088	34,972
Common stock	23	22
Additional paid-in capital	157,791	155,837
Accumulated other comprehensive income (loss)	...	(105)
Retained earnings (accumulated deficit)	(127,408)	(73,719)
Total stockholders' equity	30,406	82,035

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Aptevo Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Aptevo Therapeutics Inc common.
No dividends paid.

ARVINAS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):			
	2018	2017 (revised)	2016
Revenue	14,323,920	7,578,876	6,669,024
Research & development expense	45,193,830	28,792,902	19,942,194
General &			

administrative				
expense	12,932,168	3,546,241	3,196,250	
Total operating				
expenses	58,125,998	32,339,143	23,138,444	
Income (loss) from				
operations	(43,802,078)	(24,760,267)	(16,469,420)	
Other income, net	102,730	554,159	1,656,184	
Change in fair				
value of preferred				
unit warrant	(193,779)	5,871	14,816	
Interest income	2,470,101	201,388	427,773	
Interest expense	57,440	50,357	67,404	
Total other income	2,321,612	711,061	2,031,369	
Income (loss)				
before income taxes	(24,049,206)	(14,438,051)		
Income (benefit)				
from income taxes			(87,408)	
Net income (loss)	(41,480,466)	(24,049,206)	(14,350,643)	
Change in				
redemption value of				
redeemable				
preferred units	198,366,756	4,570,431	(1,997,020)	
Net income (loss)				
attributable to				
common shares &				
units	(239,847,222)	(28,619,637)	(12,353,623)	
Weighted average				
shares & units				
outstanding - basic	9,422,799	[□] 1,897,544	1,897,544	
Weighted average				
shares & units				
outstanding -				
diluted	9,422,799	[□] 1,897,544	1,897,544	
Year end shares &				
units outstanding	[□] 31,235,458	[□] 1,897,544	1,897,544	
Net income (loss)				
per share & units				
- basic	\$(25.45)	[□] \$(15.08)	\$(6.51)	
Net income (loss)				
per share & units				
- diluted	\$(25.45)	[□] \$(15.08)	\$(6.51)	
Number of full time				
employees	83	[□] 72	...	
Number of common				
stockholders	[□] 120	

[□] Adjusted for 1- for -3.25 stock split, September 14, 2018; [▣] Shares increased due to issuance of shares, conversion of common and incentive units and redeemable convertible preferred shares to common stock and restricted stock vesting; [▤] As of August 31, 2018; [▥] Approximately; [▦] As of March 21, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017	
		(revised)	
Cash & cash equivalents	3,190,056	30,912,391	
Marketable securities	184,637,640	8,258,982	
Account receivable	2,775,831	25,000,000	
Other receivables	2,255,966	1,040,452	
Prepaid expenses & other			
current assets	2,818,286	316,903	
Total current assets	195,677,779	65,528,728	
Laboratory equipment	3,757,265	1,952,685	
Office equipment	577,418	305,522	
Leasehold improvements	981,884	72,294	
Property, equipment &			
leasehold improvements,			
gross	5,316,567	2,330,501	
Less: accumulated			
depreciation	1,733,531	1,031,620	
Property, equipment &			
leasehold improvements,			
net	3,583,036	1,298,881	
Other assets - deposits	20,760	20,760	
Total assets	199,281,575	66,848,369	
Accounts payable	2,758,184	596,527	
Accrued employee expenses	2,795,205	1,047,022	
Accrued research &			
development expenses	357,148	1,982,525	
Accrued professional fees			
& other accrued expenses	848,923	516,389	
Accrued expenses	4,001,276	3,545,936	
Deferred revenue	16,065,957	13,553,136	

Current portion of			
long-term debt	154,461	159,265	
Total current liabilities	22,979,878	17,854,864	
Deferred revenue	37,484,714	48,545,625	
Long term debt, net of			
current portion	2,000,000	151,122	
Other non-current			
liability	150,000	...	
Preferred unit warrant			
liability	...	50,888	
Total liabilities	62,614,592	66,602,499	
Series A redeemable			
convertible preferred			
units	...	19,768,025	
Series B redeemable			
convertible preferred			
units	...	41,712,407	
Common units	...	6,167	
Incentive units	...	1,186,419	
Common stock	31,236	...	
Retained earnings			
(accumulated deficit)	(302,264,619)	(62,417,397)	
Additional paid-in			
capital	439,118,089	...	
Accumulated other			
comprehensive income			
(loss)	(217,723)	(9,751)	
Total stockholders' &			
members' equity (deficit)	136,666,983	(61,234,562)	

Recent Dividends:

1. Arvinas Inc common.
No dividends paid.

Annual Dividends:

1. Arvinas Inc common.
No dividends paid.

AUTODESK INC
Annual Report

Consolidated Income Statement, Years Ended Jan. 31

(\$000):

	2019	[□] 2018	[□] 2017
		(revised)	(revised)
Subscription			
revenue	1,802,300	894,300	443,100
Maintenance revenue	635,100	989,600	1,103,100
Total subscription			
& maintenance			
revenue	2,437,400	1,883,900	1,546,200
Other revenue	132,400	172,700	484,800
Total net revenue	2,569,800	2,056,600	2,031,000
Cost of			
subscription &			
maintenance revenue	216,000	214,400	191,700
Cost of other			
revenue	54,400	72,600	110,200
Amortization of			
developed			
technology	15,500	16,400	40,000
Total cost of			
revenue	285,900	303,400	341,900
Gross profit	2,283,900	1,753,200	1,689,100
Marketing & sales			
expenses	1,183,900	1,087,300	1,022,500
Research &			
development			
expenses	725,000	755,500	766,100
General &			
administrative			
expenses	340,100	305,200	287,800
Amortization of			
purchased			
intangibles	18,000	20,200	31,800
Restructuring &			
other exit costs,			
net	41,900	94,100	80,500
Total operating			
expenses	2,308,900	2,262,300	2,188,700
Income (loss) from			
operations	(25,000)	(509,100)	(499,600)
Interest &			
investment income			
(expense), net	(52,100)	(34,500)	(29,700)
Gain (loss) on			

foreign currency	5,100	(3,300)	(3,300)	
Gain (loss) on				
strategic				
investments	12,500	(16,400)	300	
Other income	16,800	6,000	8,500	
Income (loss)				
before income taxes	(42,700)	(557,300)	(523,800)	
Current provision				
(benefit) for				
income taxes -				
federal	(13,300)	(800)	1,600	
Deferred provision				
(benefit) for				
income taxes -				
federal	(6,700)	(19,300)	8,400	
Current provision				
(benefit) for				
income taxes -				
state	(1,800)	(300)	(1,900)	
Deferred provision				
(benefit) for				
income taxes -				
state	100	2,200	1,300	
Current provision				
(benefit) for				
income taxes -				
foreign	65,300	50,900	93,900	
Deferred provision				
(benefit) for				
income taxes -				
foreign	(5,500)	(23,100)	(45,000)	
Provision (benefit)				
for income taxes	38,100	9,600	58,300	
Net income (loss)	(80,800)	(566,900)	(582,100)	
Weighted average				
shares outstanding				
- basic	218,900	219,500	222,700	
Weighted average				
shares outstanding				
- diluted	218,900	219,500	222,700	
Year end shares				
outstanding	219,400	218,300	220,300	
Net income (loss)				
per share - basic	\$(0.37)	\$(2.58)	\$(2.61)	
Net income (loss)				
per share - diluted	\$(0.37)	\$(2.58)	\$(2.61)	
Number of employees	[□] 9,600	[□] 8,800	[□] 9,000	
Number of common				
stockholders	[□] 376	[□] 388	[□] 430	
Foreign currency				
translation				
adjustments	...	81,600	(52,100)	

[□] Reclassified to conform with 2019 presentation; [▣] As is; [▤] Approximately

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2019	2018	
		(revised)	
Cash & cash equivalents	886,000	1,078,000	
Marketable securities	67,600	245,200	
Trade accounts receivable	526,600	469,200	
Less: allowance for			
doubtful accounts	2,200	2,300	
Less: product returns			
reserve	300	200	
Less: partner programs &			
other obligations	49,800	28,500	
Accounts receivable, net	474,300	438,200	
Prepaid expenses & other			
current assets	192,100	116,500	
Total current assets	1,620,000	1,877,900	
Marketable securities	...	190,800	
Computer hardware, at			
cost	190,200	217,100	
Computer software, at			
cost	66,700	72,600	
Leasehold improvements,			
land & buildings, at			
cost	247,800	228,900	
Furniture & equipment,			
at cost	67,200	63,400	
Computer software,			
hardware, leasehold			
improvements, furniture,			

& equipment, at cost	571,900	582,000
Less: accumulated depreciation	422,200	437,000
Computer equipment, software, furniture & leasehold improvements, net	149,700	145,000
Developed technologies, net	105,600	27,100
Goodwill	2,450,800	1,620,200
Deferred income taxes, net	65,300	81,700
Other assets	337,800	170,900
Total assets	4,729,200	4,113,600
Accounts payable	101,600	94,700
Accrued compensation	280,800	250,900
Accrued income taxes	13,200	28,000
Deferred revenue	1,763,300	1,551,600
Other accrued liabilities	142,300	198,000
Total current liabilities	2,301,200	2,123,200
Long-term deferred revenue	328,100	403,500
Long term income taxes payable	21,500	41,600
Long term deferred income taxes	79,800	66,600
Long-term notes payable, net	2,087,700	1,586,000
Long-term other liabilities	121,800	148,700
Common stock & additional paid-in capital	2,071,500	1,952,700
Net unrealized gains (losses) on derivative instruments	15,000	(16,600)
Net unrealized gains (losses) on available for sale securities	3,300	1,300
Defined benefit pension components	(16,300)	(29,300)
Foreign currency translation adjustments	(137,000)	(79,200)
Accumulated other comprehensive income (loss)	(135,000)	(123,800)
Retained earnings (accumulated deficit)	(2,147,400)	(2,084,900)
Total stockholders' equity (deficit)	(210,900)	(256,000)

Recent Dividends:

1. Autodesk Inc common.

No dividends paid.

Annual Dividends:

1. Autodesk Inc common.

No dividends paid.

AUTODESK INC

Official Changes On Mar. 22, 2019, Co. appointed of Blake Irving to its Board of Directors.

AVROBIO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Research & development	35,095	15,191	2,663
General & administrative expenses	11,148	3,195	1,962
Total operating expenses	46,243	18,386	4,625
Income (loss) from operations	(46,243)	(18,386)	(4,625)
Interest income	1,726	57	6
Change in fair value of preferred stock warrant liability	162	17	...
Change in fair value of derivative liability	1,629	283	39

Other expense	53	19	6
Total other income (expense), net	(118)	(262)	(39)
Net income (loss)	(46,361)	(18,648)	(4,664)
Accretion of issuance costs on redeemable convertible preferred stock	2,243	85	305
Net income (loss) attributable to common stockholders	(48,604)	(18,733)	(4,969)
Weighted average common shares outstanding - basic	13,435	2,236	2,038
Weighted average common shares outstanding - diluted	13,435	2,236	2,038
Year end shares outstanding	23,807	2,305	2,172
Net earnings (loss) per common share - basic	\$(3.62)	\$(8.38)	\$(2.44)
Net earnings (loss) per common share - diluted	\$(3.62)	\$(8.38)	\$(2.44)
Number of full time employees	49	34	...
Number of common stockholders	16

☐ Shares increased due to the effect of issuance of common stock, conversion of preferred stock, vesting of restricted stock awards, exercise of warrants and stock option; ☒ As is; ☓ As of June 1, 2018; ☔ As of March 20, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Cash & cash equivalents	126,302	5,963	...
Tax incentive refund	1,325
Prepaid research & development costs	981	163	...
Prepaid insurance	316
Interest income receivable	220
Prepaid rent	81	122	...
Other current assets	795	60	...
Prepaid expenses & other current assets	3,718	345	...
Total current assets	130,020	6,308	...
Laboratory & office equipment	1,624	126	...
Leasehold improvements	1,260	240	...
Computer equipment & software	134	28	...
Property, plant & equipment, gross	3,018	394	...
Less: accumulated depreciation & amortization	384	45	...
Property & equipment, net	2,634	349	...
Other assets	825	365	...
Total assets	133,479	7,022	...
Accounts payable	2,784	527	...
Accrued compensation & benefits costs	2,616	794	...
Accrued research & development costs	3,969	831	...
Consulting & professional fees	320	267	...
Preferred stock issuance cost	...	85	...
Other liabilities	917	121	...
Accrued expenses & other current liabilities	7,822	2,098	...
Total current liabilities	10,606	2,625	...
Warrant to purchase redeemable convertible preferred stock	...	35	...
Derivative liability	...	371	...
Deferred rent, net of

current portion	689	126
Other long-term liability	...	500
Total liabilities	11,295	3,657
Redeemable convertible preferred stock	...	26,500
Common stock	2	...
Additional paid-in capital	193,921	339
Retained earnings (accumulated deficit)	(71,739)	(23,474)
Total stockholders' equity (deficit)	122,184	(23,135)

☐ Reclassified to conform with 2018 presentation

Recent Dividends:

1. AVROBIO Inc common.

No dividends paid.

Annual Dividends:

1. AVROBIO Inc common.

No dividends paid.

AXSOME THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Research & development expenses	23,495,055	19,957,616	21,199,860
General & administrative expenses	9,351,522	7,206,691	6,343,648
Total operating expenses	32,846,577	27,164,307	27,543,508
Income (loss) from operations	(32,846,577)	(27,164,307)	(27,543,508)
Interest & amortization of debt discount/premium (expense) income	(1,127,305)	(1,340,199)	(132,424)
Tax credit	(217,418)	(207,114)	(474,279)
Change in fair value of warrant liability	2,791,000	(646,000)	...
Net income (loss)	(30,965,464)	(28,943,392)	(27,201,653)
Weighted average shares outstanding - basic	26,883,656	22,764,606	19,150,690
Weighted average shares outstanding - diluted	26,883,656	22,764,606	19,150,690
Year end shares outstanding	30,087,213	25,492,992	19,158,417
Net income (loss) per share - basic	\$(1.15)	\$(1.27)	\$(1.42)
Net income (loss) per share - diluted	\$(1.15)	\$(1.27)	\$(1.42)
Total number of employees	29	25	22
Number of common stockholders	26	30	33

☐ As of March 11, 2019; ☒ As of March 2, 2018; ☓ As of March 2, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash	13,968,742	34,021,123
Prepaid expenses & other current assets	1,246,360	1,278,418
Total current assets	15,215,102	35,299,541
Equipment, net	51,832	68,071
Other assets	112,345	187,952
Total assets	15,379,279	35,555,564
Accounts payable	3,687,245	3,435,456
Research & development	2,266,285	1,642,154
Accrued compensation	1,051,401	704,556
Other accrued expenses	525,613	332,824
Accrued expenses & other current liabilities	3,843,299	2,679,534
Loan payable, current portion	3,291,394	3,269,346

Warrant liability	2,791,000	
Total current liabilities	10,821,938	12,175,336
Loan payable, long-term	3,619,420	6,663,005
Total liabilities	14,441,358	18,838,341
Common stock	3,009	2,549
Additional paid-in capital	108,485,219	93,299,517
Retained earnings (accumulated deficit)	(107,550,307)	(76,584,843)
Total stockholders' equity (deficit)	937,921	16,717,223

Recent Dividends:**1. Axsome Therapeutics Inc common.**

No dividends paid.

Annual Dividends:**1. Axsome Therapeutics Inc common.**

No dividends paid.

BLUE HILLS BANCORP INC

Merger Completed On Apr. 1, 2019, Co. merged with and into Independent Bank Corp. ("Independent"), with Independent continuing as the surviving corporation (the "Merger"), immediately following the merger, Co.'s wholly-owned bank subsidiary, Blue Hills Bank, merged with and into Independent's wholly-owned bank subsidiary, Rockland Trust, with Rockland Trust continuing as the surviving bank. As the result of the merger, each share of Co. common stock was converted into the right to receive \$5.25 in cash and 0.2308 of a share of Independent's common stock, with cash to be paid in lieu of fractional shares. Each outstanding share of Independent common stock remained outstanding and was unaffected by the Merger. As a result of Merger, Co. shareholders received an aggregate of approximately 6,166,383 shares of Independent common stock and an aggregate of approximately \$167,400,000 in cash, inclusive of the payment made to cash out outstanding stock options and excluding cash paid in lieu of fractional shares. As of Apr. 1, 2019, Independent had, including the shares issued in connection with the acquisition, approximately 34,303,887 shares of common stock outstanding.

BLUEPRINT MEDICINES CORP

Offering On Mar. 28, 2019, Co. announced the pricing of an underwritten public offering of 4,054,054 shares of its common stock at a public offering price of \$74.00 per share, before underwriting discounts and commissions. In addition, Co. has granted the underwriters a 30-day option to purchase up to an additional 608,108 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock were offered by Co. Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC and Wedbush Securities Inc. are acting as co-lead managers for the offering. The offering is expected to close on or about Apr. 2, 2019, subject to the satisfaction of customary closing conditions.

BLUEPRINT MEDICINES CORP

Proposed Public Offering On Mar. 27, 2019, Co. announced that it has commenced an underwritten public offering of \$300,000,000 in shares of its common stock. In addition, Co. anticipates to grant the underwriters a 30-day option to purchase up to an additional \$45,000,000 in shares of its common stock in connection with the public offering. All shares of common stock will be offered by Co. Co. anticipates to use the net proceeds of the offering to further build its commercial infrastructure and operations in support of one or more anticipated commercial launches of its drug candidates, including potential commercial launches of avapritinib in the United States and Europe, subject to regulatory approval; to fund clinical trials for avapritinib in gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM), including its planned registration-enabling Phase 3 COMPASS-2L clinical trial for second-line GIST and its ongoing registration-enabling Phase 2 PIONEER clinical trial for indolent and smoldering SM, as well as future indication expansion clinical trials; to fund clinical trials for BLU-667 in RET-driven cancers, including its planned Phase 3 clinical trial for BLU-667 in first-line RET-altered non-small cell lung cancer (NSCLC) and its planned Phase 2 clinical trial for BLU-667 in combination with osimertinib in treatment-resistant, EGFR-mutant NSCLC harboring an acquired RET alteration; to fund a planned Phase 2a clinical trial for BLU-782 in patients with fibrodysplasia ossificans progressiva; to fund manufacturing costs for ongoing and anticipated drug development efforts for its most advanced drug candidates, including a potential commercial launch of avapritinib; and the balance, if any, to fund additional discovery research efforts, its other ongoing and planned clinical trials, working capital requirements and other general corporate purposes. Goldman Sachs

& Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Guggenheim Securities, LLC and Wedbush Securities Inc. are acting as co-lead managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

BRIGHTCOVE INC

Acquisition Completed On Apr. 1, 2019, Co. and its wholly-owned subsidiaries, Othello Acquisition Corp. ("U.S. Sub") and Brightcove, S. de R.L. de C.V. ("Mexico Sub"), acquired from Ooyala, Inc. ("Ooyala"), Ooyala Global, Inc. ("Seller Parent") and Ooyala Mexico S. de R.L. de C.V., (the "Seller Subsidiary", and together with Ooyala and Seller Parent, the "Sellers"), the Sellers' online video platform (OVP) assets in exchange for Co. issued 1,056,763 unregistered shares of common stock of Co. and paid approximately \$5,910,000 in cash, which included approximately \$155,000 as a reimbursement of Seller's audit fees incurred in connection with the Acquisition. Pursuant to the Purchase Agreement, approximately \$2,650,000 of the cash consideration was placed into an escrow account to secure payment of any claims of indemnification for breaches or inaccuracies in the Sellers' representations and warranties, covenants and agreements.

CADIZ INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2018	¹ 2017 (revised)	² 2016 (revised)
Total revenues (rental income)	440	437	412
General & administrative	11,402	12,803	9,330
Depreciation	258	274	292
Operating profit (loss)	(11,220)	(12,640)	(9,210)
Interest on outstanding debt	12,594	11,279	9,664
Unrealized losses on warrants	(1,522)	2,608	...
Amortization of debt discount	4,095	3,690	4,973
Amortization of deferred loan costs	103	193	238
Interest expense	15,270	17,770	...
Interest income	223	51	...
Interest income (expense), net	(14,875)
Gain (loss) on extinguishment of debt & debt refinancing	...	(3,501)	(2,250)
Income (loss) before income taxes	(26,267)	(33,860)	(26,335)
Income tax expense (benefit)	6	4	4
Net income (loss)	(26,273)	(33,864)	(26,339)
Weighted average shares outstanding - basic	23,998	22,535	18,719
Weighted average shares outstanding - diluted	23,998	22,535	18,719
Year end shares outstanding	24,565	22,987	³ 21,769
Net income (loss) per share - basic	\$(1.09)	\$(1.50)	\$(1.41)
Net income (loss) per share - diluted	\$(1.09)	\$(1.50)	\$(1.41)
Number of full time employees	⁴ 9	⁵ 10	⁶ 9
Number of common stockholders	⁷ 71	⁸ 72	⁹ 91

¹ Reclassified to conform with 2018 presentation; ² Reclassified to conform with 2017 presentation; ³ Shares increased due to the effect of issuance of shares pursuant to stock awards, lenders shelf takedown and bond conversion; ⁴ As is; ⁵ As of March 7, 2019; ⁶ As of March 8, 2018; ⁷ As of March 10, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Cash & cash equivalents	12,558	13,030	...

Accounts receivable	38	36	...
Prepaid expenses & other current assets	408	411	...
Total current assets	13,004	13,477	...
Land & land improvements	25,064	24,781	...
Water programs	23,812	22,595	...
Buildings	1,572	1,572	...
Leasehold improvements	570	570	...
Furniture & fixtures	461	461	...
Machinery & equipment	1,422	1,337	...
Construction in progress	146	123	...
Less: accumulated depreciation	6,428	6,170	...
Property, plant, equipment & water programs, net	46,619	45,269	...
Long-term deposit/prepaid expenses	2,000
Goodwill	3,813	3,813	...
Prepaid rent	3,740	3,554	...
Security deposits	133	392	...
Total assets	69,309	66,505	...
Accounts payable	225	411	...
Accrued payroll, bonus, & benefits	1,163	1,204	...
Accrued legal & consulting	405	550	...
Accrued stock-based compensation	71	71	...
Other accrued expenses	431	456	...
Accrued liabilities - Current portion of long term debt	59	1,408	...
Warrant liabilities	865	2,387	...
Other liabilities	923
Total current liabilities	4,142	6,487	...
Long-term debt	136,246	123,768	...
Long-term lease obligations with related party, net	14,411	13,276	...
Deferred revenue	750	750	...
Other long-term liabilities	...	923	...
Total liabilities	155,549	145,204	...
Common stock	247	230	...
Additional paid-in capital	383,521	364,806	...
Retained earnings (accumulated deficit)	(470,008)	(443,735)	...
Total stockholders' equity (deficit)	(86,240)	(78,699)	...

Recent Dividends:**1. CADIZ Inc common.**

No dividends paid.

2. CADIZ Inc series F convertible preferred.

No dividends paid.

Annual Dividends:**1. CADIZ Inc common.**

No dividends paid.

2. CADIZ Inc series F convertible preferred.

No dividends paid.

CAPITAL PROPERTIES, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2018	¹ 2017 (revised)	2016 (revised)
Revenue, leasing	5,238,000	5,211,000	...
Revenues	5,118,000
Other income, interest	94,000	36,000	...
Total revenues & other income	5,332,000	5,247,000	...
Operating expenses - General & administrative	941,000	1,320,000	841,000
Impairment loss	1,651,000	2,245,000	1,483,000
Interest on dividend notes	1,832,000
Total expenses	...	112,000	578,000
Income (loss) from continuing operations before	4,424,000	3,677,000	2,902,000

income taxes	908,000	1,570,000	2,216,000
Current federal income tax expense (benefit)	499,000	542,000	770,000
Current state income tax expense (benefit)	158,000	131,000	193,000
Current income tax expense (benefit)	657,000	673,000	963,000
Deferred federal income tax expense (benefit)	(367,000)	(302,000)	(74,000)
Deferred state income tax expense (benefit)	(98,000)	27,000	(22,000)
Deferred income tax expense (benefit)	(465,000)	(275,000)	(96,000)
Income tax expense (benefit)	192,000	398,000	867,000
Income from continuing operations	716,000	1,172,000	1,349,000
Income from discontinued operations before income taxes	783,000
Discontinued operations - income tax expense	(307,000)
Income (loss) from discontinued operations, net of taxes	(119,000)	(251,000)	476,000
Gain on sale of discontinued operations, net of taxes	664,000	5,080,000	...
Income from discontinued operations	545,000	4,829,000	...
Net income (loss)	1,261,000	6,001,000	1,825,000
Weighted average shares outstanding - basic	6,599,912	6,599,912	6,599,912
Year end shares outstanding	6,599,912	6,599,912	6,599,912
Income (loss) per share from continuing operations - basic	\$0.11	\$0.18	\$0.20
Income (loss) per share from discontinued operations - basic	\$(0.02)	\$(0.04)	\$0.08
Income (loss) per share from sale of discontinued operations - basic	\$0.10	\$0.77	...
Net income (loss) per share - basic	\$0.19	\$0.91	\$0.28
Total number of employees	3	4	11
Number of class A common stockholders	377	395	415

Less: accumulated depreciation - properties on lease or held for lease	79,000	1,593,000	
Less: accumulated depreciation - office equipment	86,000	81,000	
Less: accumulated depreciation - Properties & equipment (net of accumulated depreciation)	6,951,000	8,953,000	
Cash & cash equivalents	1,147,000	5,202,000	
Funds on deposit with agent	...	462,000	
Prepaid & other assets	297,000	434,000	
Deferred income taxes associated with discontinued operations	132,000	108,000	
Total assets	8,527,000	15,159,000	
Dividends payable	...	462,000	
Property taxes	224,000	224,000	
Deposits & prepaid rent	110,000	88,000	
Accrued payroll & related costs	121,000	333,000	
Accrued professional fees	157,000	45,000	
Other liabilities	14,000	105,000	
Other liabilities	402,000	571,000	
Deferred income taxes, net	338,000	803,000	
Liabilities associated with discontinued operations	490,000	489,000	
Total liabilities	1,454,000	2,549,000	
Class A common stock	66,000	66,000	
Capital in excess of par	782,000	782,000	
Retained earnings (accumulated deficit)	6,225,000	11,762,000	
Total shareholders' equity (deficit)	7,073,000	12,610,000	

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Capital Properties, Inc. class B common.						
No dividends paid.						
2. Capital Properties, Inc. class A common.						
ExDate	Amt	Declared	Record	Payable		
12/14/2017	0.07	10/25/2017	12/15/2017	01/03/2018		
02/28/2018	0.07	01/30/2018	03/01/2018	03/15/2018		
05/09/2018	0.07	04/24/2018	05/10/2018	05/25/2018		
08/16/2018	0.07	07/31/2018	08/17/2018	08/31/2018		
11/08/2018	0.07	10/30/2018	11/09/2018	11/23/2018		
12/20/2018	0.75	12/06/2018	12/21/2018	12/28/2018		
02/08/2019	0.07	01/29/2019	02/11/2019	02/22/2019		

Annual Dividends:

1. Capital Properties, Inc. class B common.						
No dividends paid.						
2. Capital Properties, Inc. class A common.						
2018	2019					
1.10	0.07					

CARBONITE INC

Merger Completed On Mar. 26, 2019, Co.'s wholly-owned subsidiary, Matterhorn Acquisitions, Inc. ("Merger Sub"), merged with and into Webroot Inc. ("Webroot"), a private American company that provides Internet security for consumers and businesses, with Webroot continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, each issued and outstanding share of Series A Preferred Stock, par value \$0.001 per share (the "Series A Shares"), and each issued and outstanding share of common stock, par value \$0.001 per share (together with the Series A Shares, the "Shares") of Webroot (other than the Shares (i) held in treasury by Webroot or owned by any direct or indirect subsidiary of Webroot or (ii) held by stockholders who did not vote in favor of the Merger, consented thereto in writing or otherwise contractually waived or agreed to refrain from exercising their rights to appraisal and who have demanded properly in writing appraisal for such shares in accordance with Section 262 of the General Corporation Law of the State of Delaware) was converted into the right to receive a portion of the aggregate cash consideration payable in respect of the Merger, consisting of \$618,500,000, to be adjusted with respect

to cash, debt, unpaid transaction fees and expenses and working capital.

CARGURUS INC

Official Changes On Mar. 26, 2019, Co. announced the appointment of Spencer Scott as its Senior Vice President of Advertising and Digital Marketing Solutions.

CAS MEDICAL SYSTEMS INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)

Net sales from continuing operations	21,919,987	18,763,136	18,674,146
Cost of sales	9,213,763	8,505,010	8,175,487
Gross profit	12,706,224	10,258,126	10,498,659
Research & development expenses	3,181,915	3,234,101	3,272,718
Selling, general & administrative expenses	14,015,583	13,418,332	13,569,939
Total operating expenses	17,197,498	16,652,433	16,842,657
Operating income (loss)	(4,491,274)	(6,394,307)	(6,343,998)
Interest expense, net	1,469,897	1,076,400	1,048,207
Other income	42,522
Income (loss) from continuing operations before income taxes	(5,961,171)	(7,470,707)	(7,349,683)
Income tax expense (benefit)	...	(1,745,441)	(1,424,067)
Income (loss) from continuing operations	(5,961,171)	(5,725,266)	(5,925,616)
Income (loss) from discontinued operations	...	745,396	1,277,415
Gain (loss) on sale of discontinued operations	...	4,388,254	2,911,016
Income tax expense	...	(1,745,441)	(1,424,067)
Income from discontinued operations	...	3,388,209	2,764,364
Net income (loss)	(5,961,171)	(2,337,057)	(3,161,252)
Preferred stock dividend accretion	1,703,327	1,589,134	1,482,595
Net loss applicable to common stockholders	(7,664,498)	(3,926,191)	(4,643,847)
Weighted average shares outstanding - basic	27,769,706	27,260,688	26,826,792
Weighted average shares outstanding - diluted	27,769,706	27,260,688	26,826,792
Year end shares outstanding	29,255,211	28,535,697	27,342,752
Earnings (loss) per share from continuing operations - basic	\$(0.28)	\$(0.27)	\$(0.28)
Earnings (loss) per share from discontinued operations - basic	...	\$0.13	\$0.11
Net earnings (loss) per share - basic	\$(0.28)	\$(0.14)	\$(0.17)
Earnings (loss) per share from continuing operations - diluted	\$(0.28)	\$(0.27)	\$(0.28)
Earnings (loss) per share from discontinued operations - diluted	...	\$0.13	\$0.11
Net earnings (loss) per share - diluted	\$(0.28)	\$(0.14)	\$(0.17)
Total number of			

Reclassified to conform with 2018 presentation; Net of taxes - discontinued operations: \$3,560,000; As of March 1, 2019; As of March 1, 2018; As of March 1, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017	
		(revised)	
Properties on lease or held for lease - land & land improvements	4,010,000	4,701,000	
Properties on lease or held for lease - building & improvements, Steeple Street	...	5,831,000	
Total properties on lease or held for lease	4,010,000	10,532,000	
Office equipment	95,000	95,000	
Steeple Street property under contract	3,011,000	...	

employees.....	73	76	...
Number of beneficiary stockholders.....	2,402	1,887	...

□ Reclassified to conform with 2018 presentation; □ Restated to reflect the discontinued operations of non-invasive blood pressure technology product; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash & cash equivalents	3,271,999	5,652,996
Accounts receivable, gross	3,307,821	3,043,950
Less: allowance for doubtful accounts	125,000	125,000
Accounts receivable, net	3,182,821	2,918,950
Raw materials	657,019	559,737
Work in process	2,086	1,633
Finished goods	352,489	514,891
Inventories	1,011,594	1,076,261
Other current assets	620,419	353,079
Total current assets	8,086,833	10,001,286
Leasehold improvements	147,373	151,377
Equipment at customers	3,938,022	3,506,386
Machinery & equipment	4,422,720	4,593,473
Property & equipment, gross	8,508,115	8,251,236
Accumulated depreciation and amortization	6,566,877	6,080,350
Property & equipment, net	1,941,238	2,170,886
Patents & other assets	782,566	738,805
Patents pending	301,564	297,746
Accumulated amortization	262,589	234,160
Intangible & other assets, net	821,541	802,391
Total assets	10,849,612	12,974,563
Accounts payable	1,133,874	691,596
Accrued payroll	435,372	394,527
Accrued employee compensation	735,763	275,236
Accrued professional fees	398,821	316,057
Accrued warranty	50,000	65,000
Accrued sales & use tax	208,765	215,086
Other accrued expenses	370,331	385,967
Accrued expenses	2,199,052	1,651,873
Note payable	90,959	86,079
Current portion of long-term debt, less unamortized debt issuance costs	49,463	2,733,831
Liabilities associated with discontinued operations	...	35,000
Total current liabilities	3,473,348	5,198,379
Balance of bank term loan	9,289,073	7,677,026
Less current portion	49,463	2,733,831
Other long-term liabilities	400,000	320,000
Total liabilities	13,112,958	10,461,574
Series A convertible preferred stock	8,802,000	8,802,000
Series A exchangeable preferred stock	5,135,640	5,135,640
Common stock	117,365	114,487
Common stock held in treasury, at cost	101,480	101,480
Additional paid-in capital	33,171,165	31,989,207
Retained earnings (accumulated deficit)	(49,388,036)	(43,426,865)
Total stockholders' equity	(2,263,346)	2,512,989

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. CAS Medical Systems Inc series A convertible preferred. No dividends paid.
2. CAS Medical Systems Inc common. No dividends paid.
3. CAS Medical Systems Inc series A exchangeable preferred. No dividends paid.

No dividends paid.
Annual Dividends:
1. CAS Medical Systems Inc series A convertible preferred.
 No dividends paid.
2. CAS Medical Systems Inc common.
 No dividends paid.
3. CAS Medical Systems Inc series A exchangeable preferred.
 No dividends paid.

CELLULAR BIOMEDICINE GROUP INC

Annual Meeting Development On Mar. 28, 2019, Co. announced that its Annual Meeting of Shareholders on Apr. 26, 2019, at 9:00 a.m. EDT, at Co.'s office at 1345 Avenue of the Americas, 15th Floor, New York, NY, 10105.

CHEMBIO DIAGNOSTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Net product sales	26,741,020	19,322,302	13,680,107
License & royalty revenue	948,773	741,534	449,685
Research & development, milestone & grant revenue	5,719,458	3,951,591	3,739,049
Total revenues	33,409,251	24,015,427	17,868,841
Cost of product sales	21,427,243	12,921,157	9,417,505
Research & development expenses	8,526,256	8,555,381	8,427,554
Selling, general & administrative expenses	11,100,775	8,963,363	7,595,559
Acquisitions costs	337,645	58,076	...
Total costs & expenses	41,391,919	30,497,977	25,440,618
Income (loss) from operations	(7,982,668)	(6,482,550)	(7,571,777)
Interest income, net	49,498	22,485	25,548
Total other income (expense)	25,548
Income (loss) before income taxes provision (benefit)	(7,137,428)	(6,054,002)	(7,546,229)
- United States	(7,137,428)	(6,054,002)	(7,546,229)
Income (loss) before income taxes provision (benefit) - international	(795,742)	(406,063)	...
Income (loss) before income taxes provision (benefit) ...	(7,933,170)	(6,460,065)	(7,546,229)
Current federal income taxes provision (benefit)	...	(97,339)	...
Current state income taxes provision (benefit)	10,914	9,034	...
Total current income taxes provision (benefit)	10,914	(88,305)	...
Deferred federal income taxes provision (benefit)	5,778,185
Deferred state income taxes provision (benefit)	22,633
Deferred foreign income taxes provision (benefit)	(78,435)
Total deferred income taxes provision (benefit)	(78,435)	...	5,800,818
Income tax provision (benefit)	(67,521)	(88,305)	5,800,818
Net income (loss)	(7,865,649)	(6,371,760)	(13,347,047)
Weighted average shares outstanding - basic	14,432,505	12,300,031	10,622,331
Weighted average shares outstanding

- diluted	14,432,505	12,300,031	10,622,331
Year end shares outstanding	17,166,459	12,318,570	12,026,847
Earnings (loss) per share - basic	\$(0.55)	\$(0.52)	\$(1.26)
Earnings (loss) per share - diluted	\$(0.55)	\$(0.52)	\$(1.26)
Number of full time employees	295
Total number of employees	...	165	131
Number of common stockholders	132	1,590	2,030
Foreign currency translation adjustments	...	178,948	...

□ Reclassified to conform with 2018 presentation; □ Reclassified to conform with 2017 presentation; □ Shares increased due the effect of new stock from offerings, restricted stock issued and exercised of options; □ Full-time equivalent; □ Approximately; □ As of March 1, 2019; □ As of March 5, 2018; □ As of March 3, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash & cash equivalents	12,524,551	3,790,302
Accounts receivables, gross	7,415,971	2,127,340
Allowance for doubtful accounts	42,000	42,000
Accounts receivable, net	7,373,971	2,085,340
Raw materials	2,803,677	1,767,684
Work in process	263,043	286,413
Finished goods	4,784,502	2,369,521
Inventories, net	7,851,222	4,423,618
Prepaid expenses & other current assets	702,010	554,383
Total current assets	28,451,754	10,853,643
Machinery & equipment	6,070,137	4,582,759
Furniture & fixtures	35,287	449,548
Computer equipment	435,348	422,946
Leasehold improvements	2,334,512	2,258,779
Enterprise business systems	462,420	...
Less accumulated depreciation & amortization	6,463,784	5,804,800
Fixed assets, net of accumulated depreciation	2,873,920	1,909,232
Intangible assets, net	3,884,831	1,597,377
Goodwill	4,983,127	1,666,610
Deposits & other assets	717,551	589,159
Total assets	40,911,183	16,616,021
Accounts payable - suppliers	3,622,765	1,494,759
Accrued commissions	588,131	126,827
Accrued royalties or license fees	279,213	429,297
Accrued payroll	48,867	187,305
Accrued vacation	264,789	309,767
Accrued bonuses	494,318	282,500
Accrued expenses - other	590,598	215,848
Deferred revenue	422,905	50,000
Current portion of note payable	207,694	...
Total current liabilities	6,519,280	3,096,303
Note payable	171,821	99,480
Deferred tax liability	892,308	341,042
Total liabilities	7,583,409	3,536,825
Common stock	171,664	123,185
Additional paid-in capital	90,953,788	62,821,288
Retained earnings (accumulated deficit)	(57,909,874)	(50,044,225)
Accumulated other comprehensive income	112,196	178,948
Total stockholders' equity (deficit)	33,327,774	13,079,196

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Chembio Diagnostics Inc series B 9% convertible preferred.
No dividends paid.

2. Chembio Diagnostics Inc series A 8% convertible preferred.
No dividends paid.

3. Chembio Diagnostics Inc series C 7% redeemable convertible preferred.
No dividends paid.

4. Chembio Diagnostics Inc common.
No dividends paid.

Annual Dividends:

1. Chembio Diagnostics Inc series B 9% convertible preferred.
No dividends paid.

2. Chembio Diagnostics Inc series A 8% convertible preferred.
No dividends paid.

3. Chembio Diagnostics Inc series C 7% redeemable convertible preferred.
No dividends paid.

4. Chembio Diagnostics Inc common.
No dividends paid.

COMSCORE INC

Official Changes On Mar. 31, 2019, Co. announced the appointment of Irwin Gotlieb, Joanne Bradford and Kathi Love to its Board of Directors, effective Apr. 1, 2019. Also on Mar. 31, 2019, Co. announced the appointment of Dale Fuller to serve as its Interim Chief Executive Officer, effective Apr. 1, 2019.

CONNECTONE BANCORP INC (NEW)

Dividend Announcement On Mar. 27, 2019, Co., parent company of ConnectOne Bank, announced that its Board of Directors increased Co.'s quarterly cash dividend on its common stock by 20% to \$0.09 per share, payable on May 1, 2019, to shareholders of record on Apr. 15, 2019. The \$0.09 per share represents an increase of \$0.015 per share over the previous quarterly cash dividend of \$0.075 per share.

CONNS INC

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2018 (revised)	2017 (revised)	2016 (revised)
Product sales	1,077,874	1,186,197	1,199,134
Repair service agreement commissions	100,383	113,615	109,730
Service revenues	13,710	14,659	13,725
Total net sales	1,191,967	1,314,471	1,322,589
Finance charges & other revenues	324,064	282,377	290,589
Total revenues	1,516,031	1,596,848	1,613,178
Cost of goods sold	720,344	823,082	833,126
Selling, general & administrative expense	450,413	460,896	436,115
Provision for bad debts	216,875	242,294	222,177
Charges & credits	13,331	6,478	8,044
Total cost & expenses	1,400,963	1,532,750	1,499,462
Operating income (loss)	115,068	64,098	113,716
Interest expense	80,160	98,615	63,106
Gain (loss) from early extinguishment of debt	(1,367)
Loss on extinguishment of debt	(3,274)
Income (loss) before income taxes	31,634	(34,517)	49,243
Current provision (benefit) for income taxes - federal	(25,891)	(11,251)	32,820
Current provision for income taxes - state	1,184	3,519	2,242
Total current provision (benefit) for income taxes	(24,707)	(7,732)	35,062
Deferred provision			

(benefit) for income taxes - federal	49,536	(1,435)	(16,032)
Deferred provision (benefit) for income taxes - state	342	212	(642)
Total deferred provision (benefit) for income taxes	49,878	(1,223)	(16,674)
Provision (benefit) for income taxes	25,171	(8,955)	18,388
Net income (loss)	6,463	(25,562)	30,855
Weighted average shares outstanding - basic	31,192	30,776	35,084
Weighted average shares outstanding - diluted	31,778	30,776	35,557
Year end shares outstanding	31,436	30,962	30,630
Net earnings (loss) per share - basic	\$0.21	\$(0.83)	\$0.88
Net earnings (loss) per share - diluted	\$0.20	\$(0.83)	\$0.87
Number of full time employees	4,000	4,000	4,300
Number of part time employees	250	200	300
Total number of employees	4,250	4,200	4,600
Number of common stockholders	400	140	130
Number of beneficiary stockholders	5,900	6,100	5,700

Reclassified to conform with 2017 presentation; Reclassified to conform with 2018 presentation; As is; Approximately; As of March 27, 2018; As of March 23, 2017; As of March 23, 2016

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2018 (revised)	2017 (revised)
Cash & cash equivalents	9,286	23,566
Restricted cash	86,872	110,698
Customer accounts receivable, net	636,825	702,162
Other accounts receivable	71,186	69,286
Inventories	211,894	164,856
Income taxes receivable	32,362	2,150
Prepaid expenses & other current assets	31,592	14,955
Total current assets	1,080,017	1,087,673
Long-term portion of customer accounts receivable, net	650,608	615,904
Land	4,146	3,979
Buildings	1,748	913
Leasehold improvements	222,781	215,612
Equipment & fixtures	67,710	59,879
Capital leases	8,527	4,989
Construction in progress	8,097	13,572
Subtotal property & equipment	313,009	298,944
Less accumulated depreciation	169,857	139,742
Property & equipment, net	143,152	159,202
Deferred income taxes	21,565	71,442
Other assets	5,457	6,913
Total assets	1,900,799	1,941,134
Current portion of long-term debt	...	849
Current maturities of debt & capital lease obligations	907	...
Accounts payable	71,617	101,612
Accrued compensation & related expenses	21,366	13,325
Accrued expenses	44,807	26,456
Income taxes payable	2,939	3,318

Deferred revenues & other credits	22,475	21,821
Total current liabilities	164,111	167,381
Deferred rent	87,003	87,957
Revolving credit facility	77,000	177,500
Senior notes	227,000	227,000
Class A Notes	352,457	333,411
Class B Notes	312,039	348,370
Class C Notes	128,980	70,510
Capital lease obligations	4,949	2,393
Discount on debt	(2,527)	(3,089)
Deferred debt issuance costs	(8,886)	(10,853)
Less current portion of debt & capital lease obligations	907	849
Long-term debt & capital lease obligations	1,090,105	1,144,393
Other long-term liabilities	24,512	23,613
Total liabilities	1,365,731	1,423,344
Common stock	314	310
Additional paid-in capital	101,087	90,276
Retained earnings (accumulated deficit)	433,667	427,204
Total stockholders' equity	535,068	517,790

Reclassified to conform with 2017 presentation; Includes variable interest entity balance - Restricted cash: \$85,322,000; Includes variable interest entity balance - Restricted cash: \$110,698,000; Includes balances of variable-interest entity - Customer accounts receivable: \$459,708,000; Includes balances of variable-interest entity - Customer accounts receivable: \$529,108,000; Net of allowance - Long-term portion of customer accounts receivable: \$455,002,000; Net of allowance - Long-term portion of customer accounts receivable: \$320,382,000; Includes balances of variable-interest entity - Long-term debt & capital lease obligations: \$787,979,000; Includes balances of variable-interest entity - Long-term debt & capital lease obligations: \$745,581,000

Recent Dividends:

1. Conns Inc common.

No dividends paid.

Annual Dividends:

1. Conns Inc common.

No dividends paid.

COUPA SOFTWARE INC

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2019	2018 (revised)	2017 (revised)
Subscription services	233,428	164,865	117,788
Professional services & other	26,938	21,915	15,987
Total revenues	260,366	186,780	133,775
Cost of revenues: subscription services	53,153	36,481	25,055
Cost of revenues: professional services & other	30,301	23,425	21,214
Total cost of revenues	83,454	59,906	46,269
Gross profit	176,912	126,874	87,506
Research & development	61,608	44,536	30,262
Sales & marketing expenses	105,659	88,722	68,562
General & administrative expenses	57,005	38,578	24,106
Total operating expenses	224,272	171,836	122,930
Income (loss) from operations	(47,360)	(44,962)	(35,424)
Interest expense	12,518	502	14
Interest income & other, net	3,817	3,307	(1,321)

Income before income taxes - United States	(59,070)	(44,977)	(38,926)	Accounts payable	5,485	1,342	Net income (loss) per share - basic	\$(0.02)	\$0.00	\$0.00			
Income before income taxes - Foreign	3,009	2,820	2,167	Accrued compensation	23,112	11,606	Net income (loss) per share - diluted	\$(0.02)	\$0.00	\$0.00			
Income (loss) before provision for income taxes	(56,061)	(42,157)	(36,759)	Accrued expenses	11,898	6,190	Dividends per share	\$0.05			
Current state income taxes	151	116	82	Income taxes payable	2,231	5,092	Number of full time employees	101	125	125			
Current foreign income taxes	3,514	4,248	976	Other current liabilities	4,551	3,755	Number of part time employees	5	7	8			
Total current income taxes	3,665	4,364	1,058	Accrued expenses & other current liabilities	41,792	26,643	Number of common stockholders	190	200	212			
Deferred federal income taxes	(2,701)	(26)	13	Deferred revenue, current portion	179,967	125,714	□ As of March 4, 2019; □ As of March 5, 2018; □ As of March 6, 2017; □ Approximately						
Deferred state income taxes	(365)	7	1	Convertible senior notes, net	174,615	...	Consolidated Balance Sheet, Years Ended Dec. 31 (\$):						
Deferred foreign income taxes	(1,136)	(2,697)	(224)	Total current liabilities	401,859	153,699	2018 2017						
Total deferred income taxes	(4,202)	(2,716)	(210)	Convertible senior notes, net	...	163,010	Cash	958,739	508,942				
Provision (benefit) for income taxes	(537)	1,648	848	Deferred revenue, net of current portion	2,620	2,316	Money market funds	7,108,160	8,226,206				
Net income (loss)	(55,524)	(43,805)	(37,607)	Other liabilities	22,304	12,880	Cash & cash equivalents	8,066,899	8,735,148				
Net income (loss) attributable to common stockholders	(55,524)	(43,805)	(37,607)	Total liabilities	426,783	331,905	Accounts receivable, gross	2,484,585	2,169,707				
Weighted average shares outstanding - basic	57,716	52,999	19,988	Common stock	6	6	Less: allowance	30,000	30,000				
Weighted average shares outstanding - diluted	57,716	52,999	19,988	Additional paid-in capital	567,797	445,318	Accounts receivable, net	2,454,585	2,139,707				
Year end shares outstanding	60,455	55,712	50,252	Accumulated other comprehensive income (loss)	335	(298)	Other current assets	561,861	530,699				
Net income (loss) per share - basic	\$(0.96)	\$(0.83)	\$(1.88)	Retained earnings (accumulated deficit)	(254,857)	(204,481)	Total current assets	11,083,345	11,405,554				
Net income (loss) per share - diluted	\$(0.96)	\$(0.83)	\$(1.88)	Total stockholders' equity (deficit)	313,281	240,545	Computer equipment & software	1,347,020	1,485,044				
Number of full time employees	1,202	833	...	□ Reclassified to conform with 2019 presentation			Furniture & fixtures	504,628	369,595				
Total number of employees	652	Recent Dividends:			Leasehold improvements	240,328	187,062				
Number of common stockholders	109	146	351	1. Coupa Software Inc common.			Property, plant & equipment, gross	2,091,976	2,041,701				
				No dividends paid.			Less: accumulated depreciation & amortization	1,548,214	1,604,485				
				2. Coupa Software Inc convertible preferred.			Property & equipment, net	543,762	437,216				
				No dividends paid.			Goodwill	1,954,460	1,954,460				
				Annual Dividends:			Other assets	35,613	23,463				
				1. Coupa Software Inc common.			Total assets	13,617,180	13,820,693				
				No dividends paid.			Deferred revenue	8,738,445	8,304,877				
				2. Coupa Software Inc convertible preferred.			Accounts payable	94,767	58,901				
				No dividends paid.			Accrued expenses	1,311,218	1,344,526				
				CREDITRISKMONITOR.COM, INC.			Total current liabilities	10,144,430	9,708,304				
				Annual Report			Deferred taxes on income, net	490,381	514,333				
				Consolidated Income Statement, Years Ended Dec. 31 (\$):			Other liabilities	24,537	15,748				
				2018 2017 2016			Total liabilities	10,659,348	10,238,385				
				Operating revenues	13,891,004	13,385,068	12,814,390	Common stock	107,224	107,224			
				Data & product costs	5,764,535	5,426,779	4,944,053	Additional paid-in capital	29,650,760	29,559,784			
				Selling, general & administrative expenses	8,257,619	8,044,256	7,495,742	Retained earnings (accumulated deficit)	(26,800,152)	(26,084,700)			
				Depreciation & amortization	190,156	191,960	200,136	Total stockholders' equity (deficit)	2,957,832	3,582,308			
				Total operating expenses	14,212,310	13,662,995	12,639,931	Recent Dividends:					
				Income (loss) from operations	(321,306)	(277,927)	174,459	1. Creditriskmonitor.com, Inc. common.					
				Other income, net	129,111	47,216	27,183	ExDate	Amt	Declared	Record	Payable	
				Income (loss) before income taxes	(192,195)	(230,711)	201,642	11/14/2016	0.05	10/26/2016	11/16/2016	12/05/2016	
				Current federal income tax expense (benefit)	3,620	(2,746)	127,768	11/21/2017	0.05	11/01/2017	11/22/2017	12/11/2017	
				Current state income tax expense (benefit)	7,469	8,035	18,482	11/27/2018	0.05	11/14/2018	11/28/2018	12/11/2018	
				Deferred federal income tax expense (benefit)	(18,379)	(264,707)	20,444	Annual Dividends:					
				Deferred state income tax expense (benefit)	(5,573)	16,637	(17,495)	1. Creditriskmonitor.com, Inc. common.					
				Provision (benefit) for income taxes	(12,863)	(242,781)	149,199	2016	0.05	2017	0.05	2018	0.05
				Net income (loss)	(179,332)	12,070	52,443	CUMULUS MEDIA INC					
				Weighted average shares outstanding - basic	10,722,401	10,722,401	10,722,323	Annual Report					
				Weighted average shares outstanding - diluted	10,722,401	10,726,121	10,780,511	Consolidated Income Statement, Years Ended (\$000):					
				Year end shares outstanding	10,722,401	10,722,401	10,722,401	□□12/31/18 □□06/03/18 □□12/31/17 (revised)					
								Net revenues	686,436	453,924	1,135,662		
								Content costs	238,888	163,885	409,213		
								Selling, general & administrative expenses	276,551	195,278	471,300		
								Depreciation & amortization	34,060	22,046	62,239		
								LMA fees	2,471	1,809	10,884		

□ Reclassified to conform with 2019 presentation; □ As is

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2019	2018	2018
Cash & cash equivalents	141,250	412,903	(revised)
Marketable securities	180,169	...	
Accounts receivable, gross	95,344	61,375	
Less: allowance for doubtful accounts	70	9	
Accounts receivable, net of allowances	95,274	61,366	
Prepaid expenses & other current assets	10,343	10,952	
Deferred commissions, current portion	7,324	3,756	
Total current assets	434,360	488,977	
Furniture & equipment	3,595	1,897	
Software development costs	23,444	16,574	
Leasehold improvements	1,255	557	
Construction in progress	183	149	
Total property & equipment	28,477	19,177	
Less: accumulated depreciation & amortization	17,928	13,991	
Property & equipment, net	10,549	5,186	
Deferred commissions, net of current portion	18,904	3,896	
Goodwill	209,560	44,410	
Intangible assets, net	55,925	20,020	
Other assets	10,766	9,961	
Total assets	740,064	572,450	

Corporate expenses	\$31,714	\$17,169	\$59,062
Gain (loss) on exchange of assets or stations	(103)	(158)	2,499
Impairment of intangible assets & goodwill	335,909
Total operating expenses	583,787	400,345	1,346,108
Operating income (loss)	102,649	53,579	(210,446)
Reorganization items, net	...	(466,201)	31,603
Interest expense	50,718	260	126,952
Interest income	36	50	136
Gain (loss) on early extinguishment of debt	201	...	(1,063)
Other income (expense), net	(3,096)	(273)	(363)
Total non-operating income (expense), net	(53,577)	465,718	(159,845)
Income (loss) before income taxes	49,072	519,297	(370,291)
Current federal income tax expense (benefit)	6,170	(1,430)	...
Current state & local income tax expense (benefit)	8,888	4,026	4,504
Total current income tax expense (benefit)	15,058	2,596	4,504
Deferred federal income tax expense (benefit)	(20,641)	(138,311)	(157,277)
Deferred state & local income tax expense (benefit)	(6,770)	(41,144)	(10,953)
Total deferred tax expense (benefit)	(27,411)	(179,455)	(168,230)
Income tax expense (benefit)	(12,353)	(176,859)	(163,726)
Net income (loss)	61,425	696,156	(206,565)
Net income (loss) attributable to common stockholders	61,425	696,156	(206,565)
Weighted average shares outstanding - basic	20,028	29,338	29,306
Weighted average shares outstanding - diluted	20,165	29,338	29,306
Year end shares outstanding	16,556	...	29,306
Net income (loss) per share - basic	\$3.07	\$23.73	\$(7.05)
Net income (loss) per share - diluted	\$3.05	\$23.73	\$(7.05)
Number of full time employees	\$3,449	...	\$3,515
Number of part time employees	\$1,686	...	\$1,698
Total number of employees	\$5,135	...	\$5,213
Number of class A common stockholders	\$11,289	...	\$11,606
Number of class B common stockholders	\$11,72
Number of class C common stockholders	\$1

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Cash & cash equivalents	27,584	2,454	2,454
Restricted cash
Accounts receivable, gross	255,594
Less: allowance for doubtful accounts	5,483
Accounts receivable	250,111
Trade receivable	3,390
Assets held for sale	80,000
Prepaid expenses & other current assets	31,452
Total current assets	394,991
Land	79,670
Broadcasting & other equipment	77,812
Computer & capitalized software costs	17,681
Furniture & fixtures	5,269
Leasehold improvements	25,812
Buildings	28,689
Construction in process	15,946
Property & equipment, gross	250,879
Less: accumulated depreciation	14,981
Property & equipment, net	235,898
Broadcast licenses	935,652
Other intangibles assets, net	193,535
Other assets	15,076
Total assets	1,775,152
Accrued employee costs	23,599
Accrued third party content costs	28,963
Accounts payable	11,695
Accrued other expenses	37,063
Trade payable	2,578
Current portion of long-term debt	13,000
Total current liabilities	116,898
Term loan	1,230,299
Other liabilities	25,742
Deferred income taxes	12,384
Liabilities not subject to compromise	1,385,323
Total liabilities	1,385,323
Successor additional paid-in-capital	328,404
Successor retained earnings (accumulated deficit)	61,425
Total stockholders' equity (deficit)	389,829

Recent Dividends:

- Cumulus Media Inc class A common.**
No dividends paid.
- Cumulus Media Inc class C common.**
No dividends paid.
- Cumulus Media Inc class B common.**
No dividends paid.
- Cumulus Media Inc series A cumulative redeemable preferred (stated value \$1,000).**
No dividends paid.

Annual Dividends:

- Cumulus Media Inc class A common.**
No dividends paid.
- Cumulus Media Inc class C common.**
No dividends paid.
- Cumulus Media Inc class B common.**
No dividends paid.
- Cumulus Media Inc series A cumulative redeemable preferred (stated value \$1,000).**
No dividends paid.

CURIS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Royalties	10,421,000	9,849,000	7,810,000
Research & development, net	7,000	49,000	(283,000)
Total revenues	10,428,000	9,898,000	7,527,000
Cost of royalties	563,000	496,000	399,000
Research & development	24,413,000	45,096,000	31,590,000
In-process research & development	17,989,000
General & administrative	14,785,000	14,066,000	15,588,000
Total costs & expenses	39,761,000	59,658,000	65,566,000
Income (loss) from operations	(29,333,000)	(49,760,000)	(58,039,000)

Interest income	684,000	513,000	406,000
Other income (expense)	...	(104,000)	(1,000)
Interest expense	3,926,000	3,966,000	2,777,000
Total other income (expense), net	(3,242,000)	(3,557,000)	(2,372,000)
Net income (loss)	(32,575,000)	(53,317,000)	(60,411,000)
Weighted average shares outstanding - basic	33,118,393	\$29,826,693	26,557,137
Weighted average shares outstanding - diluted	33,118,393	\$29,826,693	26,557,137
Year end shares outstanding	33,159,253	\$32,831,424	28,224,805
Net income (loss) per share - basic	\$(0.98)	\$(1.79)	\$(2.25)
Net income (loss) per share - diluted	\$(0.98)	\$(1.79)	\$(2.25)
Number of full time employees	31	55	58
Number of common stockholders	\$171	\$199	\$210

Adjusted for 1-for-5 stock split, May 30, 2018; As of March 19, 2019; As of March 2, 2018; As of March 2, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash & cash equivalents	23,636,000	38,288,000
Investments	634,000	21,944,000
Accounts receivable	2,864,000	3,073,000
Prepaid expenses & other current assets	827,000	989,000
Total current assets	27,961,000	64,294,000
Laboratory equipment, computers & software	1,753,000	1,736,000
Leasehold improvements	185,000	185,000
Office furniture & equipment	354,000	354,000
Property & equipment, gross	2,292,000	2,275,000
Less - accumulated depreciation & amortization	2,025,000	1,909,000
Property & equipment, net	267,000	366,000
Long-term investment - restricted	153,000	153,000
Goodwill	8,982,000	8,982,000
Other assets	2,000	3,000
Total assets	37,365,000	73,798,000
Accounts payable	2,909,000	5,423,000
Accrued compensation	2,774,000	2,187,000
Professional fees	233,000	148,000
Accrued interest on debt	165,000	193,000
Other accrued liabilities	285,000	265,000
Current portion of long-term debt, net	6,884,000	5,886,000
Total current liabilities	13,250,000	14,102,000
Long-term debt, net	28,600,000	35,669,000
Other long-term liabilities	11,000	34,000
Total liabilities	41,861,000	49,805,000
Common stock	332,000	331,000
Additional paid-in capital	980,012,000	977,453,000
Treasury stock, at cost	...	1,524,000
Retained earnings (accumulated deficit)	(984,840,000)	(952,265,000)
Accumulated other comprehensive income (expense)	...	(2,000)
Total stockholders' equity (deficit)	(4,496,000)	23,993,000

Reclassified to conform with 2018 presentation

Recent Dividends:

- Curis Inc common.**
No dividends paid.

Annual Dividends:

- Curis Inc common.**

From June 4, 2018; Successor; Predecessor; From January 1, 2018; Reclassified to conform with 2018 presentation; Including stock-based compensation expense - Corporate expenses: \$3,404,000; Including stock-based compensation expense - Corporate expenses: \$231,000; Including stock-based compensation expense - Corporate expenses: \$1,614,000; As is; Approximately; As of March 11, 2019; As of March 21, 2018

No dividends paid.

CURIS INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, PricewaterhouseCoopers LLP, as it appeared in Co.'s 10K: "In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO. Emphasis of matter As discussed in Note 1 to the consolidated financial statements, the Company will require additional financing to fund planned future operations. Management's plans in regard to this matter are described in Note 1."

CUTERA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Net revenue - products	142,535	132,660	99,028
Net revenue - service	20,185	18,833	19,028
Total net revenue	162,720	151,493	118,056
Cost of revenue - products	66,843	56,363	40,149
Cost of revenue - service	15,495	9,020	9,772
Total cost of revenue	82,338	65,383	49,921
Gross profit	80,382	86,110	68,135
Sales & marketing expense	58,420	52,070	41,563
Research & development expense	14,359	12,874	11,232
General & administrative expense	20,995	14,090	12,943
Lease termination income	...	(4,000)	...
Total operating expenses	93,774	75,034	65,738
Income (loss) from operations	(13,392)	11,076	2,397
Interest & other income (expense), net	(123)	884	323
Income (loss) before income taxes - United States	(14,177)	11,203	2,207
Income (loss) before income taxes - foreign	662	757	513
Income (loss) before income taxes	(13,515)	11,960	2,720
Provision (benefit) for current federal income taxes	(15)	148	...
Provision (benefit) for current state income taxes	123	71	16
Provision (benefit) for current foreign income taxes	303	511	131
Total provision (benefit) for current income taxes	411	730	147
Provision (benefit) for deferred federal income taxes	15,674	(17,393)	(24)
Provision (benefit) for deferred state income taxes	1,230	(1,348)	(2)
Provision (benefit) for deferred foreign income			

taxes	(60)	(22)	22
Total provision (benefit) for deferred income taxes	16,844	(18,763)	(4)
Income tax provision (benefit)	17,255	(18,033)	143
Net income (loss)	(30,770)	29,993	2,577
Weighted average shares outstanding - basic	13,771	13,873	13,225
Weighted average shares outstanding - diluted	13,771	14,728	13,753
Year end shares outstanding	13,969	13,478	13,773
Net income (loss) per share - basic	\$(2.23)	\$2.16	\$0.19
Net income (loss) per share - diluted	\$(2.23)	\$2.04	\$0.19
Total number of employees	402	367	297
Number of common stockholders	5	7	9
Number of beneficiary stockholders	4,700	5,400	5,000

As is; As of March 01, 2019; As of March 1, 2018; As of February 28, 2017; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Cash	21,969	14,058	9,058
Money market funds	4,083	126	126
Cash & cash equivalents	26,052	14,184	9,184
Marketable investments	9,523	21,728	21,728
Accounts receivable, gross	20,894	20,786	20,786
Less: allowance for doubtful accounts	1,257	9	9
Accounts receivable, net	19,637	20,777	20,777
Raw materials	16,991	19,160	19,160
Work in process	2,306	2,744	2,744
Finished goods	8,717	6,878	6,878
Inventories	28,014	28,782	28,782
Other current assets & prepaid expenses	3,972	2,903	2,903
Total current assets	87,198	88,374	88,374
Leasehold improvements	660	640	640
Office equipment & furniture	2,835	2,370	2,370
Machinery & equipment	7,304	6,277	6,277
Property & equipment, gross	10,799	9,287	9,287
Less: accumulated depreciation	8,127	7,191	7,191
Property & equipment, net	2,672	2,096	2,096
Deferred tax assets	457	19,055	19,055
Goodwill	1,339	1,339	1,339
Other long-term assets	5,971	374	374
Total assets	97,637	111,238	111,238
Accounts payable	11,279	7,002	7,002
Accrued payroll & related expenses	9,377	12,567	12,567
Sales & marketing accruals	2,379	3,710	3,710
Accrued sales tax	2,935	2,920	2,920
Accrued warranty liability	4,666	3,508	3,508
Other accrued liabilities	3,943	4,143	4,143
Extended warranty liabilities	3,159
Deferred revenue	9,882	9,461	9,461
Total current liabilities	47,620	43,311	43,311
Deferred revenue, net of current portion	2,684	2,195	2,195
Income tax liability	394	379	379
Other long-term liabilities	553	460	460
Total liabilities	51,251	46,345	46,345
Common stock	14	13	13

Additional paid-in capital	70,451	62,025	
Retained earnings (accumulated deficit)	(24,010)	2,947	
Accumulated other comprehensive income (loss)	(69)	(92)	
Total stockholders' equity	46,386	64,893	

Recent Dividends:

1. Cutera Inc common.

No dividends paid.

Annual Dividends:

1. Cutera Inc common.

No dividends paid.

DATATRAK INTERNATIONAL INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Revenue	7,447,356	7,524,043	8,982,867
Direct costs	1,393,952	1,390,014	1,604,219
Gross profit	6,053,404	6,134,029	7,378,648
Selling, general & administrative expenses	5,211,668	5,286,852	6,044,814
Depreciation & amortization	681,011	634,970	253,467
Income (loss) from operations	160,725	212,207	1,080,367
Interest income	3,583	3,153	792
Interest expense	3,333	130,351	48,092
Other income (expense)	600	...	(6,025)
Income (loss) before income taxes	161,575	85,009	1,027,042
Income tax expense (benefit)	...	(134,687)	12,636
Net income (loss)	161,575	219,696	1,014,406
Weighted average shares outstanding - basic	2,299,067	1,947,081	1,680,859
Weighted average shares outstanding - diluted	2,334,868	2,000,223	1,833,869
Year end shares outstanding	2,313,292	2,272,250	1,766,743
Net income (loss) per share - basic	\$0.07	\$0.11	\$0.60
Net income (loss) per share - diluted	\$0.07	\$0.11	\$0.55
Number of common stockholders	87	96	101
Number of beneficiary stockholders	...	100	100

Restated to reflect adoption of FASB ASU No. 2014-09, Revenue from contracts with customers (Topic 606); Greater than

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash & cash equivalents	2,349,348	2,528,796
Marketable securities	8,230	7,550
Accounts receivables, gross	853,389	776,544
Allowance for doubtful accounts	15,000	15,000
Accounts receivable, net	838,389	761,544
Other receivable	139,812	773
Prepaid expenses	236,118	221,704
Total current assets	3,571,897	3,520,367
Equipment	355,502	349,797
Software, net of impairment	4,668,170	4,077,646
Leasehold improvements	55,425	55,425
Property & equipment, gross	5,079,097	4,482,868
Less accumulated depreciation & amortization	3,670,270	2,989,258

Property & equipment, net	1,408,827	1,493,610
Certificate of deposit	225,235	304,270
Contract costs, net	55,006	33,261
Income tax receivable	...	138,870
Deferred tax asset - noncurrent	8,568,510	8,603,535
Deferred tax asset valuation allowance - noncurrent	(8,568,510)	(8,603,535)
Deposits	16,547	20,547
Total assets	5,277,512	5,510,925
Accounts payable	85,406	99,478
Notes payable - current	44,476	40,374
Accrued payroll & other employee costs	414,000	374,000
Accrued professional fees	534,000	328,000
Other accrued expenses	23,000	168,000
Accrued expenses	971,372	869,535
Contract liability	3,042,140	3,189,014
Total current liabilities	4,143,394	4,198,401
Capital lease agreement	...	4,000
Notes payable	46,000	42,000
Less: current maturities	45,000	40,000
Long-term debt	1,359	5,865
Contract liability - long-term	477,925	1,069,898
Other long-term liabilities	150,000	150,000
Total long-term liabilities	629,284	1,225,763
Common shares	86,952,655	86,722,665
Treasury shares, at cost	18,601,506	18,628,014
Accumulated other comprehensive income (loss)	...	(2,600)
Retained earnings (accumulated deficit)	(67,846,315)	(68,005,290)
Total shareholders' equity (deficit)	504,834	86,761

federal & state	(58)	(109)
Current provision for income taxes - foreign	8	(100)
Total current provision (benefit) for income taxes	(50)	(209)
Deferred provision (benefit) for income taxes - federal & state	...	(2,363)
Deferred provision (benefit) for income taxes - foreign
Total deferred provision (benefit) for income taxes	...	(2,363)
Provision (benefit) for income taxes	(50)	(2,572)
Net income (loss)	(13,531)	(18,826)
Weighted average shares outstanding - basic	49,163	48,888
Weighted average shares outstanding - diluted	49,163	48,888
Year end shares outstanding	49,486	48,730
Net income (loss) per share - basic	\$(0.28)	\$(0.39)
Net income (loss) per share - diluted	\$(0.28)	\$(0.39)
Total number of employees	2,543	2,634
Number of common stockholders	86	87
Foreign currency translation adjustments	...	393

Less: unamortized debt issuance costs	(243)	(190)
Less: current portion of long-term debt	...	1,392
Deferred rent & lease incentives	31,839	35,718
Deferred gain on sale-leaseback, net of current portion	8,793	10,258
Other long-term liabilities	4,116	3,960
Total long-term liabilities	59,505	60,605
Common stock	622	615
Additional paid-in capital	310,393	307,557
Treasury stock at cost	92,658	92,658
Retained earnings (accumulated deficit)	(153,534)	(139,285)
Pension plans	(5,521)	(5,840)
Foreign currency	(662)	(403)
Accumulated other comprehensive income (loss)	(6,183)	(6,243)
Total stockholders' equity	58,640	69,986

Recent Dividends:
1. Destination XL Group Inc common.
 No dividends paid.
Annual Dividends:
1. Destination XL Group Inc common.
 No dividends paid.

DOCUSIGN INC
Annual Report
Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2019	2018 (revised)	2017 (revised)
Revenue - subscription	663,657	484,581	348,563
Revenue - professional services & other	37,312	33,923	32,896
Total revenue	700,969	518,504	381,459
Cost of revenue - subscription	117,764	83,834	73,363
Cost of revenue - professional services & other	74,657	34,439	29,114
Total cost of revenue	192,421	118,273	102,477
Gross profit	508,548	400,231	278,982
Sales & marketing	539,606	277,930	240,787
Research & development	185,968	92,428	89,652
General & administrative expenses	209,297	81,526	64,360
Total operating expenses	934,871	451,884	394,799
Income (loss) from operations	(426,323)	(51,653)	(115,817)
Interest expense	10,844	624	611
Interest income & other income (expense), net	8,959	3,135	1,372
Income before income taxes - United States	(460,627)	(54,485)	(109,669)
Income before income taxes - International	32,419	5,343	(5,387)
Income (loss) before provision for (benefit from) income taxes	(428,208)	(49,142)	(115,056)
Current federal income taxes	...	37	...
Current state income taxes	413	(46)	28
Current foreign income taxes	2,838	4,139	316

Restated to reflect adoption of FASB ASU No. 2014-09, Revenue from contracts with customers (Topic 606); Rounding difference, breakdown taken from the notes

Reclassified to conform with 2018 presentation; As is; As of February 2, 2019; As of March 15, 2019; As of March 16, 2018; As of March 15, 2017

Recent Dividends:
1. DataTrak International Inc. common.
 No dividends paid.
Annual Dividends:
1. DataTrak International Inc. common.
 No dividends paid.

DESTINATION XL GROUP INC
Annual Report
Consolidated Income Statement, Years Ended (\$000):

	02/02/19	02/03/18	01/28/17 (revised)
Sales	473,756	467,976	450,283
Cost of goods sold including occupancy costs	262,467	257,619	245,402
Gross profit	211,289	210,357	204,881
Selling, general & administrative expenses	183,868	193,230	173,283
Corporate restructuring charge & CEO transition costs	4,308
Impairment of assets	4,579	4,095	376
Depreciation & amortization	28,653	31,073	30,245
Total expenses	221,408	228,398	203,904
Operating income (loss)	(10,119)	(18,041)	977
Interest expense (income), net	(3,462)	(3,357)	(3,067)
Income (loss) before provision (benefit) for income taxes	(13,581)	(21,398)	(2,090)
Current provision (benefit) for income taxes -			

Consolidated Balance Sheet, Years Ended (\$000):

	02/02/19	02/03/18
Cash & cash equivalents	4,868	5,362
Accounts receivable	4,420	3,046
Inventories	106,837	103,332
Prepaid expenses & other current assets	11,535	9,927
Total current assets	127,660	121,667
Furniture & fixtures	76,809	75,895
Equipment	22,141	21,612
Leasehold improvements	119,314	117,274
Hardware & software	89,688	84,532
Construction in progress	6,078	4,981
Property & equipment, gross	314,030	304,294
Less: accumulated depreciation	221,505	193,262
Property & equipment, net of accumulated depreciation & amortization	92,525	111,032
Intangible assets	1,150	1,821
Other assets	4,741	5,885
Total assets	226,076	240,405
Current portion of long-term debt	...	1,392
Current portion of deferred gain on sale-leaseback	1,465	1,465
Accounts payable	34,418	33,987
Accrued expenses & other current liabilities	30,140	25,585
Borrowings under credit facility	41,908	47,385
Total current liabilities	107,931	109,814
FILo Loan	15,000	...
Equipment financing notes	...	501
Term loan	...	11,750

DOCUSIGN INC
Annual Report
Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2019	2018 (revised)	2017 (revised)
Revenue - subscription	663,657	484,581	348,563
Revenue - professional services & other	37,312	33,923	32,896
Total revenue	700,969	518,504	381,459
Cost of revenue - subscription	117,764	83,834	73,363
Cost of revenue - professional services & other	74,657	34,439	29,114
Total cost of revenue	192,421	118,273	102,477
Gross profit	508,548	400,231	278,982
Sales & marketing	539,606	277,930	240,787
Research & development	185,968	92,428	89,652
General & administrative expenses	209,297	81,526	64,360
Total operating expenses	934,871	451,884	394,799
Income (loss) from operations	(426,323)	(51,653)	(115,817)
Interest expense	10,844	624	611
Interest income & other income (expense), net	8,959	3,135	1,372
Income before income taxes - United States	(460,627)	(54,485)	(109,669)
Income before income taxes - International	32,419	5,343	(5,387)
Income (loss) before provision for (benefit from) income taxes	(428,208)	(49,142)	(115,056)
Current federal income taxes	...	37	...
Current state income taxes	413	(46)	28
Current foreign income taxes	2,838	4,139	316

Current income taxes	3,251	4,130	344	Software, including capitalized software development costs	27,959	24,270	Other income (expense), net	500	6,700	100
Deferred federal income taxes	(7,083)	(110)	80	Furniture & office equipment	9,511	9,692	Income (loss) before income taxes	(1,309,000)	1,704,000	1,329,400
Deferred state income taxes	(2)	15	4	Leasehold improvements	41,464	37,494	Current income tax provision (benefit)			
Deferred foreign income taxes	2,084	(901)	(72)	Total property & equipment, gross	134,167	125,543	- federal	245,600	439,300	480,500
Deferred income taxes	(5,001)	(996)	12	Less: Accumulated depreciation	66,479	66,160	Current income tax provision (benefit)			
Provision for (benefit from) income taxes	(1,750)	3,134	356	Work in progress	8,144	3,636	- state	47,800	23,800	79,500
Net income (loss)	(426,458)	(52,276)	(115,412)	Property & equipment, net	75,832	63,019	Current foreign income taxes	400	300	800
Less: preferred stock accretion	353	1,461	1,456	Goodwill	195,225	37,306	Total current income tax provision (benefit)	293,800	463,400	560,800
Net income (loss) attributable to common stockholders	(426,811)	(53,737)	(116,868)	Intangible assets, net	74,203	14,148	Deferred income tax provision (benefit)			
Weighted average shares outstanding - basic	135,163	32,294	28,020	Deferred contract acquisition costs - noncurrent	112,583	75,535	- federal	300	(456,000)	(37,700)
Weighted average shares outstanding - diluted	135,163	32,294	28,020	Other assets - noncurrent	8,833	11,170	Deferred income tax provision (benefit) - state	(12,300)	(17,700)	(89,900)
Year end shares outstanding	¹⁶ 169,303	35,700	29,439	Total assets	1,615,417	619,973	Total deferred income tax provision (benefit)	(12,000)	(473,700)	(127,600)
Net earnings (loss) per share - basic	\$(3.16)	\$(1.66)	\$(4.17)	Accounts payable	19,590	23,713	Provision (benefit) for income taxes	281,800	(10,300)	433,200
Net earnings (loss) per share - diluted	\$(3.16)	\$(1.66)	\$(4.17)	Accrued expenses	21,755	15,734	Net income (loss)	(1,590,800)	1,714,300	896,200
Total number of employees	¹⁷ 3,023	¹⁷ 2,255	...	Accrued compensation	77,553	50,852	Weighted average shares outstanding - basic	237,900	236,800	235,700
Number of common stockholders	¹⁷ ¹⁸ 248	Contract liabilities - current	381,060	270,188	Weighted average shares outstanding - diluted	238,700	237,700	236,800
				Deferred rent - current	2,452	1,758	Year end shares outstanding	238,082	237,326	236,136
				Other liabilities - current	13,903	11,574	Net income (loss) per share - basic	\$(6.69)	\$7.24	\$3.80
				Convertible senior notes, net	438,932	...	Net income (loss) per share - diluted	\$(6.66)	\$7.21	\$3.78
				Contract liabilities - noncurrent	7,712	7,736	Number of full time employees	²⁰ 57,200	²⁰ 56,300	²⁰ 55,300
				Deferred rent - noncurrent	24,195	23,044	Number of part time employees	²⁰ 124,900	²⁰ 119,800	²⁰ 121,500
				Deferred tax liability - noncurrent	4,207	2,511	Total number of employees	²⁰ 182,100	²⁰ 176,100	²⁰ 176,800
				Other liabilities - noncurrent	9,696	4,010	Number of common stockholders	²⁰ 2,507	²⁰ 2,657	²⁰ 2,813
				Total liabilities	1,001,055	411,120				
				Redeemable convertible preferred stock	...	547,501				
				Common stock	17	4				
				Additional paid-in capital	1,545,088	160,265				
				Accumulated other comprehensive income (loss)	(1,965)	3,403				
				Retained earnings (accumulated deficit)	(928,778)	(502,320)				
				Total stockholders' equity (deficit)	614,362	(338,648)				

¹⁶ Including stock-based compensation expense - cost of revenue - subscription: \$16,182,000; ¹⁷ Including stock-based compensation expense - cost of revenue - subscription: \$911,000; ¹⁸ Including stock-based compensation expense - cost of revenue - subscription: \$1,190,000; ¹⁹ Including stock-based compensation expense - cost of revenue - professional services: \$25,858,000; ²⁰ Including stock-based compensation expense - cost of revenue - professional services: \$976,000; ²¹ Including stock-based compensation expense - cost of revenue - professional services: \$1,021,000; ²² Including stock-based compensation expense - sales & marketing: \$172,115,000; ²³ Including stock-based compensation expense - sales & marketing: \$9,386,000; ²⁴ Including stock-based compensation expense - sales & marketing: \$11,187,000; ²⁵ Including stock-based compensation expense - research & development: \$74,108,000; ²⁶ Including stock-based compensation expense - research & development: \$4,896,000; ²⁷ Including stock-based compensation expense - research & development: \$10,161,000; ²⁸ Including stock-based compensation expense - general & administrative: \$122,715,000; ²⁹ Including stock-based compensation expense - general & administrative: \$13,578,000; ³⁰ Including stock-based compensation expense - general & administrative: \$11,884,000; ³¹ Shares increased due to the effects of stock options exercised, RSU settled, public offerings, redeemable convertible preferred stock converted, and warrants exercised; ³² As is; ³³ As of February 28, 2019

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2019	2018 (revised)
Cash & cash equivalents	517,811	256,867
Investments	251,203	...
Restricted cash	367	569
Accounts receivable, gross	175,148	124,050
Allowance for doubtful accounts	600	300
Accounts receivable	174,548	123,750
Contract assets - current	10,616	14,260
Prepaid expenses	18,415	16,062
Other current assets	11,561	7,287
Prepaid expenses & other current assets	29,976	23,349
Total current assets	984,521	418,795
Investments - noncurrent	164,220	...
Computer & network equipment	55,233	54,087

Recent Dividends:

1. DocuSign Inc common.

No dividends paid.

Annual Dividends:

1. DocuSign Inc common.

No dividends paid.

DOLLAR TREE INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/02/19	02/03/18 (revised)	¹¹ 01/28/17 (revised)
Net sales	22,823,300	22,245,500	20,719,200
Cost of sales	15,875,800	15,223,600	14,324,500
Gross profit	6,947,500	7,021,900	6,394,700
Selling, general & administrative expenses, excluding goodwill impairment & receivable impairment	5,160,000	5,004,300	4,689,900
Goodwill impairment	2,727,000
Receivable impairment	...	18,500	...
Selling, general & administrative expenses	7,887,000	5,022,800	4,689,900
Operating income (loss)	(939,500)	1,999,100	1,704,800
Interest expense, net	370,000	301,800	375,500

Consolidated Balance Sheet, Years Ended (\$000):

	02/02/19	¹¹ 02/03/18 (revised)
Cash & cash equivalents	422,100	1,097,800
Merchandise inventories, net	3,536,000	3,169,300
Prepaid rent	142,500	138,300
Accounts receivable, net	100,900	90,400
Prepaid store supplies	46,300	47,100
Other prepaid assets	45,500	33,400
Other current assets	335,200	309,200
Total current assets	4,293,300	4,576,300
Land	215,300	208,000
Buildings	1,300,700	1,092,500
Leasehold improvements	2,037,400	1,860,200
Furniture, fixtures, & equipment	3,348,700	3,003,300
Construction in progress	233,800	228,800
Total property, plant & equipment	7,135,900	6,392,800
Less: accumulated depreciation	3,690,600	3,192,100
Property, plant & equipment, net	3,445,300	3,200,700
Restricted cash	24,600	...
Goodwill	2,296,600	5,025,200
Favorable lease rights, net	²² 288,700	²³ 375,300
Trademark intangible asset	3,100,000	3,100,000
Total assets	13,501,200	16,332,800
Current portion of		

long-term debt	915,900	
Accounts payable	1,416,400	1,174,800
Income taxes payable	60,000	31,500
Taxes (other than income taxes)	159,500	176,600
Compensation & benefits	122,100	155,200
Insurance	106,000	105,400
Accrued interest	29,100	91,100
Accrued construction costs	43,200	45,000
Rent liabilities	37,500	34,100
Accrued utility expenses	23,100	23,900
Other current liabilities	98,800	105,600
Total current liabilities	2,095,700	2,859,100
Long-term debt, excluding current portion	4,265,300	4,762,100
Unfavorable lease rights, net	78,800	100,000
Deferred income taxes, net	973,200	985,200
Income taxes payable, long-term	35,400	43,800
Insurance	221,600	230,200
Deferred rent	142,800	136,500
Other long-term liabilities	45,500	33,600
Total liabilities	7,858,300	9,150,500
Common stock	2,400	2,400
Additional paid-in capital	2,602,700	2,545,300
Accumulated other comprehensive income (loss)	(38,300)	(32,300)
Retained earnings	3,076,100	4,666,900
Total shareholders' equity	5,642,900	7,182,300

□ Reclassified to conform with 2019 presentation; □ Accumulated amortization - favorable lease rights: \$287,800,000; □ Accumulated amortization - favorable lease rights: \$230,900,000; □ Accumulated amortization - unfavorable lease rights: \$76,900,000; □ Accumulated amortization - unfavorable lease rights: \$61,100,000

Recent Dividends:

1. Dollar Tree Inc common.

No dividends paid.

Annual Dividends:

1. Dollar Tree Inc common.

No dividends paid.

DRONE AVIATION HOLDING CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Revenues	2,722,713	562,078	1,468,462
Cost of goods sold	2,214,166	338,579	557,725
Gross profit	508,547	223,499	910,737
General & administrative expense	8,639,364	10,069,841	9,732,219
Income (loss) from operations	(8,130,817)	(9,846,342)	(8,821,482)
Debt forgiveness			75,000
Gain (loss) on debt extinguishment		(681,988)	
Derivative gain		1,831,635	562,961
Interest expense	344,496	1,627,297	349,994
Total other income (expense)	(344,496)	(477,650)	287,967
Net income (loss)	(8,475,313)	(10,323,992)	(8,533,515)
Net income (loss) attributable to common stockholders	(8,475,313)	(10,323,992)	(8,533,515)
Weighted average shares outstanding - basic	9,547,077	8,956,365	6,919,510
Weighted average shares outstanding - diluted	9,547,077	8,956,365	6,919,510
Year end shares outstanding	23,640,621	9,182,470	8,682,220
Net income (loss)			

per share - basic	\$(0.89)	\$(1.15)	\$(1.23)
Net income (loss) per share - diluted	\$(0.89)	\$(1.15)	\$(1.23)
Number of full time employees	18	21	21
Number of part time employees	2	2	2
Number of common stockholders	102	101	112
Number of beneficiary stockholders			5,600

□ Shares increased due to conversion related party convertible notes and common stock issued for cash; □ Approximately; □ As of March 21, 2019; □ As of March 23, 2018; □ As of March 17, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Accounts receivable - trade	18,000	110,065
Raw materials	136,555	114,119
Work in progress	180,041	482,770
Finished goods	523,698	398,912
In transit		5,468
Less: valuation allowance	532,369	9,572
Inventory, net	307,925	991,697
Prepaid insurance	28,828	30,847
Prepaid products & services	54,870	66,246
Prepaid rent & security deposit	5,915	5,915
Cash	2,282,365	615,375
Prepaid expenses & deposits	89,613	103,008
Total current assets	2,697,903	1,820,145
Shop machinery & equipment	87,534	87,704
Computers & electronics	32,093	35,270
Office furniture & fixtures	37,814	37,814
Vehicle		73,142
Leasehold improvements	19,514	19,514
Property & equipment, at cost	176,955	253,444
Less - accumulated depreciation	123,725	97,507
Net property & equipment	53,230	155,937
Goodwill	99,799	99,799
Intangible assets, net	705,667	997,667
Total assets	3,556,599	3,073,548
Accounts payable - trade & accrued liabilities	485,024	205,359
Accounts payable due to related party		171,981
Bank line of credit	2,000,000	1,000,000
Related party convertible note payable		1,000,000
Total current liabilities	2,485,024	2,377,340
Related party convertible notes payable		3,000,000
Total liabilities	2,485,024	5,377,340
Common stock	2,364	918
Additional paid-in capital	39,541,301	27,692,067
Retained earnings (accumulated deficit)	(38,472,090)	(29,996,777)
Total stockholders' equity (deficit)	1,071,575	(2,303,792)

Recent Dividends:

1. Drone Aviation Holding Corp series F convertible preferred.

No dividends paid.

2. Drone Aviation Holding Corp series B convertible preferred.

No dividends paid.

3. Drone Aviation Holding Corp series C convertible preferred.

No dividends paid.

4. Drone Aviation Holding Corp series G convertible preferred.

No dividends paid.

No dividends paid.
5. Drone Aviation Holding Corp series A convertible preferred.
 No dividends paid.
6. Drone Aviation Holding Corp common.
 No dividends paid.
7. Drone Aviation Holding Corp series E convertible preferred.
 No dividends paid.
8. Drone Aviation Holding Corp series B-1 convertible preferred.
 No dividends paid.
9. Drone Aviation Holding Corp series D convertible preferred.
 No dividends paid.

Annual Dividends:

1. Drone Aviation Holding Corp series F convertible preferred.

No dividends paid.

2. Drone Aviation Holding Corp series B convertible preferred.

No dividends paid.

3. Drone Aviation Holding Corp series C convertible preferred.

No dividends paid.

4. Drone Aviation Holding Corp series G convertible preferred.

No dividends paid.

5. Drone Aviation Holding Corp series A convertible preferred.

No dividends paid.

6. Drone Aviation Holding Corp common.

No dividends paid.

7. Drone Aviation Holding Corp series E convertible preferred.

No dividends paid.

8. Drone Aviation Holding Corp series B-1 convertible preferred.

No dividends paid.

9. Drone Aviation Holding Corp series D convertible preferred.

No dividends paid.

EQUILLIUM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017
Research & development expenses	4,943,149	1,333,721
General & administrative expenses	3,672,438	378,328
Total operating expenses	8,615,587	1,712,049
Income (loss) from operations	(8,615,587)	(1,712,049)
Interest expense	2,557,510	379,385
Interest income	339,620	
Change in fair value of biocon anti-dilution right	2,416,998	170,440
Total other income (expense)	(4,634,888)	(549,825)
Net income (loss)	(13,250,475)	(2,261,874)
Weighted average shares outstanding - basic	12,190,245	10,106,760
Weighted average shares outstanding - diluted	12,190,245	10,106,760
Year end shares outstanding	17,376,236	10,708,074
Net earnings (loss) per share - basic	\$(1.09)	\$(0.22)
Net earnings (loss) per share - diluted	\$(1.09)	\$(0.22)
Number of full time employees	11	
Total number of employees	11	7
Number of common stockholders	33	

□ From March 16, 2017 (inception); □ Reclassified to conform with 2018 presentation; □ Adjusted for 1-for-8.62 reverse stock split, October 1, 2018; □ Shares increased due to issuance of common stock upon conversion of promissory notes and to biocon

pursuant to certain anti-dilution rights and issuance of shares for public offering; ^⑤ As of June 30, 2018; ^⑥ Approximately; ^⑦ As of March 26, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	^⑦ 2017 (revised)
Cash & cash equivalents	28,508,534	7,103,553
Short-term investments	37,404,750	...
Prepaid expenses & other current assets	1,185,844	45,813
Total current assets	67,099,128	7,149,366
Furniture & fixtures	23,283	...
Machinery & lab equipment	23,686	...
Computer equipment	22,770	2,199
Less depreciation & amortization	6,224	122
Property & equipment, net	63,515	2,077
Total assets	67,162,643	7,151,443
Accounts payable	1,119,150	243,741
Accrued payroll & other employee benefits	559,541	15,548
Clinical studies	244,506	...
Other accruals	96,412	632
Preclinical studies	8,368	36,000
Accrued taxes	...	184,527
Accrued interest	...	88,372
Accrued expenses	908,827	325,079
Total current liabilities	2,027,977	568,820
Long-term convertible promissory notes	...	6,994,847
Long-term convertible promissory notes, related party	...	1,064,019
Biocon anti-dilution right	...	775,842
Other non-current liabilities	199,530	...
Total liabilities	2,227,507	9,403,528
Common stock	789	124
Additional paid-in capital	80,441,417	9,665
Accumulated other comprehensive gain (loss)	5,279	...
Retained earnings (accumulated deficit)	(15,512,349)	(2,261,874)
Total stockholders' equity (deficit)	64,935,136	(2,252,085)

^⑧ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Equillium Inc common.

No dividends paid.

Annual Dividends:

1. Equillium Inc common.

No dividends paid.

ETON PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2018	^⑨ 2017 (revised)
Research & development expenses	5,627	3,930
General & administrative expenses	4,694	3,220
Total operating expenses	10,321	7,150
Income (loss) from operations	(10,321)	(7,150)
Interest & other income, net	164	35
Change in fair value of warrant liability	(2,583)	(41)
Income (loss) before income taxes	(12,740)	(7,156)
Net income (loss)	(12,740)	(7,156)
Accrued dividends on redeemable convertible preferred stock	1,048	643
Deemed dividends for accretion of redeemable convertible preferred

	2018	2017
stock issuance costs	1,694	840
Deemed dividends for beneficial conversion feature of redeemable convertible preferred stock	21,747	...
Net income (loss) attributable to common stockholders	(37,229)	(8,639)
Weighted average shares outstanding - basic	6,418	3,453
Weighted average shares outstanding - diluted	6,418	3,453
Year end shares outstanding	^⑩ 17,608	6,000
Net earnings (loss) per share - basic	\$(5.80)	\$(2.50)
Net earnings (loss) per share - diluted	\$(5.80)	\$(2.50)
Number of full time employees	^⑪ 15	^⑫ 10
Number of common stockholders	^⑬ 243	^⑭ 69

^⑮ From April 27, 2017 (inception); ^⑯ Shares increased due to the effect of stock-based compensation and issuance of common stock in connection with initial public offering, including underwriter's over-allotment; ^⑰ Shares increased due to the effect of conversion of redeemable convertible preferred stock (including accrued dividends) to common stock in connection with initial public offering; ^⑱ As Is; ^⑲ As of February 28, 2019; ^⑳ As of June 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	26,735	13,156
Prepaid expenses	767	136
Total current assets	27,502	13,292
Computer hardware & software	93	46
Furniture & fixtures	98	42
Equipment	99	...
Leasehold improvements	53	42
Construction in progress	492	...
Property & equipment, gross	835	130
Less: accumulated depreciation	62	11
Property & equipment, net	773	119
Other long-term assets, net	52	32
Total assets	28,327	13,443
Accounts payable	1,421	539
Accrued liabilities	603	254
Total current liabilities	2,024	793
Warrant liability	...	520
Total liabilities	2,024	1,313
Redeemable convertible preferred stock - series A	...	19,004
Common stock	18	6
Additional paid-in capital	72,153	1,759
Retained earnings (accumulated deficit)	(45,868)	(8,639)
Total stockholders' equity (deficit)	26,303	(6,874)

Recent Dividends:

1. Eton Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Eton Pharmaceuticals Inc common.

No dividends paid.

EVO PAYMENTS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2018	2017 (revised)	2016 (revised)
Revenue	564,754	504,750	419,221
Cost of services &

products	189,375	164,480	140,659
Selling, general & administrative expense	311,353	220,971	174,198
Depreciation & amortization	87,184	74,136	64,012
Impairment of intangible assets	14,627
Total operating expenses	602,539	459,587	378,869
Income (loss) from operations	(37,785)	45,163	40,352
Interest income	2,219	1,489	1,096
Interest expense	59,759	62,876	40,658
Income from investment in unconsolidated investees	1,513	941	1,547
Gain on acquisition of unconsolidated investee	8,404
Other income (expense), net	(2,998)	(477)	72,147
Total other income (expense), net	(50,621)	(60,923)	34,132
Income before income taxes - Domestic	(122,699)	(76,255)	20,193
Income before income taxes - Foreign	34,293	60,495	54,291
Income (loss) before income taxes	(88,406)	(15,760)	74,484
Current foreign income taxes	12,735	4,711	22,193
Current federal income taxes	146	306	...
Current state income taxes	(43)	57	(105)
Current income taxes	12,838	5,074	22,088
Deferred foreign income taxes	4,217	11,294	(5,055)
Deferred federal income taxes	(5,821)	220	...
Deferred state income taxes	(790)
Deferred income taxes	(2,394)	11,514	(5,055)
Income tax expense (benefit)	10,444	16,588	17,033
Net income (loss)	(98,850)	(32,348)	57,451
Less: net income attributable to non-controlling interests in consolidated entities	(6,696)	(7,894)	(9,746)
Net income (loss) attributable to EVO	...	(40,242)	47,705
Investco, LLC	...	(40,242)	47,705
Less: net loss attributable to non-controlling interests of EVO
Investco, LLC	90,834
Net loss attributable to EVO	(14,712)
Payments, Inc.
Weighted average Class A common stock outstanding - basic	21,081
Weighted average Class A common stock outstanding - diluted	21,081
Year end units outstanding	^⑳ 81,185	12,374	11,362
Net income (loss) per share - basic	\$(0.70)
Net income (loss) per share - diluted	\$(0.70)
Total number of

employees.....	2,200	2,000	...
Number of common stockholders - class A.....	8
Number of common stockholders - class B.....	1
Number of common stockholders - class C.....	7
Number of common stockholders - class D.....	13

☐ Shares increased due to the effects of acquisition, share-based compensation, public offerings, contingent consideration settles. Employee Ownership sold, and shares converted; ☐ As is; ☐ Approximately; ☐ As of January 31, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents.....	350,697	205,142
Accounts receivable, net.....	13,248	15,881
Other receivables.....	56,518	55,345
Due from related parties.....	1,871	2,625
Inventory.....	8,867	11,210
Settlement processing assets.....	248,330	439,269
Other current assets.....	11,817	20,941
Total current assets.....	691,348	750,413
Card processing.....	128,244	102,789
Office equipment.....	41,771	37,476
Computer software.....	44,373	38,669
Leasehold improvements.....	16,234	12,764
Furniture & fixtures.....	5,673	5,410
Equipment & improvements, gross.....	236,295	197,108
Less: Accumulated depreciation.....	136,947	106,889
Foreign currency translation adjustment.....	3,698	6,368
Equipment & improvements, net.....	103,046	96,587
Goodwill.....	353,011	311,678
Intangible assets, net.....	290,139	313,483
Investment in unconsolidated investees.....	1,753	1,379
Due from related parties.....	915	109
Deferred tax asset.....	72,296	9,057
Other assets.....	21,879	25,592
Total assets.....	1,534,387	1,508,298
Settlement lines of credit.....	41,819	28,563
Current portion of long-term debt.....	7,191	75,008
Accounts payable.....	48,935	61,149
Accrued expenses.....	112,281	89,601
Settlement processing obligations.....	428,328	484,518
Due to related parties.....	4,824	7,847
Total current liabilities.....	643,378	746,686
First lien term loan.....	654,775	566,075
Second lien term loan.....	...	175,206
First lien revolver.....	42,266	44,632
Deferred purchase price.....	...	68,720
Letter of credit.....	...	1,000
Less debt issuance costs.....	(12,985)	(19,679)
Less current portion of long-term debt.....	7,191	75,008
Long-term debt, net.....	676,865	760,946
Due to related parties.....	385	675
Deferred tax liability.....	13,519	11,011
Tax receivable agreement obligations.....	47,221	...
ISO reserves.....	2,684	2,611
Other long-term liabilities.....	2,924	4,634
Total liabilities.....	1,386,976	1,526,563
Redeemable non-controlling interests.....	1,010,093	148,266
Class A units.....	...	54,453
Class C units.....	...	9,463
Class E units.....	...	71,250

Class A common stock.....	3	...
Class B common stock.....	4	...
Class D common stock.....	1	...
Additional paid-in capital.....	178,176	...
Retained earnings (accumulated deficit) attributable to class A common stock.....	(223,799)	...
Retained earnings (accumulated deficit) attributable to members of EVO Investco, LLC.....	...	(237,330)
Accumulated other comprehensive income (loss).....	(2,993)	(67,679)
Total shareholders' or members' equity (deficit).....	(48,608)	(169,843)
Nonredeemable non-controlling interests.....	(814,074)	3,312
Total equity (deficit).....	(862,682)	(166,531)

☐ Reclassified to conform with 2018 presentation; ☐ Inclusive of related party liability - tax receivable agreement obligations: \$40,700,000

Recent Dividends:

- EVO Payments Inc class B common.**
No dividends paid.
- EVO Payments Inc class D common.**
No dividends paid.
- EVO Payments Inc class C common.**
No dividends paid.
- EVO Payments Inc class A common.**
No dividends paid.

Annual Dividends:

- EVO Payments Inc class B common.**
No dividends paid.
- EVO Payments Inc class D common.**
No dividends paid.
- EVO Payments Inc class C common.**
No dividends paid.
- EVO Payments Inc class A common.**
No dividends paid.

EVOLUS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Research & development expenses.....	6,487	6,689	12,607
General & administrative expenses.....	29,146	4,819	7,033
Revaluation of contingent royalty obligation to Evolus, Inc. founders, a related party expenses.....	10,500
Depreciation & amortization expenses.....	9	218	326
Total operating expenses.....	46,142	11,726	19,966
Income (loss) from operations.....	(46,142)	(11,726)	(19,966)
Interest income.....	203
Interest expense.....	863	5	...
Other expenses, net.....	6
Income (loss) before taxes.....	(46,802)	(11,731)	(19,972)
Current federal provision (benefit) for income taxes.....	...	(775)	...
Current state provision (benefit) for income taxes.....	...	(221)	...
Total current provision (benefit) for income taxes.....	...	(996)	...
Deferred federal

provision (benefit) for income taxes.....	44	(6,276)	72
Deferred state provision (benefit) for income taxes.....	21	21	21
Total deferred provision (benefit) for income taxes.....	65	(6,255)	93
Provision (benefit) for income taxes.....	65	(7,251)	93
Net income (loss).....	(46,867)	(4,480)	(20,065)
Weighted average shares outstanding - basic.....	24,402	16,527	16,527
Weighted average shares outstanding - diluted.....	24,402	16,527	16,527
Year end shares outstanding.....	27,275	16,527	16,527
Net earnings (loss) per share - basic.....	\$(1.92)	\$(0.27)	\$(1.21)
Net earnings (loss) per share - diluted.....	\$(1.92)	\$(0.27)	\$(1.21)
Number of full time employees.....	70	21	...
Total number of employees.....	22
Number of common stockholders.....	39	2	...

☐ Reclassified to conform with 2018 presentation; ☐ Reclassified to conform with 2017 presentation; ☐ Shares increased due to preferred stock conversion upon initial public offering and issuance of common stock; ☐ As is; ☐ As of February 28, 2019; ☐ As of March 23, 2018; ☐ As of December 31, 2017; ☐ Approximately; ☐ As of March 12, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash.....	93,162	...
Prepaid expenses & other current assets.....	1,177	185
Related party receivable.....	...	72,639
Total current assets.....	94,339	72,824
Intangible asset.....	56,076	56,076
Goodwill.....	21,208	21,208
Other assets.....	221	2,125
Total assets.....	171,844	152,233
Accounts payable.....	1,558	445
Accrued expenses - payroll & related benefits.....	2,577	109
Accrued expenses - professional services & related expenses.....	931	868
Accrued expenses - other.....	210	...
Accrued expenses.....	3,718	977
Related party borrowings.....	...	72,639
Note obligation.....	...	138,687
Total current liabilities.....	5,276	212,748
Deferred rent.....	25	38
Contingent royalty obligation payable to Evolus, Inc. founders, a related party.....	50,200	...
Contingent promissory note payable to Evolus, Inc. founders, a related party.....	16,904	...
Deferred tax liability.....	15,055	14,990
Total liabilities.....	87,460	227,776
Common stock.....	1	...
Additional paid-in capital.....	207,408	...
Retained earnings (accumulated deficit).....	(123,025)	(75,543)
Total stockholders' equity (deficit).....	84,384	(75,543)

☐ Reclassified to conform with 2018 presentation

Recent Dividends:

- Evolus Inc common.**

EYEPOINT PHARMACEUTICALS INC			
Annual Report			
Consolidated Income Statement, Years Ended (\$):			
	¹ 12/31/18	06/30/18	06/30/17 (revised)
Collaborative research & development revenue	1,883,000	1,343,000	6,569,000
Royalty income	1,045,000	1,618,000	970,000
Total revenues	2,928,000	2,961,000	7,539,000
Research & development expenses	10,412,000	16,178,000	14,880,000
Sales & marketing	8,174,000	1,512,000	...
General & administrative expenses	8,901,000	11,545,000	11,235,000
Total operating expenses	27,487,000	29,235,000	26,115,000
Operating income (loss)	(24,559,000)	(26,274,000)	(18,576,000)
Interest & other income, net	367,000	101,000	91,000
Interest expense	1,642,000	720,000	...
Change in fair value of derivative liability	(18,886,000)	(26,278,000)	...
Income (loss) before income taxes - U.S. operations	(44,804,000)	(53,000,000)	(17,566,000)
Income (loss) before income taxes - non-U.S. operations	84,000	(171,000)	(919,000)
Income (loss) before income taxes	(44,720,000)	(53,171,000)	(18,485,000)
Net income (loss)	(44,720,000)	(53,171,000)	(18,485,000)
Weighted average shares outstanding - basic	85,057,000	46,226,000	35,344,000
Weighted average shares outstanding - diluted	85,057,000	46,226,000	35,344,000
Year end shares outstanding	² 95,372,236	³ 74,512,048	39,356,999
Net income (loss) per share - basic	\$(0.53)	\$(1.15)	\$(0.52)
Net income (loss) per share - diluted	\$(0.53)	\$(1.15)	\$(0.52)
Total number of employees	⁴ 55	⁵ 44	⁶ 22
Number of common stockholders	⁷ 100	⁸ 114	⁹ 15
Number of beneficiary stockholders	¹⁰ 6,300	¹¹ 8,500	¹² 5,100
Foreign currency translation adjustments	...	5,000	(21,000)

¹ For 6 months due to fiscal year end change; ² Shares increased due to the effect of exercise of warrants, stock options and vesting of stock units; ³ Shares increased due to the effect of issuance of stock, exercise of stock options and vesting of stock units; ⁴ As of March 1, 2019; ⁵ As of August 31, 2018; ⁶ As of August 31, 2017; ⁷ Approximately; ⁸ As of March 8, 2019; ⁹ As of September 13, 2018; ¹⁰ As of September 7, 2017

Consolidated Balance Sheet, Years Ended (\$):		
	12/31/18	06/30/18
Cash & cash equivalents	45,261,000	38,776,000
Accounts & other receivables	627,000	353,000
Prepaid expenses & other		

current assets	1,434,000	780,000
Inventory	279,000	...
Total current assets	47,601,000	39,909,000
Property & equipment	882,000	805,000
Leasehold improvements	101,000	101,000
Gross property & equipment	983,000	906,000
Accumulated depreciation & amortization	695,000	653,000
Property & equipment, net	288,000	253,000
Intangible assets, net	30,129,000	31,358,000
Restricted cash	150,000	150,000
Total assets	78,168,000	71,670,000
Accounts payable	2,640,000	2,940,000
Accrued personnel costs	1,998,000	1,763,000
Accrued clinical trial costs	798,000	742,000
Accrued professional fees	571,000	926,000
Accrued interest	343,000	254,000
Other accrued expenses	79,000	38,000
Accrued expenses	3,789,000	3,723,000
Accrued development milestone	15,000,000	15,000,000
Deferred revenue	30,000	...
Total current liabilities	21,459,000	21,663,000
Long-term debt	17,621,000	17,309,000
Derivative liability	...	19,780,000
Other long-term liabilities	1,455,000	1,231,000
Total liabilities	40,535,000	59,983,000
Common stock	95,000	74,000
Additional paid-in capital	445,192,000	374,766,000
Retained earnings (accumulated deficit)	(408,493,000)	(363,991,000)
Accumulated other comprehensive income	839,000	838,000
Total stockholders' equity	37,633,000	11,687,000

Recent Dividends:**1. EyePoint Pharmaceuticals Inc common.**

No dividends paid.

2. EyePoint Pharmaceuticals Inc American Depositary Receipts.

No dividends paid.

Annual Dividends:**1. EyePoint Pharmaceuticals Inc common.**

No dividends paid.

2. EyePoint Pharmaceuticals Inc American Depositary Receipts.

No dividends paid.

EYEPOINT PHARMACEUTICALS INC Auditor's Report Auditor's Comment

The following is an excerpt from the Report of the Independent Auditors, Deloitte & Touche LLP, as it appeared in Co.'s 2018 10K: "We have audited the accompanying consolidated balance sheets of EyePoint Pharmaceuticals, Inc. and subsidiaries (the "Company") as of December 31, 2018 and June 30, 2018 and 2017, the related consolidated statements of comprehensive loss, stockholders' equity, and cash flows for the six month period ended December 31, 2018, and each of the three years in the period ended June 30, 2018, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and June 30, 2018 and 2017, and the results of its operations and its cash flows for the six month period ended December 31, 2018, and each of the three years in the period ended June 30, 2018, in conformity with accounting principles generally accepted in the United States of America. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 18, 2019, expressed an unqualified opinion on the Company's internal control over financial reporting. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company's limited currently available cash, cash equivalents

and available borrowings, together with its history of losses, and the uncertainty in timing of cash receipts from its newly launched products raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

FIBROCELL SCIENCE INC Annual Report**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2018	¹ 2017 (revised)	² 2016 (revised)
Revenue from product sales	337,000
Collaboration revenue	18,000
Total revenue	355,000
Cost of product sales	696,000
Cost of collaboration revenue	1,000
Total cost of revenue	697,000
Gross profit (loss)	(342,000)
Research & development expenses	6,018,000	6,512,000	8,400,000
Research & development expenses - related party	(34,000)	5,720,000	3,724,000
Selling, general & administrative expenses	6,405,000	6,749,000	9,773,000
Impairment asset impairment expense	3,905,000
Restructuring costs	335,000
Total operating expenses	12,389,000	18,981,000	...
Income (loss) from operations	(12,389,000)	(18,981,000)	(26,479,000)
Warrant revaluation income (expense)	921,000	4,920,000	11,884,000
Derivative revaluation expense (income)	(1,662,000)	1,407,000	462,000
Interest expense	771,000	828,000	228,000
Other income (expense), net	300,000	56,000	(7,000)
Income (loss) before income taxes	(10,277,000)	(16,240,000)	(15,292,000)
Net income (loss)	(10,277,000)	(16,240,000)	(15,292,000)
Dividend paid in-kind to preferred stockholders	336,000	264,000	...
Deemed dividend on preferred stock	513,000	4,099,000	...
Net income (loss) attributable to common stockholders	(11,126,000)	(20,603,000)	(15,292,000)
Weighted average shares outstanding - basic	7,693,191	³ 3,092,543	⁴ 2,928,306
Weighted average shares outstanding - diluted	7,693,191	⁵ 3,093,727	⁶ 2,929,507
Year end shares outstanding	9,758,332	⁷ 5,188,049	⁸ 2,937,627
Net income (loss) per share - basic	\$(1.45)	⁹ \$(6.66)	¹⁰ \$(5.20)
Net income (loss) per share - diluted	\$(1.45)	¹¹ \$(6.67)	¹² \$(5.90)
Number of full time employees	19	20	23
Number of common stockholders	¹³ 33	¹⁴ 35	¹⁵ 139

¹ Reclassified to conform with 2018 presentation; ² Reclassified to conform with 2017 presentation; ³ Adjusted for 1-for-5 stock split, May 25, 2018; ⁴ Adjusted for 1-for-3 stock split,

March 13, 2017; [□] Approximately; [□] As of March 20, 2019; [□] As of March 6, 2018; [□] As of March 3, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	[□] 2017 (revised)
Cash & cash equivalents	14,430,000	17,417,000
Prepaid expenses & other current assets	105,000	485,000
Total current assets	14,535,000	17,902,000
Laboratory equipment	1,562,000	1,514,000
Computer equipment & software	319,000	318,000
Furniture & fixtures	44,000	44,000
Leasehold improvements	1,449,000	1,412,000
Construction-in-process	159,000	101,000
Total property & equipment, gross	3,533,000	3,389,000
Less: accumulated depreciation	2,311,000	1,919,000
Property & equipment, net	1,222,000	1,470,000
Other assets	1,000	39,000
Total assets	15,758,000	19,411,000
Accounts payable	452,000	862,000
Related party payable	100,000	2,303,000
Accrued professional fees	281,000	322,000
Accrued compensation	449,000	462,000
Accrued clinical trial expenses	525,000	342,000
Accrued other expenses	215,000	134,000
Accrued expenses	1,470,000	1,260,000
Deferred rent, current	150,000	...
Total current liabilities	2,172,000	4,425,000
Accrued interest payable	1,738,000	967,000
Warrant liability	152,000	1,073,000
Derivative liability	1,474,000	3,136,000
Deferred rent	665,000	803,000
Total liabilities	6,201,000	10,404,000
Common stock	10,000	5,000
Additional paid-in capital	198,627,000	187,805,000
Retained earnings (accumulated deficit)	(189,080,000)	(178,803,000)
Total shareholders' equity (deficit)	9,557,000	9,007,000

[□] Reclassified to conform with 2018 presentation

Recent Dividends:

- 1. Fibrocell Science Inc common.**
No dividends paid.
 - 2. Fibrocell Science Inc series A redeemable preferred.**
No dividends paid.
 - 3. Fibrocell Science Inc series D redeemable preferred.**
No dividends paid.
 - 4. Fibrocell Science Inc series B redeemable preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Fibrocell Science Inc common.**
No dividends paid.
 - 2. Fibrocell Science Inc series A redeemable preferred.**
No dividends paid.
 - 3. Fibrocell Science Inc series D redeemable preferred.**
No dividends paid.
 - 4. Fibrocell Science Inc series B redeemable preferred.**
No dividends paid.

FIBROCELL SCIENCE INC Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, PricewaterhouseCoopers LLP, as it appeared in Co.'s 2018 10-K: "We have audited the accompanying consolidated balance sheets of Fibrocell Science, Inc. and its subsidiaries ("the Company") as of December 31, 2018 and 2017, and the related consolidated statements of operations, stockholders' equity and cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt About the Company's Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the

Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations, has an accumulated deficit and cash outflows from operating activities that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

FIRSTHAND TECHNOLOGY VALUE FUND INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	[□] 2017 (revised)	[□] 2016 (revised)
Investment income - affiliated/controlled loan origination income	21,000	24,180	28,213
Investment income - unaffiliated interest	6,228	1,522	19,133
Investment income - affiliated/controlled interest	3,440,610	1,540,089	830,677
Total investment income	3,467,838	1,565,791	878,023
Investment advisory fees	4,128,311	2,975,982	3,281,617
Administration fees	207,292	187,846	165,024
Custody fees	32,123	22,152	11,334
Transfer agent fees	35,176	33,017	27,283
Registration & filing fees	30,600	23,100	23,100
Professional fees	375,496	535,293	779,689
Printing fees	62,376	195,892	40,835
Trustees fees	200,000	137,500	100,000
Compliance fees	114,648	107,640	188,569
Miscellaneous fees	87,830	174,670	96,075
Total gross expenses	5,273,852	4,393,092	4,713,526
Incentive fees adjustment	7,570,807	1,691,040	...
Total net expenses	12,844,659	6,084,132	4,713,526
Net investment income (loss), before taxes	(9,376,821)	(4,518,341)	(3,835,503)
Deferred tax benefit	(538,915)
Net investment income (loss)	(8,837,906)	(4,518,341)	(3,835,503)
Year end shares outstanding	7,178,770	7,302,146	7,430,697
Net investment income (loss) per share	\$(1.22)	\$(0.62)	\$(0.52)
Number of common stockholders	[□] 1,400	[□] 1,700	[□] 1,800
Number of beneficiary stockholders	[□] 12,800	[□] 13,400	[□] 16,000

[□] Reclassified to conform with 2018 presentation; [□] Approximately; [□] As of February 28, 2019; [□] As of February 28, 2018; [□] As of February 28, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	[□] 2017 (revised)
Investment securities - unaffiliated investments at acquisition cost	3,961,467	33,014,039
Investment securities - affiliated investments at acquisition cost	31,002,275	24,035,159
Investment securities - controlled investments at acquisition cost	132,313,596	117,890,661
Investment securities - total acquisition cost	167,277,338	174,939,859
Investment securities - unaffiliated investments at market value	5,696,042	40,191,055
Investment securities - affiliated investments at market value	34,045,111	24,656,252

Investment securities - controlled investments at market value

Cash	170,112,417	109,992,218
Receivable for securities sold	...	110,077
Receivable from dividends & interest	1,005	...
Other assets	2,308,366	1,794,003
Total assets	18,713	27,985
Payable to securities purchased	212,181,654	176,771,590
Incentive fees payable	365,783	...
Payable to affiliates	9,261,847	1,691,040
Deferred tax liability	2,334,727	879,085
Consulting fee payable	8,432,559	...
Accrued expenses & other payables	19,500	21,000
Total liabilities	149,279	186,876
Net assets	20,563,695	2,778,001
Common stock	191,617,959	173,993,589
Paid-in-capital	7,179	7,302
Total distributable earnings (loss)	178,770,434	180,772,769
Net assets	12,840,346	(6,786,482)
Net assets value per share	191,617,959	173,993,589
	\$26.69	\$23.83

[□] Reclassified to conform with 2018 presentation

Recent Dividends:

- 1. Firsthand Technology Value Fund Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. Firsthand Technology Value Fund Inc common.**
No dividends paid.

FIVE BELOW INC Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/02/19	02/03/18	[□] 01/28/17 (revised)
Net sales	1,559,563	1,278,208	1,000,410
Cost of goods sold	994,478	814,795	643,373
Gross profit	565,085	463,413	357,037
Selling, general & administrative expenses	377,901	306,022	243,075
Operating income	187,184	157,391	113,962
Interest income (expense), net	4,623	1,458	299
Income before income taxes	191,807	158,849	114,261
Current income tax expense (benefit) - federal	33,297	45,867	40,053
Current income tax expense (benefit) - state	8,315	6,168	4,900
Total current income tax expense (benefit)	41,612	52,035	44,953
Deferred income tax expense (benefit) - federal	2,000	4,606	(1,772)
Deferred income tax expense (benefit) - state	(1,450)	(243)	(760)
Total deferred income tax expense (benefit)	550	4,363	(2,532)
Income tax expense (benefit)	42,162	56,398	42,421
Net income	149,645	102,451	71,840
Weighted average shares outstanding - basic	55,763	55,208	54,846
Weighted average shares outstanding - diluted	56,221	55,561	55,129
Year end shares outstanding	55,759	55,438	54,905
Net income (loss) per share - basic	\$2.68	\$1.86	\$1.31
Net income (loss)			

per share - diluted	\$2.66	\$1.84	\$1.30
Number of full time employees	23,500	22,700	21,800
Number of part time employees	10,400	9,400	7,700
Number of common stockholders	86,868	60,374	32,313

Reclassified to conform with 2018 presentation; Approximately: As Is; As of March 8, 2019; As of March 9, 2018; As of March 8, 2017

Consolidated Balance Sheet, Years Ended (\$000):

	02/02/19	02/03/18
Cash & cash equivalents	251,748	112,669
Short-term investment securities	85,412	131,958
Inventories	243,636	187,037
Prepaid income taxes	1,337	2,264
Prepaid expenses & other current assets	60,124	45,434
Total current assets	642,257	479,362
Land	7,150	...
Furniture & fixtures	145,254	114,394
Leasehold improvements	166,374	133,460
Computers & equipment	69,739	44,923
Construction in process	81,368	15,251
Property & equipment, gross	469,885	308,028
Less: accumulated depreciation & amortization	168,588	127,679
Property & equipment, net	301,297	180,349
Deferred income taxes	6,126	6,676
Long-term investment securities	27,702
Other assets	2,584	1,619
Total assets	952,264	695,708
Accounts payable	103,692	73,033
Income taxes payable	20,626	25,275
Accrued salaries & wages	24,586	22,906
Other accrued expenses	104,201	43,246
Total current liabilities	253,105	164,460
Deferred rent & other liabilities	84,065	72,690
Total liabilities	337,170	237,150
Common stock	557	554
Additional paid-in capital	352,702	346,300
Retained earnings (accumulated deficit)	261,835	111,704
Total shareholders' equity (deficit)	615,094	458,558

Recent Dividends:

1. Five Below Inc series A 8% convertible preferred.

No dividends paid.

2. Five Below Inc common.

No dividends paid.

Annual Dividends:

1. Five Below Inc series A 8% convertible preferred.

No dividends paid.

2. Five Below Inc common.

No dividends paid.

FLUENT INC

Annual Report

	2018	2017	2016
	(revised)	(revised)	(revised)
Revenue	250,280,000	211,690,000	186,836,000
Cost of revenue (exclusive of depreciation & amortization)	161,560,000	146,382,000	133,798,000
Sales & marketing expenses	13,663,000	11,973,000	16,296,000
Product development	5,279,000	2,578,000	...
General & administrative expenses	36,007,000	55,094,000	54,094,000
Depreciation &			

amortization	13,174,000	13,055,000	12,631,000
Write-off of long-lived assets	1,517,000	3,626,000	...
Spin-off transaction costs	7,708,000
Write-off of intangible assets	4,055,000
Total costs & expenses	238,908,000	232,708,000	220,874,000
Income (loss) from operations	11,372,000	(21,018,000)	(34,038,000)
Interest expense, net	8,134,000	9,683,000	7,593,000
Other expenses, net	1,005,000	1,497,000
Total other income (expense)	(9,090,000)
Income (loss) before income taxes from continuing operations	3,238,000	(31,706,000)	(43,128,000)
Current income tax expense (benefit) - state	87,000
Total current income tax expense (benefit)	87,000
Deferred income tax expense (benefit) - federal	3,726,000	(7,117,000)	(14,278,000)
Deferred income tax expense (benefit) - state	81,000	(1,855,000)	(1,732,000)
Deferred income tax expense (benefit) - valuation allowance	(3,761,000)	8,972,000	1,881,000
Total deferred income tax expense (benefit)	46,000	...	(14,129,000)
Income tax expense (benefit)	46,000	...	(14,042,000)
Net income (loss) from continuing operations	3,192,000	(31,706,000)	(29,086,000)
Income (loss) from operations of discontinued operations, net	(2,084,000)	(21,500,000)	...
Income (loss) on disposal of discontinued operations, net	(19,040,000)
Net income (loss) from discontinued operations	(21,124,000)	(21,500,000)	...
Net income (loss) attributable to Cogint	(29,086,000)
Weighted average shares outstanding - basic	76,705,877	61,153,069	44,536,906
Weighted average shares outstanding - diluted	76,705,877	61,153,069	44,536,906
Year end shares outstanding	75,292,383	61,279,050	53,557,761
Earnings (loss) per share from continuing operations - basic	\$0.04	\$(0.52)	\$(0.65)
Earnings (loss) per share from discontinued operations - basic	\$(0.28)	\$(0.35)	...
Net earnings (loss) per share - basic	\$(0.23)	\$(0.87)	\$(0.65)
Earnings (loss) per share from continuing operations - diluted	\$0.04	\$(0.52)	\$(0.65)
Earnings (loss) per share from discontinued			

operations - diluted	\$(0.28)	\$(0.35)	...
Net earnings (loss) per share - diluted	\$(0.23)	\$(0.87)	\$(0.65)
Number of full time employees	170
Number of part time employees	4
Total number of employees	174	...	200
Number of common stockholders	83	...	106

Restated to reflect the spin-off of Red Violet Subsidiaries as discontinued operations; Reclassified to conform with 2017 presentation; As Is; Approximately; As of March 13, 2019; As of March 6, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
	(revised)	(revised)
Cash & cash equivalents	17,769,000	16,564,000
Account receivable, gross	50,403,000	37,902,000
Less: allowance for doubtful accounts	1,751,000	1,624,000
Accounts receivable, net	48,652,000	36,278,000
Current assets of discontinued operations	2,274,000
Total current assets	68,392,000	56,981,000
Restricted cash	1,480,000	...
Computer & network equipment	276,000	159,000
Furniture & fixtures & office equipment	564,000	245,000
Leased furniture, fixtures & office equipment	747,000	...
Leasehold improvements	1,023,000	1,023,000
Total cost of property & equipment	2,610,000	1,427,000
Less: accumulated depreciation & amortization	1,230,000	740,000
Property & equipment, net	1,380,000	687,000
Intangible assets, net	61,812,000	74,354,000
Goodwill	159,791,000	159,791,000
Other non-current assets	414,000	1,097,000
Non-current assets of discontinued operations	24,089,000
Total assets	293,269,000	316,999,000
Accounts payable	7,855,000	7,408,000
Accrued expenses & other current liabilities	21,566,000	14,967,000
Deferred revenue	444,000	265,000
Current portion of long-term debt	3,500,000	2,750,000
Current liabilities of discontinued operations	7,389,000
Total current liabilities	33,365,000	32,779,000
Promissory notes payable to certain shareholders, net	10,837,000
Long-term debt, net	51,972,000	49,376,000
Other non-current liabilities	766,000	...
Total liabilities	86,103,000	92,992,000
Common stock	38,000	31,000
Treasury stock, at cost	3,272,000	1,274,000
Additional paid-in capital	395,769,000	392,687,000
Retained earnings (accumulated deficit)	(185,369,000)	(167,437,000)
Total stockholders' equity (deficit)	207,166,000	224,007,000

Restated to reflect the spin-off of Red Violet Subsidiaries as discontinued operations

Recent Dividends:

1. Fluent Inc series A non-voting convertible preferred.

No dividends paid.

2. Fluent Inc common.

ExDate Amt Declared Record Payable
03/27/2018 0.00 03/06/2018 03/19/2018 03/26/2018

3. Fluent Inc series B non-voting convertible preferred.

No dividends paid.

Annual Dividends:

1. Fluent Inc series A non-voting convertible preferred.

No dividends paid.

2. Fluent Inc common.

2018.....0.00

3. Fluent Inc series B non-voting convertible preferred.

No dividends paid.

FULGENT GENETICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2018	2017 (revised)	2016 (revised)
Revenue	21,351	18,730	18,276
Cost of revenue	10,697	8,551	6,722
Gross profit	10,654	10,179	11,554
Research & development expenses	5,534	4,223	3,558
Selling & marketing expenses	4,652	4,205	2,469
General & administrative expenses	5,538	5,233	4,609
Total operating expenses	15,724	13,661	10,636
Operating income (loss)	(5,070)	(3,482)	918
Interest & other income (expense)	434	481	(5,386)
Income (loss) before income taxes & equity loss in investee	(4,636)	(3,001)	(4,468)
Current federal income taxes	...	(599)	616
Current state income taxes	...	(80)	58
Total current income taxes	...	(679)	674
Deferred federal income taxes	(987)	(300)	295
Deferred state income taxes	(308)	(36)	(49)
Change in valuation allowance	1,331
Total deferred income taxes	36	(336)	246
Provision for (benefit from) income taxes	36	(1,015)	920
Income (loss) before equity loss in investee	(4,672)	(1,986)	(5,388)
Equity income (loss) in investee	(935)	(524)	...
Income (loss) from continuing operations	(5,388)
Income (loss) from discontinued operations	41
Net income (loss)	(5,607)	(2,510)	(5,347)
Deemed dividend on redemption of Class D-1 preferred unit	3,727
Distribution to Class D-1 preferred unitholder	4,592
Income (loss) allocable to common shareholders	(13,666)
Weighted average common shares outstanding - basic	17,978	17,739	13,710
Weighted average common shares outstanding -			

	17,978	17,739	13,710
diluted			
Year end shares outstanding	18,172	17,847	17,676
Net earnings (loss) per share - basic	\$(0.31)	\$(0.14)	\$(1.00)
Net earnings (loss) per shares - diluted	\$(0.31)	\$(0.14)	\$(1.00)
Number of full time employees	123	98	...
Total number of employees	123	98	70
Number of common stockholders	7	7	...

Reclassified to conform with 2018 presentation; As is; As of March 1, 2019; As of March 1, 2018; As of March 1, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	6,736	6,490
Marketable securities	24,298	19,994
Trade accounts receivable, gross	6,538	4,292
Allowance for doubtful accounts	590	287
Trade accounts receivable, net	5,948	4,005
Reagents	314	231
Prepaid expenses	706	624
Prepaid income taxes	1,251	1,313
Marketable securities interest receivable	220	204
Other receivable	70	66
Other current assets	2,561	2,438
Total current assets	39,543	32,927
Marketable securities, long term	6,386	14,883
Equity method investments	1,512	1,937
Computer hardware	1,579	1,435
Computer software	495	463
Medical lab equipment	8,136	7,145
Furniture & fixtures	233	159
Leasehold improvements	802	763
Assets not yet placed in service	1,087	1,074
Property & equipment, gross	12,332	11,039
Less: Accumulated depreciation	5,886	3,767
Fixed assets, net	6,446	7,272
Deferred tax asset	...	126
Other long-term assets	17	39
Total assets	53,904	57,184
Accounts payable	1,313	2,089
Accrued liabilities	1,425	911
Total current liabilities	2,738	3,000
Other long-term liabilities	14	6
Total liabilities	2,752	3,006
Common stock	2	2
Additional paid-in capital	114,203	111,884
Accumulated other comprehensive income (loss)	(35)	(44)
Retained earnings (accumulated deficit)	(63,018)	(57,664)
Total stockholders' equity	51,152	54,178

Recent Dividends:

1. Fulgent Genetics Inc common.

No dividends paid.

Annual Dividends:

1. Fulgent Genetics Inc common.

No dividends paid.

G-III APPAREL GROUP LTD.

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$):

	2019	2018 (revised)	2017 (revised)
Net sales	3,076,208,000	2,806,938,000	2,386,435,000
Cost of goods sold	1,969,099,000	1,752,199,000	1,545,107,000
Gross profit	1,107,109,000	1,054,739,000	841,328,000
Selling, general & administrative expenses	834,763,000	855,247,000	704,436,000
Depreciation & amortization	38,819,000	37,783,000	32,481,000
Asset impairments	2,813,000	7,884,000	10,480,000
Operating profit (loss)	230,714,000	153,825,000	93,931,000
Other income (loss)	(2,960,000)	(1,413,000)	(580,000)
Interest & financing charges, net	43,924,000	42,363,000	15,589,000
Income (loss) before income taxes - United States	137,748,000	93,691,000	55,363,000
Income (loss) before income taxes - non-United States	46,082,000	16,358,000	22,399,000
Income (loss) before income taxes	183,830,000	110,049,000	77,762,000
Current income tax provision (benefit) - federal	23,463,000	28,723,000	22,925,000
Current income tax provision (benefit) - state & city	5,907,000	2,592,000	4,034,000
Current income tax provision (benefit) - foreign	10,989,000	12,532,000	6,150,000
Total current income tax provision (benefit)	40,359,000	43,847,000	33,109,000
Deferred income tax provision (benefit) - federal	4,419,000	4,084,000	(4,776,000)
Deferred income tax provision (benefit) - state & city	191,000	1,285,000	(2,807,000)
Deferred income tax provision - foreign	794,000	(1,291,000)	298,000
Total deferred income tax provision (benefit)	5,404,000	4,078,000	(7,285,000)
Income tax expense (benefit)	45,763,000	47,925,000	25,824,000
Net income (loss)	138,067,000	62,124,000	51,938,000
Net income attributable to G-III Apparel Group, Ltd.	138,067,000	62,124,000	51,938,000
Weighted average shares outstanding - basic	49,140,000	48,820,000	46,308,000
Weighted average shares outstanding - diluted	50,274,000	49,750,000	47,394,000
Year end shares outstanding	48,709,000	49,113,000	48,640,000
Net income (loss) per share - basic	\$2.81	\$1.27	\$1.12
Net income (loss) per share - diluted	\$2.75	\$1.25	\$1.10
Number of full time employees	4,100
Number of part time employees	3,300
Total number of employees	...	9,071	8,734
Number of common stockholders	20	27	28
Number of beneficiary stockholders	22,000	17,000	20,000
Foreign currency translation adjustments	...	22,200,000	(4,033,000)

Reclassified to conform with 2019 presentation; Approxi-

mately; [Ⓜ] As is; [Ⓝ] As of March 25, 2019; [Ⓟ] As of March 28, 2018; [Ⓠ] As of March 31, 2017

Consolidated Balance Sheet, Years Ended Jan. 31 (\$):		
	2019	[Ⓠ] 2018 (revised)
Cash & cash equivalents	70,138,000	45,776,000
Accounts receivable, gross	503,033,000	296,530,000
Allowance for doubtful accounts & sales discount	900,000	2,100,000
Accounts receivable, net	502,133,000	[Ⓝ] 294,430,000
Inventories	576,383,000	553,323,000
Prepaid income taxes	8,308,000	15,058,000
Prepaid expenses & other current assets	96,933,000	51,014,000
Total current assets	1,253,895,000	959,601,000
Investments in unconsolidated affiliates	66,587,000	62,422,000
Machinery & equipment	2,270,000	1,529,000
Leasehold improvements	78,403,000	77,091,000
Furniture & fixtures	97,133,000	88,733,000
Computer equipment & software	32,537,000	28,301,000
Property & equipment, gross	210,343,000	195,654,000
Less: accumulated depreciation	123,936,000	97,797,000
Property & equipment, net	86,407,000	97,857,000
Other assets, net	35,459,000	32,478,000
Other intangibles, net	42,404,000	46,405,000
Deferred income tax assets, net	22,427,000	11,439,000
Trademarks	439,742,000	442,265,000
Goodwill	261,137,000	262,710,000
Total assets	2,208,058,000	1,915,177,000
Income tax payable	8,859,000	19,748,000
Accounts payable	225,499,000	232,364,000
Accrued bonuses	44,519,000	36,137,000
Other accrued expenses	58,322,000	58,918,000
Accrued expenses	102,841,000	95,055,000
Customer refund liability	243,589,000	...
Total current liabilities	580,788,000	347,167,000
Term loan	300,000,000	300,000,000
New revolving credit facility	...	12,003,000
Note issued to LVMH Moët Hennessy Louis Vuitton Inc. (LVMH)	125,000,000	125,000,000
Subtotal	425,000,000	437,003,000
Less: net debt issuance costs	(10,014,000)	(12,626,000)
Debt discount	(28,382,000)	(33,333,000)
Notes payable, net of discount & unamortized issuance costs	386,604,000	391,044,000
Deferred income tax liabilities, net	15,128,000	15,888,000
Other non-current liabilities	36,529,000	40,389,000
Total liabilities	1,019,049,000	794,488,000
Common stock	264,000	245,000
Additional paid-in capital	464,112,000	451,844,000
Accumulated other comprehensive income (loss)	(15,194,000)	(5,522,000)
Retained earnings (accumulated deficit)	758,881,000	674,542,000
Common stock held in treasury, at cost	19,054,000	420,000
Total stockholders' equity (deficit)	1,189,009,000	1,120,689,000

[Ⓜ] Reclassified to conform with 2019 presentation; [Ⓝ] Net of accrued returns - Accounts receivable, net: \$61,200,000; [Ⓟ] Sales discounts - Accounts receivable, net: \$102,100,000

Recent Dividends:

1. G-III Apparel Group Ltd. common.

No dividends paid.

Annual Dividends:

1. G-III Apparel Group Ltd. common.

No dividends paid.

GAMING PARTNERS INTERNATIONAL CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Revenues	87,009,000	80,602,000	82,139,000
Cost of revenues	59,974,000	57,924,000	56,803,000
Gross profit	27,035,000	22,678,000	25,336,000
Marketing & sales expenses	7,469,000	6,619,000	6,407,000
General & administrative expenses	10,750,000	9,016,000	10,181,000
Research & development expenses	3,996,000	1,517,000	1,188,000
Operating income (loss)	4,820,000	5,526,000	7,560,000
Interest income	79,000	1,000	23,000
Interest expense	176,000	249,000	242,000
Gain (loss) on foreign currency transactions	(188,000)	182,000	187,000
Other income (expense), net	70,000	(19,000)	(2,000)
Other income (expense), net	(215,000)	(85,000)	(34,000)
Income (loss) before income taxes	4,813,000	5,185,000	4,532,000
- Foreign
Income (loss) before income taxes - United States	(208,000)	256,000	2,994,000
Income (loss) before income taxes	4,605,000	5,441,000	7,526,000
Current income taxes (benefit) - U.S. federal	(845,000)	(47,000)	1,035,000
Current income taxes (benefit) - U.S. state	(15,000)	182,000	43,000
Current income taxes (benefit) - foreign	712,000	494,000	619,000
Total current income taxes (benefit)	(148,000)	629,000	1,697,000
Deferred income taxes (benefit) - U.S. federal	921,000	759,000	666,000
Deferred income taxes (benefit) - U.S. state	133,000	48,000	59,000
Deferred income taxes (benefit) - foreign	(18,000)	379,000	(79,000)
Total deferred income taxes (benefit)	1,036,000	1,186,000	646,000
Income tax provision (benefit)	888,000	1,815,000	2,343,000
Net income (loss)	3,717,000	3,626,000	5,183,000
Weighted average shares outstanding - basic	7,970,000	7,930,000	7,929,000
Weighted average shares outstanding - diluted	8,051,000	8,045,000	8,042,000
Year-end shares outstanding	8,085,194	7,932,094	7,928,594
Net income (loss) per share - basic	\$0.47	\$0.46	\$0.65
Net income (loss) per share - diluted	\$0.46	\$0.45	\$0.64
Number of full time employees	719	709	730
Number of common stockholders	[Ⓠ] 70	[Ⓝ] 70	[Ⓟ] 74
Foreign currency translation adjustments	...	1,868,000	(485,000)

[Ⓠ] As of March 14, 2019; [Ⓝ] As of March 15, 2018; [Ⓟ] As of March

7, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	[Ⓠ] 2017 (revised)
Cash & cash equivalents	12,100,000	14,064,000
Accounts receivable, gross	8,193,000	7,722,000
Less allowance for doubtful accounts	187,000	307,000
Accounts receivable, net	8,006,000	7,415,000
Raw materials	9,800,000	11,637,000
Work in progress	2,787,000	2,432,000
Finished goods	3,517,000	3,502,000
Total inventories	16,104,000	17,571,000
Less non-current inventories	(2,219,000)	(2,453,000)
Inventories	13,885,000	15,118,000
Prepaid expenses	1,075,000	1,163,000
Income tax-related assets	2,650,000	1,435,000
Deposits	775,000	327,000
Refundable value added tax	591,000	996,000
Other current assets, net	28,000	78,000
Total current assets	39,110,000	40,596,000
Land	657,000	669,000
Buildings & improvements	11,306,000	11,196,000
Equipment & furniture	40,841,000	40,714,000
Vehicles	405,000	408,000
Construction in progress	412,000	529,000
Property & equipment, gross	53,621,000	53,516,000
Less accumulated depreciation	31,074,000	28,583,000
Property & equipment, net	22,547,000	24,933,000
Goodwill	10,292,000	10,292,000
Intangible assets, net	1,523,000	1,676,000
Investments	560,000	411,000
Deferred income tax asset	320,000	675,000
Inventories, non-current	2,219,000	2,453,000
Other assets, non-current	3,056,000	2,240,000
Total assets	79,627,000	83,276,000
Accounts payable	3,410,000	4,616,000
Accrued bonuses & commissions	1,381,000	953,000
Accrued salaries, wages, & related costs	1,331,000	1,359,000
Stock appreciation rights liability	1,244,000	1,153,000
Accrued vacation	942,000	964,000
Miscellaneous taxes	475,000	560,000
Accrued legal & bank fees	309,000	52,000
Accrued fixed asset acquisition liability	...	1,076,000
Other accrued expenses	475,000	368,000
Accrued liabilities	6,157,000	6,485,000
Customer deposits & deferred revenue	4,873,000	3,020,000
Current portion of long-term debt	...	1,401,000
Income taxes payable	365,000	693,000
Total current liabilities	14,805,000	16,215,000
Long-term debt	...	5,265,000
Deferred income tax liabilities	412,000	...
Other liabilities, non-current	620,000	480,000
Total liabilities	15,837,000	21,960,000
Common stock	84,000	82,000
Additional paid-in capital	20,219,000	19,272,000
Treasury stock, at cost	2,266,000	2,263,000
Retained earnings (accumulated deficit)	47,055,000	44,718,000
Foreign currency translation	(1,223,000)	(493,000)
Minimum pension liability adjustment, net of tax	(79,000)	...
Accumulated other comprehensive income (loss)	(1,302,000)	(493,000)
Total stockholders' equity	63,790,000	61,316,000

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Gaming Partners International Corp common.

ExDate	Amt	Declared	Record	Payable
11/29/2016	0.12	11/22/2016	12/01/2016	12/12/2016
12/07/2017	0.12	11/27/2017	12/08/2017	12/22/2017
12/07/2018	0.12	11/27/2018	12/10/2018	12/21/2018

Annual Dividends:

1. Gaming Partners International Corp common.

2016	0.12	2017	0.12	2018	0.12
------	------	------	------	------	------

GEMPHIRE THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
			(revised)
General & administrative expenses	8,493	10,438	5,956
Research & development expense	14,312	22,686	8,740
Total operating expenses	22,805	33,124	14,696
Income (loss) from operations	(22,805)	(33,124)	(14,696)
Interest income (expense)	(654)	(286)	114
Other income (expense)	(178)	(5)	(4)
Income (loss) before income taxes	(23,637)	(33,415)	(14,586)
Net income (loss)	(23,637)	(33,415)	(14,586)
Adjustment to redemption value on series A convertible preferred stock	(366)
Net income (loss) attributable to common stockholders	(23,637)	(33,415)	(14,952)
Weighted average shares outstanding - basic	13,806	10,349	5,809
Weighted average shares outstanding - diluted	13,806	10,349	5,809
Year end shares outstanding	□14,265	□10,633	□9,270
Net income (loss) per share - basic	\$(1.71)	\$(3.23)	\$(2.57)
Net income (loss) per share - diluted	\$(1.71)	\$(3.23)	\$(2.57)
Number of full time employees	□□9	□□18	□□16
Number of common stockholders	□□49	□□58	□□114

□ Shares increased due to the effect of issuance of common stock from follow-on public offering and exercise of stock options; □ Shares increased due to the effect of conversion of series A preferred stock to common stock, conversion of convertible notes and issuance of common stock from offering; □ As is; □ As of March 11, 2019; □ As of March 1, 2018; □ As of February 20, 2017; □ As of March 7, 2018; □ As of March 3, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	18,954	18,473
Prepaid expenses	715	490
Deferred offering costs	...	21
Other assets	17	25
Total current assets	19,686	19,009
Deposits	8	8
Total assets	19,694	19,017
Accounts payable	2,044	4,025
Accrued compensation & other payroll liabilities	137	306

Legal costs	106	91
Accrued interest	43	38
Other research & development expenses	135	522
Other general & administrative expenses	17	53
Accrued liabilities	438	1,010
Term loan - current portion	9,437	1,355
Total current liabilities	11,919	6,390
Term loan	...	8,683
Other liabilities	1	3
Total liabilities	11,920	15,076
Common stock	22	18
Additional paid-in capital	91,863	64,397
Retained earnings (accumulated deficit)	(84,111)	(60,474)
Total stockholders' equity (deficit)	7,774	3,941

Recent Dividends:

1. Gemphire Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Gemphire Therapeutics Inc common.

No dividends paid.

GENERAL FINANCE CORP

Acquisition Completed On Mar. 28, 2019, Co. wholly-owned subsidiary, Pac-Van, Inc., acquired the portable storage assets of BBS Leasing, LLP of Fort Worth, TX. Terms of the transaction were not disclosed.

GOSSAMER BIO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
			(revised)
Research & development	55,283	891	...
In process research & development	49,659	5,500	...
General & administrative expenses	44,051	262	83
Total operating expenses	148,993	6,653	83
Income (loss) from operations	(148,993)	(6,653)	(83)
Interest income	1,720
Interest expense	12	118	...
Other income	316
Total other income (expense), net	2,024	(118)	...
Net income (loss)	(146,969)	(6,771)	(83)
Weighted average shares outstanding - basic	6,505	9,161	9,161
Weighted average shares outstanding - diluted	6,505	9,161	9,161
Year end shares outstanding	8,051	9,161	9,161
Net earnings (loss) per share - basic	\$(22.59)	\$(0.74)	\$(0.01)
Net earnings (loss) per share - diluted	\$(22.59)	\$(0.74)	\$(0.01)
Number of full time employees	□□118	□□104	...
Number of part time employees	□□1	□□1	...
Total number of employees	...	□□105	...
Number of common stockholders	□□□106	□□□107	...

□ As is; □ As of February 28, 2019; □ As of December 31, 2018; □ Approximately; □ As of March 18, 2019; □ As of September 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	105,219	315
Marketable securities	123,439	...
Restricted cash	200	...
Prepaid expenses & other current assets	3,095	130
Total current assets	231,953	445
Office equipment	918	...
Computer equipment	15	...
Software	50	...
Lab equipment	1,070	...
Leasehold improvements	1,243	...
Construction in process	194	...
Total property & equipment	3,490	...
Less: accumulated depreciation	297	...
Property & equipment, net	3,193	...
Other assets	4,273	...
Total assets	239,419	445
Accounts payable	2,182	97
Accrued research & development expenses	10,653	126
Accrued compensation	4,102	34
Accrued legal fees	1,310	780
Accrued accounting fees	722	...
Accrued consulting fees	665	33
Accrued other	769	79
Accrued expenses	7,568	926
Accrued interest - short-term	...	117
Total current liabilities	20,403	1,266
Note payable to related parties	...	40
Convertible note payable	...	6,000
Accrued expenses - long-term	718	1
Total liabilities	21,121	7,307
Series seed convertible preferred stock	29,200	...
Series A convertible preferred stock	79,615	...
Series B convertible preferred stock	229,552	...
Common stock	2	...
Additional paid-in capital	33,853	32
Retained earnings (accumulated deficit)	(153,863)	(6,894)
Accumulated other comprehensive income (loss)	(61)	...
Total stockholders' equity (deficit)	(120,069)	(6,862)

Recent Dividends:

1. Gossamer Bio Inc common.

No dividends paid.

Annual Dividends:

1. Gossamer Bio Inc common.

No dividends paid.

GRANITE CITY FOOD & BREWERY LTD

Annual Report

Consolidated Income Statement, Years Ended (\$):

	12/25/18	□12/26/17	12/27/16
		(revised)	(revised)
Total revenues	133,837,780	141,174,936	...
Restaurant revenue	150,301,535
Cost of sales - food, beverage & retail	34,424,121	37,165,511	39,691,010
Cost of sales - labor	45,724,013	48,178,304	51,143,723
Cost of sales - direct restaurant operating	23,893,117	23,951,394	24,075,164
Cost of sales - occupancy	14,049,289	15,832,654	15,138,637
Cost of sales & occupancy	118,090,540	125,127,863	130,048,534
General & administrative expenses	10,699,966	11,987,736	10,420,009

				Annual Report						
				Consolidated Income Statement, Years Ended Dec. 31						
				((\$000):						
				2018	□2017	2016				
Depreciation & amortization expenses	6,906,897	7,994,832	8,697,917	Total assets	51,673,712	61,787,699	Precision oncology testing	78,407	42,088	24,496
Pre-opening expenses	...	23,288	1,718,648	Accounts payable	2,805,900	1,922,091	Development services	12,232	7,754	753
Aquisitions costs	1,419	Accrued payroll & related expenses	2,734,492	3,928,486	Total revenue	90,639	49,842	25,249
Impairment and other gain (loss) on disposal of assets	(1,158,994)	(76,693)	(305,852)	Deferred revenue from gift card sales	4,340,124	4,774,625	Cost of precision oncology testing	39,846	28,883	22,065
Exit or disposal activities	(75,420)	802,780	...	Accrued sales taxes	337,745	888,089	Cost of development services	3,364	2,735	59
Total costs & expenses	136,780,977	146,013,192	151,192,379	Accrued interest	2,021,672	608,335	Research & development expense	50,714	25,562	10,859
Operating income (loss)	(2,943,197)	(4,838,256)	(890,844)	Accrued real estate taxes	565,148	544,754	Sales & marketing expense	53,465	32,497	26,192
Interest income	...	264	8,862	Accrued credit card fees	275,189	280,524	General & administrative expense	36,192	36,777	9,921
Interest expense on capital leases	1,922,988	2,070,565	2,074,656	Accrued legal fees	45,259	358,815	Total costs & operating expenses	183,581	...	69,096
Other interest expense	2,507,430	2,105,597	1,706,346	Accrued marketing	194,592	53,309	Income (loss) from operations	(92,942)	(76,612)	(43,847)
Net interest income (expense)	(4,430,418)	(4,175,898)	(3,772,140)	Accrued rent restructure fees	269,167	856,259	Interest income	5,266	2,234	733
Income (loss) before income tax	(7,373,615)	(9,014,154)	(4,662,984)	Accrued CAM charges	534,912	415,925	Interest expense	1,251	2,702	3,018
Current income tax expense - state	(7,212)	49,442	56,852	Accrued property & equipment	...	22,868	Gain (loss) on debt extinguishment	...	(5,075)	...
Current income tax expense	(7,212)	49,442	56,852	Other accrued expenses	1,126,911	1,449,690	Other income (expense), net	4,702	(1,059)	(1)
Deferred income tax expense (benefit) - federal	(2,560,720)	(3,939,538)	(2,781,339)	Deferred rent, current portion	472,770	984,799	Income before income taxes - United States	(84,313)
Deferred income tax expense (benefit) - state	(294,596)	(340,068)	(68,427)	Line of credit, current portion	10,273,000	10,273,000	Income before income taxes - Foreign	88
Effect of change in rate used	...	7,515,023	...	Long-term debt, current portion	27,352,370	27,897,037	Income (loss) before provision for income taxes	(84,225)	(83,214)	(46,133)
Deferred income tax expense (benefit)	(2,855,316)	3,235,417	(2,849,766)	Capital lease obligations, current portion	1,198,763	1,058,183	Current state income taxes	4
Net change to valuation allowance	2,855,316	(3,235,417)	2,849,766	Total current liabilities	54,548,014	56,316,789	Current foreign income taxes	34
Income tax expense (benefit)	(7,212)	49,442	56,852	Deferred rent, net of current portion	4,809,398	5,177,497	Current income taxes	38
Net income (loss)	(7,366,403)	(9,063,596)	(4,719,836)	Other liabilities - interest rate swap	...	(5,199)	Deferred state income taxes	...	7	6
Net income (loss) available to common shareholders	...	(9,063,596)	(4,719,836)	Capital lease obligations, net of current portion	16,871,357	18,077,020	Deferred income taxes	...	7	6
Weighted average shares outstanding	14,360,981	14,360,981	14,360,981	Total liabilities	76,228,769	79,566,107	Net income (loss)	(84,263)	(83,221)	(46,139)
- basic	14,360,981	14,360,981	14,360,981	Common stock	143,610	143,610	Fair value adjustment of redeemable noncontrolling interest	(800)
Year end shares outstanding	14,360,981	14,360,981	14,360,981	Additional paid-in capital	83,231,932	82,642,178	Net income (loss) attributable to Guardant Health, Inc.	(85,063)
Net income (loss) per share - basic	\$(0.51)	\$(0.63)	\$(0.33)	Retained earnings (accumulated deficit)	(107,930,599)	(100,564,196)	Deemed dividend related to repurchase of series A convertible preferred stock	...	4,716	...
Number of common stockholders	95	Total shareholders' equity (deficit)	(24,555,057)	(17,778,408)	Deemed dividend related to repurchase of series D convertible preferred stock	...	1,058	...
□ Reclassified to conform with 2018 presentation				Recent Dividends:						
Consolidated Balance Sheet, Years Ended (\$):				1. Granite City Food & Brewery Ltd redeemable preferred.						
12/25/18				No dividends paid.						
12/26/17 (revised)				2. Granite City Food & Brewery Ltd common.						
Cash & cash equivalents				No dividends paid.						
Inventory				3. Granite City Food & Brewery Ltd series A convertible preferred.						
Prepays & other current assets, net				No dividends paid.						
Total current assets				Annual Dividends:						
Prepaid rent, net of current portion				1. Granite City Food & Brewery Ltd redeemable preferred.						
Land				No dividends paid.						
Buildings				2. Granite City Food & Brewery Ltd common.						
Leasehold improvements				No dividends paid.						
Equipment & furniture				3. Granite City Food & Brewery Ltd series A convertible preferred.						
Less accumulated depreciation				No dividends paid.						
Construction-in-progress				GRANITE CITY FOOD & BREWERY LTD Auditor's Report Auditor's Report						
Property & equipment, net				The following is an excerpt from the Report of the Independent Auditors, Schechter, Dokken, Kanter, Andrews & Selcer Ltd., as it appeared in Co.'s 2018 10-K: "Opinion In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Granite City Food & Brewery, Ltd., as of December 25, 2018 and December 26, 2017, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America. Emphasis of Matter Regarding Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter."						
Liquor licenses				GUARDANT HEALTH INC						
Trademarks										
Security deposits										
Less accumulated amortization										
Deferred loss on sale leaseback										

shares outstanding			
- diluted	30,403	12,582	13,053
Year end shares			
outstanding	85,832	11,897	13,184
Net earnings (loss)			
per share - basic	\$(2.80)	\$(7.07)	\$(3.53)
Net earnings (loss)			
per share - diluted	\$(2.80)	\$(7.07)	\$(3.53)
Number of full time employees	454	348	...
Number of common stockholders	249

Accumulated other comprehensive income (loss)	(83)	(532)	
Retained earnings (accumulated deficit)	(280,799)	(195,736)	
Total stockholders' equity	483,152	308,606	

continuing operations	(4,299)	(2,016)	...
Income (loss) from discontinued operations before income taxes	936	534	...
Income tax expense (benefit)	441	617	...
Income (loss) from discontinued operations, net of tax	1,377	1,151	...
Net income (loss)	(2,922)	(865)	(4,307)

□ Non-Consolidated; □ Shares increased due to conversion of convertible preferred stock to common stock, issuance of common stock upon initial public offering, exercise of stock options & warrants; □ As Is; □ As of June 30, 2018; □ As of March 4, 2019

□ Non-Consolidated

Recent Dividends:

1. Guardant Health Inc common.

No dividends paid.

Annual Dividends:

1. Guardant Health Inc common.

No dividends paid.

HARVARD BIOSCIENCE INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	140,544	72,280
Short-term marketable securities	278,417	149,040
Accounts receivable	35,690	12,787
Inventory	9,136	7,287
Prepaid expenses & other current assets	5,204	1,541
Total current assets	468,991	242,935
Long-term marketable securities	77,563	73,254
Machinery & equipment	23,440	15,676
Computer hardware	4,949	1,939
Leasehold improvements	13,965	6,766
Furniture & fixtures	1,522	1,347
Computer software	643	655
Construction in progress	3,118	349
Total property & equipment, gross	47,637	26,732
Less: Accumulated depreciation & amortization	16,634	10,696
Property & equipment, net	31,003	16,036
Capitalized license fees	7,800	8,739
Other assets	2,046	1,974
Total assets	587,403	342,938
Accounts payable	10,642	4,998
Accrued compensation	12,986	4,911
Accrued royalty obligations	707	766
Accrued litigation settlement expense	...	3,000
Accrued legal expenses	814	561
Accrued tax liabilities	1,470	905
Accrued information technology expenses	...	316
Accrued professional services	1,791	336
Purchases of property & equipment included in accrued expenses	343	...
Other accrued expenses	1,956	522
Accrued expenses	7,081	6,406
Capital lease, current	97	199
Deferred revenue	16,138	3,113
Total current liabilities	46,944	19,627
Capital lease, net of current portion	119	460
Deferred rent, net of current portion	7,844	6,537
Obligation related to royalty	7,338	7,708
Other long-term liabilities	206	...
Total liabilities	62,451	34,332
Redeemable noncontrolling interest	41,800	...
Convertible preferred stock	...	499,974
Common stock	1	...
Additional paid-in capital	764,033	4,900

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Revenues	120,774	77,407	104,521
Cost of revenues	57,593	38,237	56,106
Gross profit	63,181	39,170	48,415
Sales & marketing expenses	24,443	15,082	20,486
General & administrative expenses	21,382	17,525	20,950
Research & development expenses	10,988	5,645	5,392
Restructuring charges (credits)	(4)
Amortization of intangible assets	5,384	1,553	2,722
Impairment charges	676
Gain (loss) on sale of AHN Biotechnologie GmbH (AHN)	(1,190)
Total operating expenses, net	62,197	39,805	51,412
Operating income (loss)	984	(635)	(2,997)
Foreign exchange	148	(534)	737
Interest expense, net	5,367	713	639
Other income (expense), net	(3,740)	(739)	(179)
Other income (expense), net	(8,959)	(1,986)	(81)
Income (loss) before income taxes - domestic	(9,034)	(3,662)	(3,107)
Income (loss) before income taxes - foreign	1,059	1,041	29
Income (loss) from continuing operations before income taxes	(7,975)	(2,621)	(3,078)
Current federal & state income tax expense (benefit)	(191)	253	170
Current foreign income tax expense (benefit)	279	297	790
Total current income tax expense (benefit)	88	550	960
Deferred federal & state income tax expense (benefit)	(3,552)	(1,730)	166
Deferred foreign income tax expense (benefit)	(212)	575	103
Total deferred income tax expense (benefit)	(3,764)	(1,155)	269
Income tax expense (benefit)	(3,676)	(605)	1,229
Income (loss) from			

Year end shares outstanding	37,379	35,018	34,441
Earnings (loss) per share from continuing operations - basic	\$(0.12)	\$(0.06)	...
Earnings (loss) per share from discontinued operations - basic	\$0.04	\$0.03	...
Net earnings (loss) per share - basic	\$(0.08)	\$(0.02)	\$(0.13)
Earnings (loss) per share from discontinued operations - diluted	\$(0.12)	\$(0.06)	...
Earnings (loss) per share from discontinued operations - diluted	\$0.04	\$0.03	...
Net earnings (loss) per share - diluted	\$(0.08)	\$(0.02)	\$(0.13)
Number of full time employees	519	413	411
Number of part time employees	28	21	24
Total number of employees	547	434	435
Number of common stockholders	109	116	133
Foreign currency translation adjustments	(4,606)

□ Restated to reflect the discontinued operations of Denville Scientific, Inc.; □ Reclassified to conform with 2017 presentation; □ As is; □ As of March 7, 2019; □ As of March 9, 2018; □ As of March 7, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	8,173	5,192
Accounts receivable, gross	21,795	13,575
Allowance for doubtful accounts	332	193
Accounts receivable, net	21,463	13,382
Finished goods	6,936	5,779
Work in process	3,667	1,042
Raw materials	14,484	10,027
Inventories	25,087	16,848
Other receivables & other assets	3,109	3,709
Current assets held for sale	...	8,404
Total current assets	57,832	47,535
Land, buildings & leasehold improvements	2,468	2,197
Machinery & equipment	9,678	7,022
Computer equipment & software	9,685	8,819
Furniture & fixtures	1,390	1,139

1. HD Supply Holdings Inc common.
No dividends paid.

Annual Dividends:
1. HD Supply Holdings Inc common.
No dividends paid.

HEALTH EQUITY INC
Annual Report
Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2019	2018 (revised)	2017 (revised)
Service revenue	100,564	91,619	77,254
Custodial revenue	126,178	87,160	59,593
Interchange revenue	60,501	50,746	41,523
Total revenue	287,243	229,525	178,370
Service costs	76,858	70,426	51,868
Custodial costs	14,124	11,400	9,767
Interchange costs	15,068	12,783	10,380
Total cost of revenue	106,050	94,609	72,015
Gross profit	181,193	134,916	106,355
Sales & marketing expense	29,498	23,139	18,320
Technology & development expense	35,057	27,385	22,375
General & administrative expense	33,039	25,111	20,151
Amortization of acquired intangible assets	5,929	4,863	4,297
Total operating expenses	103,523	80,498	65,143
Income from operations	77,670	54,418	41,212
Other expense, net	1,852	2,229	1,092
Total other income (expense)	(1,852)	(2,229)	(1,092)
Income before income taxes	75,818	52,189	40,120
Current income tax provision (benefit) - federal	1,095	392	14,848
Current income tax provision (benefit) - state	416	130	1,823
Total current income tax provision (benefit)	1,511	522	16,671
Deferred income tax provision (benefit) - federal	1,258	4,068	(2,308)
Deferred income tax provision (benefit) - state	(850)	237	(619)
Total deferred income tax provision (benefit)	408	4,305	(2,927)
Income tax provision (benefit)	1,919	4,827	13,744
Net income (loss)	73,899	47,362	26,376
Net income (loss) attributable to common stockholders - basic	73,899	47,362	26,376
Net income (loss) attributable to common stockholders - diluted	73,899	47,362	26,376
Weighted average shares outstanding - basic	61,836	60,304	58,615
Weighted average shares outstanding - diluted	63,370	61,854	59,894
Year end shares outstanding	62,446	60,825	59,538
Net income (loss) per share - basic	\$1.20	\$0.79	\$0.45
Net income (loss) per share - diluted	\$1.17	\$0.77	\$0.44
Total number of employees	1,141	1,027	875
Number of common			

stockholders ^{□□}22 ^{□□□}27 ^{□□□□}32

[□] As is; [□] Approximately; [□] As of February 28, 2019; [□] As of February 28, 2018; [□] As of February 28, 2017

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2019	2018 (revised)	2017 (revised)
Cash & cash equivalents	361,475	199,472	
Marketable securities, at fair value	...	40,797	
Total cash, cash equivalents & marketable securities	361,475	240,269	
Accounts receivable, gross	25,793	21,810	
Less: allowance for doubtful accounts	125	208	
Accounts receivable, net	25,668	21,602	
Other current assets	7,534	3,525	
Total current assets	394,677	265,396	
Leasehold improvements	3,583	2,292	
Furniture & fixtures	4,476	4,785	
Computer equipment	9,242	8,174	
Property & equipment, gross	17,301	15,251	
Less: accumulated depreciation	9,078	7,415	
Property & equipment, net	8,223	7,836	
Intangible assets, net	79,666	83,635	
Goodwill	4,651	4,651	
Deferred tax asset	1,677	5,461	
Other assets	21,122	2,180	
Total assets	510,016	369,159	
Accounts payable	3,520	2,420	
Accrued compensation	16,981	12,549	
Accrued liabilities	8,552	5,521	
Total current liabilities	29,053	20,490	
Other long-term liabilities	2,968	2,395	
Deferred tax liability	916	...	
Total long-term liabilities	3,884	2,395	
Total liabilities	32,937	22,885	
Common stock	6	6	
Additional paid-in capital	305,223	261,237	
Accumulated other comprehensive income (loss), net	...	(269)	
Retained earnings (accumulated deficit)	171,850	85,300	
Total stockholders' equity (deficit)	477,079	346,274	

[□] Reclassified to conform with 2019 presentation

Recent Dividends:
1. HealthEquity Inc common.
No dividends paid.

Annual Dividends:
1. HealthEquity Inc common.
No dividends paid.

HORIZON BANCORP INC
Merger Completed On Mar. 26, 2019, Salin Bancshares, Inc. ("SBI"), a provider of banking and financial services, merged with and into Co., with Co. continuing as the surviving corporation (the "Merger"), immediately following the merger, SBI's wholly-owned bank subsidiary, Salin Bank and Trust Company, merged with and into Co.'s wholly-owned bank subsidiary, Horizon Bank, with Horizon Bank continuing as the surviving bank. As the result of the merger, each SBI shareholder received fixed consideration of (i) \$87,417.17 per SBI common share in cash, and (ii) 23,907.50 shares of Co. common stock for each share of SBI common stock. No fractional shares of Co. common stock were issued in the Merger, but instead were paid out in cash at the rate of \$17.02 per share. In connection with the consummation of the Merger, Co. issued 6,563,697 shares of its common stock. Based upon the closing price of Horizon common stock of \$15.65 on Mar. 25, 2019, that transaction had an implied valuation of approximately \$126,700,000. Each outstanding share of Co. common stock remained outstanding and was not changed as a result of the Merger.

ICONIX BRAND GROUP INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Licensing revenue	187,689,000	225,833,000	255,143,000
Selling, general & administrative expenses	121,429,000	114,606,000	128,759,000
Loss on termination of licenses	10,550,000	28,360,000	...
Depreciation & amortization	2,329,000	2,455,000	2,793,000
Equity earnings (loss) on joint ventures	3,043,000	(3,259,000)	3,578,000
Gain on deconsolidation of joint venture	...	3,772,000	...
Gains on sale of trademarks, net	1,268,000	875,000	38,104,000
Goodwill impairment	37,812,000	103,877,000	18,331,000
Trademark impairment	136,417,000	525,726,000	419,762,000
Investment impairment	2,500,000	16,848,000	...
Operating income (loss)	(119,037,000)	(564,651,000)	(272,820,000)
Interest expense	59,214,000	67,901,000	76,925,000
Interest income	495,000	480,000	904,000
Other income (expense), net	91,305,000	2,650,000	17,508,000
Gain (loss) on extinguishment of debt, net	4,473,000	(20,939,000)	(5,903,000)
Foreign currency translation gain (loss)	(1,153,000)	(3,071,000)	1,287,000
Total other income (expenses) - net	35,906,000	(88,781,000)	(63,129,000)
Income (loss) before income taxes - domestic	(119,031,000)	(575,547,000)	(255,003,000)
Income (loss) before income taxes - foreign	35,900,000	(77,885,000)	(80,946,000)
Income (loss) from continuing operations before income taxes	(83,131,000)	(653,432,000)	(335,949,000)
Current federal income tax provision (benefit)	(609,000)	(1,152,000)	7,140,000
Current state & local income tax provision (benefit)	(61,000)	986,000	702,000
Current foreign income tax provision	9,212,000	8,358,000	9,557,000
Total current income tax provision (benefit)	8,542,000	8,192,000	17,399,000
Deferred federal income tax provision (benefit)	(4,950,000)	(93,376,000)	(94,058,000)
Deferred state & local income tax provision (benefit)	(1,967,000)	(93,000)	594,000
Deferred foreign income tax provision	4,913,000	(10,700,000)	(2,060,000)
Total deferred income tax provision (benefit)	(2,004,000)	(104,169,000)	(95,524,000)
Provision (benefit) for income taxes	6,538,000	(95,977,000)	(78,125,000)
Net income (loss) from continuing operations	(89,669,000)	(557,455,000)	(257,824,000)
Less: net gain (loss) attributable to non-controlling interest from continuing			

				Consolidated Balance Sheet, Years Ended Dec. 31 (\$):							
				2018		2017					
						(revised)					
operations	(10,852,000)	(22,177,000)	(3,326,000)	Cash & cash equivalents	66,609,000	65,927,000	(loss)	(53,068,000)	(51,280,000)		
Net income (loss)				Restricted cash	16,026,000	48,766,000	Less: treasury stock, at cost	844,253,000	844,030,000		
from continuing operations				Accounts receivable, gross	37,691,100	74,525,000	Total Iconix Brand Group Inc. stockholders' equity (deficit)	(172,734,000)	(74,420,000)		
attributable to Iconix Brand Group, Inc.	(100,521,000)	(535,278,000)	(254,498,000)	Less: provision for doubtful accounts	20,100	7,900,000	Non-controlling interests, net of installment payments due from non-controlling interest holders	26,999,000	23,444,000		
Income (loss) from discontinued operations before income taxes	(26,232,000)	9,947,000		Accounts receivable, net	37,671,000	66,625,000	Total stockholders' equity	(145,735,000)	(50,976,000)		
Gain on sale of entertainment segment	104,099,000			Contract asset	4,802,000						
Provision for income taxes	(28,899,000)	(1,631,000)		US federal tax receivables	16,757,000	29,662,000					
Net income from discontinued operations	48,968,000	8,316,000		Notes receivables on sale of trademarks		3,097,000					
Less: net income attributable to non-controlling interest from discontinued operations	(2,943,000)	5,952,000		Note receivable in connection with acquisition of interest in Buffalo brand		2,515,000					
Net income from discontinued operations attributable to Iconix Brand Group, Inc.	46,025,000	2,364,000		Due from DHX Media, Ltd.		1,175,000					
Net income (loss) to company	(89,669,000)	(508,487,000)	(249,508,000)	Prepaid advertising	1,100,000	2,453,000					
Less: net income attributable to non-controlling interest	19,234,000	(2,626,000)		Prepaid expenses	2,451,000	4,621,000					
Net income (loss) attributable to Iconix Brand Group, Inc.	(100,521,000)	(489,253,000)	(252,134,000)	Prepaid taxes	1,755,000	2,347,000					
Weighted average shares outstanding - basic	6,734,000	5,711,000	5,233,800	Prepaid insurance	1,446,000	1,428,000					
Weighted average shares outstanding - diluted	6,734,000	5,711,000	5,233,800	Due from related parties	3,903,000	3,843,000					
Year end shares outstanding	7,839,000	5,733,900	5,703,700	Other current assets	645,000	709,000					
Net earnings (loss) per share from continuing operations - basic	\$(15.73)	\$(94.71)	\$(48.60)	Other assets - current	28,057,000	51,850,000					
Net earnings (loss) per share from discontinued operations - basic		\$8.06	\$0.50	Total current assets	153,165,000	233,168,000					
Net earnings (loss) per share - basic	\$(15.73)	\$(86.65)	\$(48.20)	Furniture, fixtures & equipment	22,525,000	21,661,000					
Net earnings (loss) per share from continuing operations - diluted	\$(15.73)	\$(94.71)	\$(48.60)	Less: accumulated depreciation	17,644,000	15,567,000					
Net earnings (loss) per share from discontinued operations - diluted		\$8.06	\$0.50	Property & equipment, net	4,881,000	6,094,000					
Net earnings (loss) per share - diluted	\$(15.73)	\$(86.65)	\$(48.20)	Prepaid interest	5,496,000	5,601,000					
Number of full time employees	122	152		Deposits	482,000	616,000					
Number of common stockholders	1,163	1,159		Other noncurrent assets	1,000	51,000					
Foreign currency translation adjustments			(7,545,000)	Other assets	5,979,000	6,268,000					
				Contract asset	14,560,000						
				Deferred income tax asset		4,492,000					
				Trademarks & other intangibles, net	337,700,000	465,722,000					
				Investments & joint ventures	89,691,000	90,887,000					
				Goodwill	26,099,000	63,882,000					
				Total assets	632,075,000	870,513,000					
				Accounts payable & accrued expenses	44,856,000	49,191,000					
				Deferred revenue	5,405,000	5,525,000					
				Current portion of long-term debt	54,263,000	44,349,000					
				Other liabilities - current	9,788,000	13,581,000					
				Total current liabilities	114,312,000	112,646,000					
				Deferred income tax liability	4,566,000	11,466,000					
				Other tax liabilities		531,000					
				Senior secured notes	365,481,000	408,174,000					
				Convertible notes	48,076,000	233,898,000					
				Variable funding note	95,273,000	91,363,000					
				Senior secured term loan, net of original issue discount	171,137,000	74,813,000					
				Unamortized debt issuance costs	(4,738,000)	(7,406,000)					
				Less current maturities	54,263,000	44,349,000					
				Long-term debt, less current maturities	620,966,000	756,493,000					
				Other liabilities	3,829,000	10,066,000					
				Total liabilities	743,673,000	891,202,000					
				Reedeemable non-controlling interests	34,137,000	30,287,000					
				Common stock	11,000	9,000					
				Additional paid-in capital	1,037,372,000	1,044,599,000					
				Retained earnings (accumulated deficit)	(312,796,000)	(223,718,000)					
				Foreign currency translation adjustments	(53,068,000)	(48,103,000)					
				Unrealized gains (losses) of available for sale securities		(3,177,000)					
				Accumulated other comprehensive income							

□ Restated to reflect the discontinued operations of entertainment operating segment; □ Adjusted for 1-for-10 stock split, March 14, 2019; □ As of March 21, 2019; □ As of March 1, 2018

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Iconix Brand Group Inc common.

No dividends paid.

Annual Dividends:

1. Iconix Brand Group Inc common.

No dividends paid.

INNERWORKINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):				
		2018	2017	2016
			(revised)	(revised)
Revenue	1,121,551,000	1,138,361,000	1,094,402,000	
Cost of goods sold	866,453,000	862,903,000	831,838,000	
Gross profit	255,098,000	275,458,000	262,564,000	
Selling, general & administrative expenses	239,124,000	227,253,000	209,524,000	
Depreciation & amortization expense	12,988,000	13,390,000	17,916,000	
Change in fair value of contingent consideration		677,000	10,417,000	
Goodwill impairment	46,319,000			
Intangible & other asset impairments	18,121,000		70,000	
Restructuring charges	6,031,000		5,615,000	
Income (loss) from operations	(67,485,000)	34,138,000	19,022,000	
Interest income	218,000	97,000	86,000	
Interest expense	7,749,000	4,729,000	4,171,000	
Other income (expense), net	(1,616,000)	(1,788,000)	(154,000)	
Total other income (expense)	(9,147,000)	(6,420,000)	(4,239,000)	
Income (loss) before taxes	(76,632,000)	27,718,000	14,783,000	
Current federal income tax expense (benefit)	(781,000)	3,076,000	477,000	
Current state income tax expense (benefit)	180,000	62,000	159,000	
Current foreign income tax expense (benefit)	4,581,000	4,078,000	5,972,000	
Total current income tax expense (benefit)	3,980,000	7,216,000	6,608,000	
Deferred federal income tax expense (benefit)	(3,250,000)	1,959,000	4,165,000	
Deferred state income tax expense (benefit)	(62,000)	1,575,000	414,000	
Deferred foreign income tax expense (benefit)	(1,129,000)	538,000	(353,000)	
Total deferred income tax expense (benefit)	(4,441,000)	4,072,000	4,226,000	
Provision (benefit) for income tax	(461,000)	11,288,000	10,834,000	
Net income (loss)	(76,171,000)	16,430,000	3,949,000	
Weighted average shares outstanding - basic	52,230,000	53,851,000	53,607,000	

Weighted average shares outstanding				1. InnerWorkings Inc common.				Net income (loss) per share - diluted			
- diluted				No dividends paid.				\$0.00 \$(0.20) \$(0.22)			
Year end shares outstanding				Annual Dividends:				Total number of employees			
51,807,000 54,055,000				1. InnerWorkings Inc common.				Number of common stockholders			
Net earnings (loss) per share - basic				No dividends paid.				Number of beneficial holders			
Net earnings (loss) per share - diluted				INNODATA INC Annual Report				Foreign currency translation adjustments			
Total number of employees				Consolidated Income Statement, Years Ended Dec. 31 (\$):				Reclassified to conform with 2018 presentation; [□] As Is; [□] Approximately; [□] As of February 22, 2019; [□] As of February 9, 2018; [□] As of February 14, 2017			
Number of common stockholders				2018 [□] 2017 (revised) (revised) 2016				Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
Foreign currency translation adjustments				Revenues				2018 [□] 2017 (revised) (revised) 2016			
. 1,732,000 (6,444,000)				Direct operating costs				Cash & cash equivalents			
[□] Restated to reflect the material weaknesses and related remediation effort on financial statement; [□] Approximately; [□] As of March 11, 2019				Selling & administrative expenses				Accounts receivable - gross			
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):				Goodwill impairment				Less: allowance for doubtful accounts			
2018 [□] 2017 (revised)				Interest income (expense), net				Accounts receivable - net			
Cash & cash equivalents				Change in fair value of contingent consideration				Prepaid expenses & other current assets			
Accounts receivable, gross				Total operating costs & expenses				Equipment			
Less: allowance for doubtful accounts				Income (loss) from operations				Software			
Accounts receivable, net				Interest income (expense), net				Furniture & equipment			
Unbilled revenue				Income (loss) before income taxes - United States				Leasehold improvements			
Inventories				Income (loss) before income taxes - foreign				Property & equipment, gross			
Prepaid expenses				Income (loss) before provision for (benefit from) income taxes				Less: accumulated depreciation & amortization			
Other current assets				Current foreign income tax expense (benefit)				Property & equipment, net			
Total current assets				Current federal income tax expense (benefit)				Other assets			
Computer equipment				Current state & local income tax expense (benefit)				Deferred income taxes			
Software, including internal use software				Total current income tax expense (benefit)				Intangibles, net			
Office equipment & furniture				Deferred foreign income tax expense (benefit)				Goodwill			
Buildings				Deferred federal income tax expense (benefit)				Total assets			
Leasehold improvements				Deferred state & local income tax expense (benefit)				Accounts payable			
Property & equipment, gross				Total deferred income tax expense (benefit)				Accrued expenses			
Less accumulated depreciation				Provision for (benefit from) income taxes				Accrued salaries, wages & related benefits			
Property & equipment, net				Net income (loss) attributable to non-controlling interests				Income & other taxes			
Goodwill				Net income (loss) attributable to Innodata Inc. & subsidiaries				Current portion of long term obligations			
Intangible assets, net				Weighted average shares outstanding - basic				Total current liabilities			
Deferred income taxes				- diluted				Deferred income taxes			
Other assets				Year end shares outstanding				Capital lease obligations			
Total assets				27,559,000 25,878,000 25,624,000				Deferred lease payments			
Accounts payable				Net income (loss) per share - basic				Microsoft licenses			
Revolving credit facility - current				\$0.00 \$(0.20) \$(0.22)				Acquisition related liability			
Other current liabilities								Lease incentive liability			
Deferred revenue								Pension obligations - accrued pension liability			
Accrued expenses								Settlement agreement			
Total current liabilities								Less: current portion of long-term obligations			
Revolving credit facility - noncurrent								Non-controlling interests			
Deferred income taxes								Common stock			
Other long-term liabilities								Additional paid-in capital			
Total liabilities								Retained earnings (accumulated deficit)			
Common stock								Pension liability adjustment			
Additional paid-in capital								Fair value of derivatives			
Treasury stock, at cost								Foreign currency translation adjustment			
Foreign currency translation adjustments								Accumulated other comprehensive income (loss)			
Accumulated other comprehensive income (loss)								Less: treasury stock, at cost			
Retained earnings (accumulated deficit)								Total stockholders' equity			
Total stockholders' equity								30,566,000 31,119,000			
183,091,000 [□] 284,545,000								[□] Restated to reflect the material weaknesses and related remediation effort on financial statement; [□] As reported by the Company			
Recent Dividends:								[□] Reclassified to conform with 2018 presentation; [□] Approxi-			

mately

Recent Dividends:**1. Innodata Inc common.**

No dividends paid.

Annual Dividends:**1. Innodata Inc common.**

No dividends paid.

INNOVIVA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2018	2017 (revised)	2016 (revised)
Royalty revenue from a related party	261,004	214,118	132,684
Revenue from collaborative arrangements from a related party, net	...	3,099	885
Total net revenue	261,004	217,217	133,569
Research & development	...	1,355	1,393
General & administrative	...	32,258	...
General & administrative - related party	20,053	...	23,188
Total operating expenses	22,753	33,613	24,581
Income (loss) from operations	238,251	183,604	108,988
Other income (expense), net	(5,702)	(7,038)	2,477
Interest income	1,660	1,311	582
Interest expense	23,954	43,601	52,416
Income before income taxes	210,255	134,276	59,631
Income tax benefit (expense), net	(196,073)	4	95
Net income (loss)	406,328	134,272	59,536
Net income attributable to noncontrolling interest	(11,272)	(129)	...
Net income (loss) attributable to Innoviva stockholders	395,056	134,143	59,536
Weighted average shares outstanding - basic	100,849	106,945	110,280
Weighted average shares outstanding - diluted	113,408	119,866	123,233
Year end shares outstanding	101,098	101,896	108,435
Net income (loss) per share - basic	\$3.92	\$1.25	\$0.54
Net income (loss) per share - diluted	\$3.53	\$1.17	\$0.53
Total number of employees	6	12	14
Number of common stockholders	79	100	106

¹ Reclassified to conform with 2018 presentation; ² Net of amortization for capitalized fees paid to a related party - royalty revenue from a related party: \$13,823,000; ³ As is; ⁴ As of February 11, 2019; ⁵ As of February 16, 2018; ⁶ As of February 24, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Cash & cash equivalents	62,417	73,336	...
Short-term marketable securities	52,491	55,739	...
Related party receivables from collaborative arrangements	83,286	70,540	...

Prepaid expenses & other current assets	849	754	...
Total current assets	199,043	200,369	...
Property & equipment, net	160	209	...
Capitalized fees paid to a related party	152,899	166,722	...
Deferred tax assets	196,054
Other assets	37	37	...
Total assets	548,193	367,337	...
Accounts payable	11	601	...
Accrued personnel-related expenses	470	1,721	...
Accrued interest payable	4,264	5,920	...
Other accrued liabilities	955	1,500	...
Current portion of long-term debt	...	25,000	...
Total current liabilities	5,700	34,742	...
Senior secured term loans	13,750	243,750	...
Convertible subordinated notes due 2023	240,984	240,984	...
Convertible senior notes due 2025	192,500	192,500	...
Total debt	447,234	677,234	...
Unamortized debt discount and issuance costs	(64,379)	(77,872)	...
Current portion of senior secured term loan	...	25,000	...
Long-term debt, net of current portion, discount and issuance costs	382,855	574,362	...
Other long-term liabilities	586	940	...
Common stock	1,011	1,019	...
Treasury stock	...	3,263	...
Additional paid-in capital	1,256,267	1,258,151	...
Accumulated other comprehensive income (loss)	(3)	(18)	...
Retained earnings (accumulated deficit)	(1,103,692)	(1,498,748)	...
Total Innoviva stockholders' equity (deficit)	153,583	(242,859)	...
Noncontrolling interest	5,469	152	...
Total stockholders' equity (deficit)	159,052	(242,707)	...

Recent Dividends:**1. Innoviva Inc class A common.**

No dividends paid.

2. Innoviva Inc common.

No dividends paid.

Annual Dividends:**1. Innoviva Inc class A common.**

No dividends paid.

2. Innoviva Inc common.

No dividends paid.

INOVO PHARMACEUTICALS INC.

Official Changes On Mar. 25, 2019, Co. announced the appointment of Dr. Ann C. Miller to its Board of Directors.

INSMED INC

Official Changes On Mar. 27, 2019, Co. announced that Mr. Paolo Tombesi, Chief Financial Officer, would be leaving Co. effective June 2, 2019. Also on Mar. 27, 2019, Co. announced the promotion of John Goll to Chief Accounting Officer.

INTEGRATED DEVICE TECHNOLOGY INC

Merger Completed On Mar. 29, 2019, Renesas Electronics Corp. ("Parent") wholly-owned subsidiary, Chapter Two Company ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a direct wholly-owned subsidiary of Parent (the "Merger"). As the result of the merger, each share of common stock of Co. issued and outstanding immediately prior to the Effective Time (other than any shares owned by Co. and its subsidiaries or Parent and its subsidiaries (including Merger Sub) or any dissenting shares) was converted into the right to receive \$49.00 per share in cash, without interest (the "Merger Consideration"). The aggregate Merger Consideration consisted of approximately \$6,300,000,000.

INTELGENX TECHNOLOGIES CORP

Options Granted On Mar. 27, 2019, Co. announced that its board of directors granted 100,000 options to acquire 100,000

common shares under the 2016 Stock Option Plan to Rodolphe Obeid, VP Operations of Co. The options have an exercise price of US\$0.69 (C\$0.92), vest over a period of two years at the rate of 25% every six months and expire on Mar. 26, 2029.

INTERNAP CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2018	2017 (revised)	2016 (revised)
Net revenues	317,373	280,718	298,297
Costs of sales & services, exclusive of depreciation & amortization	107,262	106,217	124,255
Costs of customer support	32,517	25,757	32,184
Sales, general & administrative	75,356	62,728	70,639
Depreciation & amortization	90,676	74,993	76,948
Goodwill impairment	80,105
Exit activities, restructuring & impairments	5,406	6,249	7,236
Total operating costs & expenses	311,217	275,944	391,367
Income (loss) from operations	6,156	4,774	(93,070)
Interest expense	68,132	50,476	30,909
Gain (loss) on foreign currency, net	258	(525)	(485)
Other non-operating income (loss), net	82
Total non-operating income (expenses)	(67,874)	(51,001)	(31,312)
Income (loss) before income taxes & equity in earnings (losses) of equity-method investment - United States	(64,237)	(46,648)	(120,553)
Income (loss) before income taxes & equity in earnings (losses) of equity-method investment - foreign	2,519	421	(3,829)
Income (loss) income taxes and equity in earnings of equity-method investment	(61,718)	(46,227)	(124,382)
Current federal income taxes	...	(730)	(15)
Current state income taxes	118	123	155
Current foreign income taxes	277	507	61
Total current income taxes	395	(100)	201
Deferred foreign income taxes	262	353	329
Total deferred income taxes	262	353	329
Provision (benefit) for income taxes	657	253	530
Equity in earnings (losses) of equity-method investment, net of taxes	...	1,207	170
Net income (loss)	(62,375)	(45,273)	(124,742)
Net income attributable to non-controlling interest	(125)	(70)	...
Net income (loss) attributable to Internap Corp. shareholders	(62,500)	(45,343)	(124,742)

Weighted average shares outstanding			
- basic	20,732	18,993	13,083
Weighted average shares outstanding - diluted	20,732	18,993	13,083
Year end shares outstanding	25,125	20,511	14,450
Net income (loss) per share-basic	\$(3.01)	\$(2.39)	\$(9.54)
Net income (loss) per share-diluted	\$(3.01)	\$(2.39)	\$(9.54)
Total number of employees	640	503	530
Number of common stockholders	176	491	588
Foreign currency translation adjustments	259	23	(39)

Reclassified to conform with 2018 presentation; Adjusted for 1-for-4 stock split, November 21, 2017; As is; Approximate; As of March 13, 2019; As of March 1, 2018; As of March 1, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	17,823	14,603
Account receivable, gross	21,601	19,281
Allowance for doubtful accounts	1,547	1,487
Account receivable, net	20,054	17,794
Contract assets	8,844	...
Prepaid expenses & other assets	7,377	8,673
Total current assets	54,098	41,070
Network equipment	274,322	247,190
Network equipment under capital lease	14,206	14,206
Furniture & equipment	28,583	26,246
Software	66,924	43,930
Leasehold improvements	414,212	412,631
Buildings under capital lease	269,455	227,482
Property & equipment, gross	1,067,701	971,685
Less: accumulated depreciation & amortization	589,640	513,120
Property & equipment, net	478,061	458,565
Intangible assets, net	73,042	25,666
Goodwill	116,217	50,209
Contract assets	16,104	...
Deposits & other assets	7,409	11,015
Total assets	744,931	586,525
Accounts payable	23,435	20,388
Compensation & benefits payable	7,523	6,673
Property, sales & other taxes	785	2,636
Customer credit balances	2,204	1,616
Accrued interest	1,762	1,690
Other accrued liabilities	3,266	3,293
Accrued liabilities	15,540	15,908
Deferred revenues	8,022	4,861
Capital lease obligations	9,080	11,711
Revolving credit facility	...	5,000
Term loan	321	867
Exit activities & restructuring liability	2,526	4,152
Other current liabilities	1,063	1,707
Total current liabilities	59,987	64,594
Deferred revenues	511	4,761
Capital lease obligations	262,382	223,749
Term loan	415,278	287,845
Exit activities & restructuring liability	75	664
Deferred rent	957	1,310
Deferred tax liability	2,211	1,651
Other long-term liabilities	3,473	2,983

Total liabilities	744,874	587,557
Common stock	25	21
Additional paid-in capital	1,368,968	1,327,084
Treasury stock, at cost	7,646	7,159
Retained earnings (accumulated deficit)	(1,363,019)	(1,323,723)
Accumulated items of other comprehensive income (loss)	(1,065)	(1,324)
Total stockholders' equity (deficit)	57	(1,032)
Non-controlling interest	2,794	4,069
Total Internap Corp. stockholders' deficit	(2,737)	(5,101)

As reported by the Company; Related to capital leases - Accumulated depreciation and amortization - property and equipment: \$55,198,000; Related to capital leases - Accumulated depreciation and amortization - property and equipment: \$50,253,000; Less discount and prepaid costs - Term loan: \$4,036,000; Less discount and prepaid costs - Term loan: \$2,133,000; Less discount and prepaid costs - Term loan: \$9,508,000; Less discount and prepaid costs - Term loan: \$7,655,000

Recent Dividends:

1. Internap Corp common.

No dividends paid.

Annual Dividends:

1. Internap Corp common.

No dividends paid.

INTERNATIONAL ISOTOPES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Sale of product	10,368,823	7,420,390	6,552,149
Cost of product	5,678,530	4,182,705	3,707,558
Gross profit (loss)	4,690,293	3,237,685	2,844,591
Salaries & contract labor expenses	2,311,710	2,118,257	1,782,774
General, administrative & consulting expenses	2,200,044	2,808,303	2,053,518
Research & development expenses	468,603	376,698	511,283
Total operating expenses	4,980,357	5,303,258	4,347,575
Operating income (loss)	(290,064)	(2,065,573)	(1,502,984)
Other income (expense)	86,796	(256,390)	6,605
Loss on equity method investment	...	(946,844)	...
Equity in net income of affiliate	...	53,173	73,957
Interest income	9,428	3,051	938
Interest expense	470,106	509,740	474,059
Total other income (expense)	(373,882)	(1,656,750)	(392,559)
Net income (loss)	(663,946)	(3,722,323)	(1,895,543)
Less: loss (income) attributable to noncontrolling interest	(180,630)	(34,961)	16,431
Net income (loss) attributable to International Isotopes Inc.	(844,576)	(3,757,284)	(1,879,112)
Weighted average shares outstanding - basic	411,071,598	406,361,656	403,302,425
Weighted average shares outstanding - diluted	411,071,598	406,361,656	403,302,425
Year end shares outstanding	413,168,301	406,790,703	404,999,758
Net earnings (loss) per share - basic	...	\$(0.01)	\$0.00
Net earnings (loss)

per share - diluted	...	\$(0.01)	\$0.00
Number of full time employees	30	28	26
Number of part time employees	2	2	2
Total number of employees	32	30	28
Number of common stockholders	520	522	534

Reclassified to conform with 2017 presentation; As of March 11, 2019; As of March 22, 2017; As of March 28, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash & cash equivalents	828,039	409,338
Accounts receivable	820,370	635,026
Raw materials	42,911	42,911
Work in progress	2,719,786	1,906,377
Finished goods	3,032	2,225
Inventories	2,765,729	1,951,513
Restricted cash - due to former member	...	387,455
Prepays & other current assets	315,042	344,627
Total current assets	4,729,180	3,727,959
Restricted cash	622,428	453,575
Furniture & fixtures	196,242	175,387
Transportation equipment	122,874	122,874
Plant & improvements	496,154	496,154
Production equipment	3,557,717	3,510,389
Property, plant & equipment, gross	4,372,987	4,304,804
Less accumulated depreciation	2,466,805	2,369,269
Property, plant & equipment, net	1,906,182	1,935,535
Goodwill	1,384,255	1,376,584
Patents & other intangibles, net	4,348,031	4,511,641
Total long-term assets	8,260,896	8,277,335
Total assets	12,990,076	12,005,294
Accounts payable	2,285,165	1,619,229
Accrued liabilities	939,918	1,139,477
Current portion of unearned revenue	3,783,541	2,688,128
Current portion of related party notes payable	180,000	60,000
Current installments of notes payable	7,956	7,437
Total current liabilities	7,196,580	5,514,271
Related party notes payable, net of current portion & debt discount	446,356	419,534
Notes payable, net of current portion	20,786	28,741
Unearned revenue, noncurrent	7,500	688,980
Obligation for lease disposal costs	507,968	478,424
Mandatorily redeemable convertible preferred stock	4,656,752	4,528,417
Total long-term liabilities	5,639,362	6,144,096
Total liabilities	12,835,942	11,658,367
Common stock	4,131,683	4,067,907
Additional paid-in capital	120,805,997	120,398,620
Retained earnings (accumulated deficit)	(126,541,421)	(125,696,845)
Equity (deficit) attributable to International Isotopes Inc. stockholders	(1,603,741)	(1,230,318)
Equity attributable to noncontrolling interest	1,757,875	1,577,245
Total equity	154,134	346,927

Reclassified to conform with 2018 presentation

Recent Dividends:

1. International Isotopes Inc series B mandatorily redeemable convertible preferred.

No dividends paid.

2. International Isotopes Inc common.

No dividends paid.

Annual Dividends:

1. International Isotopes Inc series B mandatorily redeemable convertible preferred.

No dividends paid.

2. International Isotopes Inc common.

No dividends paid.

IONIS PHARMACEUTICALS INC

Official Changes On Mar. 25, 2019, Co. announced that its Chief Operating Officer, Dr. Brett P. Monia, Ph.D., has been appointed to the board of directors.

KLX ENERGY SERVICES HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Jan. 31 (\$000):

	2019	2018	2017
Service revenues	495,300
Total revenues	...	320,500	152,200
Cost of sales	370,400	269,100	181,300
Selling, general & administrative expense	100,400	73,400	60,100
Research & development costs	2,400	2,000	300
Operating earnings (loss)	22,100	(24,000)	(89,500)
Interest expense, net	7,100
Earnings (loss) before income taxes - United States	...	(24,000)	(89,500)
Earnings (loss) before income taxes	15,000	(24,000)	(89,500)
Current income tax expense - state	600	100	100
Total current income tax expense	600	100	100
Income taxes expense	600	100	100
Net income (loss)	14,400	(24,100)	(89,600)
Weighted average shares outstanding - basic	20,100
Weighted average shares outstanding - diluted	20,200
Year end shares outstanding	22,600
Net earnings (loss) per share - basic	\$0.72
Net earnings (loss) per share - diluted	\$0.71
Total number of employees	1,400	1,000	...
Number of common stockholders	1,161

Ⓐ Non-consolidated; Ⓑ As is; Ⓒ Approximately; Ⓓ As of March 18, 2019

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2019	2018
Cash & cash equivalents	163,800	...
Accounts receivables - trade, gross	122,700	76,200
Allowance for doubtful accounts	3,100	2,300
Accounts receivables - trade, net	119,600	73,900
Inventories, net	15,400	10,200
Other current assets	9,500	2,000
Total current assets	308,300	86,100
Land, buildings & improvements	32,300	29,600
Machinery	202,200	125,600
Furniture & equipment	190,100	153,200
Property & equipment, gross	424,600	308,400

Less: accumulated depreciation	152,700	128,900
Property & equipment, net	271,900	179,500
Goodwill	43,200	...
Identifiable intangible assets, net	30,300	2,800
Other assets	19,100	5,400
Total assets	672,800	273,800
Accounts payable	47,300	31,800
Accrued interest	7,200	...
Accrued salaries, vacation & related benefits	13,900	6,800
Accrued bonuses	...	6,300
Accrued incentive compensation	9,100	...
Accrued property taxes	1,900	1,100
Other accrued liabilities	5,800	2,000
Accrued liabilities	30,700	16,200
Total current liabilities	85,200	48,000
Senior secured notes	250,000	...
Less unamortized debt issue costs	(7,800)	...
Long-term debt	242,200	...
Other non-current liabilities	4,700	1,200
Common stock	200	...
Additional paid-in capital	345,000	...
Former parent investment	...	1,025,800
Retained earnings (accumulated deficit)	(4,500)	(801,200)
Total stockholders' equity	340,700	224,600

Ⓐ Non-consolidated

Recent Dividends:

1. KLX Energy Services Holdings Inc common.

No dividends paid.

Annual Dividends:

1. KLX Energy Services Holdings Inc common.

No dividends paid.

KODIAK SCIENCES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Research & development	18,793	22,022	14,053
General & administrative expenses	7,581	3,499	3,098
Total operating expenses	26,374	25,521	17,151
Income (loss) from operations	(26,374)	(25,521)	(17,151)
Interest expense	5,519	1,185	6
Other income (expense), net	(4,071)	(1,230)	25
Gain (loss) on extinguishment of debt	(5,479)
Net income (loss)	(41,443)	(27,936)	(17,132)
Weighted average shares outstanding - basic	14,977	7,515	7,211
Weighted average shares outstanding - diluted	14,977	7,515	7,211
Year end shares outstanding	36,830	7,936	7,931
Net earnings (loss) per share - basic	\$(2.77)	\$(3.72)	\$(2.38)
Net earnings (loss) per share - diluted	\$(2.77)	\$(3.72)	\$(2.38)
Number of full time employees	28
Total number of employees	28	28	...
Number of common stockholders

stockholders 103 ...

Ⓐ Reclassified to conform with 2018 presentation; Ⓑ Includes attributable to related parties - Interest expense: \$3,030,000; Ⓒ Includes attributable to related parties - Interest expense: \$914,000; Ⓓ Includes other expense attributable to related parties - Other income (expense), net: \$2,736,000; Ⓔ Includes other expense attributable to related parties - Other income (expense), net: \$1,008,000; Ⓕ Includes attributable to related parties - gain (loss) on extinguishment of debt: \$1,587,000; Ⓖ Shares increased due to the effects of stock options exercised, restricted stock awards, preferred stock converted, common stock warrants exercised, convertible notes converted, and public offering; Ⓗ As is; Ⓘ As of September 1, 2018; Ⓚ Approximately; Ⓛ As of March 6, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	88,254	1,395
Prepaid expenses & other current assets	2,195	200
Total current assets	90,449	1,595
Restricted cash	140	140
Leasehold improvements	1,260	1,260
Laboratory equipment	1,133	1,174
Furniture & fixtures	225	225
Computers software	85	173
Office equipment	79	79
Computer equipment	...	52
Total property & equipment	2,782	2,963
Less: Accumulated depreciation	1,685	1,454
Property & equipment, net	1,097	1,509
Other assets	503	...
Total assets	92,189	3,244
Accounts payable	1,050	3,356
Accrued salaries & benefits	2,061	1,129
Accrued research & development	1,387	4,293
Accrued professional fees	117	19
Accrued legal fees	82	35
Accrued other liabilities	129	326
Accrued & other current liabilities	3,776	5,802
Total current liabilities	4,826	9,158
Convertible notes	...	9,921
Redeemable convertible preferred stock warrant liability	...	2,300
Other liabilities	530	586
Total liabilities	5,356	21,965
Redeemable convertible preferred stock	...	50,017
Common stock	4	1
Additional paid-in capital	197,595	584
Retained earnings (accumulated deficit)	(110,766)	(69,323)
Total stockholders' equity (deficit)	86,833	(68,738)

Ⓐ Reclassified to conform with 2018 presentation; Ⓑ Includes due to related parties Convertible notes: \$7,937,000; Ⓒ Includes attributable to warrants held by related parties; - Redeemable convertible preferred stock warrant liability: \$3,204,000

Recent Dividends:

1. Kodiak Sciences Inc common.

No dividends paid.

Annual Dividends:

1. Kodiak Sciences Inc common.

No dividends paid.

LEGACY RESERVES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Oil sales	375,444,000	239,448,000	152,507,000
Natural gas liquids ("NGL") sales	27,750,000	24,796,000	15,406,000

Natural gas sales	151,667,000	172,057,000	146,444,000
Total revenues	554,861,000	436,301,000	314,357,000
Oil & natural gas production	200,285,000	183,219,000	179,333,000
Production & other taxes	29,532,000	19,825,000	14,267,000
General & administrative expense	73,039,000	49,372,000	43,639,000
Depletion, depreciation, amortization & accretion expense	159,998,000	126,938,000	150,414,000
Impairment of long-lived assets	67,978,000	37,283,000	61,796,000
Gain (loss) on disposal of assets	23,803,000	(1,606,000)	50,095,000
Operating income (loss)	47,832,000	18,058,000	(84,997,000)
Interest income	36,000	64,000	67,000
Interest expense	117,008,000	89,206,000	79,060,000
Gain on extinguishment of debt	66,066,000	...	150,802,000
Equity in income (loss) of equity method investees	(19,000)	17,000	...
Net gains (losses) on commodity derivatives	49,172,000	17,776,000	(41,224,000)
Other income (expense)	722,000	792,000	(179,000)
Income (loss) before income taxes	46,801,000	(52,499,000)	(54,591,000)
Income tax expense (benefit)	2,968,000	1,398,000	1,229,000
Net income (loss)	43,833,000	(53,897,000)	(55,820,000)
Weighted average units outstanding - basic	105,087,000	100,049,000	98,249,000
Weighted average units outstanding - diluted	105,087,000	100,049,000	98,249,000
Year end units outstanding	109,442,278	72,694,620	72,156,097
Net income (loss) per unit - basic	\$0.42	\$(0.54)	\$(0.57)
Net income (loss) per unit - diluted	\$0.42	\$(0.54)	\$(0.57)
Number of full time employees	...	331	328
Total number of employees	337
Number of common stockholders	109	131	127

Reclassified to conform with 2018 presentation; Approximately; As of March 13, 2019; As of February 21, 2018; As of February 21, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash	1,098,000	1,246,000
Accounts receivable, net - oil & natural gas	56,615,000	62,755,000
Accounts receivable, net - joint interest owners	15,370,000	27,422,000
Fair value of derivatives	66,662,000	13,424,000
Prepaid expenses & other current assets	11,347,000	7,757,000
Total current assets	151,092,000	112,604,000
Proved oil & natural gas properties using the successful efforts method of accounting	3,471,456,000	3,529,971,000
Unproved properties	19,863,000	28,023,000
Accumulated depletion, depreciation, amortization & impairment	2,177,006,000	2,204,638,000
Other property & equipment, gross	14,779,000	14,428,000
Less: accumulated depreciation & amortization - other property & equipment	12,323,000	11,467,000

depreciation & amortization - other property & equipment	12,323,000	11,467,000
Operating rights, gross	7,017,000	7,016,000
Less: accumulated amortization - operating rights	6,123,000	5,765,000
Operating rights, net	894,000	1,251,000
Fair value of derivatives	3,135,000	14,099,000
Other assets	3,041,000	8,811,000
Total assets	1,474,931,000	1,493,082,000
Current debt, net	856,646,000	...
Accounts payable	11,227,000	13,093,000
Accrued capital expenditures	24,690,000	33,198,000
Revenue payable to joint interest owners	22,750,000	18,510,000
Accrued lease operating expense	41,227,000	18,179,000
Accrued ad valorem tax	5,255,000	5,807,000
Other accrued oil & natural gas liabilities	4,964,000	5,624,000
Fair value of derivatives	...	18,013,000
Asset retirement obligation	3,938,000	3,214,000
Other current liabilities	13,953,000	29,172,000
Total current liabilities	984,650,000	144,810,000
Credit facility	...	499,000,000
Second lien term loans	...	205,000,000
Senior notes	340,164,000	665,645,000
Convertible senior notes	128,103,000	...
Unamortized discount on senior notes	(31,517,000)	(13,101,000)
Unamortized debt issuance costs	(3,827,000)	(9,775,000)
Asset retirement obligation	248,796,000	271,472,000
Fair value of derivatives	550,000	1,075,000
Other long-term liabilities	643,000	643,000
Total liabilities	1,667,562,000	1,764,769,000
Series A preferred equity	...	55,192,000
Series B preferred equity	...	174,261,000
Incentive distribution equity	...	30,814,000
Limited partners' equity (deficit)	...	(531,794,000)
General partner's equity (deficit)	...	(160,000)
Common stock	1,094,000	...
Additional paid-in capital	24,752,000	...
Retained earnings (accumulated deficit)	(218,477,000)	...
Total stockholders'/partners' equity (deficit)	(192,631,000)	(271,687,000)

Reclassified to conform with 2018 presentation

Recent Dividends:

- Legacy Reserves Inc 8% series A fixed-to-floating rate cumulative redeemable perpetual preferred units.**
No dividends paid.
 - Legacy Reserves Inc limited partner's equity.**
No dividends paid.
 - Legacy Reserves Inc general partner's equity.**
No dividends paid.
 - Legacy Reserves Inc 8.00% series B fixed-to-floating rate cumulative redeemable perpetual preferred units.**
No dividends paid.
 - Legacy Reserves Inc incentive distribution equity.**
No dividends paid.
- Annual Dividends:**
- Legacy Reserves Inc 8% series A fixed-to-floating rate cumulative redeemable perpetual preferred units.**
No dividends paid.
 - Legacy Reserves Inc limited partner's equity.**
No dividends paid.
 - Legacy Reserves Inc general partner's equity.**
No dividends paid.
 - Legacy Reserves Inc 8.00% series B fixed-to-floating rate cumulative redeemable perpetual preferred units.**
No dividends paid.

5. Legacy Reserves Inc incentive distribution equity.

No dividends paid.

LEGACY RESERVES INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, BDO USA, LLP, as it appeared in Co. 2018 10-K: "In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, 2018 and 2017, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 (b) to the consolidated financial statements, the Company has significant obligations and commitments coming due in the near term that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1 (b). The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

LEXICON PHARMACEUTICALS, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Net product revenue	26,583,000	15,890,000	...
Collaborative agreements	36,271,000	75,621,000	79,101,000
Royalties & other revenue	355,000	178,000	155,000
Total revenues	63,209,000	91,689,000	79,256,000
Cost of sales (including finite-lived intangible asset amortization)	2,491,000	1,899,000	...
Research & development	100,243,000	152,223,000	163,973,000
Increase (decrease) in fair value of Symphony Icon, Inc. purchase liability	...	2,101,000	(703,000)
Selling, general & administrative expenses	63,754,000	66,090,000	43,157,000
Total operating expenses	166,488,000	222,313,000	206,427,000
Income (loss) from operations	(103,279,000)	(130,624,000)	(127,171,000)
Interest expense	20,777,000	6,984,000	6,567,000
Interest & other income, net	3,508,000	1,954,000	2,293,000
Net income (loss) before taxes	(120,548,000)	(135,654,000)	(131,445,000)
Income tax provision (benefit)	...	(12,661,000)	...
Net income (loss)	(120,548,000)	(122,993,000)	(131,445,000)
Weighted average shares outstanding - basic	105,830,000	105,237,000	103,863,000
Weighted average shares outstanding - diluted	105,830,000	105,237,000	103,863,000
Year end shares outstanding	105,926,000	105,589,000	...
Net income (loss) per share - basic	\$(1.14)	\$(1.17)	\$(1.27)
Net income (loss) per share - diluted	\$(1.14)	\$(1.17)	\$(1.27)
Total number of employees	202
Number of common stockholders	324

Restated to reflect the correction related to the recognition of research and development expense and accrued liabilities for its inTandem1, inTandem2 and inTandem3 clinical trials of sotagliflozin; Including stock-based compensation - Research and development: \$6,010,000; Including stock-based compensation - Research and development: \$4,905,000; Including stock-based

compensation - Research and development: \$3,938,000; ⁵ Including stock-based compensation - selling, general and administrative: \$5,686,000; ⁶ Including stock-based compensation - selling, general and administrative: \$4,567,000; ⁷ Including stock-based compensation - selling, general and administrative: \$3,514,000; ⁸ As of February 28, 2019; ⁹ Approximately; ¹⁰ As of March 8, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	¹⁰ 2017 (revised)
Cash & cash equivalents	80,386,000	61,661,000
U.S. treasury securities		
- fair value	73,974,000	222,148,000
Corporate debt securities		
- fair value	5,692,000	26,979,000
Accounts receivable, gross	5,928,000	4,829,000
Allowances	4,000	4,000
Accounts receivable, net	5,924,000	4,825,000
Raw materials	3,564,000	616,000
Work-in-process	232,000	149,000
Finished goods	884,000	1,183,000
Inventory	4,680,000	1,948,000
Prepaid expenses & other current assets	2,668,000	4,434,000
Total current assets	173,324,000	321,995,000
Computers & software	4,557,000	4,605,000
Furniture & fixtures	5,644,000	6,006,000
Laboratory equipment	3,378,000	3,423,000
Leasehold improvements	416,000	400,000
Buildings	59,212,000	59,212,000
Land	2,664,000	2,664,000
Total property & equipment	75,871,000	76,310,000
Less: accumulated depreciation & amortization	60,006,000	58,623,000
Property & equipment, net	15,865,000	17,687,000
Goodwill	44,543,000	44,543,000
Other intangible assets	50,119,000	51,885,000
Other assets	285,000	429,000
Total assets	284,136,000	436,539,000
Accounts payable	17,759,000	38,762,000
Accrued liabilities	14,482,000	12,282,000
Current portion of deferred revenue	3,395,000	40,351,000
Current portion of long-term debt, net of deferred financing costs	1,115,000	14,094,000
Total current liabilities	36,751,000	105,489,000
Deferred revenue, net of current portion	23,651,000	24,903,000
Long-term debt, net of deferred financing costs	243,887,000	231,576,000
Deferred tax liabilities	6,014,000	6,014,000
Other long-term liabilities	238,000	292,000
Total liabilities	310,541,000	368,274,000
Common stock	106,000	106,000
Additional paid-in capital	1,447,954,000	1,435,526,000
Retained earnings (accumulated deficit)	(1,471,577,000)	(1,365,241,000)
Accumulated other comprehensive gain (loss)	(12,000)	(222,000)
Treasury stock, at cost	2,876,000	1,904,000
Total Lexicon Pharmaceuticals, Inc. stockholders' equity (deficit)	(26,405,000)	68,265,000
Total equity (deficit)	(26,405,000)	68,265,000

¹¹ Restated to reflect the correction related to the recognition of research and development expense and accrued liabilities for its inTandem1, inTandem2 and inTandem3 clinical trials of so-tagliflozin

Recent Dividends:

1. Lexicon Pharmaceuticals, Inc. common.
No dividends paid.

Annual Dividends:

1. Lexicon Pharmaceuticals, Inc. common.
No dividends paid.

LYFT INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Revenue	2,156,616	1,059,881	343,298
Cost of revenue	1,243,400	659,533	279,011
Operations & support	338,402	183,513	97,880
Research & development	300,836	136,646	64,704
Sales & marketing expenses	803,751	567,015	434,344
General & administrative expenses	447,938	221,446	159,962
Total costs & expenses	3,134,327	1,768,153	1,035,901
Income (loss) from operations	(977,711)	(708,272)	(692,603)
Interest income, net	66,462	20,243	6,964
Other income, net	652	284	3,246
Income before income taxes - Foreign	(900,642)	(687,743)	(682,393)
Income before income taxes - United States	(9,955)	(2)	...
Income (loss) before provision for income taxes	(910,597)	(687,745)	(682,393)
Current state income taxes	1,250	556	401
Current foreign income taxes	116
Current income taxes	1,366	556	401
Deferred income taxes	(628)
Deferred foreign income taxes	(628)
Provision for income taxes	738	556	401
Net income (loss)	(911,335)	(688,301)	(682,794)
Weighted average shares outstanding - basic	21,176	19,371	18,413
Weighted average shares outstanding - diluted	21,176	19,371	18,413
Year end shares outstanding	22,438	19,916	18,734
Net earnings (loss) per share - basic	\$(43.04)	\$(35.53)	\$(37.08)
Net earnings (loss) per share - diluted	\$(43.04)	\$(35.53)	\$(37.08)
Total number of employees	¹² 4,791
Number of class A common stockholders	¹³ 2,301
Number of class B common stockholders	¹⁴ 8
Number of stockholders	¹⁵ 2,309

¹⁶ As Is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	517,690	1,106,102
Short-term investments	1,520,180	1,284,642
Prepaid expenses & other current assets	282,572	172,951
Total current assets	2,320,442	2,563,695
Bike fleet	65,985	...
Leasehold improvements	39,727	14,135
Computer equipment & software	11,366	1,915
Furniture & fixtures	262	144
Construction in progress	3,629	1,155
Total property &		

equipment, gross	120,969	17,349
Less: Accumulated depreciation	11,712	3,141
Property & equipment, net	109,257	14,208
Goodwill	152,085	...
Intangible assets, net	117,733	4,349
Restricted cash & cash equivalents	187,374	72,817
Restricted investments	863,713	360,882
Other assets	9,439	776
Total assets	3,760,043	3,016,727
Accounts payable	32,343	66,874
Insurance reserves	810,273	376,538
Ride-related accruals	188,602	101,078
Insurance-related accruals	98,062	27,447
Legal accruals	81,139	41,788
Insurance claims payable & related fees	65,897	48,434
Other accrued & other current liabilities	172,503	34,659
Accrued & other current liabilities	606,203	253,406
Total current liabilities	1,448,819	696,818
Other liabilities	30,458	15,298
Total liabilities	1,479,277	712,116
Redeemable convertible preferred stock	5,152,047	4,284,049
Additional paid-in capital	73,916	55,568
Accumulated other comprehensive income (loss)	133	(1,011)
Retained earnings (accumulated deficit)	(2,945,330)	(2,033,995)
Total members' equity (deficit)	(2,871,281)	(1,979,438)

Recent Dividends:

1. Lyft Inc class A common.

No dividends paid.

2. Lyft Inc class B common.

No dividends paid.

Annual Dividends:

1. Lyft Inc class A common.

No dividends paid.

2. Lyft Inc class B common.

No dividends paid.

LYFT INC

Offering On Mar. 28, 2019, Co. announced the pricing of its initial public offering of its Class A common stock at a price of \$72.00 per share. Co. is offering 32,500,000 shares of its Class A common stock, plus up to an additional 4,875,000 shares that the underwriters have the option to purchase. The shares are expected to begin trading on the Nasdaq Global Select Market on Mar. 29, 2019 under the ticker symbol "LYFT" and the offering is expected to close on Apr. 2, 2019, subject to customary closing conditions. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC, Jefferies LLC, UBS Securities LLC, Stifel, Nicolaus & Company, Inc., RBC Capital Markets, LLC and KeyBanc Capital Markets Inc. are acting as book-running managers.

MAGENTA THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	¹⁷ 2017	¹⁸ 2016
Research & development	41,340	27,899	5,782
General & administrative expenses	18,623	7,828	3,486
Total operating expenses	59,963	35,727	9,268
Income (loss) from operations	(59,963)	(35,727)	(9,268)
Interest expense	163
Interest & other income, net	2,448	236	...
Total other income (expense), net	2,448	236	(163)
Net income (loss)	(57,515)	(35,491)	(9,431)

Accretion of redeemable convertible preferred stock to redemption value	88	213	107
Cumulative dividends on redeemable convertible preferred stock	...	437	197
Reversal of cumulative dividends on redeemable convertible preferred stock	...	(634)	...
Net income (loss) attributable to common stockholders	(57,603)	(35,507)	(9,735)
Weighted average shares outstanding - basic	18,390	1,857	149
Weighted average shares outstanding - diluted	18,390	1,857	149
Year end shares outstanding	33,305	2,351	1,348
Net earnings (loss) per share - basic	\$(3.13)	\$(19.12)	\$(65.15)
Net earnings (loss) per share - diluted	\$(3.13)	\$(19.12)	\$(65.15)
Number of full time employees	59	48	...
Number of common stockholders	54

Retained earnings (accumulated deficit)	(102,726)	(45,211)
Total stockholders' equity (deficit)	145,648	(42,118)

□ Non-consolidated

Recent Dividends:
1. Magenta Therapeutics Inc common.
 No dividends paid.

Annual Dividends:
1. Magenta Therapeutics Inc common.
 No dividends paid.

MAJOR LEAGUE FOOTBALL INC
Earnings, 9 mos. to Jan 31(Consol. - \$):

	2019	2018
Cost & expenses	168,754	234,092
Operating income	(168,754)	(234,092)
Other income (expense), net	(218,700)	32,486
Net income	(484,967)	(264,933)
Earnings common share		
Primary	\$(0.01)	...
Fully Diluted	\$(0.01)	...
Common Shares:		
Full Diluted	62,810,229	56,753,433
Year-end	71,993,073	57,999,488

MARCHEX INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Revenue	85,251,000	90,291,000	129,547,000
Service costs	47,804,000	49,339,000	76,970,000
Sales & marketing expenses	13,788,000	15,652,000	22,307,000
Product development expenses	15,423,000	18,094,000	28,446,000
General & administrative expenses	10,881,000	13,567,000	21,754,000
Amortization of intangible assets from acquisitions	781,000
Acquisition & disposition related costs	662,000
Acquisition related costs	462,000
Impairment of goodwill	63,305,000
Income (loss) from operations	(3,888,000)	(6,361,000)	(83,897,000)
Interest income	1,054,000	316,000	(42,000)
Other income (expense), net	(73,000)
Total other income (expense)	(115,000)
Income (loss) from continuing operations before provision for income taxes - United States	(2,312,000)	(6,022,000)	(83,920,000)
Income (loss) from continuing operations before provision for income taxes - foreign	(522,000)	(23,000)	(92,000)
Income (loss) before provision for income taxes	(2,834,000)	(6,045,000)	(84,012,000)
Current provision (benefit) for income taxes - federal	(48,000)
Current provision (benefit) for income taxes - state	30,000	42,000	54,000
Deferred provision (benefit) for income taxes -

federal	(9,830,000)
Deferred provision (benefit) for income taxes - foreign	(138,000)
Valuation allowance	9,830,000
Income tax expense (benefit)	(156,000)	42,000	54,000
Income (loss) from continuing operations	(84,066,000)
Net income (loss)	(2,678,000)	(6,087,000)	(84,066,000)
Dividends applicable to participating securities	...	355,000	...
Net income (loss) applicable to common stockholders	(2,678,000)	(6,442,000)	(84,066,000)
Weighted average class A shares outstanding - basic	5,056,000	5,056,000	5,190,000
Weighted average class B shares outstanding - basic	37,390,000	37,657,000	36,550,000
Weighted average class B shares outstanding - diluted	42,446,000	42,713,000	41,740,000
Year end shares outstanding	42,021,000	43,792,000	43,060,000
Net income (loss) per class B share - continuing operations - basic	\$(2.01)
Net income (loss) per class B share - basic	\$(0.06)	\$(0.15)	\$(2.01)
Net income (loss) per class B share - continuing operations - diluted	\$(2.01)
Net income (loss) per class B share - diluted	\$(0.06)	\$(0.15)	\$(2.01)
Dividends paid per share	...	\$0.50	...
Number of full time employees	254	225	291
Number of class A common stockholders	2	2	2
Number of class B common stockholders	36	37	42
Total number of stockholders	38	39	44

□ Reclassified to conform with 2018 presentation; □ Reclassified to conform with 2017 presentation; □ Approximately; □ As of March 14, 2019; □ As of March 9, 2018; □ As of March 6, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash & cash equivalents	45,230,000	104,190,000
Accounts receivable, gross	16,846,000	15,486,000
Allowance for doubtful accounts	648,000	626,000
Accounts receivable, net	16,198,000	14,860,000
Prepaid expenses & other current assets	2,657,000	2,041,000
Total current assets	64,085,000	121,091,000
Computer & other related equipment	18,839,000	19,157,000
Purchased & internally developed software	6,878,000	6,687,000
Furniture & fixtures	1,023,000	1,071,000
Leasehold improvements	1,275,000	1,168,000
Property & equipment, gross	28,015,000	28,083,000
Less: accumulated depreciation & amortization	25,094,000	25,678,000

□ Non-consolidated; □ As is; □ As of April 30, 2018; □ Approximately; □ As of February 28, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	58,345	51,402
Marketable securities	84,225	...
Restricted cash	...	165
Prepaid expenses & other current assets	2,751	936
Total current assets	145,321	52,503
Restricted cash	1,780	...
Laboratory & computer equipment	4,160	2,120
Furniture & fixtures	743	77
Leasehold improvements	6,399	141
Total property & equipment, gross	11,302	2,338
Less accumulated depreciation & amortization	1,090	382
Property & equipment, net	10,212	1,956
Other assets	...	4
Total assets	157,313	54,463
Accounts payable	3,492	167
Accrued external research & development expenses	2,619	1,531
Accrued payroll & related expenses	2,526	1,330
Accrued professional fees	787	963
Accrued leasehold improvements	501	...
Other accrued expenses	494	151
Accrued expenses & other current liabilities	6,927	3,975
Total current liabilities	10,419	4,142
Long-term liabilities	1,246	...
Total liabilities	11,665	...
Redeemable convertible preferred stock	...	92,439
Common stock	33	2
Additional paid-in capital	248,349	3,091
Accumulated other comprehensive income (loss)	(8)	...

Property & equipment, net.....	2,921,000	2,405,000
Other assets, net.....	917,000	326,000
Goodwill.....	24,442,000	...
Intangible assets from acquisitions, net.....	20,697,000	...
Total assets.....	113,062,000	123,822,000
Accounts payable.....	5,968,000	4,928,000
Accrued expenses & other current liabilities.....	5,807,000	5,585,000
Current portion of acquisition-related liabilities.....	1,215,000	...
Deferred revenue & deposits.....	1,782,000	313,000
Dividends payable.....	...	21,907,000
Total current liabilities.....	14,772,000	32,733,000
Other non-current liabilities.....	1,287,000	1,090,000
Deferred tax liabilities.....	1,531,000	...
Non-current portion of acquisition-related liabilities.....	446,000	...
Total liabilities.....	18,036,000	33,823,000
Class A common stock.....	53,000	53,000
Class B common stock.....	370,000	387,000
Additional paid-in capital.....	350,801,000	343,268,000
Retained earnings (accumulated deficit).....	(256,198,000)	(253,709,000)
Total stockholders' equity.....	95,026,000	89,999,000

Recent Dividends:**1. Marchex Inc class A common.**

No dividends paid.

2. Marchex Inc class B common.

ExDate	Amt	Declared	Record	Payable
03/07/2018	0.50	12/12/2017	03/08/2018	03/21/2018

3. Marchex Inc 4.75% convertible exchangeable preferred.

No dividends paid.

Annual Dividends:**1. Marchex Inc class A common.**

No dividends paid.

2. Marchex Inc class B common.

2018.....0.50

3. Marchex Inc 4.75% convertible exchangeable preferred.

No dividends paid.

MOMENTA PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2018	2017	2016
		(revised)	(revised)
Product revenue.....	39,684,000	66,803,000	74,648,000
Research & development revenue.....	35,905,000	72,079,000	34,971,000
Total collaboration revenue.....	75,589,000	138,882,000	109,619,000
Research & development expenses.....	124,004,000	149,226,000	119,880,000
General & administrative expenses.....	85,105,000	82,207,000	64,466,000
Other operating expense.....	30,000,000
Restructuring expense.....	17,807,000
Total operating expenses.....	256,916,000	231,433,000	184,346,000
Operating income (loss).....	(181,327,000)	(92,551,000)	(74,727,000)
Interest income.....	6,194,000	4,427,000	2,226,000
Other income (expense), net.....	(928,000)	28,000	51,498,000
Total other income.....	5,266,000	4,455,000	53,724,000
Net income (loss).....	(176,061,000)	(88,096,000)	(21,003,000)
Weighted average shares outstanding - basic.....	77,845,000	73,136,000	68,656,000

Weighted average shares outstanding - diluted.....	77,845,000	73,136,000	68,656,000
Year end shares outstanding.....	98,464,000	76,355,000	71,076,000
Net income (loss) per share - basic.....	\$(2.26)	\$(1.20)	\$(0.31)
Net income (loss) per share - diluted.....	\$(2.26)	\$(1.20)	\$(0.31)
Total number of employees.....	131	279	290
Number of common stockholders.....	20	30	33

□ Shares increased due to the effect of issuance of common stock and exercise of stock options and employee stock purchase plan; □ Approximately; □ As of February 11, 2019; □ As of February 9, 2018; □ As of February 8, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Cash & cash equivalents.....	248,334,000	73,651,000	...
Marketable securities.....	174,076,000	269,017,000	...
Collaboration receivable.....	11,371,000	15,048,000	...
Prepaid expenses & other current assets.....	6,318,000	6,798,000	...
Assets held-for-sale.....	1,324,000
Restricted cash.....	...	2,412,000	...
Total current assets.....	441,423,000	366,926,000	...
Marketable securities, long-term.....	27,001,000	37,222,000	...
Computer equipment.....	3,189,000	3,061,000	...
Software.....	11,076,000	11,062,000	...
Office furniture & equipment.....	873,000	2,530,000	...
Laboratory equipment.....	18,348,000	51,315,000	...
Leasehold improvements.....	23,932,000	25,356,000	...
Less: accumulated depreciation.....	36,474,000	63,408,000	...
Property & equipment, net.....	20,944,000	29,916,000	...
Restricted cash.....	37,898,000	20,620,000	...
Intangible assets, net.....	2,883,000	4,036,000	...
Other long-term assets.....	1,414,000	711,000	...
Total assets.....	531,563,000	459,431,000	...
Accounts payable.....	9,352,000	11,456,000	...
Accrued expenses.....	14,060,000	20,528,000	...
Accrued contract research & manufacturing costs.....	2,944,000	8,843,000	...
Accrued compensation.....	8,106,000	8,743,000	...
Accrued professional fees.....	2,372,000	2,429,000	...
Other accrued expenses.....	638,000	513,000	...
Accrued restructuring.....	3,235,000
Collaboration liabilities.....	4,721,000	9,258,000	...
Deferred revenue.....	3,916,000	2,866,000	...
Other current liabilities.....	16,227,000	379,000	...
Total current liabilities.....	51,511,000	44,487,000	...
Deferred revenue, net of current portion.....	1,774,000	30,751,000	...
Other long term liabilities.....	17,270,000	10,039,000	...
Total liabilities.....	70,555,000	85,277,000	...
Common stock.....	10,000	8,000	...
Additional paid-in capital.....	1,208,025,000	939,654,000	...
Accumulated other comprehensive income (loss).....	(87,000)	(140,000)	...
Retained earnings (accumulated deficit).....	(743,826,000)	(562,254,000)	...
Treasury stock, at cost.....	3,114,000	3,114,000	...
Total stockholders' equity (deficit).....	461,008,000	374,154,000	...

□ Reclassified to conform with 2018 presentation

Recent Dividends:**1. Momenta Pharmaceuticals Inc common.**

No dividends paid.

Annual Dividends:**1. Momenta Pharmaceuticals Inc common.**

No dividends paid.

MTBC INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2018	2017	2016
		(revised)	(revised)
Net revenue.....	50,545,781	31,810,635	24,493,443
Direct operating costs.....	31,252,535	17,679,070	13,416,627
Selling & marketing expense.....	1,611,982	1,106,698	1,224,243
General & administrative expense.....	16,264,473	11,738,201	12,458,820
Research & development expense.....	1,029,510	1,081,832	902,186
Change in contingent consideration.....	73,271	151,423	(715,495)
Depreciation & amortization expense.....	2,853,827	4,299,943	5,108,035
Restructuring charges.....	...	275,628	...
Total operating expenses.....	53,085,598	36,332,795	32,394,416
Operating income (loss).....	(2,539,817)	(4,522,160)	(7,900,973)
Interest income.....	100,788	16,944	36,411
Interest expense.....	351,168	1,324,219	682,083
Foreign exchange gain (loss).....	434,806	248,517	(92,160)
Other income (expense).....	59,526	83,567	38,884
Income (loss) before income taxes - United States.....	(4,111,539)	(6,949,433)	(9,577,372)
Income (loss) before income taxes - foreign.....	1,815,674	1,452,082	977,451
Income (loss) before income taxes.....	(2,295,865)	(5,497,351)	(8,599,921)
Current provision (benefit) for income taxes - federal.....	(1,661)
Current provision (benefit) for income taxes - state.....	49,000	31,028	17,805
Current provision (benefit) for income taxes - foreign.....	1,341	10,235	6,397
Current provision (benefit) for income taxes.....	50,341	41,263	22,541
Deferred provision (benefit) for income taxes - state.....	17,621	19,359	38,492
Deferred provision (benefit) for income taxes.....	(207,726)	26,542	174,261
Income tax provision (benefit).....	(157,385)	67,805	196,802
Net income (loss).....	(2,138,480)	(5,565,156)	(8,796,723)
Preferred stock dividend.....	4,823,987	2,030,295	752,525
Net income (loss) attributable to common shareholders.....	(6,962,467)	(7,595,451)	(9,549,248)
Weighted average shares outstanding - basic.....	11,721,232	11,010,432	10,036,988
Weighted average shares outstanding - diluted.....	11,721,232	11,010,432	10,036,988
Year end shares outstanding.....	11,829,758	11,530,591	10,051,553
Net earnings (loss) per share - basic.....	\$(0.59)	\$(0.69)	\$(0.95)

Net earnings (loss) per share - diluted	\$(0.59)	\$(0.69)	\$(0.95)
Number of full time employees	2,400	1,700	2,050
Number of common stockholders	4,000	10,800	600
Foreign currency translation adjustments			22,889

□ Approximately; □ As of January 31, 2019; □ As of January 31, 2018; □ As of January 19, 2018; □ As of March 1, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2018	2017	
		(revised)	
Cash	14,472,483	4,362,232	
Accounts receivable, gross	7,520,474	4,064,463	
Allowance for doubtful accounts	189,000	185,000	
Accounts receivable, net	7,331,474	3,879,463	
Contract asset	2,608,631		
Inventory	444,437		
Current assets - related party	25,203	25,203	
Prepaid expenses & other current assets	1,191,445	662,822	
Total current assets	26,073,673	8,929,720	
Computer equipment	2,389,865	1,776,463	
Office furniture & equipment	1,089,014	1,078,729	
Transportation equipment	828,417	719,947	
Leasehold improvements	727,519	880,273	
Assets not placed in service	50,362	4,415	
Total property, & equipment	5,085,177	4,459,827	
Less accumulated depreciation	3,252,990	3,074,084	
Property & equipment - net	1,832,187	1,385,743	
Intangible assets - net	6,634,003	2,509,544	
Goodwill	12,593,795	12,263,943	
Other assets	489,703	436,713	
Total assets	47,623,361	25,525,663	
Accounts payable	2,438,267	991,859	
Accrued compensation	1,731,063	1,137,351	
Accrued expenses	1,589,009	616,778	
Deferred rent (current portion)	90,657	81,826	
Deferred revenue (current portion)	25,355	62,104	
Accrued liability to related party	10,663	10,675	
Notes payable - (current portion)	277,776	168,718	
Contingent consideration (current portion)	526,432	505,557	
Dividend payable	1,468,724	747,147	
Total current liabilities	8,157,946	4,322,015	
Notes payable	222,400	120,899	
Deferred rent	189,366	333,788	
Deferred revenue	18,949	28,615	
Contingent consideration		97,854	
Deferred tax liability	164,346	372,072	
Total liabilities	8,753,007	5,275,243	
Preferred stock	2,136	1,087	
Common stock	12,571	12,272	
Additional paid-in capital	65,142,460	45,129,517	
Retained earnings (accumulated deficit)	(24,203,745)	(23,509,386)	
Accumulated other comprehensive income (loss)	(1,421,068)	(721,070)	
Treasury stock	662,000	662,000	
Total shareholders' equity	38,870,354	20,250,420	

Recent Dividends:
1. MTBC Inc common.
 No dividends paid.

2. MTBC Inc 11% series A cumulative redeemable perpetual preferred.
 No dividends paid.
Annual Dividends:
1. MTBC Inc common.
 No dividends paid.
2. MTBC Inc 11% series A cumulative redeemable perpetual preferred.
 No dividends paid.

MUSTANG BIO INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)
Total revenues	0		
Research & development	21,104	7,943	2,468
Research & development - licenses acquired	3,360	12,433	6,079
General & administrative expenses	6,759	11,409	2,816
Total operating expenses	31,223	31,785	11,363
Income (loss) from operations	(31,223)	(31,785)	(11,363)
Interest income	569	505	16
Interest expense - related party			253
Interest expense	8	8	895
Change in fair value of derivative liabilities			(159)
Total other income (expense)	561	497	(1,291)
Net income (loss)	(30,662)	(31,288)	(12,654)
Weighted average shares outstanding - basic	26,949	25,253	11,027
Weighted average shares outstanding - diluted	26,949	25,253	11,027
Year end shares outstanding	27,610	26,236	16,165
Net earnings (loss) per share - basic	\$(1.14)	\$(1.24)	\$(1.15)
Net earnings (loss) per share - diluted	\$(1.14)	\$(1.24)	\$(1.15)
Number of full time employees	38	6	0
Number of part time employees			3
Number of common stockholders	519	516	488

□ Reclassified to conform with 2017 presentation; □ Shares increased due to issuance for Founders Agreement, license expenses, cash stock-based compensation expenses, and exercise of warrants; □ Shares increased due to the effect of issuance of common shares for Founder Agreement and cash and NSC note exchange of class A preferred stock and common stock; □ As is; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)
Cash & cash equivalents	16,469	34,975	
Short-term investments (certificates of deposit)	17,604	26,002	
Interest receivable on short-term investments (certificates of deposit)	37	106	
Prepaid expenses	1,015	278	
Total current assets	35,125	61,361	
Property, plant & equipment, net	6,465	140	
Fixed assets - construction in process	393	1,241	
Restricted cash	500	500	
Other assets	271	251	
Total assets	42,754	63,493	

Account payable & accrued expenses	5,381	3,474
Payables & accrued expenses - related party	236	137
Total current liabilities	5,617	3,611
Deferred rent payable	741	50
Total liabilities	6,358	3,661
Common stock	3	3
Common stock issuable	2,085	9,558
Additional paid-in capital	113,378	98,679
Retained earnings (accumulated deficit)	(79,070)	(48,408)
Total stockholders' equity (deficit)	36,396	59,832

Recent Dividends:

1. Mustang Bio Inc class A common.
 No dividends paid.
2. Mustang Bio Inc class A preferred.
 No dividends paid.
3. Mustang Bio Inc common.
 No dividends paid.
Annual Dividends:
1. Mustang Bio Inc class A common.
 No dividends paid.
2. Mustang Bio Inc class A preferred.
 No dividends paid.
3. Mustang Bio Inc common.
 No dividends paid.

NATIONAL COMMERCE CORP

Merger Completed On Apr. 1, 2019, Co. merged with and into CenterState Bank Corp. ("CSFL"), with CSFL continuing as the surviving corporation (the "Merger"), immediately following the Merger. Co.'s wholly-owned subsidiary bank, National Bank of Commerce ("NBC"), merged with and into CSFL's wholly-owned subsidiary bank, CenterState Bank, N.A. ("CenterState Bank"), with CenterState Bank continuing as the surviving national bank subsidiary of CSFL. As the result of the merger, Co.'s stockholders received 1.65 (the "Exchange Ratio") shares of CSFL common stock for each outstanding share of Co. common stock held immediately prior to the effective time of the Merger (the "Effective Time"), with cash payable in lieu of any fractional shares (the "Merger Consideration"). Each option or warrant to purchase shares of Co. common stock was assumed by CSFL according to its terms and was converted into an option or warrant, as applicable, to purchase the number of shares of CSFL common stock equal to the product obtained by multiplying the Exchange Ratio by the number of shares of Co. common stock that such Co. stock option or warrant, as applicable, entitled the holder thereof to purchase, at an exercise price equal to the quotient obtained by dividing the exercise price per share of Co.'s stock option or warrant, as applicable, by the Exchange Ratio. The deferrals of Co. common stock representing equity awards and director fees credited to participant accounts under the National Commerce Corporation Deferral of Compensation Plan were converted into the right to receive the Merger Consideration in respect of each such deferred share, net of withholding taxes. Immediately prior to the Effective Time, the outstanding performance share awards with respect to shares of Co. common stock for the four-year performance periods ending on Dec. 31, 2019, 2020 and 2021, all of which were to be measured over a performance period that was not completed prior to the Effective Time, vested in the amounts determined by the Compensation Committee of Co.'s board of directors in accordance with the applicable award agreements and the Merger Agreement. These performance share awards were cancelled at the Effective Time in exchange for the right to receive the Merger Consideration in respect of each share of Co. common stock underlying the performance share awards, net of withholding taxes. As a result of the Merger, CSFL issued approximately 34,668,731 shares of CSFL common stock to former holders of Co. common stock, which, based on the closing price of CSFL common stock on Mar. 29, 2019, had a value of approximately \$826,000,000. Additionally, at the Effective Time, pursuant to the terms and conditions set forth in the Merger Agreement, CSFL assumed all rights and obligations of Co. under and relating to (i) Co.'s outstanding 6.0% Fixed-to-Floating Rate Subordinated Notes due June 1, 2026, in the aggregate principal amount of \$25,000,000 (the "6.0% Notes"), and (ii) Co.'s outstanding 6.50% Fixed-to-Floating Subordinated Notes due June 30, 2027, in the aggregate principal amount of \$13,000,000. In connection with the assumption by CSFL of all rights and obligations of Co. under and relating to the 6.0% Notes, Co., CSFL and The Bank of

New York Mellon Trust Company, N.A., as trustee, paying agent and registrar (the "Trustee"), entered into a Second Supplemental Indenture, which amended and supplemented the Indenture, dated May 19, 2016, between Co. and the Trustee, as amended and supplemented by the First Supplemental Indenture, dated May 19, 2016, between Co. and the Trustee.

NEW FORTRESS ENERGY LLC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	[□] 2017 (revised)	[□] 2016 (revised)
Operating revenue	96,906	82,104	18,615
Other revenue	15,395	15,158	2,780
Total revenues	112,301	97,262	21,395
Cost of sales	95,742	78,692	22,747
Operations & maintenance	9,589	7,456	5,205
Selling, general & administrative expense	62,137	33,343	18,160
Depreciation & amortization	3,321	2,761	2,341
Total operating expenses	170,789	122,252	48,453
Operating income (loss)	(58,488)	(24,990)	(27,058)
Interest expense	11,248	6,456	5,105
Other income, net	784	301	53
Gain (loss) on extinguishment of debt	(9,568)	...	(1,177)
Income (loss) before taxes	(78,520)	(31,145)	(33,287)
Current income taxes	7	5	...
Deferred income taxes	(345)	521	(361)
Tax provision (benefit)	(338)	526	(361)
Net income (loss)	(78,182)	(31,671)	(32,926)
Net income (loss) attributable to non-controlling interest	106
Net income (loss) attributable to members	(78,076)	(31,671)	(32,926)
Weighted average shares outstanding - basic	67,933	65,006	58,753
Weighted average shares outstanding - diluted	67,933	65,006	58,753
Year end shares outstanding	67,983	65,665	65,000
Net earnings (loss) per share - basic	\$(1.15)	\$(0.49)	\$(0.56)
Net earnings (loss) per share - diluted	\$(1.15)	\$(0.49)	\$(0.56)
Number of full time employees	[□] 140	[□] 147	...
Number of common stockholders - class A	[□] 1
Number of common stockholders - class B	[□] 1

[□] Reclassified to conform with 2018 presentation; [□] As Is; [□] As of September 30, 2018; [□] As of March 20, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	[□] 2017 (revised)	[□] 2016 (revised)
Cash & cash equivalents	78,301	84,708	13,623
Restricted cash	30	13,623	19,417
Receivable, net	[□] 28,530	19,417	1,178
Finance leases, net	943	1,178	15,611
LNG & natural gas inventory	15,611	10,593	348
Materials, supplies & other	348	559	15,959
Inventory	15,959	11,152	...

Prepaid LNG	16,170	16,665	...
Prepaid charter costs	925	1,581	...
Prepaid expenses	1,244	5,260	...
Deposits	1,622	1,238	...
Due from affiliate	890	131	...
Other current assets	9,166
Prepaid expenses & other current assets	30,017	24,875	...
Total current assets	153,780	154,953	...
Available-for-sale investment	3,656	6,333	...
Restricted cash	22,522	20,000	...
Construction in progress	254,700	35,413	...
LNG liquefaction facilities	65,631	63,607	...
ISO containers & other equipment	15,873	10,495	...
Land	12,779
Leasehold improvements	7,229
Vehicles	1,178	551	...
Computer equipment	741	289	...
Less: Accumulated depreciation	9,391	5,592	...
Property, plant & equipment, net	94,040	69,350	...
Finance leases, net	92,207	94,077	...
Deferred tax assets, net	185
Intangibles, net	43,057
Easements	1,159	810	...
Port access rights	12,671
Initial lease costs	9,200
Nonrefundable deposits for land	10,810
Other non-current assets	1,415	254	...
Total other non-current assets	35,255	1,064	...
Total assets	699,402	381,190	...
Current portion of long-term debt	272,192	5,828	...
Accounts payable	43,177	6,352	...
Accrued construction costs	41,343	4,572	...
Accrued initial public offering costs	5,296
Accrued bonuses	12,582	8,620	...
Other accrued expenses	8,291	4,307	...
Accrued liabilities	67,512	17,499	...
Due to affiliates	4,481	2,091	...
Other current liabilities	17,393	329	...
Total current liabilities	404,755	32,099	...
Term Loan Facility	272,192
Montego Bay Loan	...	36,504	...
Miami loan	...	38,749	...
Total long-term debt	272,192	75,253	...
Current portion of long-term debt	272,192	5,828	...
Long-term debt	...	69,425	...
Deferred tax liability, net	...	160	...
Other long-term liabilities	12,000	596	...
Total liabilities	416,755	102,280	...
Members' capital	426,741	406,591	...
Stock subscription receivable	...	(50,000)	...
Retained earnings (accumulated deficit)	(158,423)	(80,347)	...
Accumulated other comprehensive income (loss)	(11)	2,666	...
Non-controlling interests	14,340
Total members' equity	282,647	278,910	...

[□] Reclassified to conform with 2018 presentation; [□] Net of allowances - receivables: \$257,000

Recent Dividends:

1. New Fortress Energy LLC class B common.

No dividends paid.

2. New Fortress Energy LLC class A common.

No dividends paid.

Annual Dividends:

1. New Fortress Energy LLC class B common.

No dividends paid.

2. New Fortress Energy LLC class A common.

No dividends paid.

NEWTEK BUSINESS SERVICES CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	[□] 2017 (revised)	[□] 2016 (revised)
Investment income from non-affiliate investments - interest income	23,067,000	18,018,000	11,158,000
Investment income from non-affiliate investments - servicing income	8,552,000	7,206,000	6,160,000
Investment income from non-affiliate investments - other income	4,526,000	3,236,000	2,714,000
Investment income from non-control or affiliate investments - dividend income	65,000
Investment income from controlled investments - interest income	740,000	653,000	360,000
Investment income from controlled investments - dividend income	12,565,000	9,747,000	10,573,000
Investment income from controlled investments - other income	...	54,000	...
Total investment income	49,515,000	38,914,000	30,965,000
Salaries & benefits expenses	21,082,000	19,292,000	15,234,000
Interest expenses - notes payable - securitization trusts	8,748,000	5,537,000	3,976,000
Interest expenses - bank notes payable	1,473,000	1,188,000	1,260,000
Interest expenses - notes due 2022	707,000	707,000	708,000
Interest expenses - notes due 2021	718,000	3,164,000	2,181,000
Interest expenses - notes due 2023	3,483,000
Interest expenses - notes payable - related parties	916,000	780,000	260,000
Interest expenses - other	21,000	21,000	55,000
Interest expenses	16,066,000	11,397,000	8,440,000
Depreciation & amortization expenses	484,000	402,000	296,000
Professional fees	3,094,000	3,009,000	3,274,000
Origination & servicing expenses	8,362,000	5,871,000	6,046,000
Change in fair value of contingent consideration liabilities	51,000	455,000	...
Gain (loss) on extinguishment of debt	1,059,000
Other general & administrative costs	6,907,000	7,279,000	6,935,000
Total expenses	57,003,000	46,795,000	40,225,000
Net investment income (loss)	(7,488,000)	(7,881,000)	(9,260,000)
Weighted average shares outstanding - basic	18,714,000	17,327,000	14,541,000
Weighted average shares outstanding - diluted	18,714,000	17,327,000	14,541,000
Year end shares outstanding	18,919,000	18,457,000	14,624,000

Net investment income (loss) per share - basic	\$(0.40)	\$(0.45)	\$(0.64)
Net investment income (loss) per share - diluted	\$(0.40)	\$(0.45)	\$(0.64)
Dividends & distributions declared per common share	\$1.80	\$1.64	\$1.53
Total number of employees	175	162	137
Number of common stockholders	2,97	2,131	2,118

Reclassified to conform with 2018 presentation; Approximately: As of March 15, 2019; As of March 12, 2018; As of March 9, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Investments, at fair value - small business administration ("SBA") unguaranteed		
non-affiliate investments	349,402,000	278,034,000
Investments, at fair value - SBA guaranteed		
non-affiliate investments	19,100,000	25,490,000
Investments, at fair value - controlled investments	171,585,000	153,156,000
Investments, at fair value - non-control or affiliate investments	1,000,000	
Investments, at fair value - investments in money market funds	9,000	9,000
Cash	2,316,000	2,464,000
Restricted cash	29,034,000	18,074,000
Broker receivable	42,617,000	8,539,000
Due from related parties	3,232,000	2,255,000
Servicing assets, at fair value	21,360,000	19,359,000
Other assets	13,686,000	12,231,000
Total assets	653,341,000	519,611,000
Bank notes payable	34,700,000	
Notes due 2022	8,019,000	7,936,000
Notes due 2021		39,114,000
Notes due 2023	55,564,000	
Notes payable - securitization trust	216,507,000	162,201,000
Notes payable - related parties	16,840,000	7,001,000
Due to related parties	4,000	
Deferred tax liabilities	9,241,000	8,164,000
Due to participants & SBA	10,682,000	6,420,000
Accrued payroll & related expenses	3,635,000	3,401,000
Accrued interest	569,000	334,000
Deferred rent & other lease related liabilities	2,217,000	2,378,000
Loan processing, servicing & other loan related expenses	2,406,000	1,991,000
Contingent consideration liabilities	1,733,000	913,000
Other accounts payable, accrued expenses & other liabilities	3,779,000	1,429,000
Total liabilities	365,896,000	241,282,000
Common stock	379,000	369,000
Additional paid-in capital	254,498,000	247,363,000
Accumulated undistributed earnings (losses)	32,568,000	30,597,000
Total Newtek Business Services, Inc. stockholders' equity	287,445,000	278,329,000
Total net assets	287,445,000	278,329,000
Net assets value per common share	\$15.19	\$15.08

Reclassified to conform with 2018 presentation; Cost - investments, at fair value - small business administration ("SBA") unguaranteed non-affiliate investments: \$355,589,000; Includes related to securitization trusts - investments, at fair value - small business administration ("SBA") unguaranteed non-affiliate investments: \$323,388,000; Cost - investments, at fair value - small business administration ("SBA") unguaranteed non-affiliate investments: \$287,690,000; Includes related to securitization trusts - investments, at fair value - small business administration ("SBA") unguaranteed non-affiliate investments: \$265,174,000; Cost - investments, at fair value - small business administration guaranteed non-affiliate investments: \$17,217,000; Cost - investments, at fair value - small business administration guaranteed non-affiliate investments: \$22,841,000; Cost - investments, at fair value - controlled investments: \$74,279,000; Cost - investments, at fair value - controlled investments: \$57,085,000; Cost - investments, at fair value - non-control or affiliate investments: \$1,000,000; Cost - investments, at fair value - investments in money market funds: \$9,000

Recent Dividends:

I. Newtek Business Services Corp common.

ExDate	Amt	Declared	Record	Payable
01/05/2016	0.40	12/16/2015	01/07/2016	01/19/2016
03/18/2016	0.35	02/24/2016	03/22/2016	03/31/2016
06/16/2016	0.35	06/09/2016	06/20/2016	06/30/2016
09/16/2016	0.43	09/07/2016	09/20/2016	09/30/2016
12/13/2016	0.40	11/16/2016	12/15/2016	12/30/2016
03/16/2017	0.36	03/06/2017	03/20/2017	03/31/2017
05/26/2017	0.40	05/04/2017	05/31/2017	06/30/2017
09/21/2017	0.44	08/21/2017	09/22/2017	09/29/2017
12/15/2017	0.44	11/09/2017	12/18/2017	12/28/2017
03/19/2018	0.40	01/18/2018	03/20/2018	03/30/2018
06/14/2018	0.42	05/11/2018	06/15/2018	06/29/2018
09/14/2018	0.48	08/23/2018	09/17/2018	09/28/2018
12/17/2018	0.50	10/29/2018	12/18/2018	12/28/2018
03/14/2019	0.40	02/15/2019	03/15/2019	03/29/2019

Annual Dividends:

I. Newtek Business Services Corp common.

2016	2017	2018
1.93	1.64	1.80
2019	0.40	

NII HOLDINGS INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

	2018	2017 (revised)	2016 (revised)
Service & other revenues	605,492	848,806	963,209
Handset & accessory revenues	15,205	21,888	21,837
Operating revenues	620,697	870,694	985,046
Cost of service (exclusive of depreciation & amortization included below)	287,598	370,435	364,648
Cost of handsets & accessories	18,571	40,207	29,273
Selling, general & administrative	308,828	510,168	560,760
Impairment, restructuring & other charges, net	18,949	175,358	1,384,811
Depreciation	15,119	20,451	135,429
Amortization	13,497	14,995	36,954
Total operating expenses	662,562	1,131,614	2,511,875
Operating income (loss)	(41,865)	(260,920)	(1,526,829)
Interest expense, net	100,513	118,605	113,732
Interest income	12,357	41,507	37,689
Foreign currency transaction gains (losses), net	(49,008)	(1,271)	76,615
Other income (expense), net	(7,217)	(7,485)	(10,514)
Total other income			

(expense)	(144,381)	(85,854)	(9,942)
Income (loss) from continuing operations before income taxes - U.S.	(13,706)	(41,143)	(53,843)
Income (loss) from continuing operations before income taxes - non-U.S.	(172,540)	(305,631)	(1,482,928)
Income (loss) from continuing operations before income taxes	(186,246)	(346,774)	(1,536,771)
Current foreign income taxes (benefit)	...	(5,779)	291
Total current income taxes provision (benefit)	...	(5,779)	291
Deferred federal income taxes (benefit)	(2,864)
Deferred state income taxes (benefit), net of federal tax benefit	(319)
Deferred foreign income taxes (benefit)	...	(568)	...
Total deferred income taxes provision (benefit)	...	(568)	(3,183)
Income tax provision (benefit)	...	(6,347)	(2,892)
Income (loss) from continuing operations	(186,246)	(340,427)	(1,533,879)
Income (loss) from discontinued operations, net of income taxes	(8,414)	1,005	(19,994)
Net income (loss)	(194,660)	(339,422)	(1,553,873)
Net income (loss) attributable to noncontrolling interest	51,580	46,275	...
Net income (loss) attributable to NII Holdings, Inc.	(143,080)	(293,147)	(1,553,873)
Weighted average shares outstanding - basic	100,675	100,332	100,098
Weighted average shares outstanding - diluted	100,675	100,332	100,098
Year end shares outstanding	101,323	100,384	100,258
Income (loss) per share from continuing operations - basic	\$(1.86)	\$(3.40)	\$(15.32)
Income (loss) per share from discontinued operations - basic	\$(0.08)	\$0.01	\$(0.20)
Net income (loss) per share - basic	\$(1.94)	\$(3.39)	\$(15.52)
Income (loss) per share from continuing operations - diluted	\$(1.86)	\$(3.40)	\$(15.32)
Income (loss) per share from discontinued operations - diluted	\$(0.08)	\$0.01	\$(0.20)
Net income (loss) per share - diluted	\$(1.94)	\$(3.39)	\$(15.52)
Total number of employees	2,640	...	2,645
Number of common stockholders	2,97	...	2,118

Foreign currency translation adjustments	38,804	7,360	169,785	Brazil spectrum financing	30,864	17,261	attributable to common stockholders	9,523	0	(14,202)	
¹ Successor company; ² Restated to reflect correction of errors regarding the result of improperly recording expenses for certain non-income based tax credits & restructuring charges for certain transmitter & receiver sites; ³ Reclassified to conform with 2018 presentation; ⁴ As is; ⁵ As of February 28, 2019; ⁶ Approximately; ⁷ As of March 3, 2017				Other long-term liabilities	39,049	43,845	Weighted average shares outstanding				
Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):				Total liabilities	1,241,399	1,224,710	- basic	24,862	⁸ 2,735	2,500	
2018				Common stock	101	100	Weighted average shares outstanding				
⁹ 2017 (revised)				Paid-in capital	2,143,240	2,139,299	- diluted	29,959	¹⁰ 2,735	2,500	
Cash & cash equivalents	142,486	193,888	16,711	Retained earnings (accumulated deficit)	(2,236,883)	(2,127,903)	Year end shares outstanding	36,705	¹¹ 2,979	2,539	
Short-term investments	32,329	16,711		Cumulative foreign currency translation adjustment	(8,435)	(47,239)	Net earnings (loss) per share - basic	\$0.38	¹² \$0.00	\$(5.68)	
Accounts receivable, gross	119,522	148,726		Accumulated other comprehensive income (loss)	(8,435)	(47,239)	Net earnings (loss) per share - diluted	\$0.32	¹³ \$0.00	\$(5.68)	
Less: allowance for doubtful accounts	19,637	42,011		Total NII Holdings, Inc. stockholders' equity (deficit)	(101,977)	(35,743)	Total number of employees	¹⁴ 1,000			
Accounts receivable, net	99,885	106,715		Noncontrolling interest	(79,592)	(75,445)	Number of full time employees	¹⁵ 1,130			
Handset & accessory inventory	1,949	3,163		Total equity (deficit)	(181,569)	(111,188)	Number of stockholders	¹⁶ 202			
Cash in escrow	106,089	110,024		¹ Successor company; ² Restated to reflect correction of errors regarding the result of improperly recording expenses for certain non-income based tax credits & restructuring charges for certain transmitter & receiver sites							
Brazil judicial deposits	57,175	43,648		Recent Dividends:							
Value-added taxes	43,803	37,191		1. NII Holdings Inc. common (new).							
Deferred commissions	21,460			No dividends paid.							
Cash collateral related to performance bonds	618	50,340		2. NII Holdings Inc. common.							
Other prepaid assets	9,381	14,231		No dividends paid.							
Other current assets	7,390	8,583		Annual Dividends:							
Total current assets	522,565	584,494		1. NII Holdings Inc. common (new).							
Land	417	489		No dividends paid.							
Building & leasehold improvements	650	935		2. NII Holdings Inc. common.							
Network equipment, communication towers & network software	108,876	82,493		No dividends paid.							
Software, office equipment, furniture, fixtures & other property, plant & equipment	31,482	22,498		NLIGHT INC							
Less: accumulated depreciation & amortization	26,858	11,461		Annual Report							
Construction in progress	29,363	22,308		Consolidated Income Statement, Years Ended Dec. 31 (\$000):							
Property, plant & equipment, net	143,930	117,262		2018	¹⁷ 2017 (revised)	2016 (revised)					
Intangible assets, net	162,156	191,757		Revenues	191,359	138,580	101,325				
Brazil judicial deposits	116,220	110,758		Cost of revenues	124,398	94,306	78,159				
Cash collateral related to contingencies	47,899	55,027		Gross profit	66,961	44,274	23,166				
Deferred commissions	16,037			Research & development	21,054	15,123	15,239				
Other assets	51,023	54,224		Sales, general, & administrative	28,844	19,353	17,265				
Total assets	1,059,830	1,113,522		Total operating expenses	49,898	34,476	32,504				
Accounts payable	39,147	42,284		Income (loss) from operations	17,063	9,798	(9,338)				
Accrued contingencies	74,111	78,006		Interest income (expense), net	728	(1,269)					
Network system & information technology	52,207	48,702		Interest expense, net			2,229				
Accrued non-income based taxes	37,817	30,044		Other expenses	253	1,834	753				
Accrued payroll related items & commissions	27,100	32,613		Income before income taxes - United States	10,901	(9,064)	(19,006)				
License fees	20,706	17,501		Income before income taxes - Foreign	6,637	15,759	6,686				
Other accrued expenses & current liabilities	87,049	101,263		Income (loss) before provision for income taxes	17,538	6,695	(12,320)				
Current portion of long-term debt	21,350	7,990		Current state income taxes	9		8				
Total current liabilities	359,487	358,403		Current foreign income taxes	5,032	5,200	1,632				
Equipment financing	238,380	242,883		Current income taxes	5,041	5,200	1,640				
Bank loans	169,946	200,567		Deferred foreign income taxes (benefit)	(1,441)	(342)	242				
Spectrum financing	104,344	122,044		Deferred income taxes (benefit)	(1,441)	(342)	242				
Convertible senior notes	72,264			Income tax benefit	3,600	4,858	1,882				
Capital leases & tower financing obligations	69,273	90,213		Net income (loss)	13,938	1,837	(14,202)				
Less: current portion	21,350	7,990		Less: Income allocated to preferred stockholders	4,415	1,837					
Non-current withholding taxes	78,440	67,356		Net income (loss)							
Accrued lease termination & other restructuring charges	67,125	90,128		Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):							
Conversion option for convertible senior notes	33,577			2018							
Accrued interest on				¹⁸ 2017 (revised)							
				Cash & cash equivalents	149,478	149,478	36,687				
				Accounts receivable, gross	26,831	26,831	13,791				
				Allowance for doubtful accounts	303	303	438				
				Accounts receivable, net	26,528	26,528	13,353				
				Raw materials	14,174	14,174	11,326				
				Work in process & semi-finished goods	12,807	12,807	6,039				
				Finished goods	8,348	8,348	12,205				
				Inventory	35,329	35,329	29,570				
				Prepaid expenses	1,654	1,654	1,248				
				Value-added tax receivable, net	1,489	1,489	1,291				
				Vendor prepayments	1,263	1,263	1,391				
				Prepaid tax & duties	2,777	2,777	946				
				Other prepaid expenses & other current assets	103	103	97				
				Prepaid expenses & other current assets	7,286	7,286	4,973				
				Total current assets	218,621	218,621	84,583				
				Computer hardware & software	4,143	4,143	3,732				
				Manufacturing & lab equipment	50,797	50,797	43,432				
				Office equipment & furniture	1,127	1,127	1,053				
				Leasehold improvements	19,207	19,207	18,580				
				Total property & equipment, gross	75,274	75,274	66,797				
				Less: accumulated depreciation	53,812	53,812	48,829				
				Property & equipment, net	21,462	21,462	17,968				
				Intangible assets, net	2,686	2,686	1,836				
				Goodwill	1,387	1,387	1,387				
				Demonstration assets, net	1,982	1,982	2,224				
				Deferred tax assets, net	3,114	3,114	1,807				
				Other assets	878	878	343				
				Other assets	5,974	5,974	4,374				
				Total assets	250,130	250,130	110,148				
				Accounts payable	12,068	12,068	12,920				
				Accrued payroll	6,474	6,474	6,201				
				Product warranty, current	2,669	2,669	3,589				
				Income tax payable	258	258	931				
				Other accrued expenses	1,307	1,307	1,929				
				Accrued liabilities	10,708	10,708	12,650				
				Customer advances	493	493	575				
				Deferred revenue	227	227	386				
				Current portion of long-term debt	91	91	2,363				
				Total current liabilities	23,587	23,587	28,894				
				Non-current income taxes payable	6,472	6,472	3,930				
				Term & revolving loans			17,200				

2014 Finland equipment loans	41	80
Capital leases, various	110	191
Total debt	151	17,471
Less: debt issuance costs	(42)	...
Total long-term debt	109	17,471
Less: current portion of long-term debt	91	2,363
Long-term debt	18	15,108
Other long-term liabilities	2,270	933
Total liabilities	32,347	48,865
Convertible preferred shares	...	12
Common stock	15	2
Additional paid in capital	324,656	180,657
Accumulated other comprehensive income (loss)	(2,157)	(719)
Retained earnings (accumulated deficit)	(104,731)	(118,669)
Total stockholders' equity (deficit)	217,783	61,283

Income (loss) before provision (benefit) for income taxes - foreign	(2,465)	(12,730)	(8,294)
Income (loss) from continuing operations before provision (benefit) for income taxes & share of net income from joint venture	(261,034)	(58,873)	(30,866)
Current income tax expense (benefit) - U.S. federal	8,150	(47,916)	(2,595)
Current income tax expense (benefit) - state	584	(12,226)	679
Current income tax expense (benefit) - foreign	3,086	4,310	2,004
Total current income tax expense (benefit)	11,820	(55,832)	88
Deferred income tax expense (benefit) - U.S. federal	(16,129)	(25,017)	(9,679)
Deferred income tax expense (benefit) - state	(780)	3,009	(6,406)
Deferred income tax expense (benefit) - valuation allowance	(3,565)	710	1,882
Deferred income tax expense (benefit) - foreign	(2,303)	(1,896)	(1,323)
Total deferred income tax expense (benefit)	(22,777)	(23,194)	(15,526)
Provision (benefit) for income taxes	(10,957)	(79,026)	(15,438)
Share of net income (loss) from joint venture	(14,390)	5,211	5,938
Income (loss) from continuing operations	(264,467)	25,364	(9,490)
Income (loss) from discontinued operations, net of tax	...	137,688	16,153
Net income (loss)	(264,467)	163,052	6,663
Weighted average shares outstanding - basic	31,678	27,433	27,016
Weighted average shares outstanding - diluted	31,678	27,755	27,016
Year end shares outstanding	42,104	27,572	27,249
Income (loss) per share - continuing operations - basic	\$(8.35)	\$0.92	\$(0.35)
Income (loss) per share - discontinued operations - basic	...	\$5.02	\$0.60
Net income (loss) per share - basic	\$(8.35)	\$5.94	\$0.25
Income (loss) per share - continuing operations - diluted	\$(8.35)	\$0.91	\$(0.35)
Income (loss) per share - discontinued operations - diluted	...	\$4.96	\$0.60
Net income (loss) per share - diluted	\$(8.35)	\$5.87	\$0.25
Cash dividends per common share	\$0.28	\$0.28	\$0.28
Number of full time employees	5,479	3,884	...

Number of temporary employees 512 523 ...
 Number of common stockholders 8,100 5,557 ...
 Reclassified to conform with 2018 presentation; As is; Full-time equivalent employees; Approximately; As of March 8, 2019; As of March 19, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	17,988	224,446
Trade	135,260	110,165
Less - allowance for doubtful accounts	1,839	1,719
Accounts receivable, net	133,421	108,446
Raw materials	52,930	37,337
Work in process	42,578	27,669
Finished goods	27,107	17,611
Inventories	122,615	82,617
Income tax receivable	946	43,253
Other current assets	21,901	18,518
Total current assets	296,871	477,280
Land & building	69,455	54,833
Machinery & equipment	401,729	302,470
Construction in process	35,122	14,346
Property, plant & equipment, gross	506,306	371,649
Less - accumulated depreciation	145,278	112,369
Property, plant & equipment, net	361,028	259,280
Goodwill	439,452	454,612
Intangible assets, net	376,248	237,702
Investment in joint venture	20,364	39,822
Other non-current assets	7,607	6,307
Total assets	1,501,570	1,475,003
Accounts payable	65,694	52,990
Accrued salaries, wages & benefits	24,636	21,145
Current maturities of long-term debt	31,280	17,283
Other current liabilities	23,420	17,003
Total current liabilities	145,030	108,421
Deferred tax liabilities	93,482	71,564
Non-current income tax payable	3,875	5,593
Senior secured term loan	532,063	534,250
Incremental term loan	279,000	291,000
Senior secured revolver	38,720	...
International lines of credit & other loans	9,810	3,315
Less: current maturities of long-term debt	31,280	17,283
Less: unamortized debt issuance costs	(16,842)	(20,477)
Other non-current liabilities	29,417	12,516
Total liabilities	1,083,275	988,899
Common stock	421	275
Additional paid-in capital	511,545	292,494
Retained earnings	(62,046)	211,080
Accumulated other comprehensive income (loss)	(31,625)	(17,745)
Total stockholders' equity	418,295	486,104

Reclassified to conform with 2018 presentation

Recent Dividends:
1. nLight Inc common.
 No dividends paid.
Annual Dividends:
1. nLight Inc common.
 No dividends paid.

NN, INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Net sales	770,657	619,793	584,954
Cost of sales (exclusive of depreciation & amortization shown separately below)	588,205	459,080	428,843
Selling, general & administrative expense	93,583	74,112	64,144
Acquisition related costs excluded from selling, general & administrative expense	5,871	344	...
Depreciation & amortization	71,128	52,406	50,721
Other operating expense (income), net	6,089	351	809
Goodwill impairment	182,542
Restructuring & integration expense, net	2,127	386	5,658
Income (loss) from operations	(178,888)	33,114	34,779
Interest expense	61,243	52,085	62,870
Loss on extinguishment of debt & write off of unamortized debt issuance costs	(19,562)	(42,087)	(2,589)
Derivative payments on interest rate swap	(609)
Derivative loss (gain) on change in interest rate swap fair value	...	101	(2,448)
Other income (expense), net	(1,341)	2,084	2,871
Income (loss) before provision (benefit) for income taxes - United States	(263,499)	(71,603)	(39,160)

Reclassified to conform with 2018 presentation

Recent Dividends:
1. NN, Inc common.

ExDate	Amt	Declared	Record	Payable
02/17/2016	0.07	01/25/2016	02/19/2016	03/04/2016
06/01/2016	0.07	05/11/2016	06/03/2016	06/17/2016
08/31/2016	0.07	08/11/2016	09/02/2016	09/16/2016
11/30/2016	0.07	11/21/2016	12/02/2016	12/16/2016
02/15/2017	0.07	01/23/2017	02/17/2017	03/03/2017
05/31/2017	0.07	05/19/2017	06/02/2017	06/16/2017
08/30/2017	0.07	08/14/2017	09/01/2017	09/15/2017

11/30/2017	0.07	11/14/2017	12/01/2017	12/15/2017
02/15/2018	0.07	01/18/2018	02/16/2018	03/02/2018
05/31/2018	0.07	05/21/2018	06/01/2018	06/15/2018
08/30/2018	0.07	08/09/2018	09/03/2018	09/17/2018
11/30/2018	0.07	11/16/2018	12/03/2018	12/17/2018
02/14/2019	0.07	02/04/2019	02/15/2019	03/01/2019

Annual Dividends:
1. NN, Inc common.

2016	0.28	2017	0.28	2018	0.28
2019	0.07				

NOBILITY HOMES, INC.

Earnings, 3 mos. to (Consol. - \$):

	02/02/19	02/03/18
Cost & expenses	9,267,943	8,555,661
Operating income	1,771,831	1,090,157
Interest income	152,443	35,937
Other income (expense), net	132,930	28,783
Net before taxes	2,057,204	1,154,877
Income taxes	521,398	138,641
Net income	1,535,806	1,016,236
Earnings common share		
Primary	\$0.40	\$0.25
Fully Diluted	\$0.40	\$0.25
Common Shares:		
Full Diluted	3,876,085	3,999,202
Year-end	3,873,731	3,993,069

Consolidated Balance Sheet Items, as of (\$):

Assets:	2019
Cash & equivalents	28,018,644
Inventories	8,043,359
Current assets	46,830,568
Net property & equip.	4,919,197
Total assets	57,916,234
Liabilities:	
Current liabilities	7,329,718
Stockholders' equity	50,586,516
Net current assets	39,500,850

NOVAN INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
License & collaboration revenue	5,982,000	2,271,000	...
Research & development services revenue	9,000	375,000	...
Total revenue	5,991,000	2,646,000	...
Research & development expenses	23,045,000	25,212,000	46,489,000
General & administrative expenses	11,507,000	13,113,000	13,337,000
Total operating expenses	34,552,000	38,325,000	59,826,000
Operating income (loss)	(28,561,000)	(35,679,000)	(59,826,000)
Interest income	297,000	87,000	...
Interest expense	1,047,000	1,048,000	...
Change in the fair value of warrant liability	16,566,000
Other income, net	72,000	19,000	...
Total other income (expense)	15,888,000	(942,000)	127,000
Income (loss) from continuing operations	(59,699,000)
Net income (loss)	(12,673,000)	(36,621,000)	(59,699,000)
Weighted average shares outstanding - basic	25,795,721	15,981,247	5,985,985
Weighted average shares outstanding - diluted	25,795,721	15,981,247	5,985,985
Year end shares outstanding	26,056,735	16,005,408	15,939,992
Income (loss) per share from			

continuing operations - basic	\$(9.97)
Net income (loss) per share - basic	\$(0.49)	\$(2.29)	\$(9.97)
Income (loss) per share from continuing operations - diluted	\$(9.97)
Net income (loss) per share - diluted	\$(0.49)	\$(2.29)	\$(9.97)
Total number of employees	48	59	62
Number of common stockholders	144	177	326

Restated to reflect adoption of ASC Topic 606, Revenue from Contracts with Customers; Reclassified to conform with 2017 presentation; Shares increased due to the effects of stock options exercised and public offering; Shares increased due to initial public offering and conversion of preferred stock; Approximately: As of March 19, 2019; As of March 22, 2018; As is; As of March 17, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	8,194,000	2,524,000
Deferred offering costs	49,000	297,000
Prepaid expenses & other current assets	1,107,000	883,000
Total current assets	9,350,000	3,704,000
Restricted cash	539,000	539,000
Intangible assets	75,000	75,000
Other assets	530,000	192,000
Computer equipment	577,000	529,000
Furniture & fixtures	312,000	354,000
Laboratory equipment	7,442,000	6,819,000
Office equipment	400,000	400,000
Building related to facility lease obligation	10,557,000	10,557,000
Leasehold improvements	1,168,000	1,000,000
Property & equipment, gross	20,456,000	19,659,000
Less: Accumulated depreciation & amortization	4,588,000	3,035,000
Property & equipment, net	15,868,000	16,624,000
Total assets	26,362,000	21,134,000
Accounts payable	1,250,000	479,000
Accrued compensation	1,467,000	2,168,000
Accrued outside research & development services	563,000	1,392,000
Accrued legal & professional fees	498,000	504,000
Other accrued expenses	871,000	1,700,000
Deferred revenue, current portion	4,401,000	2,631,000
Capital lease obligation, current portion	11,000	11,000
Total current liabilities	9,061,000	8,885,000
Deferred revenue, net of current portion	2,566,000	5,946,000
Capital lease obligation, net of current portion	10,000	21,000
Warrant liability	1,240,000	...
Other long-term liabilities	289,000	...
Facility financing obligation	7,998,000	7,998,000
Total liabilities	21,164,000	22,850,000
Common stock	3,000	2,000
Additional paid-in-capital	177,677,000	158,091,000
Treasury stock, at cost	155,000	155,000
Retained earnings (accumulated deficit)	(172,327,000)	(159,654,000)
Total stockholders' equity (deficit)	5,198,000	(1,716,000)

Restated to reflect adoption of ASC Topic 606, Revenue from Contracts with Customers

Recent Dividends:

1. Novan Inc common.

No dividends paid.

Annual Dividends:

1. Novan Inc common.

No dividends paid.

NOVAN INC

Auditor's Report Auditor's Report

NOVAVAX, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Government contract revenue	2,184,000
Grant & other revenue	34,288,000	31,176,000	13,169,000
Total revenue	34,288,000	31,176,000	15,353,000
Research & development	173,797,000	168,435,000	237,939,000
General & administrative	34,409,000	34,451,000	46,527,000
Total expenses	208,206,000	202,886,000	284,466,000
Income (loss) from operations	(173,918,000)	(171,710,000)	(269,113,000)
Investment income	2,674,000	1,946,000	2,143,000
Interest expense	13,612,000	14,072,000	12,965,000
Other income (expense)	108,000	67,000	(31,000)
Net income (loss)	(184,748,000)	(183,769,000)	(279,966,000)
Weighted average shares outstanding - basic	369,757,000	292,669,000	270,802,000
Weighted average shares outstanding - diluted	369,757,000	292,669,000	270,802,000
Year end shares outstanding	384,450,607	323,229,390	271,245,967
Net income (loss) per share - basic	\$(0.50)	\$(0.63)	\$(1.03)
Net income (loss) per share - diluted	\$(0.50)	\$(0.63)	\$(1.03)
Number of full time employees	379	347	355
Number of common stockholders	349	359	381

Reclassified to conform with 2017 presentation; As of March 12, 2019; As of March 9, 2018; As of February 23, 2017; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	70,154,000	106,307,000
Marketable securities	21,980,000	50,996,000
Restricted cash	10,847,000	28,234,000
Laboratory supplies	11,974,000	13,085,000
Other prepaid expenses & other current assets	4,321,000	4,689,000
Total current assets	119,276,000	203,311,000
Restricted cash	958,000	890,000
Machinery & equipment	35,723,000	35,409,000
Leasehold improvements	22,276,000	23,664,000
Computer hardware	4,763,000	5,091,000
Construction in progress	1,347,000	1,129,000
Property & equipment, gross	64,109,000	65,293,000
Less: accumulated depreciation	35,683,000	29,306,000
Property & equipment, net	28,426,000	35,987,000
Intangible assets, net	6,541,000	7,873,000
Goodwill	51,967,000	53,563,000
Other non-current assets	810,000	869,000
Total assets	207,978,000	302,493,000
Accounts payable	9,301,000	5,613,000
Accrued employee benefits & compensation	9,632,000	11,186,000
Research & development accruals	8,476,000	17,542,000
Other accrued expenses	1,442,000	882,000
Accrued interest	5,078,000	5,078,000

Deferred revenue.....	10,010,000	25,625,000
Other current liabilities.....	1,600,000	7,749,000
Total current liabilities.....	45,539,000	73,675,000
Deferred revenue.....	2,500,000	2,500,000
Convertible notes payable.....	319,187,000	317,763,000
Other non-current liabilities.....	8,687,000	10,287,000
Total liabilities.....	375,913,000	404,225,000
Common stock.....	3,849,000	3,237,000
Additional paid-in capital.....	1,140,964,000	1,020,457,000
Retained earnings (accumulated deficit).....	(1,299,107,000)	(1,114,359,000)
Treasury stock, cost basis.....	2,450,000	2,450,000
Accumulated other comprehensive income (loss).....	(11,191,000)	(8,617,000)
Total stockholders' equity (deficit).....	(167,935,000)	(101,732,000)

properly exercised their appraisal rights under the Delaware General Corporation Law) will automatically be canceled and converted into the right to receive \$24.50 per Share in cash, without interest (the "Merger Consideration"). In addition, at or immediately prior to the Effective Time, (i) each option to purchase Shares that has an exercise price per Share that is less than the Merger Consideration will be canceled and converted into the right to receive the Merger Consideration, net of the applicable exercise price, and in the case of each unvested option, payable at the times and subject to the contingencies specified in the Merger Agreement (but in no event later than the end of the calendar year in which the Effective Time occurs), (ii) each option to purchase Shares that has an exercise price per Share that is equal to or greater than the Merger Consideration will be canceled without payment, (iii) each vested restricted stock unit award will be canceled and converted into the right to receive the Merger Consideration, and (iv) each unvested restricted stock unit award will be canceled and converted into the right to receive the Merger Consideration, payable on the same vesting schedule that applied to such award, subject to certain conditions specified in the Merger Agreement. The transaction has been approved by Co.'s and Quantenna's boards of directors and is expected to close in the second half of 2019. No approval of the stockholders of Co. is required in connection with the proposed transaction.

OSIRIS THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016
Revenue.....	142,824	118,514	109,374
Cost of revenue.....	38,139	32,681	30,733
Research & development expense.....	6,764	4,138	6,324
Sales & marketing expense.....	67,542	61,545	59,057
General & administrative expense.....	19,626	22,139	17,356
Shareholder litigation expense.....	900
Total operating expenses.....	94,832	87,822	82,737
Income (loss) from continuing operations.....	9,853	(1,989)	(4,096)
Other income (expense), net.....	675	(645)	417
Income (loss) before income taxes from continuing operations.....	10,528	(2,634)	(3,679)
Current federal income tax expense (benefit).....	(1,041)	(1,526)	...
Current state income tax expense (benefit).....	208	128	104
Total current income tax expense (benefit).....	(833)	(1,398)	104
Deferred federal income tax expense (benefit).....	(23,936)	...	(31)
Deferred state income tax expense (benefit).....	(1,236)	...	(3)
Total deferred income tax expense (benefit).....	(25,172)	...	(34)
Income tax expense (benefit).....	(26,005)	(1,398)	70
Net income (loss) from continuing operations.....	36,533	(1,236)	(3,749)
Discontinued operations, net of tax.....	368	10,021	...
Net income (loss)	36,901	8,785	(3,749)
Weighted average shares outstanding - basic.....	34,526	34,524	34,999
Weighted average shares outstanding			

Year end shares outstanding.....	34,573	34,525	34,999
Net income (loss) per share - continuing operations - basic.....	\$1.06	\$(0.04)	\$(0.11)
Net income (loss) per share - discontinued operations - basic.....	\$0.01	\$0.29	...
Net income (loss) per share basic.....	\$1.07	\$0.25	\$(0.11)
Net income (loss) per share - discontinued operations - diluted.....	\$1.06	\$(0.04)	\$(0.11)
Net income (loss) per share-diluted.....	\$1.07	\$0.25	\$(0.11)
Number of full time employees.....	342	337	...
Number of part time employees.....	16	13	...
Total number of employees.....	358	350	...
Number of common stockholders.....	121	121	...

As reported from December 31, 2017 10K; As is; As of March 23, 2018; Approximately; As of March 1, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents.....	16,367	3,081
Certificates of deposit.....	10,044	...
Short-term investments.....	8,276	24,807
Trade receivables, net.....	22,469	26,053
Raw materials & supplies.....	1,049	1,330
Work-in-process.....	5,337	5,605
Finished goods.....	6,764	6,350
Inventory, gross.....	13,150	13,285
Less reserve for excess & obsolete inventory.....	3,536	2,007
Inventory, net.....	9,614	11,278
Insurance receivable.....	...	4,788
Prepaid expenses & other current assets.....	3,477	2,920
Total current assets.....	70,247	72,927
Laboratory & manufacturing equipment.....	2,792	3,083
Computer hardware, furniture & fixtures.....	921	1,134
Leasehold improvements.....	6,359	6,344
Less accumulated depreciation & amortization.....	7,190	6,974
Property & equipment, net.....	2,882	3,587
Deferred income taxes, net.....	25,205	...
Other assets.....	3,168	1,608
Total assets.....	101,502	78,122
Accounts payable.....	4,144	5,269
Accrued payroll & related.....	3,098	1,980
Accrued commissions.....	5,968	5,651
Accrued accounting & audit fees.....	1,859	905
Accrued lease liabilities.....	321	120
Other accrued liabilities.....	2,574	743
Accrued liabilities.....	13,820	9,399
Accrued shareholder litigation.....	900	18,500
Other current liabilities.....	1,728	1,934
Total current liabilities.....	20,592	35,102
Other long-term liabilities.....	2,382	1,626

Recent Dividends:

1. Novavax, Inc. common.

No dividends paid.

Annual Dividends:

1. Novavax, Inc. common.

No dividends paid.

NOVAVAX, INC.

Auditor's Report Auditor's Report

The following is an excerpt from the Report of Independent Auditors, Ernst & Young LLP, as it appeared in Co.'s 2018 10-K report: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Novavax, Inc. (the Company) as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive loss, changes in stockholders' equity (deficit), and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 18, 2019 expressed an unqualified opinion thereon. The Company's Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency and has stated that substantial doubt exists about the Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ON SEMICONDUCTOR CORP

Merger Development On Mar. 27, 2019, Co., Raptor Operations Sub, Inc., a wholly-owned subsidiary of Co. ("Merger Subsidiary"), and Quantenna Communications, Inc. ("Quantenna"), entered into a definitive Agreement and Plan of Merger (the "Merger Agreement"). The acquisition consideration represents equity value of approximately \$1,070,000,000 and enterprise value of approximately \$936,000,000, after accounting for Quantenna's net cash of approximately \$136,000,000 at the end of fourth quarter of 2018. Pursuant to the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and into Quantenna (the "Merger"), with Quantenna continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Co. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Quantenna's common stock, par value \$0.0001 per share (the "Shares"), outstanding immediately prior to the Effective Time (other than Shares held by (a) Co. or its subsidiaries immediately prior to the Effective Time, (b) Quantenna as treasury stock and (c) stockholders of Quantenna who

Total liabilities	250,513	261,692
Common stock	3	3
Additional paid-in capital	657,981	494,732
Retained earnings (accumulated deficit)	(458,897)	(254,692)
Accumulated other comprehensive income (loss)	(584)	(599)
Treasury stock, at cost	66,757	63,816
Equity attributable to stockholders of Overstock.com, Inc.	131,746	175,628
Equity attributable to noncontrolling interests	78,960	(3,505)
Total stockholders' equity	210,706	172,123

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Overstock.com Inc (DE) blockchain voting series A preferred.

ExDate	Amt	Declared	Record	Payable
11/30/2017	0.16	11/07/2017	12/01/2017	12/15/2017
11/29/2018	0.16	11/12/2018	11/30/2018	12/14/2018

2. Overstock.com Inc (DE) common.

No dividends paid.

3. Overstock.com Inc (DE) voting series B preferred.

No dividends paid.

4. Overstock.com Inc (DE) redeemable common.

No dividends paid.

Annual Dividends:

1. Overstock.com Inc (DE) blockchain voting series A preferred.

2017	0.16	2018	0.16
------	------	------	------

2. Overstock.com Inc (DE) common.

No dividends paid.

3. Overstock.com Inc (DE) voting series B preferred.

No dividends paid.

4. Overstock.com Inc (DE) redeemable common.

No dividends paid.

PATRICK INDUSTRIES INC

Official Changes On Mar. 25, 2019, Co. announced the appointments of Ms. Pamela Klyn, Mr. Derrick Mayes and Mr. Denis Suggs to its Board of Directors.

PAYCHEX INC

Earnings, 9 mos. to Feb 28(Consol. - \$000):

	2019	2018
Total Revenues	2,792,100	2,532,000
Cost & expenses	1,735,300	1,542,600
Operating income	1,056,800	989,400
Interest income	9,100	8,700
Interest expense	8,400	3,200
Other income (expense), net		600
Net before taxes	1,057,500	995,500
Income taxes	253,500	219,100
Net income	804,000	776,400
Earnings common share		
Primary	\$2.24	\$2.16
Fully Diluted	\$2.22	\$2.15
Common Shares:		
Full Diluted	361,600	361,600
Year-end	359,400	

PC-TEL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Revenues	82,979	91,437	85,006
Cost of revenues	51,898	52,626	50,595
Gross profit (loss)	31,081	38,811	34,411
Research & development	11,851	11,142	10,158
Sales & marketing	12,083	12,630	12,716
General & administrative	12,355	13,110	11,905
Amortization of intangible assets	418	496	531

Restructuring charges	234		
Total operating expenses	36,707	37,378	35,544		
Operating income (loss)	(5,626)	1,433	(1,133)		
Other income, net	564	105	112		
Income (loss) before income taxes - domestic	(5,033)	917	(3,695)		
Income (loss) before income taxes - foreign	(29)	621	2,674		
Income (loss) before income taxes	(5,062)	1,538	(1,021)		
Current provision (benefit) for federal income taxes	(22)	142	(5)		
Current provision (benefit) for state income taxes	32	34	12		
Current provision (benefit) for foreign income taxes	721		
Total current provision (benefit) for income taxes	10	176	728		
Deferred provision (benefit) for federal income tax	6,337	(1,720)	10,123		
Deferred provision (benefit) for state income taxes	1,333	(878)	917		
Deferred provision (benefit) foreign income taxes	147	(49)	8		
Total deferred provision (benefit) for income taxes	7,817	(2,647)	11,048		
Provision (benefit) for income taxes	7,827	(2,471)	11,776		
Net income (loss) from continuing operations	(12,889)	4,009	(12,797)		
Net income (loss) from discontinued operations, net of income tax expense	...	(187)	(4,884)		
Net income (loss)	(12,889)	3,822	(17,681)		
Weighted average shares outstanding - basic	17,186	16,626	16,151		
Weighted average shares outstanding - diluted	17,186	16,913	16,151		
Year end shares outstanding	18,271	17,807	17,335		
Income (loss) per share from continuing operations - basic	\$(0.75)	\$0.24	\$(0.79)		
Income (loss) per share from discontinued operations - basic	\$0.00	\$(0.01)	\$(0.30)		
Net income (loss) per share - basic	\$(0.75)	\$0.23	\$(1.09)		
Income (loss) per share from continuing operations - diluted	\$(0.75)	\$0.24	\$(0.79)		
Income (loss) per share from discontinued operations - diluted	\$0.00	\$(0.01)	\$(0.30)		
Net income (loss) per share - diluted	\$(0.75)	\$0.23	\$(1.09)		
Cash dividends per share	\$0.22	\$0.21	\$0.20		

Number of full time employees	454	484	...
Number of common stockholders	35	36	...
Foreign currency translation adjustments	(367)

Reclassified to conform with 2018 presentation; Restated to reflect Co.'s Network Engineering Services business as discontinued operations; As is; Full-time equivalent employees; As of March 13, 2019; As of March 15, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	4,329	5,559
Short-term investment securities	30,870	32,499
Accounts receivables, gross	15,927	18,943
Allowance for doubtful accounts	63	319
Accounts receivable, net	15,864	18,624
Raw materials	7,023	6,849
Work in process	1,388	962
Finished goods	4,437	4,945
Inventories, net	12,848	12,756
Prepaid expenses & other assets	1,416	1,605
Total current assets	65,327	71,043
Building	6,351	6,351
Computers & office equipment	10,963	10,873
Manufacturing & test equipment	13,573	13,012
Furniture & fixtures	1,318	1,288
Leasehold improvements	1,529	1,444
Motor vehicles	20	20
Less: accumulated depreciation & amortization	23,386	22,389
Land	1,770	1,770
Property & equipment, net	12,138	12,369
Goodwill	3,332	3,332
Intangible assets, net	1,029	2,113
Deferred tax assets, net	...	7,734
Other noncurrent assets	45	72
Total assets	81,871	96,663
Accounts payable	6,083	5,471
Accrued payroll, bonuses & other employee benefits	1,409	2,780
Accrued inventory receipts	1,396	1,730
Accrued paid time off	936	1,011
Accrued employee stock purchase plan	343	314
Accrued warranties	339	382
Accrued income & sales taxes	186	243
Customer refunds for estimated returns	154	197
Deferred revenues	149	189
Accrued professional fees & contractors	346	155
Accrued real estate taxes	148	148
Short-term obligations under capital leases	91	97
Other accrued liabilities	304	235
Total current liabilities	11,884	12,952
Capital leases	132	180
Deferred rent	87	89
Other long-term liabilities	162	123
Total liabilities	12,265	13,344
Common stock	18	18
Additional paid-in capital	133,859	134,505
Retained earnings (accumulated deficit)	(64,055)	(51,258)
Foreign translation adjustment	(216)	54

Accumulated other comprehensive income (loss)	(216)	54
Total stockholders' equity (deficit) of PCTEL, Inc.	69,606	83,319

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. PC-Tel Inc common.

ExDate	Amt	Declared	Record	Payable
02/04/2016	0.05	01/28/2016	02/08/2016	02/16/2016
05/04/2016	0.05	04/22/2016	05/06/2016	05/13/2016
08/04/2016	0.05	07/25/2016	08/08/2016	08/15/2016
11/04/2016	0.05	10/25/2016	11/08/2016	11/15/2016
02/06/2017	0.05	01/27/2017	02/08/2017	02/15/2017
05/04/2017	0.05	04/28/2017	05/08/2017	05/15/2017
08/04/2017	0.06	06/26/2017	08/08/2017	08/15/2017
11/07/2017	0.06	10/27/2017	11/08/2017	11/15/2017
02/07/2018	0.06	01/26/2018	02/08/2018	02/15/2018
05/07/2018	0.06	04/27/2018	05/08/2018	05/15/2018
08/07/2018	0.06	07/24/2018	08/08/2018	08/15/2018
11/07/2018	0.06	10/26/2018	11/08/2018	11/15/2018
02/07/2019	0.06	01/25/2019	02/08/2019	02/15/2019

Annual Dividends:

1. PC-Tel Inc common.

2016.....0.20	2017.....0.21	2018.....0.22
2019.....0.06		

PHARMA-BIO SERV INC

Earnings, 3 mos. to Jan 31(Consol. - \$):

	2019	2018
Total Revenues	4,566,197	3,726,596
Cost & expenses	4,133,696	3,515,658
Operating income	432,501	210,938
Other income (expense), net	81,474	17,771
Net before taxes	513,975	228,709
Income taxes	42,955	2,701,023
Income discount oper.		(191,698)
Net income	471,020	(2,664,012)
Earnings common share		
Primary	\$0.02	\$(0.12)
Fully Diluted	\$0.02	\$(0.12)
Common Shares:		
Full Diluted	23,119,027	23,065,290
Year-end	22,996,083	

Consolidated Balance Sheet Items, as of (\$):

Assets: 2019

Cash & equivalents 15,798,526

Current assets 23,340,791

Net property & equip. 274,265

Total assets 25,282,818

Liabilities:

Current liabilities 2,051,579

Long-term debt 42,518

Stockholders' equity 20,685,771

Net current assets 21,289,212

PHASEBIO PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Grant revenues	668
Research & development	15,455	6,210	7,376
General & administrative expenses	4,857	2,328	2,125
Total operating expenses	20,312	8,538	9,501
Income (loss) from operations	(19,644)	(8,538)	(9,501)
Interest income	387	52	29
Interest expense	3,924	2,723	...
Change in fair value of warrant liability	11	1,019	252
Change in fair value of derivative			

liability	(676)	(57)	...
Total other income (expense)	(4,202)	(1,709)	281
Net income (loss)	(23,846)	(10,247)	(9,220)
Weighted average shares outstanding - basic	5,305	743	743
Weighted average shares outstanding - diluted	5,305	743	743
Year end shares outstanding	□24,498	746	776
Net earnings (loss) per share - basic	\$(4.49)	\$(13.78)	\$(12.41)
Net earnings (loss) per share - diluted	\$(4.49)	\$(13.78)	\$(12.41)
Number of full time employees	□22	□□18	...
Number of part time employees	□2
Total number of employees	□24
Number of common stockholders	□□93

□ Shares increased due to the effect of conversion of preferred stock warrants into common stock, exercise of warrant and stock options, and issuance of shares in initial public offering; □ As Is; □ As of September 30, 2018; □ As of March 15, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	□2017	□2016
Cash & cash equivalents	61,031	13,406	...
Restricted cash	20	20	...
Other receivable	233
Prepaid expenses & other assets	1,344	340	...
Total current assets	62,628	13,766	...
Lab equipment	1,764	1,681	...
Computer hardware, software & telephone	228	174	...
Furniture & fixtures	98	70	...
Leasehold improvements	50	22	...
Property & equipment, gross	2,140	1,947	...
Less: accumulated depreciation & amortization	1,785	1,645	...
Property & equipment, net	355	302	...
Other assets	43	31	...
Total assets	63,026	14,099	...
Convertible promissory notes, net of discount	12,095	...
Derivative liability	3,028	...
Current portion of long-term debt	761	...
Accounts payable	1,806	430	...
Accrued clinical & related costs	1,358	197	...
Accrued compensation & related costs	914	346	...
Accrued interest	194	628	...
Other accrued expenses	305	110	...
Accrued expenses	2,771	1,281	...
Total current liabilities	4,577	17,595	...
Preferred stock warrant liability	1,656	...
Deferred rent	22	5	...
Long-term debt	7,500	2,625	...
Total liabilities	12,099	21,881	...
Redeemable convertible preferred stock	89,634	...
Common stock	25	1	...
Treasury stock	24	24	...
Additional paid-in capital	173,837	1,672	...
Retained earnings (accumulated deficit)	(122,911)	(99,065)	...
Total shareholders' equity (deficit)	50,927	(97,416)	...

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. PhaseBio Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. PhaseBio Pharmaceuticals Inc common.

No dividends paid.

PREFORMED LINE PRODUCTS CO.

Acquisition Development On Apr. 1, 2019, Co. announced that it has signed an agreement to acquire MICOS TELCOM s.r.o., a leading manufacturer of passive components for high-speed telecommunications networks. Terms of the transaction were not disclosed.

PRGX GLOBAL, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	□2017	□2016
Revenue, net	171,776	161,620	140,844
Cost of revenues	104,825	102,052	91,299
Selling, general & administrative expenses	50,456	46,941	39,399
Depreciation of property, equipment & software assets	7,370	4,569	5,033
Amortization of intangible assets	3,395	3,634	1,832
Acquisition-related adjustments loss (income)	(1,628)	(2,283)	...
Total operating expenses	164,418	154,913	137,563
Operating income (loss) from continuing operations	7,358	6,707	3,281
Foreign currency transaction gains (losses) on short-term intercompany balances	(1,002)	2,190	(84)
Interest expense	1,824	1,785	107
Interest income	161	246	260
Other income (loss) ..	(21)	160	121
Earnings (loss) before income taxes - United States	(4,673)	(6,502)	(5,306)
Earnings (loss) before income taxes - foreign	9,345	14,020	8,777
Net income (loss) from continuing operations before income tax	4,672	7,518	3,471
Current state income tax provision (benefit) ...	70	1	...
Current foreign income tax provision (benefit) ...	2,920	2,230	2,103
Total current income tax provision (benefit) ...	2,990	2,231	2,103
Deferred federal income tax provision (benefit) ...	(145)	(155)	...
Deferred foreign income tax provision (benefit) ...	(1,524)	886	(861)
Total deferred income tax provision (benefit) ...	(1,669)	731	(861)
Income tax expense (benefit)	1,321	2,962	1,242
Net income (loss) from continuing operations	3,351	4,556	2,229
Income (loss) from discontinued operations	1,242	(1,372)	(1,324)
Net income (loss) from discontinued			

operations	1,242	(1,372)	(1,324)
Net income (loss)	4,593	3,184	905
Weighted average shares outstanding - basic	22,811	21,937	21,969
Weighted average shares outstanding - diluted	23,434	22,111	22,016
Year end shares outstanding	23,186	22,419	21,846
Earnings (loss) per share - continuing operations - basic	\$0.14	\$0.21	\$0.10
Earnings (loss) per share - discontinued operations - basic	\$0.06	\$(0.06)	\$(0.06)
Net earnings (loss) per share - basic	\$0.20	\$0.15	\$0.04
Earnings (loss) per share - continuing operations - diluted	\$0.14	\$0.21	\$0.10
Earnings (loss) per share - discontinued operations - diluted	\$0.06	\$(0.06)	\$(0.06)
Net earnings (loss) per share - diluted	\$0.20	\$0.15	\$0.04
Total number of employees	1,600	1,500	1,500
Number of common stockholders	101	104	133
Number of beneficiary stockholders	2,429	2,165	2,510
Foreign currency translation adjustments	...	(180)	(507)

Reclassified to conform with 2018 presentation; As is; Approximately; As January 31, 2017; As of February 28, 2019; As of February 28, 2018; As of March 8, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Cash & cash equivalents	13,973	18,823	51
Restricted cash	46	51	...
Billed contract receivables	43,878	36,058	...
Unbilled contract receivables	2,987	2,709	...
Contract receivables, net	46,865	38,767	...
Employee advances & miscellaneous receivables	567	1,665	...
Total receivables	47,432	40,432	...
Prepaid expenses & other current assets	3,144	4,608	...
Total current assets	64,595	63,914	...
Computer & other equipment	20,517	32,655	...
Furniture & fixtures	1,694	2,761	...
Leasehold improvements	3,463	3,916	...
Software	39,578	34,234	...
Property & equipment, gross	65,252	73,566	...
Less accumulated depreciation & amortization	43,224	56,088	...
Property & equipment, net	22,028	17,478	...
Goodwill	17,531	17,648	...
Intangible assets, net	14,945	18,478	...
Unbilled receivables	1,608	894	...
Deferred income taxes	3,561	1,538	...
Other assets	561	268	...
Total assets	124,829	120,218	...
Accounts payable & accrued expenses	7,515	8,548	...
Accrued payroll & related expenses	15,073	13,078	...
Refund liabilities	6,497	7,864	...

Deferred revenue	2,428	1,431	...
Current portion of debt	48	48	...
Current portion of long-term incentive compensation liability	...	5,116	...
Business acquisition obligations	4,162	3,759	...
Total current liabilities	35,723	39,844	...
Revolving facility	21,535	13,469	...
Capital lease obligations	66	105	...
Less current portion	48	48	...
Noncurrent business acquisition obligations	...	5,135	...
Refund liabilities	100	957	...
Deferred income taxes	666
Other long-term liabilities	458	442	...
Total liabilities	58,500	59,904	...
Common stock	232	224	...
Additional paid-in capital	582,574	580,032	...
Retained earnings (accumulated deficit)	(515,456)	(520,049)	...
Accumulated other comprehensive income (loss)	(1,021)	107	...
Total shareholders' equity (deficit)	66,329	60,314	...

Reclassified to conform with 2018 presentation; Net of allowances - Contract receivables: \$1,024,000; Net of allowances - Contract receivables: \$1,499,000; Net of allowances - Employee advances and miscellaneous receivables: \$176,000; Net of allowances - Employee advances and miscellaneous receivables: \$292,000

PRINCIPIA BIOPHARMA INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Revenue	69,137	5,247	...
Research & development expenses	40,533	25,390	22,290
General & administrative expenses	11,462	6,443	4,763
Total operating expenses	51,995	31,833	27,053
Income (loss) from operations	17,142	(26,586)	(27,053)
Other income (expense), net	(653)	5,096	308
Interest income	1,678	16	5
Interest expense	...	7,223	3,898
Income before income taxes - U.S.	18,226	(28,589)	(30,511)
Income before income taxes - Foreign	(59)	(108)	(127)
Income (loss) before income taxes	18,167	(28,697)	(30,638)
Net income (loss)	18,167	(28,697)	(30,638)
Allocation of undistributed earnings to participating securities	13,250
Net income (loss) attributable to common stockholders	4,917	(28,697)	(30,638)
Weighted average shares outstanding - basic	7,623	570	512
Weighted average shares outstanding - diluted

- diluted	8,627	570	512
Year end shares outstanding	23,865	627	531
Net income (loss) per common share - basic	\$0.65	\$(50.37)	\$(59.89)
Net income (loss) per common share - diluted	\$0.57	\$(50.37)	\$(59.89)
Number of full time employees	69	53	...
Number of common stockholders	101

Reclassified to conform with 2018 presentation; Adjusted for 1-for-9.0839 stock split, August 31, 2018; Shares increased due to conversion of preferred stock at initial public offering, issuance of common stock from initial public offering, warrants, stock options and vesting of early exercise shares; As Is; As of March 12, 2019; As of August 31, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	34,489	41,054
Short-term marketable securities	142,436	...
Restricted cash	82	100
Other accounts receivable	2,104	378
Prepaid expenses	1,661	1,400
Prepaid expenses & other current assets	3,765	1,778
Total current assets	180,772	42,932
Laboratory equipment	2,500	1,617
Computer equipment	508	281
Furniture & fixtures	392	10
Leasehold improvements	420	203
Total property & equipment, gross	3,820	2,111
Less: accumulated depreciation & amortization	2,154	1,902
Property & equipment, net	1,666	209
Long-term restricted cash	567	82
Long-term marketable securities	3,712	...
Other long-term assets	8,804	280
Total assets	195,521	43,503
Accounts payable	4,439	3,405
Deferred revenue	5,616	44,134
Accrued research & development liabilities	1,520	1,177
Accrued other liabilities	993	253
Accrued compensation	4,312	2,262
Total current liabilities	16,880	51,231
Deferred revenue, less current portion	...	5,619
Long-term deferred rent	8,781	8
Convertible preferred stock warrant liability	...	1,576
Total liabilities	25,661	58,434
Convertible preferred stock	...	128,531
Common stock	2	1
Additional paid-in-capital	302,393	7,201
Accumulated other comprehensive income (loss)	(128)	(90)
Retained earnings (accumulated deficit)	(132,407)	(150,574)
Total stockholders' equity (deficit)	169,860	(143,462)

Reclassified to conform with 2018 presentation

Recent Dividends:
1. Principia Biopharma Inc common. No dividends paid.
Annual Dividends:
1. Principia Biopharma Inc common. No dividends paid.

QUANTENNA COMMUNICATIONS INC

Merger Development On Mar. 27, 2019, ON Semiconductor Corp. ("ON Semiconductor"), Raptor Operations Sub, Inc., a wholly-owned subsidiary of ON Semiconductor ("Merger Subsidiary"), and Co., entered into a definitive Agreement and Plan of Merger (the "Merger Agreement"). The acquisition consideration represents equity value of approximately \$1,070,000,000 and enterprise value of approximately \$936,000,000, after accounting for Co.'s net cash of approximately \$136,000,000 at the end of fourth quarter of 2018. Pursuant to the terms and conditions set forth in the Merger Agreement, Merger Subsidiary will be merged with and into Co. (the "Merger"), with Co. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of ON Semiconductor. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Co.'s common stock, par value \$0.0001 per share (the "Shares"), outstanding immediately prior to the Effective Time (other than Shares held by (a) ON Semiconductor or its subsidiaries immediately prior to the Effective Time, (b) Co. as treasury stock and (c) stockholders of Co. who properly exercised their appraisal rights under the Delaware General Corporation Law) will automatically be canceled and converted into the right to receive \$24.50 per Share in cash, without interest (the "Merger Consideration"). In addition, at or immediately prior to the Effective Time, (i) each option to purchase Shares that has an exercise price per Share that is less than the Merger Consideration will be canceled and converted into the right to receive the Merger Consideration, net of the applicable exercise price, and in the case of each unvested option, payable at the times and subject to the contingencies specified in the Merger Agreement (but in no event later than the end of the calendar year in which the Effective Time occurs), (ii) each option to purchase Shares that has an exercise price per Share that is equal to or greater than the Merger Consideration will be canceled without payment, (iii) each vested restricted stock unit award will be canceled and converted into the right to receive the Merger Consideration, and (iv) each unvested restricted stock unit award will be canceled and converted into the right to receive the Merger Consideration, payable on the same vesting schedule that applied to such award, subject to certain conditions specified in the Merger Agreement. The transaction has been approved by ON Semiconductor's and Co.'s boards of directors and is expected to close in the second half of 2019. No approval of the stockholders of ON Semiconductor is required in connection with the proposed transaction.

QUANTERIX CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2018	2017 (revised)	2016 (revised)
Product revenue	23,365	14,124	10,601
Service & other revenue	12,117	6,766	5,012
Collaboration & license revenue	2,150	1,074	1,972
Total revenue	37,632	22,874	17,585
Cost of product revenue	12,729	7,742	6,299
Cost of services & other revenue	6,955	5,145	3,163
Cost of license revenue, related party	375
Total costs of goods sold & services	19,684	12,887	9,837
Gross profit	17,948	9,987	7,748
Research & development	15,805	16,304	16,993
Selling, general & administrative expense	33,693	19,688	12,466
Total operating expenses	49,498	35,992	29,459
Income (loss) from operations	(31,550)	(26,005)	(21,711)
Interest income (expense), net	46	(951)	(1,298)
Other income (expense), net	(7)	(63)	(164)
Income (loss) before income taxes			

- United States	(31,436)	(27,019)	(23,173)
Income (loss) before income taxes			
- Foreign	(75)
Income (loss) before income taxes	(31,511)	(27,019)	(23,173)
Current income tax provision (benefit) - state	18
Total current income tax provision (benefit)	18
Deferred income tax provision (benefit) - federal	2
Deferred income tax provision (benefit) - state	5
Total deferred income tax provision (benefit)	7
Income tax provision	25
Net income (loss)	(31,536)	(27,019)	(23,173)
Accretion of preferred stock redemption value	...	4,110	4,437
Accrued dividends on preferred stock	...	59	8
Net income (loss) attributable to common stockholders	(31,536)	(31,188)	(27,618)
Weighted average common shares outstanding - basic	21,994	3,757	2,143
Weighted average common shares outstanding - diluted	21,994	3,757	2,143
Year end shares outstanding	22,369	21,707	2,315
Net income (loss) per common share - basic	\$(1.43)	\$(8.30)	\$(12.89)
Net income (loss) per common share - diluted	\$(1.43)	\$(8.30)	\$(12.89)
Total number of employees	177	126	122
Number of stockholders	23,53	24,66	24,75

fering; ⁽²²⁾ As is; ⁽²³⁾ As of September 30, 2017; ⁽²⁴⁾ Approximately; ⁽²⁵⁾ As of March 1, 2019; ⁽²⁶⁾ As of March 1, 2018; ⁽²⁷⁾ As of October 31, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	44,429	79,682
Accounts receivable, gross	6,828	5,635
Less: reserve for doubtful accounts	36	36
Accounts receivable	6,792	5,599
Raw materials	1,546	1,032
Work in process	2,331	968
Finished goods	2,068	1,571
Inventory	5,945	3,571
Prepaid expenses & other current assets	2,330	400
Total current assets	59,496	89,252
Restricted cash	1,000	...
Laboratory & manufacturing equipment	4,127	2,969
Office furniture & equipment	789	689
Computers & software	786	459
Leasehold improvements	244	180
Property & equipment, gross	5,946	4,297
Less: accumulated depreciation	3,023	2,423
Property & equipment, net	2,923	1,874
Intangible assets, net	2,348	...
Goodwill	1,308	...
Other non-current assets	536	653
Total assets	67,611	91,779
Accounts payable	5,110	3,552
Accrued compensation & benefits	4,449	2,624
Accrued inventory	599	835
Accrued royalties	323	221
Accrued professional services	723	346
Accrued development costs	795	1,559
Accrued other	689	599
Other accrued expenses	3,129	3,560
Deferred revenue	5,437	4,942
Current portion of long term debt	...	5,036
Total current liabilities	18,125	19,714
Deferred revenue, net of current portion	520	1,709
Long-term debt, net of current portion	7,623	4,346
Other non-current liabilities	278	144
Total liabilities	26,546	25,913
Common stock	22	22
Additional paid-in capital	216,931	210,196
Retained earnings (accumulated deficit)	(175,888)	(144,352)
Total stockholders' equity	41,065	65,866

⁽¹⁾ Reclassified to conform with 2018 presentation; ⁽²⁾ Including related parties - Accounts receivable: \$48,000; ⁽³⁾ Including related parties - Accounts receivable: \$123,000; ⁽⁴⁾ Including related parties - Accounts payable: \$36,000; ⁽⁵⁾ Including related parties - Other accrued expenses: \$226,000; ⁽⁶⁾ Including related parties - Other accrued expenses: \$170,000; ⁽⁷⁾ Including related parties - Deferred revenue: \$33,000; ⁽⁸⁾ Including related parties - Deferred revenue: \$1,182,000; ⁽⁹⁾ Including related parties - Deferred revenue, net of current portion: \$1,074,000

Recent Dividends:**1. Quanterix Corp common.**

No dividends paid.

Annual Dividends:**1. Quanterix Corp common.**

No dividends paid.

RADNET INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Service fee revenue, net of contractual allowances & discounts	868,741,000	857,178,000	821,587,000
Provision for bad debts	...	46,555,000	45,387,000
Net service fee revenue	...	810,623,000	776,200,000
Revenue under capitation arrangements	106,405,000	111,563,000	108,335,000
Total net revenue	975,146,000	922,186,000	884,535,000
Cost of operations, excluding depreciation & amortization	867,547,000	802,377,000	775,801,000
Depreciation & amortization expense	72,899,000	66,796,000	66,610,000
Gain (loss) on sale & disposal of equipment	2,054,000	(1,142,000)	(767,000)
Loss on impairment	3,937,000
Severance costs	1,931,000	1,821,000	2,877,000
Total operating expenses	944,260,000	872,136,000	846,055,000
Income (loss) from operations	30,886,000	50,050,000	38,480,000
Interest expense	43,456,000	40,623,000	43,455,000
Meaningful use incentive	...	250,000	2,808,000
Equity in earnings (losses) of joint ventures	11,377,000	13,554,000	9,767,000
Gain on re-measurement of pre-existing interest	39,539,000
Gain on sale of imaging centers & medical practice	...	3,146,000	...
Gain on return of common stock	5,032,000
Other income (expenses)	181,000	8,000	(196,000)
Income (loss) before income taxes	38,527,000	26,385,000	12,436,000
Current provision for (benefit from) income taxes - federal	(765,000)	871,000	88,000
Current provision for (benefit from) income taxes - state	7,263,000	4,906,000	914,000
Current provision for (benefit from) income taxes - other	20,000	23,000	28,000
Deferred provision for (benefit from) income taxes - federal	(2,020,000)	21,389,000	2,539,000
Deferred provision for (benefit from) income taxes - state	(4,104,000)	(2,879,000)	863,000
Provision for (benefit from) income taxes	394,000	24,310,000	4,432,000
Net income (loss)	38,133,000	2,075,000	8,004,000
Net income (loss) attributable to noncontrolling interests	(5,890,000)	(2,022,000)	(774,000)
Net income (loss) attributable to RadNet, Inc. common stockholders	32,243,000	53,000	7,230,000

Weighted average shares outstanding

	2018	2017	2016
- basic	48,114,275	46,880,775	46,244,188
Weighted average shares outstanding - diluted	48,678,999	47,401,921	46,655,032
Year end shares outstanding	48,977,485	47,723,915	46,574,904
Net income (loss) per common share - basic	\$0.67	\$0.00	\$0.16
Net income (loss) per common share - diluted	\$0.66	\$0.00	\$0.15
Number of full time employees	5,706	5,441	5,134
Number of part time employees	2,163	2,084	2,226
Total number of employees	7,869	7,525	7,360
Number of common stockholders	1,083	1,083	835
Number of beneficiary stockholders	5,000	5,000	4,000
Foreign currency translation adjustments	...	26,000	(49,000)

□ As of March 12, 2019; □ As of March 5, 2018; □ As of March 9, 2017; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	10,389,000	51,322,000
Accounts receivable	148,919,000	155,518,000
Due from affiliates	595,000	2,343,000
Prepaid expenses & other current assets	46,288,000	26,168,000
Asset held for sale	2,499,000	...
Total current assets	208,690,000	235,351,000
Land	250,000	250,000
Medical equipment	449,776,000	380,439,000
Computer & office equipment, furniture & fixtures	102,798,000	96,382,000
Software development costs	6,391,000	6,391,000
Leasehold improvements	337,878,000	273,436,000
Equipment under capital lease	12,119,000	17,180,000
Property & equipment, gross	909,212,000	774,078,000
Less: accumulated depreciation	563,483,000	529,511,000
Property & equipment, net before less equipment held for sale	345,729,000	244,567,000
Less: equipment transferred to other assets	...	(266,000)
Property & equipment, net	345,729,000	244,301,000
Goodwill	418,093,000	256,776,000
Other intangible assets	40,593,000	40,422,000
Deferred financing costs	1,354,000	1,895,000
Investment in joint ventures	37,973,000	52,435,000
Deferred tax assets	31,506,000	30,852,000
Deposits & other assets	25,392,000	6,947,000
Total assets	1,109,330,000	868,979,000
Accounts payable	68,040,000	28,538,000
Accrued expenses	60,958,000	67,298,000
Accrued salary & benefits	37,167,000	30,670,000
Accrued professional fees	14,863,000	9,303,000
Due to affiliates	13,089,000	16,387,000
Deferred revenue related to software sales	2,398,000	2,606,000
Current portion of deferred rent	3,735,000	2,714,000
Current portion of notes payable	33,653,000	30,224,000
Current portion of		

obligations under capital

leases	5,614,000	3,866,000
Total current liabilities	239,517,000	191,606,000
Deferred rent, net of current portion	31,542,000	26,251,000
Notes payable, net of current portion	626,507,000	572,365,000
Obligations under capital lease, net of current portion	6,505,000	2,672,000
Other non-current liabilities	5,006,000	6,160,000
Total liabilities	909,077,000	799,054,000
Common stock	5,000	5,000
Additional paid-in-capital	242,835,000	212,261,000
Accumulated other comprehensive gain (loss)	2,259,000	(548,000)
Retained earnings (deficit)	(117,915,000)	(150,158,000)
Total RadNet, Inc.'s stockholders' equity (deficit)	127,184,000	61,560,000
Non-controlling interests	73,069,000	8,365,000
Total equity (deficit)	200,253,000	69,925,000

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. RadNet Inc common.

No dividends paid.

Annual Dividends:

1. RadNet Inc common.

No dividends paid.

RAMACO RESOURCES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Coal sales	227,574,000	58,798,000	2,167,000
Coal processing	...	2,238,000	3,049,000
Total revenue	227,574,000	61,036,000	5,216,000
Cost of coal sales	176,555,000	58,308,000	1,796,000
Cost of coal processing	...	2,213,000	2,601,000
Other operating costs & expenses	...	258,000	416,000
Asset retirement obligation accretion	494,000	405,000	229,000
Depreciation & amortization	12,423,000	3,154,000	252,000
Selling, general & administrative	14,006,000	12,591,000	7,452,000
Total cost & expenses	203,478,000	76,929,000	12,746,000
Operating income (loss)	24,096,000	(15,893,000)	(7,530,000)
Interest & dividend income	36,000	295,000	139,000
Other income	2,518,000	204,000	...
Interest expense	1,463,000	23,000	124,000
Income (loss) before tax	25,187,000	(15,417,000)	(7,515,000)
Current state income taxes	4,000
Current income taxes	4,000
Deferred federal income taxes	(111,000)
Deferred state income taxes	220,000
Deferred income taxes	109,000
Income tax expense	113,000
Net income (loss)	25,074,000	(15,417,000)	(7,515,000)
Weighted average shares outstanding-basic	40,039,000	37,578,000	39,062,576
Weighted average shares outstanding-diluted	40,263,000	37,578,000	39,062,576
Year-end shares outstanding	40,082,467	39,559,366	39,062,576

Net earnings (loss) per share - basic	\$0.63	\$(0.41)	\$0.00
Net earnings (loss) per share - diluted	\$0.62	\$(0.41)	\$0.00
Total number of employees	349	268	31
Number of common stockholders	33	28	9

Reclassified to conform with 2018 presentation; As of March 24, 2017; As of March 21, 2018; As of March 15, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):			
	2018	2017	(revised)
Cash & cash equivalents	6,951,000	5,934,000	
Short-term investments	...	5,200,000	
Accounts receivable	10,729,000	7,166,000	
Inventories	14,185,000	10,058,000	
Prepaid expenses	3,154,000	1,104,000	
Total current assets	35,019,000	29,462,000	
Plant & equipment at cost	109,911,000	80,455,000	
Construction in progress	12,066,000	7,626,000	
Capitalized mine development cost	43,037,000	30,776,000	
Less: accumulated depreciation & amortization	15,809,000	3,406,000	
Property, plant & equipment, net	149,205,000	115,451,000	
Advanced coal royalties	3,045,000	2,867,000	
Other assets	975,000	318,000	
Total assets	188,244,000	148,098,000	
Accounts payable	16,393,000	19,533,000	
Accrued expenses	8,094,000	2,821,000	
Asset retirement obligations	71,000	71,000	
Current portion of long-term debt	5,000,000	...	
Financed insurance payable	287,000	...	
Total current liabilities	29,845,000	22,425,000	
Asset retirement obligations	12,707,000	12,276,000	
Term loan	9,589,000	...	
Debt issuance cost	(115,000)	...	
Total debt	9,474,000	...	
Less: current portion of long-term debt	5,000,000	...	
Long-term debt	4,474,000	...	
Deferred tax liability	109,000	...	
Total liabilities	47,135,000	34,701,000	
Common stock	401,000	396,000	
Additional paid-in capital	150,926,000	148,293,000	
Retained earnings (accumulated deficit)	(10,218,000)	(35,292,000)	
Stockholders' equity	141,109,000	113,397,000	
Total equity (deficit)	141,109,000	113,397,000	

Recent Dividends:

1. Ramaco Resources Inc common. No dividends paid.

Annual Dividends:

1. Ramaco Resources Inc common. No dividends paid.

RESTORATION ROBOTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)
Revenue	21,956	21,297	15,600
Cost of revenue	12,450	12,150	10,431
Gross profit	9,506	9,147	5,169
Research & development	8,374	7,135	7,474
Sales & marketing expenses	18,204	14,390	12,483
General &			

administrative expenses	8,834	4,904	4,144
Total operating expenses	35,412	26,429	24,101
Income (loss) form operations	(25,906)	(17,282)	(18,932)
Interest expense	2,224	2,027	2,483
Gain on sale of investment	...	1,851	...
Other income (expense), net	(549)	(328)	(431)
Total other income (expense), net	(2,773)	(504)	(2,914)
Income (loss) before income taxes	(28,477)	(17,732)	(21,696)
- Domestic	(28,477)	(17,732)	(21,696)
Income (loss) before income taxes - Foreign	(202)	(54)	(150)
Net income (loss) before provision for income taxes	(28,679)	(17,786)	(21,846)
Current state income taxes	9	4	4
Current foreign income taxes	38	56	16
Current income taxes	47	60	20
Deferred state income taxes	...	(4)	(4)
Deferred foreign income taxes	(16)
Deferred income taxes	...	(4)	(20)
Provision for income taxes	47	56	...
Net income (loss)	(28,726)	(17,842)	(21,846)
Weighted average shares outstanding - basic	33,512	7,383	1,613
Weighted average shares outstanding - diluted	33,512	7,383	1,613
Year end shares outstanding	40,677	28,940	1,615
Net earnings (loss) per share - basic	\$(0.86)	\$(2.42)	\$(13.54)
Net earnings (loss) per share - diluted	\$(0.86)	\$(2.42)	\$(13.54)
Total number of employees	102	87	...
Number of common stockholders	538	661	...
Leasehold improvements	874	869	
Furniture & fixtures	457	270	
Total property & equipment, gross	5,763	4,789	
Less accumulated depreciation & amortization	4,464	3,651	
Property & equipment, net	1,299	1,138	
Restricted cash	83	100	
Other assets	100	...	
Total assets	30,973	32,970	
Accounts payable	3,815	2,044	
Accrued compensation	1,771	1,630	
Other accrued liabilities	2,337	1,125	
Deferred revenue	1,407	1,517	
Current portion of long-term debt, net	49	7,730	
Total current liabilities	9,379	14,046	
Other long-term liabilities	594	459	
Long-term debt, net	19,418	5,271	
Total liabilities	29,391	19,776	
Common stock	4	3	
Additional paid-in capital	194,841	177,757	
Accumulated other comprehensive income (loss)	(50)	(79)	
Retained earnings (accumulated deficit)	(193,213)	(164,487)	
Total stockholders' equity (deficit)	1,582	13,194	

Reclassified to conform with 2018 presentation; Discount - Current portion of long-term debt, net: \$270,000; Discount - Long-term debt, net: \$29,000

Recent Dividends:

1. Restoration Robotics Inc common. No dividends paid.

Annual Dividends:

1. Restoration Robotics Inc common. No dividends paid.

RESTORATION ROBOTICS INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Grant Thornton LLP, as it appeared in Co.'s 2018 10-K: "Opinion on the financial statements We have audited the accompanying consolidated balance sheets of Restoration Robotics, Inc. (a Delaware corporation) and subsidiaries (the "Company") as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders' equity (deficit), and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America. Going concern uncertainty The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred net operating losses, negative cash flows from operations since inception, and has an accumulated deficit as of December 31, 2018. These conditions, along with other matters as set forth in Note 2, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

RESTORBIO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)
Research & development	31,065	16,839	...
General & administrative			

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
		(revised)
Cash & cash equivalents	16,122	23,545
Accounts receivable, gross	8,341	4,093
Allowance for doubtful accounts	1,772	229
Accounts receivable, net	6,569	3,864
Raw materials	2,464	...
Work-in-process	323	...
Finished goods	2,735	2,761
Inventory	5,522	2,761
Prepaid expenses & other current assets	1,278	1,562
Total current assets	29,491	31,732
Computer hardware & software	901	721
Equipment	3,531	2,929

expenses	8,640	2,043	1
Total operating expenses	39,705	18,882	1
Income (loss) from operations	(39,705)	(18,882)	(1)
Other income (expense), net	2,117	(14,896)	...
Income (loss) before income taxes	(37,588)	(33,778)	(1)
Income tax expense	26
Net income (loss)	(37,614)	(33,778)	(1)
Weighted average shares outstanding - basic	26,439	4,010	1,978
Weighted average shares outstanding - diluted	26,439	4,010	1,978
Year end shares outstanding	28,055	4,563	2,083
Net earnings (loss) per share - basic	\$(1.42)	\$(8.42)	\$0.00
Net earnings (loss) per share - diluted	\$(1.42)	\$(8.42)	\$0.00
Number of full time employees	21	7	7
Number of common stockholders	7	12	...

From July 5, 2016 (inception); Reclassified to conform with 2017 presentation; Shares increased due to the effect of public offering issuance of common stock, vesting of restricted shares, exercise of stock options & conversion of convertible preferred stock into common stock; Shares increased due to the issuance for PureTech Health LLC and vesting of restricted shares; As is; As of March 15, 2019; As of March 23, 2018; As of January 16, 2018; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	7,042	53,349
Marketable securities	100,986	...
Prepaid expenses	1,491	792
Deferred offering costs	...	929
Other current assets	15	84
Total current assets	109,534	55,154
Restricted cash	84	...
Leasehold improvements	65	...
Machinery & equipment	38	38
Furniture & fixtures	194	...
Computers	76	6
Office equipment	11	...
Software	22	...
Property & equipment, gross	406	44
Less: accumulated depreciation	85	5
Property & equipment, net	321	39
Total assets	109,939	55,193
Accounts payable	2,989	1,515
Accrued payroll & related expenses	1,189	394
Accrued research & development expenses	1,028	3,250
Deferred offering costs	...	238
Other accrued liabilities	510	105
Accrued liabilities	2,727	3,987
Total current liabilities	5,716	5,502
Other liabilities	19	...
Total liabilities	5,735	5,502
Redeemable convertible preferred stock, series A	...	41,674
Redeemable convertible preferred stock, series B	...	39,946
Common stock	3	1
Additional paid-in capital	175,635	1,849
Retained earnings (accumulated deficit)	(71,393)	(33,779)
Other comprehensive income (loss)	(41)	...
Total stockholders' equity (deficit)

equity (deficit)	104,204	(31,929)
------------------	---------	----------

Reclassified to conform with 2018 presentation; Including related party amounts - Accounts payable: \$32,000

Recent Dividends:

- resTORbio Inc series A redeemable convertible preferred. No dividends paid.
- resTORbio Inc series B redeemable convertible preferred. No dividends paid.
- resTORbio Inc common. No dividends paid.

Annual Dividends:

- resTORbio Inc series A redeemable convertible preferred. No dividends paid.
- resTORbio Inc series B redeemable convertible preferred. No dividends paid.
- resTORbio Inc common. No dividends paid.

RIGEL PHARMACEUTICALS INC
Official Changes On Mar. 26, 2019, Co. announced the appointment of Ms. Jane Wasman to its Board of Directors, replacing Dr. Peter S. Ringrose, Ph.D., who would retire from its board of directors, effective in May.

RISE GOLD CORP
Earnings, 6 mos. to Jan 31 (Consol. - Can\$):

	2019	2018
Cost & expenses	3,113,438	1,517,127
Net income	(3,127,443)	(1,517,127)
Earnings common share		
Primary	Can\$(0.03)	Can\$(0.02)
Fully Diluted	Can\$(0.03)	Can\$(0.02)
Common Shares:		
Full Diluted	121,164,610	69,996,744
Year-end	145,990,357	80,944,982

ROCKWELL MEDICAL, INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Net sales	63,388,617	57,300,281	53,284,166
Cost of sales	64,973,157	53,598,390	46,531,648
Gross profit (loss)	(1,584,540)	3,701,891	6,752,518
Selling, general & administrative expenses	23,082,304	23,303,409	21,120,901
Settlement expense, net of reimbursement	1,030,000
Research & product development	5,642,317	6,321,400	5,840,346
Research & development - licenses acquired (related party)	1,100,000
Operating income (loss)	(32,439,161)	(25,922,918)	(20,208,729)
Realized gain (loss) on investments	(222,338)	(792,207)	...
Interest & investment income	810,340
Interest income	535,328	790,226	...
Other income (expenses)	313	2,873	...
Foreign currency gain	...	742	...
Total other income	313,303	1,634	...
Income (loss) before income taxes	(19,398,389)
Foreign income taxes	404,527
Income tax expense	404,527
Net income (loss)	(32,125,858)	(25,921,284)	(19,802,916)
Weighted average shares outstanding - basic	52,824,486	51,067,412	50,676,180
Weighted average shares outstanding - diluted	52,824,486	51,067,412	50,676,180
Year end shares outstanding	57,034,154	51,768,424	51,527,711
Net earnings (loss)

per share - basic	\$(0.61)	\$(0.51)	\$(0.39)
Net earnings (loss) per share - diluted	\$(0.61)	\$(0.51)	\$(0.39)
Number of full time employees	269	300	300
Total number of employees	300
Number of common stockholders	26	30	23
Foreign currency translation adjustments	(10,762,000)	1,134,000	(671,000)

Reclassified to conform with 2018 presentation; Approximately; As of February 28, 2019; As of February 28, 2018; As of February 28, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash & cash equivalents	22,713,980	8,406,917
Investments available-for-sale	10,818,059	24,648,459
Accounts receivable, gross	6,981,618	6,366,566
Less reserve	2,104	11,000
Accounts receivable, net	6,979,514	6,355,566
Insurance receivable	371,217	...
Inventory	4,038,778	7,637,384
Prepaid & other current assets	1,903,682	1,779,992
Total current assets	46,825,230	48,828,318
Leasehold improvements	929,849	824,087
Machinery & equipment	4,800,774	7,893,566
Information technology & office equipment	2,459,832	2,327,524
Laboratory equipment	668,977	631,666
Transportation equipment	...	242,277
Property & equipment, gross	8,859,432	11,919,120
Less accumulated depreciation	6,221,139	9,370,142
Property & equipment, net	2,638,293	2,548,978
Inventory, non-current	1,637,000	5,986,752
Goodwill	920,745	920,745
Other non-current assets	536,516	494,847
Total assets	52,557,784	58,779,640
Accounts payable	4,492,071	4,222,159
Accrued research & development expense	86,820	400,024
Accrued compensation & benefits	1,525,599	1,991,874
Other accrued liabilities	3,517,342	2,323,814
Accrued liabilities	5,129,761	4,715,712
Settlement payable	416,668	...
Deferred license revenue	2,252,868	...
Customer deposits	63,143	205,303
Other current liability - related party	850,000	...
Total current liabilities	13,204,511	9,143,174
Deferred license revenue	12,076,399	16,723,318
Total liabilities	25,280,910	25,866,492
Common shares	299,601,960	273,210,907
Retained earnings (accumulated deficit)	(272,388,234)	(240,262,376)
Accumulated other comprehensive income (loss)	63,148	(35,383)
Total shareholders' equity (deficit)	27,276,874	32,913,148

Reclassified to conform with 2018 presentation

Recent Dividends:

- Rockwell Medical, Inc common. No dividends paid.

Annual Dividends:

- Rockwell Medical, Inc common. No dividends paid.

ROCKWELL MEDICAL, INC
Auditor's Report Auditor's Report
 The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2018 Annual Re-

port: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Rockwell Medical Inc. and Subsidiaries (the "Company") as of December 31, 2018, the related consolidated statements of operations, comprehensive loss, changes in shareholders' equity and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph - Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred a significant net loss of \$32.1 million and operating cash flow deficit of \$20.4 million during the year ended December 31, 2018, has an accumulated deficit of \$272.4 million as of December 31, 2018 and needs to raise additional funds to meet its obligations, sustain its operations and execute on its longer term business plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ROSS STORES, INC.

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/02/19	02/03/18 (revised)	01/28/17 (revised)
Sales	14,983,541	14,134,732	12,866,757
Cost of goods sold	10,726,277	10,042,638	9,173,705
Selling, general & administrative expense	2,216,550	2,043,698	1,890,408
Interest on long-term debt	17,900	18,578	18,573
Other interest expense	1,004	979	1,022
Capitalized interest	2,497	710	26
Interest income	26,569	11,171	3,081
Interest income (expense), net	10,162	(7,676)	(16,488)
Total costs & expenses	12,932,665	12,094,012	11,080,601
Earnings (loss) before taxes	2,050,876	2,040,720	1,786,156
Current federal income taxes expense (benefit)	357,170	660,017	632,872
Current state income taxes expense (benefit)	74,472	52,853	44,333
Total current income taxes expense (benefit)	431,642	712,870	677,205
Deferred federal income taxes expense (benefit)	33,913	(40,468)	(8,350)
Deferred state income taxes expense (benefit)	(2,136)	5,565	(353)
Total deferred income taxes expense (benefit)	31,777	(34,903)	(8,703)
Provision (benefits) for taxes on earnings	463,419	677,967	668,502
Net earnings (loss)	1,587,457	1,362,753	1,117,654
Weighted average shares outstanding - basic	369,533	381,174	392,124
Weighted average shares outstanding - diluted	372,678	384,329	394,958
Year end shares outstanding	368,242	379,618	391,893
Net earnings (loss) per share - basic	\$4.30	\$3.58	\$2.85
Net earnings (loss) per share - diluted	\$4.26	\$3.55	\$2.83
Dividends per common share	\$0.54

Total number of employees 88,100 82,700 78,600
Number of common stockholders 904 886 847

As is; Approximately; As of February 3, 2018; As of March 11, 2019; As of March 12, 2018; As of March 6, 2017

Consolidated Balance Sheet, Years Ended (\$000):

	02/02/19	02/03/18 (revised)
Cash & cash equivalents	1,412,912	1,290,294
Short-term investments	...	512
Accounts receivable	96,711	87,868
Merchandise inventory	1,750,442	1,641,735
Prepaid expenses & other current assets	143,954	130,748
Total current assets	3,404,019	3,151,157
Land & buildings	1,126,051	1,109,173
Fixtures & equipment	2,783,198	2,603,318
Leasehold improvements	1,175,921	1,093,634
Construction-in-progress	171,538	102,054
Property & equipment, gross	5,256,708	4,908,179
Less accumulated depreciation & amortization	2,781,507	2,525,715
Property & equipment, net	2,475,201	2,382,464
Long-term investments	125	712
Deferred compensation	124,558	120,613
Restricted cash & investments	53,765	53,969
Other long-term assets	16,023	13,136
Total assets	6,073,691	5,722,051
Accounts payable	1,177,104	1,059,844
Accrued expenses & other current liabilities	431,596	431,706
Accrued payroll & benefits	363,035	349,879
Income taxes payable	37,749	...
Current portion of long-term debt	...	84,973
Total current liabilities	2,009,484	1,926,402
Long-term debt	312,440	311,994
Income taxes	77,872	120,660
Deferred compensation	124,558	120,613
Deferred rent	81,442	73,059
Tenant improvement allowances	25,418	21,668
Other long-term liabilities	12,423	12,541
Deferred income taxes	124,308	85,806
Common stock	3,682	3,796
Additional paid-in capital	1,375,965	1,292,364
Treasury stock	372,663	318,279
Accumulated other comprehensive income	...	27
Retained earnings (accumulated deficit)	2,298,762	2,071,400
Total stockholders' equity	3,305,746	3,049,308

Recent Dividends:

1. Ross Stores, Inc. common.

ExDate	Amt	Declared	Record	Payable
03/10/2016	0.14	03/01/2016	03/14/2016	03/31/2016
06/03/2016	0.14	05/18/2016	06/07/2016	06/30/2016
08/31/2016	0.14	08/17/2016	09/02/2016	09/30/2016
12/05/2016	0.14	11/16/2016	12/07/2016	12/30/2016
03/08/2017	0.16	02/28/2017	03/10/2017	03/31/2017
06/02/2017	0.16	05/17/2017	06/06/2017	06/30/2017
09/06/2017	0.16	08/16/2017	09/07/2017	09/29/2017
11/30/2017	0.16	11/15/2017	12/01/2017	12/29/2017
03/16/2018	0.23	03/06/2018	03/19/2018	03/30/2018
06/11/2018	0.23	05/23/2018	06/12/2018	06/29/2018
09/12/2018	0.23	08/22/2018	09/13/2018	09/28/2018
12/06/2018	0.23	11/19/2018	12/07/2018	12/28/2018
03/15/2019	0.26	03/05/2019	03/18/2019	03/29/2019

Annual Dividends:

1. Ross Stores, Inc. common.

2016.....0.54 2017.....0.64 2018.....0.90
2019.....0.26

SB ONE BANCORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016
Interest income - loans receivable, including fees	51,359	32,953	26,862
Interest income - securities, taxable	3,507	1,437	1,443
Interest income - securities, tax-exempt	1,744	1,274	832
Interest income - interest-bearing deposits	99	35	23
Total interest income	56,709	35,699	29,160
Interest bearing deposits - NOW	1,527	584	313
Interest bearing deposits - money market	1,952	843	148
Interest bearing deposits - savings	818	285	286
Interest bearing deposits - time	3,781	1,872	1,702
Interest expense - deposits	8,078	3,584	2,449
Interest expense - borrowings	3,288	1,749	1,922
Interest expense - subordinated debentures	1,263	1,278	391
Total interest expense	12,629	6,611	4,762
Net interest income	44,080	29,088	24,398
Provision for loan losses	1,437	1,586	1,291
Net interest income after provision for loan losses	42,643	27,502	23,107
Service fees on deposits accounts	1,290	1,123	975
ATM & debit card fees	983	777	767
Bank owned life insurance	761	522	308
Insurance commissions & fees	6,640	5,326	4,796
Investment brokerage fees	104	24	75
Net gain (loss) on sales of securities	36	(9)	444
Net gain (loss) on sale & disposal of premises & equipment	9	7	(19)
Other income	926	515	483
Salaries & employee benefits	20,710	14,773	13,078
Occupancy, net	2,776	1,880	1,859
Data processing	3,351	2,173	2,108
Furniture & equipment expenses	1,194	938	993
Advertising & promotion	587	308	311
Professional fees	1,412	1,173	788
Director fees	550	399	450
Federal Deposits Insurance Corporation assessment	529	263	508
Insurance	210	279	280
Stationary & supplies	285	148	191
Merger related expenses	5,804	1,187	...
Loan collection costs	255	122	140

Net expenses & write-downs related to foreclosed real estate	324	283	458	Building & building improvements	15,194	6,744	development	36,310	19,944	12,477
Amortization of intangible assets	247	Leasehold improvements	3,351	2,182	General & administrative	14,382	5,085	4,112
Other expenses	2,176	1,691	1,421	Furniture, fixtures & equipment	8,382	6,048	Total operating expenses	50,692	25,029	16,589
Income (loss) before income taxes	12,982	10,170	8,351	Assets in progress	879	172	Income (loss) from operations	(50,692)	(25,029)	(16,210)
Current federal income taxes (benefit)	2,112	2,859	2,175	Premises & equipment, gross	31,184	16,886	Interest income (expense), net	1,422	44	(19)
Current state income taxes (benefit)	1,393	983	644	Less: accumulated depreciation	11,969	8,497	Other income (expense), net	(56)	(10)	22
Current income tax provisions (benefit)	3,505	3,842	2,819	Premises & equipment, net	19,215	8,389	Total other income (expense)	1,366	34	3
Deferred federal income taxes (benefit)	(51)	741	(40)	Accrued interest receivable	6,546	2,472	Net income (loss)	(49,326)	(24,995)	(16,207)
Deferred state income taxes (benefit)	(395)	(104)	49	Goodwill & intangible assets	29,446	2,820	Weighted average common units outstanding - basic	1,603
Deferred income tax provisions (benefit)	(446)	637	9	Bank-owned life insurance	35,778	22,054	Weighted average shares outstanding - basic	15,655	1,634	...
Provision (benefit) for income taxes	3,059	4,479	2,828	Other assets	9,710	7,303	Weighted average common units outstanding - diluted	1,603
Net income (loss)	9,923	5,691	5,523	Total assets	1,795,703	979,383	Year end units outstanding	1,603
Weighted average shares outstanding - basic	7,875	5,359	4,619	Non-interest bearing deposits	259,807	146,167	Year end shares outstanding	26,218	3,971	...
Weighted average shares outstanding - diluted	7,921	5,404	4,651	Savings, money market & interest-bearing demand deposits	705,258	417,527	Net earnings (loss) per unit - basic	\$(10.11)
Year end shares outstanding	9,533	6,041	4,741	Time deposits of less than \$100,000	205,372	84,299	Net earnings (loss) per share - basic	\$(3.15)	\$(15.30)	...
Net earnings (loss) per share - basic	\$1.26	\$1.06	\$1.20	Time deposits of \$100,000 & over	183,502	114,498	Net earnings (loss) per units - diluted	\$(10.11)
Net earnings (loss) per share - diluted	\$1.25	\$1.05	\$1.19	Total deposits	1,353,939	762,491	Net earnings (loss) per share - diluted	\$(3.15)	\$(15.30)	...
Dividends per common share	\$0.28	\$0.22	\$0.16	Short-term borrowings	175,295	55,350	Number of full time employees	65	50	...
Number of full time employees	216	140	131	Long-term borrowings	44,611	35,000	Number of common stockholders	62
Number of part time employees	21	16	17	Accrued interest payable & other liabilities	8,555	4,501				
Number of common stockholders	637	520	544	Subordinated debentures	27,859	27,848				
				Total liabilities	1,610,259	885,190				
				Common stock	150,419	65,274				
				Deferred Compensation obligation under Rabbi Trust	(1,647)	(1,399)				
				Retained earnings (accumulated deficit)	35,192	27,532				
				Accumulated other comprehensive income (loss)	(167)	1,387				
				Stock held by Rabbi Trust	1,647	1,399				
				Total stockholders' equity (deficit)	185,444	94,193				

Reclassified to conform with 2018 presentation; Fair value - Securities held to maturity, at amortized cost: \$4,152,000; Fair value - Securities held to maturity, at amortized cost: \$5,430,000

Shares increased due to the effect of conversion of convertible preferred stock into common stock, sale of common shares sold in IPO for offering and exercise of stock options; As is; As of March 1, 2019; As of May 7, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	115,069	56,461
Marketable securities	60,576	1,498
Prepaid expenses & other current assets	2,296	1,242
Total current assets	177,941	59,201
Laboratory equipment	3,585	2,074
Furniture & fixtures	219	151
Machinery & equipment	75	7
Leasehold improvements	1,578	1,498
Construction in progress	89	...
Total property & equipment, gross	5,546	3,730
Less: accumulated depreciation & amortization	2,356	1,549
Property & equipment, net	3,190	2,181
Restricted cash	205	205
Other long-term assets	...	50
Total assets	181,336	61,637
Accounts payable	3,303	1,359
Accrued payroll & related expenses	2,826	1,174
Accrued external research & development expense	3,284	1,225
Accrued professional & consulting expense	890	382
Accrued other	157	15
Accrued expenses	7,157	2,796
Deferred rent	16	228
Loan & capital lease payable	438	641

Shares increased due to the effect of shares issued in mergers and restricted stock granted; Shares increased due to the effect of additional issuance of common stock and the restricted stock granted; As is; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & due from banks	11,768	3,270
Interest-bearing deposits with other banks	14,910	8,376
Interest bearing time deposits with other banks	200	100
Securities available for sale, at fair value	182,139	98,730
Securities held to maturity, at cost	4,078	5,304
Other Bank Stock, at cost	11,764	4,925
Commercial & industrial loans	81,709	54,759
Construction loans	142,321	42,484
Commercial real estate loans	878,449	551,445
Residential real estate	370,955	171,844
Consumer & other loans	2,393	1,130
Total loans	1,475,827	821,662
Less: unearned net loan origination costs (fees)	1,052	962
Less: allowance for loan losses	8,775	7,335
Net loans receivable	1,466,000	813,365
Foreclosed real estate	4,149	2,275
Land & land improvements	3,378	1,740

Recent Dividends:

1. SB One Bancorp common.					
ExDate	Amt	Declared	Record	Payable	
02/09/2016	0.04	01/28/2016	02/11/2016	02/25/2016	
05/09/2016	0.04	04/27/2016	05/11/2016	05/25/2016	
08/08/2016	0.04	07/27/2016	08/10/2016	08/24/2016	
11/07/2016	0.04	10/27/2016	11/09/2016	11/23/2016	
02/07/2017	0.04	01/26/2017	02/09/2017	02/23/2017	
05/08/2017	0.06	04/26/2017	05/10/2017	05/24/2017	
08/08/2017	0.06	08/01/2017	08/10/2017	08/24/2017	
11/09/2017	0.06	10/27/2017	11/10/2017	11/24/2017	
02/06/2018	0.06	01/25/2018	02/07/2018	02/21/2018	
05/08/2018	0.07	04/25/2018	05/09/2018	05/23/2018	
08/08/2018	0.07	07/25/2018	08/09/2018	08/23/2018	
11/08/2018	0.07	10/24/2018	11/12/2018	11/26/2018	
02/19/2019	0.07	01/23/2019	02/20/2019	03/06/2019	

Annual Dividends:

1. SB One Bancorp common.			
2016	0.16	2017	0.22
2019	0.08	2018	0.29

SCHOLAR ROCK HOLDING CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):			
	2018	2017 (revised)	2016
Collaboration revenue	379
Research &

Deferred revenue	20,209	...
Total current liabilities	31,123	5,024
Long-term portion of deferred rent	871	468
Long-term portion of loan & capital lease payable	24	398
Warrant to purchase redeemable security	...	37
Long-term portion of deferred revenue	42,695	...
Total liabilities	74,713	5,927
Convertible preferred stock	...	109,232
Common stock	26	4
Additional paid-in capital	213,453	4,001
Accumulated other comprehensive income (loss)	(8)	(2)
Retained earnings (accumulated deficit)	(106,848)	(57,525)
Total stockholders' equity	106,623	(53,522)

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Scholar Rock Holding Corp common.

No dividends paid.

Annual Dividends:

1. Scholar Rock Holding Corp common.

No dividends paid.

SCHOLASTIC CORP.

Acquisition Completed On Mar. 27, 2019, Co.'s wholly-owned subsidiary, Scholastic UK Ltd., acquired a majority ownership position in Make Believe Ideas Ltd. ("MBI"), the innovative UK-based publisher of children's books founded by Jo Bicknell in 2004. Terms of the transaction were not disclosed.

SCHOLASTIC CORP.

Earnings, 9 mos. to Feb 28 (Consol. - \$000):

	2019	2018
Total Revenues	1,183,200	1,132,200
Cost & expenses	1,148,900	1,120,500
Operating income	(7,000)	(18,300)
Other income (expense), net	(1,100)	(55,400)
Net before taxes	(5,800)	(73,200)
Income taxes	(3,500)	(17,400)
Net income	(2,300)	(55,800)
Balance for common	(2,300)	(55,800)
Earnings common share		
Primary	\$(0.07)	\$(1.59)
Fully Diluted	\$(0.07)	\$(1.59)
Common Shares:		
Full Diluted	35,200	35,100
Year-end	35,300	34,734

SCPHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

	2018	2017	2016
		(revised)	(revised)
Research & development	15,948	14,331	11,856
General & administrative expenses	13,719	9,105	6,054
Total operating expenses	29,667	23,436	17,910
Income (loss) from operations	(29,667)	(23,436)	(17,910)
Other income (expense)	(56)	75	38
Interest income	1,712	341	7
Interest expense	1,432	797	6,512
Net income (loss)	(29,443)	(23,817)	(24,377)
Weighted average shares outstanding - basic	18,556	2,963	975
Weighted average shares outstanding - diluted	18,556	2,963	975
Year end shares outstanding	18,569	18,534	1,070

Net earnings (loss) per share - basic	\$(1.59)	\$(8.04)	\$(25.01)
Net earnings (loss) per share - diluted	\$(1.59)	\$(8.04)	\$(25.01)
Number of full time employees	21
Number of part time employees	2
Total number of employees	23	29	28
Number of common stockholders	32	40	...

Non-consolidated; Shares increased due to the effect of IPO, conversion of preferred stock, exercise of stock options and vesting of restricted stock; As is; As of September 30, 2017; As of March 19, 2019; As of March 16, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash	...	118,298
Cash & cash equivalents	89,478	...
Prepaid expenses	1,757	823
VAT receivable	479	655
Other current assets	179	107
Total current assets	91,893	119,883
Restricted cash	182	182
Office equipment	10	10
Office furniture	116	116
Computer equipment	8	8
Leasehold improvements	95	95
Total property & equipment, gross	229	229
Less: accumulated depreciation	65	26
Property & equipment, net	164	203
Right-of-use lease assets - operating (Type B), net	1,506	...
Deposits & other assets	10	7
Total assets	93,755	120,275
Accounts payable	587	1,591
Contract research & development	1,492	1,610
Employee compensation & related costs	860	871
Consulting & professional service fees	356	287
State taxes	165	192
Financing related costs	...	90
Other accrued expenses	49	13
Accrued expenses	2,922	3,063
Term loan, short term	2,811	314
Current portion of lease obligation - operating (Type B)	353	...
Other current liabilities	...	2
Total current liabilities	6,673	4,970
Term loan, long term	6,826	9,105
Long term lease obligation - operating (Type B)	1,353	...
Deferred rent, long term	...	151
Other liabilities	159	52
Total liabilities	15,011	14,278
Common stock	2	2
Additional paid-in capital	175,201	173,011
Retained earnings (accumulated deficit)	(96,459)	(67,016)
Total stockholders' equity (deficit)	78,744	105,997

Non-consolidated

Recent Dividends:

1. scPharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. scPharmaceuticals Inc common.

No dividends paid.

SERVICESTRONG INTERNATIONAL, INC.

Annual Meeting Development On Mar. 22, 2019, Co. announced that its Annual Meeting of Stockholders will be held on May 14, 2019, at 3:00 p.m. local time at Co.'s Headquarters located at 717 17th Street, 5th Floor, Denver, CO, 80202.

SERVICESTRONG INTERNATIONAL, INC.

Stock Split Development On Mar. 22, 2019, Co. announced that at its Annual Meeting of Stockholders to be held on May 14, 2019, Co. will be asking its Stockholders to authorize Co.'s Board of Directors, in its discretion, to amend Co.'s certificate of incorporation to effect a reverse stock split of Co. common stock in a ratio of not less than one-for-four and not more than one-for-six, to be determined by the board of directors.

SPLUNK INC

Annual Report

Consolidated Income Statement, Years Ended Jan. 31

	2019	2018	2017
		(revised)	(revised)
License revenues	1,030,277	741,302	543,510
Maintenance & services revenues	772,733	567,830	400,054
Total revenues	1,803,010	1,309,132	943,564
Cost of revenues - license	22,527	13,398	11,965
Cost of revenues - maintenance & services	322,149	243,011	179,088
Total cost of revenues	344,676	256,409	191,053
Gross profit	1,458,334	1,052,723	752,511
Research & development	441,969	301,114	295,850
Sales & marketing	1,029,950	777,876	639,404
General & administrative expenses	237,588	159,143	153,359
Total operating expenses	1,709,507	1,238,133	1,088,613
Operating income (loss)	(251,173)	(185,410)	(336,102)
Interest income	31,458	8,943	5,720
Interest expense	41,963	8,794	8,549
Other income (expense), net	(1,513)	(3,600)	(3,022)
Total interest & other income (expense), net	(12,018)	(3,451)	(5,851)
Income (loss) before income taxes - United States	(289,896)	(207,607)	(354,776)
Income (loss) before income taxes - International	26,705	18,746	12,823
Income (loss) before income taxes	(263,191)	(188,861)	(341,953)
Current federal income taxes	7,532
Current state income taxes	422	301	274
Current foreign income taxes	8,496	5,878	5,559
Total current income taxes	16,450	6,179	5,833
Deferred federal income taxes	(3,313)	(2,825)	165
Deferred state income taxes	...	(362)	15
Deferred foreign income taxes	(751)	(1,635)	(506)
Total deferred income taxes	(4,064)	(4,822)	(326)
Provision for income taxes	12,386	1,357	5,507
Net income (loss)	(275,577)	(190,218)	(347,460)
Weighted average shares outstanding - basic	145,707	139,866	133,910
Weighted average shares outstanding - diluted	145,707	139,866	133,910
Year end shares outstanding	149,167	142,835	137,169
Net earnings (loss) per share - basic	\$(1.89)	\$(1.36)	\$(2.59)

Net earnings (loss) per share - diluted	\$(1.89)	\$(1.36)	\$(2.59)
Total number of employees	14,400
Number of common stockholders	21

Restated to reflect adoption of ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers; Includes stock-based expenses - Cost of revenues: \$37,501,000; Includes stock-based expenses - Cost of revenues: \$33,605,000; Includes stock-based expenses - Cost of revenues: \$30,971,000; Includes stock-based expenses - Research and development: \$137,171,000; Includes stock-based expenses - Research and development: \$106,690,000; Includes stock-based expenses - Research and development: \$129,388,000; Includes stock-based expenses - Sales and marketing: \$190,422,000; Includes stock-based expenses - Sales and marketing: \$159,240,000; Includes stock-based expenses - Sales and marketing: \$161,164,000; Includes stock-based expenses - General and administrative: \$76,836,000; Includes stock-based expenses - General and administrative: \$58,928,000; Includes stock-based expenses - General and administrative: \$56,518,000; As is; Approximately

Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):

	2019	2018	2017
Cash & cash equivalents	1,876,165	545,947	545,947
Investments, current	881,220	619,203	619,203
Accounts receivable, gross	470,103	396,880	396,880
Allowance for doubtful accounts	445	467	467
Accounts receivable, net	469,658	396,413	396,413
Prepaid expenses & other current assets	73,197	70,021	70,021
Deferred commissions, current	78,223	52,451	52,451
Total current assets	3,378,463	1,684,035	1,684,035
Investments, non-current	110,588	5,375	5,375
Computer equipment & software	79,887	69,457	69,457
Furniture & fixtures	18,872	18,090	18,090
Leasehold & building improvements	79,064	67,348	67,348
Building	82,250	82,250	82,250
Property & equipment, gross	260,073	237,145	237,145
Less: accumulated depreciation & amortization	101,797	76,265	76,265
Property & equipment, net	158,276	160,880	160,880
Intangible assets, net	91,622	48,142	48,142
Goodwill	503,388	161,382	161,382
Deferred commissions, non-current	64,766	37,920	37,920
Other assets	193,140	41,711	41,711
Total assets	4,500,243	2,139,445	2,139,445
Accounts payable	20,418	11,040	11,040
Accrued compensation	226,061	145,365	145,365
Accrued expenses & other liabilities	125,641	84,631	84,631
Deferred revenue, current	673,018	489,913	489,913
Total current liabilities	1,045,138	730,949	730,949
Convertible senior notes, net	1,634,474
Deferred revenue, non-current	204,929	178,792	178,792
Other liabilities, non-current	95,245	98,383	98,383
Total non-current liabilities	1,934,648	277,175	277,175
Total liabilities	2,979,786	1,008,124	1,008,124
Common stock	149	143	143
Accumulated other comprehensive income (loss)	(2,506)	156	156
Additional paid-in capital	2,754,858	2,086,893	2,086,893
Retained earnings (accumulated deficit)	(1,232,044)	(955,871)	(955,871)

Total stockholders' equity (deficit)	1,520,457	1,131,321	1,131,321
--	-----------	-----------	-----------

Restated to reflect adoption of ASU No. 2014-09 (Topic 606), Revenue from Contracts with Customers

Recent Dividends:
1. Splunk Inc common.
 No dividends paid.
Annual Dividends:
1. Splunk Inc common.
 No dividends paid.

STEIN MART, INC. Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/02/19	02/03/18 (revised)	01/28/17 (revised)
Net sales	1,257,598	1,318,633	1,360,518
Other revenue	15,134	13,936	14,071
Total revenue	1,272,732	1,332,569	1,374,589
Cost of merchandise sold	919,812	987,692	1,001,539
Selling, general & administrative expenses	348,061	376,111	369,484
Operating income (loss)	4,859	(31,234)	3,566
Interest income (expense), net	(10,882)	(4,788)	(3,884)
Income (loss) before income taxes	(6,023)	(36,022)	(318)
Current federal income tax expense (benefit)	(7,222)	...
Current state income tax expense (benefit)	(25)	(1,254)	...
Total current income tax expense (benefit)	(25)	(8,476)	...
Deferred federal income tax expense (benefit)	(3,665)	...
Deferred state income tax expense (benefit)	443	...
Total deferred income tax expense (benefit)	(3,222)	...
Income tax expense (benefit)	(25)	(11,698)	(719)
Net income (loss)	(5,998)	(24,324)	401
Income allocated to participating securities	2	...
Net income (loss) available to common shareholders	(5,998)	(24,326)	...
Weighted average shares outstanding - basic	46,706	46,342	...
Weighted average shares outstanding - diluted	46,706	46,342	...
Year end shares outstanding	47,874	47,978	...
Net income (loss) per share - basic	\$(0.13)	\$(0.52)	\$0.01
Net income (loss) per share - diluted	\$(0.13)	\$(0.52)	\$0.01
Dividends per common share	\$0.07	\$0.30
Total number of employees	9,500
Number of common stockholders	766

Restated to reflect adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606); As is; Approximately; As of March 25, 2019

Consolidated Balance Sheet, Years Ended (\$000):

	02/02/19	02/03/18 (revised)	01/28/17 (revised)
Net sales	280,841,419	201,147,682	138,565,782
Cost of sales	229,604,080	173,066,732	121,661,303
Gross profit	51,237,339	28,080,950	16,904,479
Selling, general & administrative expense	27,691,874	24,874,589	22,672,872
Acquisition related			

Cash & cash equivalents	9,049	10,400	10,400
Inventories	255,884	270,237	270,237
Prepaid expenses & other current assets	28,326	26,620	26,620
Total current assets	293,259	307,257	307,257
Fixtures, equipment & software	245,289	245,718	245,718
Leasehold improvements	131,309	137,407	137,407
Less: accumulated depreciation & amortization	252,760	231,997	231,997
Property & equipment, net	123,838	151,128	151,128
Other assets	24,108	24,973	24,973
Total assets	441,205	483,358	483,358
Accounts payable	89,646	119,388	119,388
Current portion of debt	13,738	13,738
Compensation & employee benefits	9,271	7,732	7,732
Unredeemed gift & merchandise return cards	12,246	12,180	12,180
Property taxes	18,852	17,451	17,451
Accrued vacation	4,365	7,632	7,632
Other accrued expenses & other current liabilities	32,916	33,458	33,458
Total current liabilities	167,296	211,579	211,579
Revolving credit facility	119,100	142,387	142,387
Term loan	35,000
Promissory note	13,738	13,738
Total debt	154,100	156,125	156,125
Current maturities	(13,738)	(13,738)
Debt issuance costs	(847)
Long-term debt	153,253	142,387	142,387
Deferred rent	39,708	40,860	40,860
Other liabilities	33,897	40,214	40,214
Total liabilities	394,154	435,040	435,040
Common stock	479	480	480
Additional paid-in capital	60,172	56,002	56,002
Retained earnings (accumulated deficit)	(13,853)	(7,918)	(7,918)
Accumulated other comprehensive income (loss)	253	(246)	(246)
Total shareholders' equity (deficit)	47,051	48,318	48,318

Restated to reflect adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606)

Recent Dividends:
1. Stein Mart, Inc. common.

ExDate	Amt	Declared	Record	Payable
12/29/2015	0.07	12/09/2015	12/31/2015	01/15/2016
03/30/2016	0.07	03/15/2016	04/01/2016	04/15/2016
06/28/2016	0.07	06/21/2016	06/30/2016	07/15/2016
09/27/2016	0.07	09/16/2016	09/29/2016	10/14/2016
12/28/2016	0.07	12/15/2016	12/30/2016	01/13/2017
03/29/2017	0.07	03/14/2017	03/31/2017	04/14/2017
	0.00			07/14/2017
	0.00			04/14/2017

Annual Dividends:
1. Stein Mart, Inc. common.
 2016 0.30
 2017 0.15

STV GROUP, INC. Official Changes On Mar. 26, 2019, Co.'s Senior Counsel, Kristina S. Raevska has been promoted to the position of Vice President of Co.

SYNALLOY CORP. Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Net sales	280,841,419	201,147,682	138,565,782
Cost of sales	229,604,080	173,066,732	121,661,303
Gross profit	51,237,339	28,080,950	16,904,479
Selling, general & administrative expense	27,691,874	24,874,589	22,672,872
Acquisition related			

costs	1,211,797	794,983	106,227
Earn-out adjustments	1,430,682	688,523	...
Loss (gain) on sale-leaseback	(334,273)	(334,273)	2,371,778
Operating income (loss)	21,237,259	2,057,128	(8,246,398)
Interest expense	2,210,506	985,366	932,572
Change in fair value of interest rate swap	19,484	96,696	(12,997)
Other income (expense), net	(2,572,598)	310,043	...
Income (loss) before income taxes	16,473,639	1,478,501	(9,191,967)
Current income taxes provision (benefit) - federal	3,468,673	1,067,490	(980,495)
Current income taxes provision (benefit) - state	290,459	106,832	190,230
Total current income taxes provision (benefit)	3,759,132	1,174,322	(790,265)
Deferred income taxes provision (benefit) - federal	(107,879)	(1,043,384)	(1,329,302)
Deferred income taxes provision (benefit) - state	(275,043)	6,201	(78,433)
Total deferred income taxes provision (benefit)	(382,922)	(1,037,183)	(1,407,735)
Provision for income taxes (benefit from)	3,376,210	137,139	(2,198,000)
Net income (loss) from continuing operations	13,097,429	1,341,362	(6,993,967)
Net income (loss) from discontinued operations, net of tax	(99,334)
Net income (loss)	13,097,429	1,341,362	(7,093,301)
Weighted average shares outstanding - basic	8,806,079	8,704,730	8,649,745
Weighted average shares outstanding - diluted	8,877,609	8,727,487	8,649,745
Year end shares outstanding	8,875,721	8,733,231	8,669,310
Income (loss) per share from continuing operations - basic	\$1.49	\$0.15	\$(0.81)
Income (loss) per share from discontinued operations - basic	\$(0.01)
Net income (loss) per share - basic	\$1.49	\$0.15	\$(0.82)
Income (loss) per share from continuing operations - diluted	\$1.48	\$0.15	\$(0.81)
Income (loss) per share from discontinued operations - diluted	\$(0.01)
Net income (loss) per share - diluted	\$1.48	\$0.15	\$(0.82)
Dividends declared & paid	\$0.25	\$0.13	...
Total number of employees	607	533	412
Number of common shareholders	442	468	525

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):	
	2018
	(revised)
Cash & cash equivalents	2,220,272
Accounts receivable, gross	41,234,358
Less allowance for doubtful accounts	169,107
Accounts receivable, net	41,065,251
Raw materials	59,778,767
Work-in-process	21,033,532
Finished goods	33,389,087
Total inventories, net	114,201,386
Prepaid expenses & other current assets	9,983,416
Total current assets	167,470,325
Land	62,916
Leasehold improvements	1,162,942
Buildings	412,301
Machinery, fixtures & equipment	91,514,620
Machinery & equipment under capital lease	1,416,114
Construction-in-progress	3,643,795
Property, plant & equipment, gross	98,212,688
Less accumulated depreciation	57,288,233
Property, plant & equipment, net	40,924,455
Goodwill	9,799,992
Intangible assets, net	9,696,112
Deferred charges, net & other non-current assets	507,962
Total assets	228,398,846
Accounts payable	25,073,698
Accrued salaries, wages & commissions	5,208,495
Accrued taxes, other than income taxes	852,116
Current portion of earn-out liability	2,906,822
Advances from customers	177,518
Accrued insurance	321,000
Accrued professional fees	256,296
Warranty reserve	38,020
Accrued benefit plans	265,605
Accrued insurance financing liability	347,440
Customer rebate liability	701,361
Current portion, environmental reserves	...
Current portion, deferred gain sale-leaseback	334,273
Current portion of capital lease obligation	267,028
Other accrued items	487,712
Total current liabilities	37,237,384
Revolving line of credit	76,405,458
Long-term portion of earn-out liability	4,702,562
Long-term deferred sale-leaseback gain	5,599,077
Deferred income taxes	252,988
Other long-term liabilities	1,717,291
Common stock	10,300,000
Capital in excess of par value	36,520,840
Retained earnings (accumulated deficit)	68,965,410
Accumulated other comprehensive income (loss)	...
Less: cost of common stock in treasury	13,302,164
Total shareholders' equity (deficit)	102,484,086

10/24/2017	0.13	10/05/2017	10/25/2017	11/06/2017
11/29/2018	0.25	11/16/2018	11/30/2018	12/12/2018

Annual Dividends:
I. Synalloy Corp. common.

2017.....0.13 2018.....0.25

SYNDAX PHARMACEUTICALS INC

Offering On Mar. 27, 2019, Co. announced that it has entered into an agreement with Biotechnology Value Fund, L.P. ("BVF") and other leading life sciences investors for the purchase of 4,366,666 shares of common stock at a purchase price of \$6.00 per share, representing a premium of 30% to the share price as of market close on Mar. 26, as well as warrants to purchase up to 2,183,331 shares of common stock at an exercise price of \$12.00 per share, and warrants to purchase up to 2,183,335 shares of common stock at an exercise price of \$18.00 per share. Co. anticipates aggregate gross proceeds from the offering will be approximately \$26,200,000 (excluding any proceeds to be received upon exercise of the warrants). Closing of the transaction is expected to occur on or about Mar. 29, 2019.

TEXAS INSTRUMENTS INC.

Annual Meeting Development On Mar. 26, 2019, Co. announced that its Annual Meeting of Stockholders will be held on Apr. 25, 2019 at 8:30 a.m. (Central time), in the auditorium on Co.'s property at 12500 TI Boulevard, Dallas, TX.

TILRAY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	2016
		(revised)	(revised)
Revenue	43,130	20,538	12,644
Cost of sales	28,855	9,161	9,974
Gross margin	14,275	11,377	2,670
Research & development expenses	4,264	3,171	1,136
Sales & marketing expenses	15,366	7,164	3,599
General & administrative expenses	31,307	8,401	4,890
Stock-based compensation expense	20,988	139	94
Operating income (loss)	(57,650)	(7,498)	(7,049)
Foreign exchange gain (loss), net	(7,234)	1,363	186
Interest expense, net	9,110	1,686	1,019
Other income (expense), net	1,820	12	(1)
Income before income taxes expense (recovery)			
- Canada	(25,333)	(7,411)	(7,883)
Income before income taxes expense (recovery)			
- U.S.	(42,418)
Income before income taxes expense (recovery)			
- Portugal	(2,208)
Income before income taxes expense (recovery)			
- other countries	(2,215)	(398)	...
Income (loss) before income taxes expense (recovery)	(72,174)	(7,809)	(7,883)
Deferred income tax expense (recovery)	(4,485)
Current income tax expense (recovery)	34
Net income (loss)	(67,723)	(7,809)	(7,883)
Weighted average shares outstanding - basic	83,010	75,000	75,000
Weighted average shares outstanding			

Recent Dividends:

I. Synalloy Corp. common.

ExDate Amt Declared Record Payable

Ⓜ Reclassified to conform with 2018 presentation; Ⓜ Reclassified to conform with 2017 presentation; Ⓜ As of March 12, 2019; Ⓜ As of March 9, 2018; Ⓜ As of March 10, 2017

- diluted	83,010	75,000	75,000
Year end shares outstanding	93,171
Net earnings (loss) per share - basic	\$(0.82)	\$(0.10)	\$(0.11)
Net earnings (loss) per share - diluted	\$(0.82)	\$(0.10)	\$(0.11)
Number of full time employees	...	313	...
Number of part time employees	...	17	...
Total number of employees	688	330	...
Number of class 2 common stockholders	85

Reclassified to conform with 2018 presentation; As Is; As of June 4, 2018; Approximately; As of March 25, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016 (revised)
Cash & cash equivalents	487,255	2,323	...
Short-term investments	30,335
Accounts receivable, gross	16,817	991	8
Allowance	292	8	...
Accounts receivable, net	16,525	983	...
Other receivables	969	1,131	...
Raw materials	2,132	163	...
Work-in-process - dry cannabis	9,982	1,396	...
Work-in-process - cannabis extracts	2,830	30	...
Finished goods - dry cannabis	113	3,501	...
Finished goods - cannabis extracts	1,083	2,158	...
Finished goods - accessories	71	173	...
Inventory	16,211	7,421	...
Prepaid expenses & other current assets	3,007	545	...
Total current assets	554,302	12,403	...
Land	4,498	2,547	...
Buildings & leasehold improvements	51,111	19,569	...
Laboratory & manufacturing equipment	6,131	2,815	...
Office & computer equipment	970	571	...
Assets under capital lease	9,661	9,191	...
Construction in process	15,343	9,872	...
Property & equipment, gross	87,714	44,565	...
Less: accumulated depreciation & amortization	7,500	4,580	...
Property & equipment, net	80,214	39,985	...
Intangible assets, net	4,486	934	...
Investments	16,911
Deposits & other assets	754	626	...
Total assets	656,667	53,948	...
Accounts payable	10,649	5,563	...
Accrued expenses & other current liabilities	14,818	2,021	...
Accrued obligations under capital lease	470	379	...
Current portion of long-term debt	...	9,432	...
Privateer Holdings debt facilities	...	32,826	...
Total current liabilities	25,937	50,221	...
Accrued obligations under capital lease	8,286	8,579	...
Deferred tax liability	4,424
Convertible senior notes due 2023, net of issuance cost	420,367
Total liabilities	459,014	58,800	...
Class 1 common stock	2
Class 2 common stock	8

Additional paid-in capital	302,057	31,736	...
Accumulated other comprehensive income (loss)	3,763	3,866	...
Retained earnings (accumulated deficit)	(108,177)	(40,454)	...
Total stockholders' equity (deficit)	197,653	(4,852)	...

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Tiltray Inc class 1 common. No dividends paid.

2. Tiltray Inc class 2 common. No dividends paid.

Annual Dividends:

1. Tiltray Inc class 1 common. No dividends paid.

2. Tiltray Inc class 2 common. No dividends paid.

TONIX PHARMACEUTICALS HOLDING CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Research & development expense	17,558,000	13,342,000	28,533,000
General & administrative expense	8,764,000	7,949,000	10,436,000
Total costs & expenses	26,322,000	21,291,000	38,969,000
Operating income (loss)	(26,322,000)	(21,291,000)	(38,969,000)
Interest income, net	233,000	168,000	127,000
Net income (loss)	(26,089,000)	(21,123,000)	(38,842,000)
Preferred stock deemed dividend	3,266,000
Net income (loss) available to common stockholders	(29,355,000)	(21,123,000)	...
Weighted average shares outstanding			
- basic	1,094,867	666,509	252,102
Weighted average shares outstanding - diluted	1,094,867	666,509	252,102
Year end shares outstanding	3,251,970	785,874	391,918
Net income (loss) per common share - basic	\$(26.81)	\$(31.70)	\$(154.10)
Net income (loss) per common share - diluted	\$(26.81)	\$(31.70)	\$(154.10)
Number of full time employees	12	14	...
Number of common stockholders	104	106	...
Foreign currency translation adjustments	...	(5,000)	(17,000)

Reclassified to conform with 2018 presentation; Restated to reflect the adoption of FASB ASU No 2016-18, (Topic 230); Adjusted for 1-for-10 stock split, November 28, 2018; Shares increased due to issuance of common stock related to restricted stock, 2017 Purchase Agreement, at-the-market offering, commitment shares, warrants and conversion of convertible preferred stock; As of March 13, 2019; As of March 1, 2018; As of March 7, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash	25,034,000	25,496,000
Contract-related	525,000	494,000
Other prepaid expenses & other current assets	497,000	453,000
Prepaid expenses & other

current assets	1,022,000	947,000
Total current assets	26,056,000	26,443,000
Office furniture & equipment	317,000	311,000
Leasehold improvements	23,000	23,000
Total property, plant & equipment	340,000	334,000
Less: accumulated depreciation & amortization	297,000	243,000
Property & equipment, net	43,000	91,000
Restricted cash	100,000	89,000
Intangible asset	120,000	120,000
Security deposits	...	11,000
Total assets	26,319,000	26,754,000
Accounts payable	1,404,000	1,296,000
Contract-related	475,000	519,000
Compensation & compensation-related expenses	614,000	65,000
Professional fees & other accrued expenses	162,000	246,000
Accrued expenses	1,251,000	830,000
Total current liabilities	2,655,000	2,126,000
Deferred rent payable	...	12,000
Total liabilities	2,655,000	2,138,000
Common stock	3,000	1,000
Additional paid in capital	212,154,000	186,990,000
Retained earnings (accumulated deficit)	(188,452,000)	(162,363,000)
Accumulated other comprehensive income (loss)	(41,000)	(12,000)
Total stockholders' equity (deficiency)	23,664,000	24,616,000

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Tonix Pharmaceuticals Holding Corp common. No dividends paid.

Annual Dividends:

1. Tonix Pharmaceuticals Holding Corp common. No dividends paid.

TONIX PHARMACEUTICALS HOLDING CORP

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2018 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Tonix Pharmaceuticals Holding Corp. and subsidiaries (the "Company") as of December 31, 2018 and 2017, and the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2018 and 2017, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has continuing losses and negative cash flows from operating activities which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ULTA BEAUTY INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	02/02/19	02/03/18 (revised)	01/28/17 (revised)
Net sales	6,716,615	5,884,506	4,854,737
Cost of sales	4,307,304	3,787,697	3,107,508
Gross profit	2,409,311	2,096,809	1,747,229
Selling, general & administrative expenses	1,535,464	1,287,232	1,073,834

Other current liabilities	14,770	10,657	
Total current liabilities	139,298	207,347	
Bank borrowings, net of current portion	331,549	39,893	
Deferred tax liability	15,834	9,981	
Deferred rent & other liabilities	27,808	5,886	
Total liabilities	514,489	263,107	
Common stock	40	34	
Additional paid-in capital	290,424	188,639	
Common shares held in treasury, at cost	3,337	3,337	
Retained earnings (accumulated deficit)	149,718	113,122	
Accumulated other comprehensive income (loss)	(547)	1,847	
Ultra Clean Holdings, Inc. stockholders' equity	436,298	300,305	
Noncontrolling interest	14,690	...	
Total stockholders equity	450,988	300,305	

- diluted	4,594,319	4,594,319	4,594,319
Year end shares outstanding	4,594,319	4,594,319	4,594,319
Net earnings (loss) per share - basic	\$0.95	\$0.84	\$0.56
Net earnings (loss) per share - diluted	\$0.95	\$0.84	\$0.56
Dividends per common share	\$1.05	\$1.42	...
Number of full time employees	23	22	29
Number of part time employees	6	9	4
Total number of employees	29	31	33
Number of common stockholders	450	706	734

12/08/2017	0.50	11/29/2017	12/11/2017	12/18/2017
12/08/2017	0.50	11/29/2017	12/11/2017	12/18/2017
05/29/2018	0.50	05/16/2018	05/30/2018	06/13/2018
12/07/2018	0.55	11/28/2018	12/10/2018	12/17/2018

Annual Dividends:
1. United-Guardian, Inc. common.
 2016.....0.75 2017.....1.42 2018.....1.05

UNITED-GUARDIAN, INC.
New Accountant On Mar. 21, 2019, Co. dismissed Raich Ende Malter & Co. LLP as its independent public accounting firm. On Mar. 25, 2019, Co. engaged Baker Tilly Virchow Krause, LLP as its new independent public accounting firm.

UNIVERSAL LOGISTICS HOLDINGS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):	2018	2017 (revised)	2016 (revised)
Truckload services	313,811	302,914	281,213
Brokerage services	367,579	278,187	219,898
Intermodal services	251,074	153,726	143,004
Dedicated services	121,023	93,505	95,332
Value-added services	408,221	388,333	333,304
Total operating revenues	1,461,708	1,216,665	1,072,751
Purchased transportation & equipment rent	716,019	577,485	509,775
Direct personnel & related benefits	354,654	314,364	265,316
Operating supplies & expenses	122,736	115,420	103,013
Commission expense	37,381	33,213	32,350
Occupancy expense	30,701	30,575	31,923
General & administrative expenses	31,523	31,518	29,368
Insurance & claims expense	30,475	41,881	17,724
Depreciation & amortization expense	54,425	46,995	36,702
Total operating expenses	1,377,914	1,191,451	1,026,171
Income from operations	83,794	25,214	46,580
Interest income	76	92	157
Interest expense	14,669	9,538	8,266
Other non-operating income (expense), net	188	1,373	934
Income before provision for income taxes - U.S. domestic	71,441	28,360	40,172
Income before provision for income taxes - Foreign	2,052	(11,219)	(767)
Income before income taxes	69,389	17,141	39,405
Current provision (benefit) for income taxes - U.S. federal	7,266	5,394	7,432
Current provision (benefit) for income taxes - state	3,556	2,227	748
Current provision (benefit) for income taxes - foreign	427	688	284
Current provision for income taxes	11,249	8,309	8,464
Deferred provision (benefit) for income taxes - U.S. federal	5,873	(14,264)	6,521

Reclassified to conform with 2018 presentation

Recent Dividends:
1. Ultra Clean Holdings Inc common.

No dividends paid.

Annual Dividends:
1. Ultra Clean Holdings Inc common.

No dividends paid.

ULTRA CLEAN HOLDINGS INC

Official Changes On Mar. 25, 2019, Co. announced the appointment of Mr. Vijayan Chinnasami as Chief Operating Officer.

UNITED-GUARDIAN, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Gross sales	14,458,055	13,434,460	11,144,462
Sales allowances & returns	688,654	466,255	367,595
Net sales	13,769,401	12,968,205	10,776,867
Cost of sales	5,667,295	5,301,352	4,882,644
Operating expenses	2,122,746	1,785,160	1,852,833
Research & development	399,517	646,079	651,828
Total costs & expenses	8,189,558	7,732,591	7,387,305
Income (loss) from operations	5,579,843	5,235,614	3,389,562
Investment income	231,986	281,868	306,505
Gain (loss) on sale of marketable securities	(333,138)	33,297	...
Gain (loss) on trade-in of equipment	(12,837)
Total other income & expense (net)	(113,989)	315,165	...
Income (loss) before provision for income taxes	5,465,854	5,550,779	3,696,067
Current income taxes - federal	893,768	1,738,132	1,058,714
Current income taxes (benefit) - state	27	117	(3,501)
Total current income taxes	893,795	1,738,249	1,055,213
Deferred income taxes (benefit) - federal	219,728	(31,760)	59,712
Total deferred income taxes (benefit)	219,728	(31,760)	59,712
Provision for income taxes	1,113,523	1,706,489	1,114,925
Net income (loss)	4,352,331	3,844,290	2,581,142

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash & cash equivalents	550,135	724,721
Marketable securities	7,622,196	7,721,568
Accounts receivable, gross	1,689,462	1,926,635
Less: allowance for doubtful accounts	16,895	21,220
Accounts receivable, net	1,672,567	1,905,415
Raw materials	467,842	363,739
Work in process	30,057	39,004
Finished products	984,252	937,780
Inventories (net)	1,482,151	1,340,523
Prepaid expenses & other current assets	159,364	157,964
Prepaid income taxes	200,687	331
Total current assets	11,687,100	11,850,522
Land	69,000	69,000
Factory equipment & fixtures	4,406,174	4,363,978
Building & improvements	2,801,582	2,793,402
Total property, plant & equipment	7,276,756	7,226,380
Less accumulated depreciation	6,448,831	6,283,493
Total property, plant, & equipment, net	827,925	942,887
Other assets, net	29,647	59,471
Total assets	12,544,672	12,852,880
Accounts payable	186,797	354,285
Accrued bonuses	242,000	200,000
Accrued distribution fees	315,242	254,863
Payroll & related expenses	159,385	152,903
Accrued annual report	66,618	62,510
Accrued audit fees	43,668	43,268
Accrued reserve for outdated material	160,533	127,768
Accrued sales rebates	15,000	12,000
Accrued computer services	16,593	...
Other accrued expenses	21,596	28,015
Income taxes payable	...	55,848
Dividends payable	138,719	130,923
Total current liabilities	1,366,151	1,422,383
Deferred income taxes	253,583	33,855
Common stock	459,432	459,432
Accumulated other comprehensive income (loss)	...	466,025
Retained earnings (accumulated deficit)	10,465,506	10,471,185
Total stockholders' equity	10,924,938	11,396,642

Recent Dividends:
1. United-Guardian, Inc. common.

ExDate	Amt	Declared	Record	Payable
05/27/2016	0.35	05/18/2016	06/01/2016	06/15/2016
12/08/2016	0.40	11/30/2016	12/12/2016	12/19/2016
05/25/2017	0.42	05/17/2017	05/30/2017	06/12/2017

Deferred provision (benefit) for income taxes - state	(855)	(1,113)	140	Other receivables	19,130	17,511	equity (deficit)	209,299	168,765
Deferred provision (benefit) for income taxes - foreign	944	(3,944)	36	Due from affiliates	5,247	2,685			
Deferred provision for income taxes	5,962	(19,321)	6,697	Prepaid income taxes	...	4,515			
Income tax expense (benefit)	17,211	(11,012)	15,161	Prepaid expenses & other current assets	19,830	16,103			
Net income	52,178	28,153	24,244	Total current assets	275,258	228,666			
Weighted average shares outstanding - basic	28,383	28,425	28,411	Transportation equipment	267,094	236,667			
Weighted average shares outstanding - diluted	28,390	28,428	28,411	Land, buildings & related assets	128,805	102,977			
Year end shares outstanding	28,379	28,382	28,430	Other operating assets	104,559	105,434			
Net earnings per common share - basic	\$1.84	\$0.99	\$0.85	Information technology equipment	26,135	23,985			
Net earnings per common share - diluted	\$1.84	\$0.99	\$0.85	Construction in process	7,960	3,903			
Dividends per common share	\$0.53	\$0.28	\$0.28	Property & equipment, gross	534,553	472,966			
Number of full time employees	²³ 6,275	Less accumulated depreciation	231,319	205,771			
Total number of employees	²³ 6,335	²³ 8,231	...	Property & equipment, net	303,234	267,195			
Number of common stockholders	²³ ²³ 9	²³ ²⁴ ²⁶ 11	²³ ²⁴ ²⁷ 11	Goodwill	145,152	74,484			
Foreign currency translation adjustments	(1,161)	Intangible assets, gross	176,399	88,160			
				Less: accumulated amortization - intangible assets	62,624	56,901			
				Intangible assets, net	113,775	31,259			
				Deferred income taxes	2,549	4,154			
				Other assets	3,179	4,834			
				Total assets	843,147	610,592			
				Accounts payable	92,019	84,380			
				Due to affiliates	17,764	11,964			
				Accrued payroll related items	11,476	9,854			
				Accrued driver escrow liabilities	3,923	3,785			
				Accrued commissions, taxes & other	9,727	10,490			
				Insurance & claims	31,679	37,727			
				Income taxes payable	2,678	...			
				Current portion of long-term debt	51,903	40,870			
				Total current liabilities	221,169	199,070			
				Asset-based loan (ABL) facility	...	70,225			
				Westport Axle Corporation (Westport) facility - term loan	...	22,500			
				Credit & security agreement - revolver	80,588	...			
				Credit & security agreement - term loan	150,000	...			
				Equipment financing	126,162	112,205			
				Real estate financing	45,864	44,309			
				Margin facility	541	...			
				Unamortization debt issuance costs	(2,703)	(1,261)			
				Total debts	400,452	247,978			
				Less current portion of long-term debt	51,903	40,870			
				Long-term debt, net of current portion	348,549	207,108			
				Deferred income taxes	59,228	32,361			
				Other long-term liabilities	4,902	3,288			
				Total long-term liabilities	412,679	242,757			
				Common stock	30,967	30,943			
				Paid-in capital	4,230	3,841			
				Treasury stock, at cost	52,462	51,532			
				Retained earnings	231,525	186,226			
				Accumulated other comprehensive income (loss) - unrealized holding gain (loss) on available-for-sale securities	...	²³ 3,823			
				Accumulated other comprehensive income (loss) - interest rate swaps	²³ 298	²³ 197			
				Accumulated other comprehensive income (loss) - foreign currency translation adjustments	(5,259)	(4,733)			
				Total shareholders'					

¹ Reclassified to conform with 2017 presentation; ² Including related party amounts - Truckload services: \$900,000; ³ Including related party amounts - Truckload services: \$1,100,000; ⁴ Including related party amounts - Truckload services: \$1,090,000; ⁵ Including related party amounts - Purchased transportation & equipment rent: \$1,240,000; ⁶ Including related party amounts - Purchased transportation & equipment rent: \$35,000; ⁷ Including related party amounts - Purchased transportation & equipment rent: \$233,000; ⁸ Including related party amounts - Direct personnel and related benefits: \$38,811,000; ⁹ Including related party amounts - Direct personnel and related benefits: \$35,743,000; ¹⁰ Including related party amounts - Direct personnel and related benefits: \$26,267,000; ¹¹ Including related party amounts - Operating supplies and expenses: \$2,428,000; ¹² Including related party amounts - Operating supplies and expenses: \$2,652,000; ¹³ Including related party amounts - Operating supplies and expenses: \$2,656,000; ¹⁴ Including related party amounts - Occupancy expense: \$14,295,000; ¹⁵ Including related party amounts - Occupancy expense: \$17,046,000; ¹⁶ Including related party amounts - Occupancy expense: \$17,174,000; ¹⁷ Including related party amounts - General and administrative expenses: \$7,407,000; ¹⁸ Including related party amounts - General and administrative expenses: \$6,742,000; ¹⁹ Including related party amounts - General and administrative expenses: \$5,557,000; ²⁰ Including related party amounts - Insurance and claims expense: \$14,246,000; ²¹ Including related party amounts - Insurance and claims expense: \$16,281,000; ²² Including related party amounts - Insurance and claims expense: \$15,362,000; ²³ As is; ²⁴ Approximately; ²⁵ As of March 4, 2019; ²⁶ As of March 5, 2018; ²⁷ As of March 6, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	¹ 2017
	(revised)	
Cash & cash equivalents	5,727	1,672
Marketable securities	9,333	15,144
Accounts receivable, gross	217,763	172,366
Less: allowance for doubtful accounts	1,772	1,330
Accounts receivable, net	215,991	171,036

¹ Reclassified to conform with 2018 presentation; ² Net of income taxes - Accumulated other comprehensive income (loss) - unrealized holding gain (loss) on available-for-sale securities: \$1,090,000; ³ Net of income taxes - Interest rate swaps: \$94,000; ⁴ Net of income taxes - Interest rate swaps: \$63,000

Recent Dividends:

1. Universal Logistics Holdings Inc common.

ExDate	Amt	Declared	Record	Payable
03/03/2016	0.07	02/25/2016	03/07/2016	03/17/2016
05/05/2016	0.07	04/28/2016	05/09/2016	05/19/2016
08/04/2016	0.07	07/28/2016	08/08/2016	08/18/2016
11/03/2016	0.07	10/27/2016	11/07/2016	11/17/2016
03/02/2017	0.07	02/23/2017	03/06/2017	03/16/2017
05/04/2017	0.07	04/27/2017	05/08/2017	05/18/2017
08/03/2017	0.07	07/27/2017	08/07/2017	08/17/2017
11/03/2017	0.07	10/26/2017	11/06/2017	11/16/2017
03/02/2018	0.07	02/22/2018	03/05/2018	03/15/2018
05/04/2018	0.10	04/26/2018	05/07/2018	05/17/2018
08/03/2018	0.10	07/26/2018	08/06/2018	08/16/2018
11/02/2018	0.10	10/25/2018	11/05/2018	11/15/2018
03/01/2019	0.10	02/21/2019	03/04/2019	03/14/2019
03/01/2019	0.11	02/21/2019	03/04/2019	03/14/2019

Annual Dividends:

1. Universal Logistics Holdings Inc common.

2016	0.28	2017	0.28	2018	0.39
2019	0.22				

US ECOLOGY, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2018	2017	2016
		(revised)	(revised)
Revenue	565,928	504,042	477,665
Direct operating costs	395,834	350,915	330,070
Gross profit (loss)	170,094	153,127	147,595
Selling, general & administrative expenses	92,340	84,466	77,566
Impairment charges	3,666	8,903	...
Operating income (loss)	74,088	59,758	70,029
Interest income	215	62	96
Interest expense	12,130	18,157	17,317
Foreign currency gain (loss)	55	516	(138)
Gain (loss) on divestiture	2,034
Other income (expense)	2,630	791	597
Total other income (expense)	(9,230)	(16,788)	(14,728)
Income (loss) before income taxes - domestic	46,147	26,051	47,859
Income (loss) before income taxes - foreign	18,711	16,919	7,442
Income (loss) before income taxes	64,858	42,970	55,301
Current U.S. federal income taxes	2,239	11,157	17,866
Current state income taxes	2,368	2,482	3,324
Current foreign income taxes	4,746	5,398	2,459
Total current income taxes	9,353	19,037	23,649
Deferred U.S. federal income taxes	5,675	(27,029)	(1,790)
Deferred state income taxes	172	2,323	(275)
Deferred foreign income taxes	63	(726)	(535)
Total deferred income taxes	5,910	(25,432)	(2,600)

Income tax expense (benefit).....	15,263	(6,395)	21,049	Treasury stock, at cost.....	370	68	foreign.....	9,842	24,308	18,120	
Net income (loss)	49,595	49,365	34,252	Foreign currency translation adjustments.....	(14,697)	(8,603)	Total current provision for income taxes.....	10,559	29,887	19,713	
Weighted average shares outstanding - basic.....	21,888	21,758	21,704	Unrealized gain (loss) on interest rate hedge.....	906	(501)	Deferred provision for (benefit from) income taxes - federal.....	(4,099)	4,734	(8,179)	
Weighted average shares outstanding - diluted.....	22,047	21,902	21,789	Accumulated other comprehensive income (loss).....	(13,791)	(9,104)	Deferred provision for (benefit from) income taxes - state.....	(2,687)	(58)	(842)	
Year end shares outstanding.....	22,032	21,846	21,773	Total stockholders' equity.....	359,217	324,077	Deferred provision for (benefit from) income taxes - foreign.....	3,769	(12,209)	(7,920)	
Net income (loss) per share - basic.....	\$2.27	\$2.27	\$1.58	Recent Dividends:							
Net income (loss) per share - diluted.....	\$2.25	\$2.25	\$1.57	1. US Ecology, Inc. common. No dividends paid.							
Dividends per common share.....	\$0.72	\$0.72	...	Annual Dividends:							
Total number of employees.....	1,700	1,550	1,450	1. US Ecology, Inc. common. No dividends paid.							
Number of beneficiary stockholders.....	19,537	14,079	13,923	VERINT SYSTEMS, INC							
Foreign currency translation adjustments.....	(6,094)	4,046	1,379	Annual Report							
				Consolidated Income Statement, Years Ended Jan. 31 (\$000):							
				2019	2018	2017					
					(revised)	(revised)					
				Product revenue.....	454,650	399,662	378,504				
				Service & support revenue.....	775,097	735,567	683,602				
				Total revenue.....	1,229,747	1,135,229	1,062,106				
				Cost of revenue - product.....	129,922	131,989	123,279				
				Cost of revenue - service & support.....	293,888	276,582	261,978				
				Amortization of acquired technology & backlog.....	25,403	38,216	37,372				
				Total cost of revenue.....	449,213	446,787	422,629				
				Gross profit.....	780,534	688,442	639,477				
				Research & development, net.....	209,106	190,643	171,070				
				Selling, general & administrative.....	426,183	414,960	406,952				
				Amortization of other acquired intangible assets.....	31,010	34,209	44,089				
				Total operating expenses.....	666,299	639,812	622,111				
				Operating income (loss).....	114,235	48,630	17,366				
				Interest income.....	4,777	2,477	1,048				
				Interest expense.....	37,344	35,959	34,962				
				Gains (losses) on early retirements of debt.....	...	(2,150)	...				
				Foreign exchange gains (losses), net.....	(5,519)	6,760	(2,743)				
				Gain (losses) on derivative financial instruments, net.....	2,511	(17)	(322)				
				Other expense, net.....	898	841	3,861				
				Total other income (expense), net.....	(36,473)	(29,730)	(40,840)				
				Income (loss) before provision for income taxes - domestic.....	(12,927)	(44,502)	(60,722)				
				Income (loss) before provision for income taxes - foreign.....	90,689	63,402	37,248				
				Income (loss) before provision for income taxes.....	77,762	18,900	(23,474)				
				Current provision for (benefit from) income taxes - federal.....	(1,582)	4,364	604				
				Current provision for (benefit from) income taxes - state.....	2,299	1,215	989				
				Current provision for income taxes -							
Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):											
				2018	2017						
				(revised)	(revised)						
Cash & cash equivalents.....	31,969	27,042									
Trade receivables.....	118,909	96,760									
Unbilled revenue.....	26,538	16,176									
Other receivables.....	2,241	637									
Allowance for doubtful accounts.....	2,998	2,796									
Prepaid expenses & other current assets.....	10,938	9,138									
Income taxes receivable.....	7,071	...									
Total current assets.....	194,668	146,957									
Cell development costs.....	146,155	142,144									
Land & improvements.....	50,481	36,499									
Buildings & improvements.....	91,358	87,034									
Railcars.....	17,299	17,299									
Vehicles & other equipment.....	154,014	122,697									
Construction in progress.....	14,554	23,334									
Total property & equipment, gross.....	473,861	429,007									
Accumulated depreciation & amortization.....	215,418	194,575									
Property & equipment, net.....	258,443	234,432									
Restricted cash & investments.....	4,941	5,802									
Intangible assets, net.....	279,666	222,812									
Goodwill.....	207,177	189,373									
Other assets.....	3,003	2,700									
Total assets.....	947,898	802,076									
Accounts payable.....	17,754	14,868									
Deferred revenue.....	10,451	8,532									
Accrued liabilities.....	35,524	22,888									
Accrued salaries & benefits.....	16,732	14,242									
Income taxes payable.....	505	2,970									
Current portion of closure & post-closure obligations.....	2,266	2,330									
Total current liabilities.....	83,232	65,830									
Long-term closure & post-closure obligations.....	76,097	73,758									
Revolving credit facility.....	364,000	277,000									
Other long-term liabilities.....	2,146	3,828									
Deferred income taxes, net.....	63,206	57,583									
Total liabilities.....	588,681	477,999									
Common stock.....	220	218									
Additional paid-in capital.....	183,834	177,498									
Retained earnings (accumulated deficit).....	189,324	155,533									
				2019	2018	2017					
				(revised)	(revised)	(revised)					
Consolidated Balance Sheet, Years Ended Jan. 31 (\$000):											
				2019	2018	2017					
				(revised)	(revised)	(revised)					
Cash & bank time deposits.....				...	337,756	...					
Money market funds.....				...	186	...					
Cash & cash equivalents.....				369,975	337,942	...					
Restricted cash & cash equivalents & restricted bank time deposits.....				42,262	33,303	...					
Corporate debt securities (available for sale).....				...	2,002	...					
Bank time deposits.....				...	4,564	...					
Short-term investments.....				32,329	6,566	...					
Accounts receivable, gross.....				379,463	298,524	...					
Less: allowance for doubtful accounts.....				3,800	2,200	...					
Accounts receivable, net.....				375,663	296,324	...					
Contract assets.....				63,389					
Raw materials.....				10,875	9,870	...					
Work-in-process.....				5,567	6,269	...					
Finished goods.....				8,510	3,732	...					
Inventories.....				24,952	19,871	...					
Deferred cost of revenue.....				10,302	6,096	...					
Prepaid expenses & other current assets.....				87,474	82,090	...					
Total current assets.....				1,006,346	782,192	...					
Land & buildings.....				10,632	10,276	...					
Leasehold improvements.....				31,694	29,793	...					
Software.....				51,950	54,032	...					

As is; Approximately; As of January 23, 2019; As of January 17, 2018; As of January 4, 2017

As is; Approximately; As of March 15, 2019; As of March 15, 2018; As of March 15, 2017

Equipment, furniture & other property & equipment	164,351	135,548	interest rate swap designated as hedge	(3,043)	...	provision (benefit) for income taxes	(4,809)	(1,210)	42
Property & equipment, gross	258,627	229,649	Foreign currency translation adjustments	(141,201)	(106,772)	Total deferred provision (benefit) for income taxes	(6,616)
Less: accumulated depreciation & amortization	158,493	140,560	Accumulated other comprehensive income (loss)	(145,225)	(103,460)	Change in valuation allowance	16,955	8,426	6,616
Property & equipment, net	100,134	89,089	Total Verint Systems Inc. stockholders' equity (deficit)	1,249,236	1,120,592	Provision (benefit) for income taxes	22	6	6
Goodwill	1,417,481	1,388,299	Noncontrolling interests	11,568	11,744	Net income (loss)	(61,104)	(59,601)	(26,979)
Intangible assets, gross	755,447	746,127	Total stockholders' equity	1,260,804	1,132,336	Accretion of redeemable convertible preferred stock	...	4,470	3,204
Less: total accumulated amortization	530,264	520,034				Net income (loss) attributable to common stockholders	(61,104)	(64,071)	(30,183)
Intangible assets, net	225,183	226,093	☐ Reclassified to conform with 2018 presentation			Weighted average shares outstanding			
Capitalized software development costs, net	13,342	9,228	Recent Dividends:			- basic	17,573	10,333	2,068
Long-term deferred cost of revenue	4,630	2,804	1. Verint Systems, Inc common.			Weighted average shares outstanding			
Deferred income taxes	21,040	30,878	No dividends paid.			- diluted	17,573	10,333	2,068
Long-term restricted cash & time deposits	23,193	28,402	2. Verint Systems, Inc series A convertible preferred.			Year end shares outstanding	19,335	16,159	2,621
Deferred commissions	29,815	...	No dividends paid.			Net income (loss) per share - basic	\$(3.48)	\$(6.20)	\$(14.59)
Deferred debt issuance costs, net	2,836	3,668	Annual Dividends:			Net income (loss) per share - diluted	\$(3.48)	\$(6.20)	\$(14.59)
Long-term security deposits	3,760	4,139	1. Verint Systems, Inc common.			Number of full time employees	☐☐317	☐☐219	☐☐150
Other assets	19,267	15,828	No dividends paid.			Number of part time employees	☐☐8
Total assets	2,867,027	2,580,620	2. Verint Systems, Inc series A convertible preferred.			Total number of employees	☐☐325
Accounts payable	71,621	84,639	VERITONE INC			Number of common stockholders	☐☐49	☐☐44	...
Compensation & benefits	96,703	83,216	Annual Report			Foreign currency translation adjustments	...	(1)	...
Billings in excess of costs & estimated earnings on uncompleted contracts	...	46,062	Consolidated Income Statement, Years Ended Dec. 31 (\$000):						
Income taxes	7,497	14,464		2018	☐2017 (revised)	☐2016 (revised)			
Professional & consulting fees	3,929	8,752	Net revenues	27,047	14,413	8,911			
Distributor & agent commissions	11,446	12,255	Cost of revenues	6,479	1,070	1,577			
Taxes other than income taxes	20,428	11,424	Gross profit (loss)	20,568	13,343	7,334			
Contingent consideration - current portion	28,415	13,187	Sales & marketing expenses	22,470	14,699	8,279			
Other accrued expenses & other current liabilities	40,063	30,905	Research & development expenses	22,095	13,970	7,900			
Current maturities of long-term debt	4,343	4,500	General & administrative expenses	37,993	31,436	14,935			
Contract liabilities	377,376	196,107	Total operating expenses	82,558	60,105	31,114			
Total current liabilities	661,821	505,511	Income (loss) from operations	(61,990)	(46,762)	(23,780)			
Convertible senior notes	400,000	400,000	Interest income (expense), net	803	(4,025)	...			
Term loan	418,625	422,875	Stock warrants issued	...	5,790	...			
Other debt	92	250	Write-off of deferred debt discounts & issuance costs	...	10,132	...			
Less: unamortized debt discounts & issuance costs	(36,589)	(50,141)	Gain (loss) on fair value change of warrant liability	184	7,114	...			
Less: current maturities	4,343	4,500	Other expense	79			
Long-term debt	777,785	768,484	Other income (expense), net	908	(12,833)	(3,193)			
Long-term contract liabilities	30,094	24,519	Income (loss) before provision for income taxes - U.S. of America	(61,169)	(59,595)	...			
Deferred income taxes	43,171	35,305	Income (loss) before provision for income taxes - foreign	87			
Unrecognized tax benefits, including interest & penalties	33,063	41,014	Income (loss) before provision for income taxes	(61,082)	(59,595)	(26,973)			
Contingent consideration - long-term portion	32,925	49,149	Current state provision (benefit) for income taxes	6	6	6			
Deferred rent expense	12,254	12,168	Current foreign provision (benefit) for income taxes	16			
Obligations for severance compensation	2,601	3,028	Total current provision (benefit) for income taxes	22	6	6			
Capital lease obligations - long-term portion	3,067	3,315	Deferred federal provision (benefit) for income taxes	(12,146)	(7,216)	(6,658)			
Other liabilities	9,442	5,791	Deferred state						
Total liabilities	1,606,223	1,448,284							
Common stock	67	65							
Additional paid-in capital	1,586,266	1,519,724							
Treasury stock, at cost	57,598	57,425							
Retained earnings (accumulated deficit)	(134,274)	(238,312)							
Unrealized gains on derivative financial instruments designated as hedges, net	(981)	3,312							
Unrealized gain on									

☐ Reclassified to conform with 2018 presentation; ☐ Reclassified to conform with 2017 presentation; ☐ As is; ☐ As of February 28, 2019; ☐ As of February 28, 2018; ☐ As of March 31, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	☐2017 (revised)
Cash & cash equivalents	37,539	29,545
Marketable securities	13,565	39,598
Accounts receivable, gross	29,182	7,729
Less: allowance for doubtful accounts	40	38
Accounts receivable, net	29,142	7,691
Expenditures billable to clients	2,695	4,163
Prepaid expenses & other current assets	3,579	2,808
Total current assets	86,520	83,805
Property & equipment	2,019	378
Leasehold improvements	2,875	27
Construction in progress	...	435
Property, equipment & improvements, gross	4,894	840
Less: accumulated depreciation	886	160
Property, equipment & improvements, net	4,008	680
Intangible assets, net	20,480	3,154
Goodwill	5,509	139
Other assets	1,237	780
Total assets	117,754	88,558
Accounts payable	28,714	13,338
Accrued media payments	7,416	5,999
Client advances	9,639	3,477
Accrued compensation	6,570	3,117
Other accrued liabilities	3,746	1,325
Total current liabilities	56,085	27,256
Other liabilities	1,386	...
Total liabilities	57,471	27,256
Common stock	19	16
Additional paid-in capital	230,674	170,728

Retained earnings (accumulated deficit)	(170,411)	(109,307)
Accumulated other comprehensive income (loss)	1	(135)
Total stockholders' equity (deficit)	60,283	61,302

[¶] Reclassified to conform with 2018 presentation

Recent Dividends:

1. Veritone Inc common.

No dividends paid.

Annual Dividends:

1. Veritone Inc common.

No dividends paid.

VERMILLION INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017	[¶] 2016 (revised)
Product revenue	2,772	2,853	2,320
Service revenue	281	268	322
Total revenue	3,053	3,121	2,642
Cost of revenue - product	2,044	1,756	1,974
Cost of revenue - services	1,098	1,158	724
Total cost of revenue	[¶] 3,142	[¶] 2,914	[¶] 2,698
Gross profit (loss)	(89)	207	(56)
Research & development	[¶] 550	[¶] 837	[¶] 2,172
Sales & marketing	[¶] 5,642	[¶] 4,268	[¶] 6,798
General & administrative	[¶] 5,052	[¶] 5,543	[¶] 5,928
Total operating expenses	11,244	10,648	14,898
Income (loss) from operations	(11,333)	(10,441)	(14,954)
Interest income (expense), net	(22)	(42)	(28)
Other income (expense), net	(16)	(14)	14
Net income (loss)	(11,371)	(10,497)	(14,968)
Deemed dividend on warrant repricing	942	...
Net income (loss) attributable to common stockholders	(11,371)	(11,439)	(14,968)
Weighted average shares outstanding - basic	70,086	56,944	52,198
Weighted average shares outstanding - diluted	70,086	56,944	52,198
Year end shares outstanding	[¶] 75,501	60,036	52,328
Net income (loss) per share - basic	\$(0.16)	\$(0.20)	\$(0.29)
Net income (loss) per share - diluted	\$(0.16)	\$(0.20)	\$(0.29)
Number of full time employees	[¶] 43	[¶] 39	[¶] 33
Number of part time employees	[¶] 1	...
Number of common stockholders	[¶] 1090	[¶] 1795	[¶] 1098

[¶] Reclassified to conform with 2017 presentation; [¶] Including non-cash stock-based compensation expense - Cost of revenue: \$124,000; [¶] Including non-cash stock-based compensation expense - Cost of revenue: \$136,000; [¶] Including non-cash stock-based compensation expense - Cost of revenue: \$115,000; [¶] Including non-cash stock-based compensation expense - Research & development: \$6,000; [¶] Including non-cash stock-based compensation expense - Research & development: \$9,000; [¶] Including non-cash stock-based compensation expense - Research & development: \$71,000; [¶] Including non-cash stock-based compensation expense - Sales & marketing: \$102,000; [¶] Including

non-cash stock-based compensation expense - Sales & marketing: \$160,000; [¶] Including non-cash stock-based compensation expense - Sales & marketing: \$108,000; [¶] Including non-cash stock-based compensation expense - General & administrative: \$869,000; [¶] Including non-cash stock-based compensation expense - General & administrative: \$1,134,000; [¶] Including non-cash stock-based compensation expense - General & administrative: \$885,000; [¶] Shares increased due to the effects of public offerings, preferred stock converted, restricted stock awards, and stock options exercised; [¶] As is; [¶] As of March 4, 2019; [¶] As of February 28, 2018; [¶] As of March 8, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017
Cash & cash equivalents	9,360	5,539
Accounts receivable	786	205
Prepaid expenses & other current assets	550	459
Inventories	92	102
Total current assets	10,788	6,305
Machinery & equipment	1,367	1,400
Demonstration equipment	39	39
Computer equipment & software	1,109	1,055
Furniture & fixtures	137	120
Leasehold improvements	706	706
Gross property & equipment	3,358	3,320
Accumulated depreciation & amortization	2,750	2,139
Property & equipment, net	608	1,181
Other assets	12	11
Total assets	11,408	7,497
Accounts payable	950	745
Payroll & benefits related expenses	853	867
Collaboration & research agreements expenses	366	358
Professional services	329	216
Other accrued liabilities	277	209
Short-term debt	189	185
Other current liabilities	29
Total current liabilities	2,964	2,609
Long-term debt	1,292	1,481
Total liabilities	4,256	4,090
Common stock	75	60
Additional paid-in capital	414,001	399,400
Retained earnings (accumulated deficit)	(406,924)	(396,053)
Total stockholders' equity (deficit)	7,152	3,407

Recent Dividends:

1. Vermillion Inc common.

No dividends paid.

Annual Dividends:

1. Vermillion Inc common.

No dividends paid.

VERMILLION INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, BDO USA, LLP, as it appeared in Co.'s 2018 10-K: **"Opinion on the Consolidated Financial Statements** We have audited the accompanying consolidated balance sheets of Vermillion, Inc. (the "Company") and subsidiaries as of December 31, 2018 and 2017, the related consolidated statements of operations, changes in stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. **Going Concern Uncertainty** The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has net cash flows deficiencies that raise substantial

doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

VICTORY CAPITAL HOLDINGS INC (DE)

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	[¶] 2017 (revised)	[¶] 2016 (revised)
Investment management fees	352,683	343,811	248,482
Fund administration & distribution fees	60,729	65,818	49,401
Total revenues	413,412	409,629	297,883
Personnel compensation & benefits	145,880	144,111	122,615
Distribution & other asset-based expenses	94,680	103,439	77,497
General & administrative expenses	30,005	33,996	26,628
Depreciation & amortization	23,277	29,910	30,405
Change in value of consideration payable for acquisition of business	(37)	(294)	(378)
Acquisition-related costs	4,346	2,094	6,619
Restructuring & integration costs	742	6,205	10,012
Total operating expenses	298,893	319,461	273,398
Income from operations	114,519	90,168	24,485
Interest income & other income (expense)	(2,856)	(2,913)	1,086
Interest expense	17,289	41,569	29,544
Amortization of debt issuance costs	1,708	3,657	2,749
Amortization of debt discount	700	1,544	999
Interest rate cap expense	767	327
Compass EMP (CEMP) base payment accretion expense	467	638	718
Other interest expense & other financing costs	530	292	305
Interest income (expense) & other financing income (costs)	(20,694)	(48,467)	(34,642)
Gain (loss) on debt extinguishment	(6,058)	(330)	...
Total other income (expense), net	(29,608)	(51,710)	(33,556)
Income (loss) before income taxes	84,911	38,458	(9,071)
Current federal tax expense (benefit)	13,130	640	(3)
Current state tax expense (benefit)	3,944	779	93
Current foreign tax expense (benefit)	17	22	(10)
Total current tax expense (benefit)	17,091	1,441	80
Deferred federal tax expense (benefit)	3,577	9,162	(2,728)
Deferred state tax expense (benefit)	549	2,010	(388)
Deferred foreign tax expense (benefit)	(10)	19	36
Total deferred tax expense (benefit)	4,116	11,191	(3,080)

Income tax expense (benefit).....	21,207	12,632	(3,000)	Class A treasury stock	8,045	...	undistributed income allocated to participating securities	118,000	222,000	251,000
Net income (loss)	63,704	25,826	(6,071)	Class B treasury stock	21,719	20,899	Net income attributable to common shareholders	3,420,000	4,840,000	5,650,000
Weighted average shares outstanding - basic	66,295	54,931	50,018	Unrealized gain (loss) available-for-sale securities	(59)	51	Weighted average shares outstanding - basic	4,358,000	4,299,000	4,503,000
Weighted average shares outstanding - diluted	70,511	59,577	50,018	Cumulative translation adjustment	(27)	13	Weighted average shares outstanding - diluted	4,358,000	4,299,000	4,503,000
Year end shares outstanding	67,562	55,119	54,786	Accumulated other comprehensive income (loss)	(86)	64	Year end shares outstanding	4,496,494	4,454,829	...
Net earnings (loss) per share - basic	\$0.96	\$0.47	\$(0.12)	Retained earnings (retained deficit)	(119,709)	(183,888)	Net income (loss) per share - basic	\$0.78	\$1.13	\$1.25
Net earnings (loss) per share - diluted	\$0.90	\$0.43	\$(0.12)	Total stockholders' equity	455,548	231,183	Net income (loss) per share - diluted	\$0.78	\$1.13	\$1.25
Dividends per common share	\$2.42	...				Dividends paid per common share	\$0.68	\$0.68	\$0.68
Total number of employees	263	267	276				Number of full time employees	153
Number of common stockholders	45				Number of common stockholders	106
Number of class A common stockholders	14,555,975	14,555,975	...				Foreign currency translation adjustments	698,000	(160,000)
Number of class B common stockholders	52,940,026	52,940,026	...							

□ Reclassified to conform with 2018 presentation; □ As is; □ Approximately; □ As of September 30, 2017; □ As of February 7, 2018; □ As of February 28, 2019; □ As of March 13, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017	2016
Cash & cash equivalents	51,491	12,921	...
Investment management fees receivable	37,980	42,264	...
Fund administration & distribution fees receivable	3,153	3,925	...
Other receivables	2,987	9,728	...
Prepaid expenses	2,664	5,441	...
Available-for-sale securities, at fair value	601	677	...
Trading securities, at fair value	12,719	10,659	...
Equipment, purchased software & implementation costs	17,071	14,685	...
Leasehold improvements	3,209	2,720	...
Furniture & fixtures	1,541	1,501	...
Total property & equipment, gross	21,821	18,906	...
Less: Accumulated depreciation & amortization	13,041	10,062	...
Property & equipment, net	8,780	8,844	...
Goodwill	284,108	284,108	...
Other intangible assets, net	387,679	408,000	...
Other assets	9,349	6,055	...
Total assets	801,511	792,622	...
Accounts payable	607	327	...
Accrued compensation & benefits	30,228	29,305	...
Accrued expenses	19,743	21,669	...
Consideration payable for acquisition of business	5,838	9,856	...
Deferred compensation plan liability	12,719	10,659	...
Deferred tax liability, net	6,212	4,068	...
Other liabilities	1,759	2,330	...
Term loan	280,000	499,750	...
Unamortized debt issuance cost	(7,629)	(11,442)	...
Unamortized debt discount	(3,514)	(5,083)	...
Long-term debt, net	268,857	483,225	...
Total liabilities	345,963	561,439	...
Common stock	572	...
Class A common stock	153
Class B common stock	553
Additional paid-in capital	604,401	435,334	...

Recent Dividends:

1. Victory Capital Holdings Inc (DE) class B common. No dividends paid.
2. Victory Capital Holdings Inc (DE) class A common. No dividends paid.

Annual Dividends:

1. Victory Capital Holdings Inc (DE) class B common. No dividends paid.
2. Victory Capital Holdings Inc (DE) class A common. No dividends paid.

WAYSIDE TECHNOLOGY GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017	2016
Net sales	181,444,000	160,567,000	164,609,000
Cost of sales	154,524,000	133,491,000	137,278,000
Gross profit	26,920,000	27,076,000	27,331,000
Selling, general & administrative expenses	20,319,000	19,263,000	18,715,000
Separation expenses	2,446,000
Income (loss) from operations	4,155,000	7,813,000	8,616,000
Interest, net	907,000	699,000	318,000
Foreign currency transaction gains (loss)	55,000	41,000	(1,000)
Income (loss) before income taxes - United States	3,960,000	6,929,000	7,514,000
Income before income taxes - foreign	1,157,000	1,624,000	1,419,000
Income (loss) before provision for income taxes	5,117,000	8,553,000	8,933,000
Current provision (benefit) for income taxes - federal	967,000	2,253,000	2,515,000
Current provision (benefit) for income taxes - state	327,000	552,000	55,000
Current provision (benefit) for income taxes - foreign	292,000	408,000	357,000
Total current provision (benefit) for income tax	1,586,000	3,213,000	2,927,000
Deferred provision (benefit) for income taxes - federal	(11,000)	273,000	102,000
Deferred provision (benefit) for income taxes - state	4,000	5,000	3,000
Total deferred provision (benefit) for income tax	(7,000)	278,000	105,000
Provision (benefit) for income taxes	1,579,000	3,491,000	3,032,000
Net income (loss)	3,538,000	5,062,000	5,901,000
Less distributed &			

□ Restated to reflect the adoption of ASC 606 Revenue from Contracts with Customers; □ Restated to reflect the correction of error related to earning per share calculation method; □ Approximately; □ As of February 19, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017
Cash & cash equivalents	14,883,000	5,530,000
Accounts receivable, gross	82,136,000	79,039,000
Allowance for doubtful accounts	785,000	862,000
Accounts receivable, net	81,351,000	78,177,000
Inventory, net	1,473,000	2,794,000
Vendor prepayments	3,172,000	6,837,000
Prepaid expenses & other current assets	1,988,000	1,718,000
Total current assets	102,867,000	95,056,000
Equipment	2,146,000	1,988,000
Leasehold improvements	1,332,000	1,335,000
Total equipment & leasehold improvements	3,478,000	3,323,000
Less accumulated depreciation & amortization	1,890,000	1,495,000
Equipment & leasehold improvements, net	1,588,000	1,828,000
Accounts receivable - long-term, net	3,156,000	7,437,000
Other assets	215,000	231,000
Deferred income taxes	145,000	138,000
Total assets	107,971,000	104,690,000
Trade accounts payable	62,751,000	60,075,000
Accrued expenses	3,902,000	5,122,000
Total current liabilities	66,653,000	65,197,000
Deferred rent & tenant allowances	745,000	781,000
Total liabilities	67,398,000	65,978,000
Common stock	53,000	53,000
Additional paid-in capital	32,392,000	31,257,000
Treasury stock, at cost	13,447,000	14,207,000
Retained earnings (accumulated deficit)	22,994,000	22,522,000
Foreign currency translation adjustments	(1,419,000)	(913,000)
Accumulated other comprehensive income (loss)	(1,419,000)	(913,000)
Total stockholders' equity	40,573,000	38,712,000

□ Restated to reflect the adoption of ASC 606 Revenue from Contracts with Customers

Recent Dividends:

1. Wayside Technology Group Inc common.

ExDate	Amt	Declared	Record	Payable
02/11/2016	0.17	02/02/2016	02/16/2016	02/26/2016
05/06/2016	0.17	04/25/2016	05/10/2016	05/17/2016
08/04/2016	0.17	07/27/2016	08/08/2016	08/18/2016
11/04/2016	0.17	10/25/2016	11/08/2016	11/18/2016
02/14/2017	0.17	02/02/2017	02/16/2017	02/27/2017
05/08/2017	0.17	04/27/2017	05/10/2017	05/17/2017
08/09/2017	0.17	07/25/2017	08/11/2017	08/18/2017
11/09/2017	0.17	10/24/2017	11/10/2017	11/17/2017
03/02/2018	0.17	02/26/2018	03/05/2018	03/12/2018
05/11/2018	0.17	05/02/2018	05/14/2018	05/21/2018
08/10/2018	0.17	08/01/2018	08/13/2018	08/22/2018
11/09/2018	0.17	10/30/2018	11/13/2018	11/20/2018
03/06/2019	0.17	02/22/2019	03/07/2019	03/13/2019

Annual Dividends:

1. Wayside Technology Group Inc common.

2016	0.68	2017	0.68	2018	0.68
2019	0.17				

WOODSTOCK HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	4,844,713	4,850,090
Cost & expenses	5,115,379	5,170,903
Net income	(270,666)	(320,813)
Earnings common share		
Primary	\$(0.16)	\$(0.19)
Fully Diluted	\$(0.16)	\$(0.19)
Common Shares:		
Year-end	2,819,862	2,121,858

Y-MABS THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)	2016
Research & development	34,269	14,307	13,855
General & administrative expenses	8,961	4,937	3,184
Total operating expenses	43,230	19,244	17,039
Income (loss) from operations	(43,230)	(19,244)	(17,039)
Interest & other income/(expenses)	(44)	83	...
Other (expense)/income, net	(18)
Income before income taxes - United States	(42,456)	(18,975)	(16,915)
Income before income taxes - Foreign	(818)	(186)	(142)
Income (loss) before provision for income taxes	(43,274)	(19,161)	(17,057)
Net income (loss)	(43,274)	(19,161)	(17,057)
Weighted average shares outstanding - basic	28,772	19,398	14,087
Weighted average shares outstanding - diluted	28,772	19,398	14,087
Year end shares outstanding	34,194	26,750	16,553
Net earnings (loss) per share - basic	\$(1.50)	\$(0.99)	\$(1.21)
Net earnings (loss) per share - diluted	\$(1.50)	\$(0.99)	\$(1.21)
Number of full time employees	32	29	...
Number of common stockholders	55

Reclassified to conform with 2018 presentation; As is; As of March 14, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	147,840	90,483
Restricted cash	31	32
Other current assets	3,661	840
Total current assets	151,532	91,355
Property & equipment, net	205	...
Deferred offering costs	...	772
Other assets	187	...
Total assets	151,924	92,127
Accounts payable	5,872	5,909
Accrued milestone payments	1,475	875
Accrued clinical costs	63	212
Accrued compensation & board fees	1,144	810
Accrued rent	44	...
Other accrued liabilities	525	119
Accrued liabilities	3,251	2,016
Total current liabilities	9,123	7,925
Accrued milestone royalty payments	2,050	2,050
Other liabilities	224	...
Total liabilities	11,397	9,975
Common stock	3	3
Additional paid-in capital	225,352	123,879
Accumulated other comprehensive income (loss)	7	(169)
Retained earnings (accumulated deficit)	(84,835)	(41,561)
Total stockholders' equity	140,527	82,152

Recent Dividends:

1. Y-mAbs Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Y-mAbs Therapeutics Inc common.

No dividends paid.

YOGAWORKS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2018	2017 (revised)	2016 (revised)
Net revenues	59,593,624	54,513,945	55,090,208
Cost of revenues	23,775,911	20,558,001	20,535,177
Center operations expenses	28,019,341	23,476,691	22,469,539
General & administrative expenses	17,907,687	16,026,758	11,066,545
Depreciation & amortization expenses	8,106,130	8,896,002	8,893,093
Goodwill impairment expenses	12,653,819	7,488,399	...
Asset impairment expenses	4,442,513	206,543	...
Total cost of revenues & operating expenses	94,905,401	76,652,394	(62,964,354)
Income (loss) from operations	(35,311,777)	(22,138,449)	(7,874,146)
Interest income (expense), net	143,973	(1,343,445)	(1,587,084)
Net income (loss) before provision for (benefit from) income taxes	(35,167,804)	(23,481,894)	(9,461,230)
Current state provision for (benefit from) income taxes	19,122	13,995	6,784
Total current provision for (benefit from) income taxes	19,122	13,995	6,784
Deferred federal provision for			

	2018	2017 (revised)	2016 (revised)
income taxes	(46,754)	29,322	...
Deferred state provision for (benefit from) income taxes	(12,781)	7,186	...
Provision for (benefit from) income taxes	19,122	(45,540)	43,292
Net income (loss)	(35,186,926)	(23,436,354)	(9,504,522)
Less preferred rights dividend on redeemable preferred stock	995,743	4,634,662	...
Net income (loss) attributable to common stockholders	(35,186,926)	(24,432,097)	(14,139,184)
Weighted average shares outstanding - basic	16,422,693	9,680,988	7,796
Weighted average shares outstanding - diluted	16,422,693	9,680,988	7,796
Year end shares outstanding	16,494,838	16,332,510	7,559
Net income (loss) per share - basic	\$(2.14)	\$(2.52)	\$(191.60)
Net income (loss) per share - diluted	\$(2.14)	\$(2.52)	\$(191.60)
Number of full time employees	60	1,300	...
Number of part time employees	2,900	700	...
Total number of employees	2,960	2,000	2,000
Number of common stockholders	16	10	8

Reclassified to conform with 2017 presentation; Adjusted for 1-for-10 reverse stock split, March 24, 2017; Adjusted for 1-for-1.333520 reverse stock split, July 14, 2017; Shares increased due to the effect of conversion of redeemable of preferred stock and convertible note, issuance of common stock, and vesting of restricted stock units; Approximately; As of August 10, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2018	2017 (revised)
Cash & cash equivalents	11,447,318	22,095,216
Inventories	1,148,449	1,212,608
Prepaid expenses & other current assets	936,757	1,145,067
Total current assets	13,532,524	24,452,891
Computer equipment & purchased software	670,022	1,130,653
Furniture & fixtures	2,744,580	3,633,677
Leasehold improvements	26,792,887	25,367,841
Other equipment	213,546	174,885
Construction-in-progress	1,075,634	...
Total property & equipment	31,496,669	30,307,056
Less accumulated depreciation & amortization	21,270,725	19,888,853
Property & equipment, net	10,225,944	10,418,203
Intangible assets, net	13,291,502	22,142,275
Goodwill	663,954	12,768,773
Other non-current assets	1,327,775	1,224,179
Total assets	39,041,699	71,006,321
Accounts payable & accrued expenses	4,905,204	3,794,569
Accrued compensation	1,802,047	1,947,134
Deferred revenue	7,276,578	7,187,948
Current portion of deferred rent	124,319	122,607
Total current liabilities	14,108,148	13,052,258
Deferred rent, net of current portion	3,975,391	3,418,886
Total liabilities	18,083,539	16,471,144
Common stock	16,496	16,333
Additional paid-in capital	113,260,161	111,650,415

Retained earnings		
(accumulated deficit)	(92,318,497)	(57,131,571)
Total stockholders'		
equity (deficit)	20,958,160	54,535,177

Recent Dividends:**1. YogaWorks Inc common.**

No dividends paid.

Annual Dividends:**1. YogaWorks Inc common.**

No dividends paid.

YOGAWORKS INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, BDO USA, LLP, as it appeared in Co.'s 2018 10-K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of YogaWorks, Inc. (the "Company") and subsidiaries as of December 31, 2018 and 2017, the related consolidated statements of operations, redeemable preferred stock, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, 2018 and 2017, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and is dependent on additional financing that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2019 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.